{"initialLink":"https://newrepublic.com/article/162000/bill-gates-impeded-global-access-covid-vaccines","sanitizedLink":"https://newrepublic.com/article/162000/bill-gates-impeded-global-access-covid-vaccines","finalLink":"https://newrepublic.com/article/162000/bill-gates-impeded-global-access-covid-vaccines","htmlEmbed":"<script>window.contexterSetup=window.contexterSetup||function(){window.contexterSetupComplete=!0;class ContexterLink extends HTMLAnchorElement{constructor(){super()}connectedCallback(){this.setAttribute(\"target\",\"_blank\")}}customElements.define(\"contexter-link\",ContexterLink,{extends:\"a\"}),customElements.define(\"contexter-inner\",class extends HTMLElement{constructor(){super()}attributeChangedCallback(name,oldValue,newValue){}connectedCallback(){this.className=\"contexter-box__inner\"}}),customElements.define(\"contexter-thumbnail\",class extends HTMLElement{constructor(){super()}attributeChangedCallback(name,oldValue,newValue){}connectedCallback(){this.className=\"contexter-box__thumbnail\"}}),customElements.define(\"contexter-byline\",class extends HTMLElement{constructor(){super()}attributeChangedCallback(name,oldValue,newValue){}connectedCallback(){this.className=\"contexter-box__byline\"}}),customElements.define(\"contexter-keywordset\",class extends HTMLElement{constructor(){super()}attributeChangedCallback(name,oldValue,newValue){}connectedCallback(){this.className=\"contexter-box__keywordset\"}}),customElements.define(\"contexter-linkset\",class extends HTMLElement{constructor(){super()}attributeChangedCallback(name,oldValue,newValue){}connectedCallback(){this.className=\"contexter-box__linkset\"}}),customElements.define(\"contexter-meta\",class extends HTMLElement{constructor(){super()}attributeChangedCallback(name,oldValue,newValue){}connectedCallback(){this.className=\"contexter-box__meta\"}}),customElements.define(\"contexter-summary\",class extends HTMLElement{constructor(){super()}attributeChangedCallback(name,oldValue,newValue){}connectedCallback(){this.className=\"p-summary entry-summary\"}}),customElements.define(\"contexter-box-head\",class extends HTMLElement{constructor(){super()}connectedCallback(){this.className=\"contexter-box__head\"}}),customElements.define(\"contexter-box-inner\",class extends HTMLElement{constructor(){super()}connectedCallback(){}});class ContexterBox extends HTMLElement{constructor(){super(),this.first=!0,this.shadow=this.attachShadow({mode:\"open\"})}connectedCallback(){if(this.first){this.first=!1;var style=document.createElement(\"style\"),lightDomStyle=(style.innerHTML=`:host {--background: #f5f6f7;--border: darkblue;--blue: #0000ee;--font-color: black;--inner-border: black;font-family: Franklin,Arial,Helvetica,sans-serif;font-size: 14px;background: var(--background);width: 600px;color: var(--font-color);min-height: 90px;display: block;padding: 8px;border: 1px solid var(--border);cursor: pointer;box-sizing: border-box;margin: 6px;contain: content;margin: 6px auto;}// can only select top-level nodes with slotted::slotted(*) {max-width: 100%;display:block;}::slotted([slot=thumbnail]) {max-width: 100%;display:block;}::slotted([slot=header]) {width: 100%;font-size: 1.25rem;font-weight: bold;display:block;margin-bottom: 6px;}::slotted([slot=author]) {max-width: 50%;font-size: 12px;display:inline-block;float: left;}::slotted([slot=time]) {max-width: 50%;font-size: 12px;display:inline-block;float: right;}::slotted([slot=summary]) {width: 100%;margin-top: 6px;padding: 10px 2px;border-top: 1px solid var(--inner-border);font-size: 15px;display:inline-block;margin-bottom: 6px;}contexter-meta {height: auto;margin-bottom: 4px;width: 100%;display: grid;position: relative;min-height: 16px;grid-template-columns: repeat(2, 1fr);}::slotted([slot=keywords]) {width: 80%;padding: 2px 4px;border-top: 1px solid var(--inner-border);font-size: 11px;display: block;float: right;font-style: italic;text-align: right;grid-column: 2/2;grid-row: 1;align-self: end;justify-self: end;}::slotted([slot=keywords]):empty {border-top: 0px solid var(--inner-border);}::slotted([slot=archive-link]) {font-size: 1em;display: inline;}::slotted([slot=archive-link])::after {content: \"|\";display: inline;color: var(--font-color);text-decoration: none;margin: 0 .5em;}::slotted([slot=read-link]) {font-size: 1em;display: inline;}contexter-linkset {width: 80%;padding: 2px 4px;font-size: 13px;float: left;font-weight: bold;grid-row: 1;grid-column: 1/2;align-self: end;justify-self: start;}/* Extra small devices (phones, 600px and down) */@media only screen and (max-width: 600px) {:host {width: 310px;}}/* Small devices (portrait tablets and large phones, 600px and up) */@media only screen and (min-width: 600px) {...}/* Medium devices (landscape tablets, 768px and up) */@media only screen and (min-width: 768px) {...}/* Large devices (laptops/desktops, 992px and up) */@media only screen and (min-width: 992px) {...}/* Extra large devices (large laptops and desktops, 1200px and up) */@media only screen and (min-width: 1200px) {...}@media (prefers-color-scheme: dark){:host {--background: #354150;--border: #1f2b37;--blue: #55b0ff;--font-color: #ffffff;--inner-border: #787a7c;background: var(--background);border: 1px solid var(--border)}}`,document.createElement(\"style\"));lightDomStyle.innerHTML=`contexter-box {contain: content;}contexter-box .read-link {font-weight: bold;}contexter-box a {color: #0000ee;}contexter-box img {width: 100%;border: 0;padding: 0;margin: 0;}/* Extra small devices (phones, 600px and down) */@media only screen and (max-width: 600px) {...}/* Small devices (portrait tablets and large phones, 600px and up) */@media only screen and (min-width: 600px) {...}/* Medium devices (landscape tablets, 768px and up) */@media only screen and (min-width: 768px) {...}/* Large devices (laptops/desktops, 992px and up) */@media only screen and (min-width: 992px) {...}/* Extra large devices (large laptops and desktops, 1200px and up) */@media only screen and (min-width: 1200px) {...}@media (prefers-color-scheme: dark){contexter-box a {color: #55b0ff;}}`,this.appendChild(lightDomStyle),this.shadow.appendChild(style);const innerContainer=document.createElement(\"contexter-box-inner\"),innerSlotThumbnail=(this.shadow.appendChild(innerContainer),document.createElement(\"slot\")),innerSlotHeader=(innerSlotThumbnail.name=\"thumbnail\",innerContainer.appendChild(innerSlotThumbnail),document.createElement(\"slot\")),innerSlotAuthor=(innerSlotHeader.name=\"header\",innerContainer.appendChild(innerSlotHeader),document.createElement(\"slot\")),innerSlotTime=(innerSlotAuthor.name=\"author\",innerContainer.appendChild(innerSlotAuthor),document.createElement(\"slot\")),innerSlotSummary=(innerSlotTime.name=\"time\",innerContainer.appendChild(innerSlotTime),document.createElement(\"slot\")),metaContainer=(innerSlotSummary.name=\"summary\",innerContainer.appendChild(innerSlotSummary),document.createElement(\"contexter-meta\")),innerSlotInfo=(innerContainer.appendChild(metaContainer),document.createElement(\"slot\")),linkContainer=(innerSlotInfo.name=\"keywords\",metaContainer.appendChild(innerSlotInfo),document.createElement(\"contexter-linkset\")),innerSlotArchiveLink=(metaContainer.appendChild(linkContainer),document.createElement(\"slot\")),innerSlotReadLink=(innerSlotArchiveLink.name=\"archive-link\",linkContainer.appendChild(innerSlotArchiveLink),document.createElement(\"slot\"));innerSlotReadLink.name=\"read-link\",linkContainer.appendChild(innerSlotReadLink),this.className=\"contexter-box\",this.onclick=e=>{if(!e.target.className.includes(\"read-link\")&&!e.target.className.includes(\"title-link\")){const mainLinks=this.querySelectorAll(\"a.main-link\");mainLinks[0].click()}}}}}customElements.define(\"contexter-box\",ContexterBox)},window.contexterSetupComplete||window.contexterSetup();</script><contexter-box class=\"link-card h-entry hentry\" itemscope=\"\" itemtype=\"https://schema.org/CreativeWork\"><contexter-thumbnail class=\"thumbnail\" slot=\"thumbnail\"></contexter-thumbnail><contexter-box-head slot=\"header\" class=\"p-name entry-title\" itemprop=\"headline\"><contexter-box-head slot=\"header\" class=\"p-name entry-title\" itemprop=\"headline\"><a is=\"contexter-link\" href=\"https://newrepublic.com/article/162000/bill-gates-impeded-global-access-covid-vaccines\" itemprop=\"url\">How Bill Gates Impeded Global Access to Covid Vaccines</a></contexter-box-head></contexter-box-head><contexter-byline class=\"p-author author\" slot=\"author\"><span class=\"p-name byline\" rel=\"author\" itemprop=\"author\">Alexander Zaitchik</span></contexter-byline><time class=\"dt-published published\" slot=\"time\" itemprop=\"datePublished\" datetime=\"2023-11-28T00:00:00.000Z\">11/27/2023</time><contexter-summary class=\"p-summary entry-summary\" itemprop=\"abstract\" slot=\"summary\"><p>Through his hallowed foundation, the world’s de facto public health czar has been a stalwart defender of monopoly medicine.</p></contexter-summary><contexter-keywordset itemprop=\"keywords\" slot=\"keywords\"><span rel=\"category tag\" class=\"p-category\" itemprop=\"keywords\">The Soapbox</span>, <span rel=\"category tag\" class=\"p-category\" itemprop=\"keywords\">Covid-19</span>, <span rel=\"category tag\" class=\"p-category\" itemprop=\"keywords\">Bill Gates</span>, <span rel=\"category tag\" class=\"p-category\" itemprop=\"keywords\">Bill & Melinda Gates Foundation</span>, <span rel=\"category tag\" class=\"p-category\" itemprop=\"keywords\">World Health Organization</span>, <span rel=\"category tag\" class=\"p-category\" itemprop=\"keywords\">World Trade Organization</span>, <span rel=\"category tag\" class=\"p-category\" itemprop=\"keywords\">coronavirus vaccine</span>, <span rel=\"category tag\" class=\"p-category\" itemprop=\"keywords\">pandemic</span>, <span rel=\"category tag\" class=\"p-category\" itemprop=\"keywords\">Big Pharma</span>, <span rel=\"category tag\" class=\"p-category\" itemprop=\"keywords\">pharmaceutical</span>, <span rel=\"category tag\" class=\"p-category\" itemprop=\"keywords\">AstraZeneca</span>, <span rel=\"category tag\" class=\"p-category\" itemprop=\"keywords\">GlaxoSmithKline</span>, <span rel=\"category tag\" class=\"p-category\" itemprop=\"keywords\">Johnson & Johnson</span>, <span rel=\"category tag\" class=\"p-category\" itemprop=\"keywords\">Pfizer</span>, <span rel=\"category tag\" class=\"p-category\" itemprop=\"keywords\">HIV</span>, <span rel=\"category tag\" class=\"p-category\" itemprop=\"keywords\">AIDS</span>, <span rel=\"category tag\" class=\"p-category\" itemprop=\"keywords\">Nelson Mandela</span>, <span rel=\"category tag\" class=\"p-category\" itemprop=\"keywords\">South Africa</span>, <span rel=\"category tag\" class=\"p-category\" itemprop=\"keywords\">Oxfam</span>, <span rel=\"category tag\" class=\"p-category\" itemprop=\"keywords\">Médecins Sans Frontieres</span>, <span rel=\"category tag\" class=\"p-category\" itemprop=\"keywords\">The Insecurity Complex</span>, <span rel=\"category tag\" class=\"p-category\" itemprop=\"keywords\">Politics</span></contexter-keywordset><a is=\"contexter-link\" href=\"https://newrepublic.com/article/162000/bill-gates-impeded-global-access-covid-vaccines\" class=\"read-link main-link\" itemprop=\"sameAs\" slot=\"read-link\">Read</a></contexter-box>","linkId":"2441d0f414a3c2f7c31408e8e4835cadc4656f1d","data":{"originalLink":"https://newrepublic.com/article/162000/bill-gates-impeded-global-access-covid-vaccines","sanitizedLink":"https://newrepublic.com/article/162000/bill-gates-impeded-global-access-covid-vaccines","canonical":"https://newrepublic.com/article/162000/bill-gates-impeded-global-access-covid-vaccines","htmlText":"<!doctype html>\n<html lang=\"en-us\">\n  <head>\n    <meta charset=\"utf-8\">\n    <title data-react-helmet=\"true\">Bill Gates, Vaccine Monster | The New Republic</title>\n    \n<!-- Favicons -->\n  <link rel=\"apple-touch-icon\" sizes=\"57x57\" href=\"//assets.newrepublic.com/assets/favicons/apple-touch-icon-57x57.png\">\n  <link rel=\"apple-touch-icon\" sizes=\"60x60\" href=\"//assets.newrepublic.com/assets/favicons/apple-touch-icon-60x60.png\">\n  <link rel=\"apple-touch-icon\" sizes=\"72x72\" href=\"//assets.newrepublic.com/assets/favicons/apple-touch-icon-72x72.png\">\n  <link rel=\"apple-touch-icon\" sizes=\"76x76\" href=\"//assets.newrepublic.com/assets/favicons/apple-touch-icon-76x76.png\">\n  <link rel=\"apple-touch-icon\" sizes=\"114x114\" href=\"//assets.newrepublic.com/assets/favicons/apple-touch-icon-114x114.png\">\n  <link rel=\"apple-touch-icon\" sizes=\"120x120\" href=\"//assets.newrepublic.com/assets/favicons/apple-touch-icon-120x120.png\">\n  <link rel=\"apple-touch-icon\" sizes=\"144x144\" href=\"//assets.newrepublic.com/assets/favicons/apple-touch-icon-144x144.png\">\n  <link rel=\"apple-touch-icon\" sizes=\"152x152\" href=\"//assets.newrepublic.com/assets/favicons/apple-touch-icon-152x152.png\">\n  <link rel=\"apple-touch-icon\" sizes=\"180x180\" href=\"//assets.newrepublic.com/assets/favicons/apple-touch-icon-180x180.png\">\n  <link rel=\"icon\" type=\"image/png\" href=\"//assets.newrepublic.com/assets/favicons/favicon-32x32.png\" sizes=\"32x32\">\n  <link rel=\"icon\" type=\"image/png\" href=\"//assets.newrepublic.com/assets/favicons/favicon-194x194.png\" sizes=\"194x194\">\n  <link rel=\"icon\" type=\"image/png\" href=\"//assets.newrepublic.com/assets/favicons/favicon-96x96.png\" sizes=\"96x96\">\n  <link rel=\"icon\" type=\"image/png\" href=\"//assets.newrepublic.com/assets/favicons/android-chrome-192x192.png\" sizes=\"192x192\">\n  <link rel=\"icon\" type=\"image/png\" href=\"//assets.newrepublic.com/assets/favicons/favicon-16x16.png\" sizes=\"16x16\">\n  <link rel=\"manifest\" href=\"//assets.newrepublic.com/assets/favicons/manifest.json\">\n  <link rel=\"mask-icon\" href=\"//assets.newrepublic.com/assets/favicons/safari-pinned-tab.svg\" color=\"#000000\">\n  <link rel=\"shortcut icon\" href=\"//assets.newrepublic.com/assets/favicons/favicon.ico\">\n  <meta name=\"msapplication-TileColor\" content=\"#ffffff\">\n  <meta name=\"msapplication-TileImage\" content=\"//assets.newrepublic.com/assets/favicons/mstile-144x144.png\">\n  <meta name=\"msapplication-config\" content=\"//assets.newrepublic.com/assets/favicons/browserconfig.xml\">\n  <meta name=\"theme-color\"\n      content=\"#FFFFFF\"\n      media=\"(prefers-color-scheme: light)\">\n  <meta name=\"theme-color\"\n      content=\"#000000\"\n      media=\"(prefers-color-scheme: dark)\">\n<!-- /Favicons -->\n\n<!-- OneTrust Cookies Consent Notice start -->\n<script src=\"https://cdn.cookielaw.org/scripttemplates/otSDKStub.js\"  type=\"text/javascript\" charset=\"UTF-8\"\ndata-domain-script=\"831d1c84-5f38-447b-bfae-50d0c3e3709d\"></script>\n<script type=\"text/javascript\">\nfunction OptanonWrapper() { }\n</script>\n<!-- OneTrust Cookies Consent Notice end -->\n\n<!-- Blink script -->\n  <script id=\"blink-widget-main\" src=\"//blink.net/1.0/blink-sdk.js?clientId=newrepublic.com\"></script>\n  <script type=\"text/plain\" class=\"optanon-category-C0001\">\n    if (blinkSDK) {\n        blinkSDK.setEnableAnalyticsStorage(true);\n    } else {\n        window.addEventListener(\"blinkPaywallLoaded\", function() {\n            blinkSDK.setEnableAnalyticsStorage(true);\n        });\n    }\n  </script>\n<!-- End Blink script -->\n\n<script>\n  // Read more here:\n  // https://my.onetrust.com/s/article/UUID-d81787f6-685c-2262-36c3-5f1f3369e2a7?language=en_US\n  //\n\n  // Define dataLayer and the gtag function.\n  window.dataLayer = window.dataLayer || [];\n  function gtag(){dataLayer.push(arguments);}\n\n  // Default consent configuration for EU and US-CA users\n  gtag('consent', 'default', {\n    ad_storage: \"denied\",\n    ad_user_data: \"denied\",\n    analytics_storage: \"denied\",\n    ad_personalization: \"denied\",\n    functionality_storage: \"granted\",\n  });\n\n  // Consent configuration for US users (excluding CA)\n  gtag('consent', 'default', {\n    ad_storage: \"granted\",\n    ad_user_data: \"granted\",\n    analytics_storage: \"granted\",\n    ad_personalization: \"granted\",\n    functionality_storage: \"granted\",\n    'region': ['US']\n  });\n\n</script>\n<!-- Google Tag Manager -->\n<script>(function (w, d, s, l, i) { w[l] = w[l] || []; w[l].push({ 'gtm.start': new Date().getTime(), event: 'gtm.js' });\nvar f = d.getElementsByTagName(s)[0], j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.setAttributeNode(d.createAttribute('data-ot-ignore')); j.setAttribute('class','optanon-category-C0001');\nj.async = true;j.src = 'https://www.googletagmanager.com/gtm.js?id=' + i + dl;\nf.parentNode.insertBefore(j, f); })(window, document, 'script', 'dataLayer', 'GTM-NMWSH2N');\n</script>\n<!-- End Google Tag Manager -->\n<script type=\"text/javascript\">var _sf_startpt=(new Date()).getTime()</script>\n<!-- Twitter widget -->\n<script async src=\"https://platform.twitter.com/widgets.js\" charset=\"utf-8\"></script>\n<!-- End Twitter widget -->\n\n<script data-cfasync=\"false\" type=\"text/javascript\">\n  (()=>{\"use strict\";var t={455:(t,e,n)=>{n.d(e,{Z:()=>c});var r=n(81),o=n.n(r),i=n(645),a=n.n(i)()(o());a.push([t.id,'div.vjul89{position:fixed;top:0;left:0;width:100%;height:100%;background:rgba(0,0,0,.4);z-index:999999}div.vjul89 *{box-sizing:border-box}div.vjul89 div._12nslk{position:fixed;top:50%;left:50%;transform:translate(-50%, -50%);display:flex;flex-direction:column;justify-content:flex-start;min-height:25vh;width:50%;background-color:#fff;border:none;border-radius:1em;box-shadow:0 0 10px rgba(0,0,0,.3);text-align:center;font-size:13px;font-family:Arial,Helvetica,sans-serif;font-weight:bold;line-height:2;color:#000}div.vjul89 div._12nslk *:before,div.vjul89 div._12nslk *:after{content:\"\";display:none}@media screen and (max-width: 479px){div.vjul89 div._12nslk{font-size:13px;width:90%}}@media screen and (min-width: 480px){div.vjul89 div._12nslk{font-size:14px;width:80%}}@media screen and (min-width: 608px){div.vjul89 div._12nslk{font-size:14px;width:70%}}@media screen and (min-width: 960px){div.vjul89 div._12nslk{font-size:16px;width:70%}}@media screen and (min-width: 1200px){div.vjul89 div._12nslk{font-size:16px;width:840px}}div.vjul89 div._12nslk header{width:100%;background-color:rgba(0,0,0,0);border:0;color:inherit;display:block;font-size:1em;font-family:inherit;letter-spacing:normal;margin:0;opacity:1;outline:none;padding:1em 2em;position:static;text-align:center}div.vjul89 div._12nslk header img{display:inline;margin:0 0 16px 0;padding:0;max-width:240px;max-height:60px}div.vjul89 div._12nslk header h2{display:block;line-height:1.3;padding:0;font-family:inherit;font-weight:normal;font-style:normal;text-decoration:initial;text-align:center;font-size:1.75em;margin:0;color:inherit}div.vjul89 div._12nslk header h2:not(img+*){margin-top:30px}div.vjul89 div._12nslk header span._1j92dmv{position:absolute;top:0;right:15px;font-size:2em;font-weight:normal;cursor:pointer;color:inherit}div.vjul89 div._12nslk header span._1j92dmv:hover{filter:brightness(115%)}div.vjul89 div._12nslk section{width:100%;margin:0;padding:1em 2em;text-align:center;font-family:inherit;color:inherit;background:rgba(0,0,0,0)}div.vjul89 div._12nslk section p{display:block;margin:0 0 1em 0;line-height:1.5;text-align:center;font-size:1em;font-family:inherit;color:inherit;overflow-wrap:break-word;font-weight:normal;font-style:normal;text-decoration:initial}div.vjul89 div._12nslk section p:last-of-type{margin:0 0 1.5em 0}div.vjul89 div._12nslk section._1dbtlod{display:block}div.vjul89 div._12nslk section._1dbtlod._1aoxcqu{display:none}div.vjul89 div._12nslk section._1dbtlod a._1sqext2._1jiu99w{color:var(--_1jiu99w)}div.vjul89 div._12nslk section._1dbtlod a._1sqext2.lqlwtr{text-decoration:var(--lqlwtr)}div.vjul89 div._12nslk section._1dbtlod a._1sqext2.wa438v:visited{color:var(--wa438v)}div.vjul89 div._12nslk section._1dbtlod div._1aki86k{display:block;margin:.75em;padding:0}div.vjul89 div._12nslk section._1dbtlod div._1aki86k p.yuofri{max-width:80%;margin:0 auto;padding:0;font-size:.85em;color:inherit;font-style:normal;font-weight:normal;cursor:pointer}div.vjul89 div._12nslk section.wybx21{display:block}div.vjul89 div._12nslk section.wybx21._1aoxcqu{display:none}div.vjul89 div._12nslk section.wybx21 h4._19qz5gz{color:inherit;text-align:initial;font-weight:normal;font-family:inherit;font-size:1.125em;margin:0 0 .5em .5em}div.vjul89 div._12nslk section.wybx21 div.d1fv9q{display:flex;margin:1.5em 0}div.vjul89 div._12nslk section.wybx21 div.d1fv9q ul.d4g70m{max-height:300px;flex:2;list-style:none;overflow-y:auto;margin:0 1em 0 0;padding-inline-start:0}@media screen and (min-width: 608px){div.vjul89 div._12nslk section.wybx21 div.d1fv9q ul.d4g70m{flex:1;margin:0 2em 0 0}}div.vjul89 div._12nslk section.wybx21 div.d1fv9q ul.d4g70m li{padding:.75em;cursor:pointer;background:rgba(0,0,0,.05);font-weight:bold}div.vjul89 div._12nslk section.wybx21 div.d1fv9q ul.d4g70m li:hover{background:rgba(0,0,0,.075)}div.vjul89 div._12nslk section.wybx21 div.d1fv9q ul.d4g70m li._3e6yaf{color:var(--_1rbefr0);background:var(--_19gqudc)}div.vjul89 div._12nslk section.wybx21 div.d1fv9q div._15fsyju{max-height:300px;overflow-y:auto;flex:3;display:flex;flex-direction:column;justify-content:space-between;text-align:initial}div.vjul89 div._12nslk section.wybx21 div.d1fv9q div._15fsyju ol._18x2pnc{display:none;list-style-type:decimal;text-align:initial;padding:0;margin:0 2em;font-weight:normal}div.vjul89 div._12nslk section.wybx21 div.d1fv9q div._15fsyju ol._18x2pnc._3e6yaf{display:block}div.vjul89 div._12nslk section.wybx21 div.d1fv9q div._15fsyju p{margin:1em 0 0;text-align:inherit;font-style:italic}div.vjul89 div._12nslk section.wybx21 button.lppg7q{font-size:1em;text-transform:initial}div.vjul89 div._12nslk button._19r2sxa{width:auto;height:auto;max-width:90%;cursor:pointer;display:inline-block;letter-spacing:normal;margin:.75em;opacity:1;outline:none;overflow-wrap:break-word;font-family:inherit;font-weight:normal;font-style:normal;text-decoration:initial;text-transform:uppercase;text-align:center;color:#fff;font-size:1.15em;padding:.75em 2em;padding-inline:2em;padding-block:.75em;line-height:normal;background:#40c28a;border:none;border-radius:.25em;box-shadow:none}div.vjul89 div._12nslk button._19r2sxa:hover{filter:brightness(115%);box-shadow:none}div.vjul89 div._12nslk a._1133rtj{height:50px;width:50px;position:absolute;bottom:5px;right:5px}div.vjul89 div._12nslk a._1133rtj img{position:initial;height:100%;width:100%;filter:drop-shadow(1px 1px 1px var(--_1u0adfa))}',\"\"]);const c=a},645:t=>{t.exports=function(t){var e=[];return e.toString=function(){return this.map((function(e){var n=\"\",r=void 0!==e[5];return e[4]&&(n+=\"@supports (\".concat(e[4],\") {\")),e[2]&&(n+=\"@media \".concat(e[2],\" {\")),r&&(n+=\"@layer\".concat(e[5].length>0?\" \".concat(e[5]):\"\",\" {\")),n+=t(e),r&&(n+=\"}\"),e[2]&&(n+=\"}\"),e[4]&&(n+=\"}\"),n})).join(\"\")},e.i=function(t,n,r,o,i){\"string\"==typeof t&&(t=[[null,t,void 0]]);var a={};if(r)for(var c=0;c<this.length;c++){var s=this[c][0];null!=s&&(a[s]=!0)}for(var l=0;l<t.length;l++){var u=[].concat(t[l]);r&&a[u[0]]||(void 0!==i&&(void 0===u[5]||(u[1]=\"@layer\".concat(u[5].length>0?\" \".concat(u[5]):\"\",\" {\").concat(u[1],\"}\")),u[5]=i),n&&(u[2]?(u[1]=\"@media \".concat(u[2],\" {\").concat(u[1],\"}\"),u[2]=n):u[2]=n),o&&(u[4]?(u[1]=\"@supports (\".concat(u[4],\") {\").concat(u[1],\"}\"),u[4]=o):u[4]=\"\".concat(o)),e.push(u))}},e}},81:t=>{t.exports=function(t){return t[1]}},379:t=>{var e=[];function n(t){for(var n=-1,r=0;r<e.length;r++)if(e[r].identifier===t){n=r;break}return n}function r(t,r){for(var i={},a=[],c=0;c<t.length;c++){var s=t[c],l=r.base?s[0]+r.base:s[0],u=i[l]||0,d=\"\".concat(l,\" \").concat(u);i[l]=u+1;var f=n(d),v={css:s[1],media:s[2],sourceMap:s[3],supports:s[4],layer:s[5]};if(-1!==f)e[f].references++,e[f].updater(v);else{var h=o(v,r);r.byIndex=c,e.splice(c,0,{identifier:d,updater:h,references:1})}a.push(d)}return a}function o(t,e){var n=e.domAPI(e);n.update(t);return function(e){if(e){if(e.css===t.css&&e.media===t.media&&e.sourceMap===t.sourceMap&&e.supports===t.supports&&e.layer===t.layer)return;n.update(t=e)}else n.remove()}}t.exports=function(t,o){var i=r(t=t||[],o=o||{});return function(t){t=t||[];for(var a=0;a<i.length;a++){var c=n(i[a]);e[c].references--}for(var s=r(t,o),l=0;l<i.length;l++){var u=n(i[l]);0===e[u].references&&(e[u].updater(),e.splice(u,1))}i=s}}},569:t=>{var e={};t.exports=function(t,n){var r=function(t){if(void 0===e[t]){var n=document.querySelector(t);if(window.HTMLIFrameElement&&n instanceof window.HTMLIFrameElement)try{n=n.contentDocument.head}catch(t){n=null}e[t]=n}return e[t]}(t);if(!r)throw new Error(\"Couldn't find a style target. This probably means that the value for the 'insert' parameter is invalid.\");r.appendChild(n)}},216:t=>{t.exports=function(t){var e=document.createElement(\"style\");return t.setAttributes(e,t.attributes),t.insert(e,t.options),e}},565:(t,e,n)=>{t.exports=function(t){var e=n.nc;e&&t.setAttribute(\"nonce\",e)}},795:t=>{t.exports=function(t){if(\"undefined\"==typeof document)return{update:function(){},remove:function(){}};var e=t.insertStyleElement(t);return{update:function(n){!function(t,e,n){var r=\"\";n.supports&&(r+=\"@supports (\".concat(n.supports,\") {\")),n.media&&(r+=\"@media \".concat(n.media,\" {\"));var o=void 0!==n.layer;o&&(r+=\"@layer\".concat(n.layer.length>0?\" \".concat(n.layer):\"\",\" {\")),r+=n.css,o&&(r+=\"}\"),n.media&&(r+=\"}\"),n.supports&&(r+=\"}\");var i=n.sourceMap;i&&\"undefined\"!=typeof btoa&&(r+=`\n/*# sourceMappingURL=data:application/json;base64,`.concat(btoa(unescape(encodeURIComponent(JSON.stringify(i)))),\" */\")),e.styleTagTransform(r,t,e.options)}(e,t,n)},remove:function(){!function(t){if(null===t.parentNode)return!1;t.parentNode.removeChild(t)}(e)}}}},589:t=>{t.exports=function(t,e){if(e.styleSheet)e.styleSheet.cssText=t;else{for(;e.firstChild;)e.removeChild(e.firstChild);e.appendChild(document.createTextNode(t))}}}},e={};function n(r){var o=e[r];if(void 0!==o)return o.exports;var i=e[r]={id:r,exports:{}};return t[r](i,i.exports,n),i.exports}n.n=t=>{var e=t&&t.__esModule?()=>t.default:()=>t;return n.d(e,{a:e}),e},n.d=(t,e)=>{for(var r in e)n.o(e,r)&&!n.o(t,r)&&Object.defineProperty(t,r,{enumerable:!0,get:e[r]})},n.o=(t,e)=>Object.prototype.hasOwnProperty.call(t,e),n.nc=void 0,(()=>{const t={randomUUID:\"undefined\"!=typeof crypto&&crypto.randomUUID&&crypto.randomUUID.bind(crypto)};let e;const r=new Uint8Array(16);function o(){if(!e&&(e=\"undefined\"!=typeof crypto&&crypto.getRandomValues&&crypto.getRandomValues.bind(crypto),!e))throw new Error(\"crypto.getRandomValues() not supported. See https://github.com/uuidjs/uuid#getrandomvalues-not-supported\");return e(r)}const i=[];for(let t=0;t<256;++t)i.push((t+256).toString(16).slice(1));function a(t,e=0){return(i[t[e+0]]+i[t[e+1]]+i[t[e+2]]+i[t[e+3]]+\"-\"+i[t[e+4]]+i[t[e+5]]+\"-\"+i[t[e+6]]+i[t[e+7]]+\"-\"+i[t[e+8]]+i[t[e+9]]+\"-\"+i[t[e+10]]+i[t[e+11]]+i[t[e+12]]+i[t[e+13]]+i[t[e+14]]+i[t[e+15]]).toLowerCase()}const c=function(e,n,r){if(t.randomUUID&&!n&&!e)return t.randomUUID();const i=(e=e||{}).random||(e.rng||o)();if(i[6]=15&i[6]|64,i[8]=63&i[8]|128,n){r=r||0;for(let t=0;t<16;++t)n[r+t]=i[t];return n}return a(i)};var s=n(379),l=n.n(s),u=n(795),d=n.n(u),f=n(569),v=n.n(f),h=n(565),p=n.n(h),m=n(216),y=n.n(m),g=n(589),b=n.n(g),w=n(455),x={};x.styleTagTransform=b(),x.setAttributes=p(),x.insert=v().bind(null,\"head\"),x.domAPI=d(),x.insertStyleElement=y();l()(w.Z,x);w.Z&&w.Z.locals&&w.Z.locals;function k(t){return k=\"function\"==typeof Symbol&&\"symbol\"==typeof Symbol.iterator?function(t){return typeof t}:function(t){return t&&\"function\"==typeof Symbol&&t.constructor===Symbol&&t!==Symbol.prototype?\"symbol\":typeof t},k(t)}function L(){L=function(){return e};var t,e={},n=Object.prototype,r=n.hasOwnProperty,o=Object.defineProperty||function(t,e,n){t[e]=n.value},i=\"function\"==typeof Symbol?Symbol:{},a=i.iterator||\"@@iterator\",c=i.asyncIterator||\"@@asyncIterator\",s=i.toStringTag||\"@@toStringTag\";function l(t,e,n){return Object.defineProperty(t,e,{value:n,enumerable:!0,configurable:!0,writable:!0}),t[e]}try{l({},\"\")}catch(t){l=function(t,e,n){return t[e]=n}}function u(t,e,n,r){var i=e&&e.prototype instanceof y?e:y,a=Object.create(i.prototype),c=new T(r||[]);return o(a,\"_invoke\",{value:A(t,n,c)}),a}function d(t,e,n){try{return{type:\"normal\",arg:t.call(e,n)}}catch(t){return{type:\"throw\",arg:t}}}e.wrap=u;var f=\"suspendedStart\",v=\"suspendedYield\",h=\"executing\",p=\"completed\",m={};function y(){}function g(){}function b(){}var w={};l(w,a,(function(){return this}));var x=Object.getPrototypeOf,E=x&&x(x(O([])));E&&E!==n&&r.call(E,a)&&(w=E);var j=b.prototype=y.prototype=Object.create(w);function C(t){[\"next\",\"throw\",\"return\"].forEach((function(e){l(t,e,(function(t){return this._invoke(e,t)}))}))}function S(t,e){function n(o,i,a,c){var s=d(t[o],t,i);if(\"throw\"!==s.type){var l=s.arg,u=l.value;return u&&\"object\"==k(u)&&r.call(u,\"__await\")?e.resolve(u.__await).then((function(t){n(\"next\",t,a,c)}),(function(t){n(\"throw\",t,a,c)})):e.resolve(u).then((function(t){l.value=t,a(l)}),(function(t){return n(\"throw\",t,a,c)}))}c(s.arg)}var i;o(this,\"_invoke\",{value:function(t,r){function o(){return new e((function(e,o){n(t,r,e,o)}))}return i=i?i.then(o,o):o()}})}function A(e,n,r){var o=f;return function(i,a){if(o===h)throw new Error(\"Generator is already running\");if(o===p){if(\"throw\"===i)throw a;return{value:t,done:!0}}for(r.method=i,r.arg=a;;){var c=r.delegate;if(c){var s=I(c,r);if(s){if(s===m)continue;return s}}if(\"next\"===r.method)r.sent=r._sent=r.arg;else if(\"throw\"===r.method){if(o===f)throw o=p,r.arg;r.dispatchException(r.arg)}else\"return\"===r.method&&r.abrupt(\"return\",r.arg);o=h;var l=d(e,n,r);if(\"normal\"===l.type){if(o=r.done?p:v,l.arg===m)continue;return{value:l.arg,done:r.done}}\"throw\"===l.type&&(o=p,r.method=\"throw\",r.arg=l.arg)}}}function I(e,n){var r=n.method,o=e.iterator[r];if(o===t)return n.delegate=null,\"throw\"===r&&e.iterator.return&&(n.method=\"return\",n.arg=t,I(e,n),\"throw\"===n.method)||\"return\"!==r&&(n.method=\"throw\",n.arg=new TypeError(\"The iterator does not provide a '\"+r+\"' method\")),m;var i=d(o,e.iterator,n.arg);if(\"throw\"===i.type)return n.method=\"throw\",n.arg=i.arg,n.delegate=null,m;var a=i.arg;return a?a.done?(n[e.resultName]=a.value,n.next=e.nextLoc,\"return\"!==n.method&&(n.method=\"next\",n.arg=t),n.delegate=null,m):a:(n.method=\"throw\",n.arg=new TypeError(\"iterator result is not an object\"),n.delegate=null,m)}function P(t){var e={tryLoc:t[0]};1 in t&&(e.catchLoc=t[1]),2 in t&&(e.finallyLoc=t[2],e.afterLoc=t[3]),this.tryEntries.push(e)}function Y(t){var e=t.completion||{};e.type=\"normal\",delete e.arg,t.completion=e}function T(t){this.tryEntries=[{tryLoc:\"root\"}],t.forEach(P,this),this.reset(!0)}function O(e){if(e||\"\"===e){var n=e[a];if(n)return n.call(e);if(\"function\"==typeof e.next)return e;if(!isNaN(e.length)){var o=-1,i=function n(){for(;++o<e.length;)if(r.call(e,o))return n.value=e[o],n.done=!1,n;return n.value=t,n.done=!0,n};return i.next=i}}throw new TypeError(k(e)+\" is not iterable\")}return g.prototype=b,o(j,\"constructor\",{value:b,configurable:!0}),o(b,\"constructor\",{value:g,configurable:!0}),g.displayName=l(b,s,\"GeneratorFunction\"),e.isGeneratorFunction=function(t){var e=\"function\"==typeof t&&t.constructor;return!!e&&(e===g||\"GeneratorFunction\"===(e.displayName||e.name))},e.mark=function(t){return Object.setPrototypeOf?Object.setPrototypeOf(t,b):(t.__proto__=b,l(t,s,\"GeneratorFunction\")),t.prototype=Object.create(j),t},e.awrap=function(t){return{__await:t}},C(S.prototype),l(S.prototype,c,(function(){return this})),e.AsyncIterator=S,e.async=function(t,n,r,o,i){void 0===i&&(i=Promise);var a=new S(u(t,n,r,o),i);return e.isGeneratorFunction(n)?a:a.next().then((function(t){return t.done?t.value:a.next()}))},C(j),l(j,s,\"Generator\"),l(j,a,(function(){return this})),l(j,\"toString\",(function(){return\"[object Generator]\"})),e.keys=function(t){var e=Object(t),n=[];for(var r in e)n.push(r);return n.reverse(),function t(){for(;n.length;){var r=n.pop();if(r in e)return t.value=r,t.done=!1,t}return t.done=!0,t}},e.values=O,T.prototype={constructor:T,reset:function(e){if(this.prev=0,this.next=0,this.sent=this._sent=t,this.done=!1,this.delegate=null,this.method=\"next\",this.arg=t,this.tryEntries.forEach(Y),!e)for(var n in this)\"t\"===n.charAt(0)&&r.call(this,n)&&!isNaN(+n.slice(1))&&(this[n]=t)},stop:function(){this.done=!0;var t=this.tryEntries[0].completion;if(\"throw\"===t.type)throw t.arg;return this.rval},dispatchException:function(e){if(this.done)throw e;var n=this;function o(r,o){return c.type=\"throw\",c.arg=e,n.next=r,o&&(n.method=\"next\",n.arg=t),!!o}for(var i=this.tryEntries.length-1;i>=0;--i){var a=this.tryEntries[i],c=a.completion;if(\"root\"===a.tryLoc)return o(\"end\");if(a.tryLoc<=this.prev){var s=r.call(a,\"catchLoc\"),l=r.call(a,\"finallyLoc\");if(s&&l){if(this.prev<a.catchLoc)return o(a.catchLoc,!0);if(this.prev<a.finallyLoc)return o(a.finallyLoc)}else if(s){if(this.prev<a.catchLoc)return o(a.catchLoc,!0)}else{if(!l)throw new Error(\"try statement without catch or finally\");if(this.prev<a.finallyLoc)return o(a.finallyLoc)}}}},abrupt:function(t,e){for(var n=this.tryEntries.length-1;n>=0;--n){var o=this.tryEntries[n];if(o.tryLoc<=this.prev&&r.call(o,\"finallyLoc\")&&this.prev<o.finallyLoc){var i=o;break}}i&&(\"break\"===t||\"continue\"===t)&&i.tryLoc<=e&&e<=i.finallyLoc&&(i=null);var a=i?i.completion:{};return a.type=t,a.arg=e,i?(this.method=\"next\",this.next=i.finallyLoc,m):this.complete(a)},complete:function(t,e){if(\"throw\"===t.type)throw t.arg;return\"break\"===t.type||\"continue\"===t.type?this.next=t.arg:\"return\"===t.type?(this.rval=this.arg=t.arg,this.method=\"return\",this.next=\"end\"):\"normal\"===t.type&&e&&(this.next=e),m},finish:function(t){for(var e=this.tryEntries.length-1;e>=0;--e){var n=this.tryEntries[e];if(n.finallyLoc===t)return this.complete(n.completion,n.afterLoc),Y(n),m}},catch:function(t){for(var e=this.tryEntries.length-1;e>=0;--e){var n=this.tryEntries[e];if(n.tryLoc===t){var r=n.completion;if(\"throw\"===r.type){var o=r.arg;Y(n)}return o}}throw new Error(\"illegal catch attempt\")},delegateYield:function(e,n,r){return this.delegate={iterator:O(e),resultName:n,nextLoc:r},\"next\"===this.method&&(this.arg=t),m}},e}function E(t,e,n,r,o,i,a){try{var c=t[i](a),s=c.value}catch(t){return void n(t)}c.done?e(s):Promise.resolve(s).then(r,o)}var j=\"ZnMtYWRiLWVycg\",C=function(){var t,e=(t=L().mark((function t(){var e,n,r,o,i;return L().wrap((function(t){for(;;)switch(t.prev=t.next){case 0:if(document.body){t.next=3;break}return t.next=3,new Promise((function(t){return document.addEventListener(\"DOMContentLoaded\",t)}));case 3:for(e=[\"YWQ=\",\"YmFubmVyLWFk\",\"YmFubmVyX2Fk\",\"YmFubmVyLWFkLWNvbnRhaW5lcg==\",\"YWQtc2lkZXJhaWw=\",\"c3RpY2t5YWRz\",\"aW1wcnRudC1jbnQ=\"],(n=document.createElement(\"div\")).textContent=Math.random().toString(),n.setAttribute(atob(\"ZGF0YS1mcmVlc3Rhci1hZA==\"),\"123\"),r=0;r<e.length;r++)n.classList.add(atob(e[r]));if(n.style.display=\"block\",document.body.appendChild(n),o=window.getComputedStyle(n),i=null==o?void 0:o.display,n.remove(),\"none\"!==i){t.next=15;break}throw new Error(j);case 15:case\"end\":return t.stop()}}),t)})),function(){var e=this,n=arguments;return new Promise((function(r,o){var i=t.apply(e,n);function a(t){E(i,r,o,a,c,\"next\",t)}function c(t){E(i,r,o,a,c,\"throw\",t)}a(void 0)}))});return function(){return e.apply(this,arguments)}}(),S=function(t){return new Promise((function(e,n){var r=document.createElement(\"script\");try{r.src=t,r.addEventListener(\"load\",(function(){e()})),r.addEventListener(\"error\",(function(){n(j)})),document.head.appendChild(r)}catch(t){n(t)}finally{r.remove()}}))};function A(t){return A=\"function\"==typeof Symbol&&\"symbol\"==typeof Symbol.iterator?function(t){return typeof t}:function(t){return t&&\"function\"==typeof Symbol&&t.constructor===Symbol&&t!==Symbol.prototype?\"symbol\":typeof t},A(t)}function I(){I=function(){return e};var t,e={},n=Object.prototype,r=n.hasOwnProperty,o=Object.defineProperty||function(t,e,n){t[e]=n.value},i=\"function\"==typeof Symbol?Symbol:{},a=i.iterator||\"@@iterator\",c=i.asyncIterator||\"@@asyncIterator\",s=i.toStringTag||\"@@toStringTag\";function l(t,e,n){return Object.defineProperty(t,e,{value:n,enumerable:!0,configurable:!0,writable:!0}),t[e]}try{l({},\"\")}catch(t){l=function(t,e,n){return t[e]=n}}function u(t,e,n,r){var i=e&&e.prototype instanceof y?e:y,a=Object.create(i.prototype),c=new T(r||[]);return o(a,\"_invoke\",{value:C(t,n,c)}),a}function d(t,e,n){try{return{type:\"normal\",arg:t.call(e,n)}}catch(t){return{type:\"throw\",arg:t}}}e.wrap=u;var f=\"suspendedStart\",v=\"suspendedYield\",h=\"executing\",p=\"completed\",m={};function y(){}function g(){}function b(){}var w={};l(w,a,(function(){return this}));var x=Object.getPrototypeOf,k=x&&x(x(O([])));k&&k!==n&&r.call(k,a)&&(w=k);var L=b.prototype=y.prototype=Object.create(w);function E(t){[\"next\",\"throw\",\"return\"].forEach((function(e){l(t,e,(function(t){return this._invoke(e,t)}))}))}function j(t,e){function n(o,i,a,c){var s=d(t[o],t,i);if(\"throw\"!==s.type){var l=s.arg,u=l.value;return u&&\"object\"==A(u)&&r.call(u,\"__await\")?e.resolve(u.__await).then((function(t){n(\"next\",t,a,c)}),(function(t){n(\"throw\",t,a,c)})):e.resolve(u).then((function(t){l.value=t,a(l)}),(function(t){return n(\"throw\",t,a,c)}))}c(s.arg)}var i;o(this,\"_invoke\",{value:function(t,r){function o(){return new e((function(e,o){n(t,r,e,o)}))}return i=i?i.then(o,o):o()}})}function C(e,n,r){var o=f;return function(i,a){if(o===h)throw new Error(\"Generator is already running\");if(o===p){if(\"throw\"===i)throw a;return{value:t,done:!0}}for(r.method=i,r.arg=a;;){var c=r.delegate;if(c){var s=S(c,r);if(s){if(s===m)continue;return s}}if(\"next\"===r.method)r.sent=r._sent=r.arg;else if(\"throw\"===r.method){if(o===f)throw o=p,r.arg;r.dispatchException(r.arg)}else\"return\"===r.method&&r.abrupt(\"return\",r.arg);o=h;var l=d(e,n,r);if(\"normal\"===l.type){if(o=r.done?p:v,l.arg===m)continue;return{value:l.arg,done:r.done}}\"throw\"===l.type&&(o=p,r.method=\"throw\",r.arg=l.arg)}}}function S(e,n){var r=n.method,o=e.iterator[r];if(o===t)return n.delegate=null,\"throw\"===r&&e.iterator.return&&(n.method=\"return\",n.arg=t,S(e,n),\"throw\"===n.method)||\"return\"!==r&&(n.method=\"throw\",n.arg=new TypeError(\"The iterator does not provide a '\"+r+\"' method\")),m;var i=d(o,e.iterator,n.arg);if(\"throw\"===i.type)return n.method=\"throw\",n.arg=i.arg,n.delegate=null,m;var a=i.arg;return a?a.done?(n[e.resultName]=a.value,n.next=e.nextLoc,\"return\"!==n.method&&(n.method=\"next\",n.arg=t),n.delegate=null,m):a:(n.method=\"throw\",n.arg=new TypeError(\"iterator result is not an object\"),n.delegate=null,m)}function P(t){var e={tryLoc:t[0]};1 in t&&(e.catchLoc=t[1]),2 in t&&(e.finallyLoc=t[2],e.afterLoc=t[3]),this.tryEntries.push(e)}function Y(t){var e=t.completion||{};e.type=\"normal\",delete e.arg,t.completion=e}function T(t){this.tryEntries=[{tryLoc:\"root\"}],t.forEach(P,this),this.reset(!0)}function O(e){if(e||\"\"===e){var n=e[a];if(n)return n.call(e);if(\"function\"==typeof e.next)return e;if(!isNaN(e.length)){var o=-1,i=function n(){for(;++o<e.length;)if(r.call(e,o))return n.value=e[o],n.done=!1,n;return n.value=t,n.done=!0,n};return i.next=i}}throw new TypeError(A(e)+\" is not iterable\")}return g.prototype=b,o(L,\"constructor\",{value:b,configurable:!0}),o(b,\"constructor\",{value:g,configurable:!0}),g.displayName=l(b,s,\"GeneratorFunction\"),e.isGeneratorFunction=function(t){var e=\"function\"==typeof t&&t.constructor;return!!e&&(e===g||\"GeneratorFunction\"===(e.displayName||e.name))},e.mark=function(t){return Object.setPrototypeOf?Object.setPrototypeOf(t,b):(t.__proto__=b,l(t,s,\"GeneratorFunction\")),t.prototype=Object.create(L),t},e.awrap=function(t){return{__await:t}},E(j.prototype),l(j.prototype,c,(function(){return this})),e.AsyncIterator=j,e.async=function(t,n,r,o,i){void 0===i&&(i=Promise);var a=new j(u(t,n,r,o),i);return e.isGeneratorFunction(n)?a:a.next().then((function(t){return t.done?t.value:a.next()}))},E(L),l(L,s,\"Generator\"),l(L,a,(function(){return this})),l(L,\"toString\",(function(){return\"[object Generator]\"})),e.keys=function(t){var e=Object(t),n=[];for(var r in e)n.push(r);return n.reverse(),function t(){for(;n.length;){var r=n.pop();if(r in e)return t.value=r,t.done=!1,t}return t.done=!0,t}},e.values=O,T.prototype={constructor:T,reset:function(e){if(this.prev=0,this.next=0,this.sent=this._sent=t,this.done=!1,this.delegate=null,this.method=\"next\",this.arg=t,this.tryEntries.forEach(Y),!e)for(var n in this)\"t\"===n.charAt(0)&&r.call(this,n)&&!isNaN(+n.slice(1))&&(this[n]=t)},stop:function(){this.done=!0;var t=this.tryEntries[0].completion;if(\"throw\"===t.type)throw t.arg;return this.rval},dispatchException:function(e){if(this.done)throw e;var n=this;function o(r,o){return c.type=\"throw\",c.arg=e,n.next=r,o&&(n.method=\"next\",n.arg=t),!!o}for(var i=this.tryEntries.length-1;i>=0;--i){var a=this.tryEntries[i],c=a.completion;if(\"root\"===a.tryLoc)return o(\"end\");if(a.tryLoc<=this.prev){var s=r.call(a,\"catchLoc\"),l=r.call(a,\"finallyLoc\");if(s&&l){if(this.prev<a.catchLoc)return o(a.catchLoc,!0);if(this.prev<a.finallyLoc)return o(a.finallyLoc)}else if(s){if(this.prev<a.catchLoc)return o(a.catchLoc,!0)}else{if(!l)throw new Error(\"try statement without catch or finally\");if(this.prev<a.finallyLoc)return o(a.finallyLoc)}}}},abrupt:function(t,e){for(var n=this.tryEntries.length-1;n>=0;--n){var o=this.tryEntries[n];if(o.tryLoc<=this.prev&&r.call(o,\"finallyLoc\")&&this.prev<o.finallyLoc){var i=o;break}}i&&(\"break\"===t||\"continue\"===t)&&i.tryLoc<=e&&e<=i.finallyLoc&&(i=null);var a=i?i.completion:{};return a.type=t,a.arg=e,i?(this.method=\"next\",this.next=i.finallyLoc,m):this.complete(a)},complete:function(t,e){if(\"throw\"===t.type)throw t.arg;return\"break\"===t.type||\"continue\"===t.type?this.next=t.arg:\"return\"===t.type?(this.rval=this.arg=t.arg,this.method=\"return\",this.next=\"end\"):\"normal\"===t.type&&e&&(this.next=e),m},finish:function(t){for(var e=this.tryEntries.length-1;e>=0;--e){var n=this.tryEntries[e];if(n.finallyLoc===t)return this.complete(n.completion,n.afterLoc),Y(n),m}},catch:function(t){for(var e=this.tryEntries.length-1;e>=0;--e){var n=this.tryEntries[e];if(n.tryLoc===t){var r=n.completion;if(\"throw\"===r.type){var o=r.arg;Y(n)}return o}}throw new Error(\"illegal catch attempt\")},delegateYield:function(e,n,r){return this.delegate={iterator:O(e),resultName:n,nextLoc:r},\"next\"===this.method&&(this.arg=t),m}},e}function P(t,e,n,r,o,i,a){try{var c=t[i](a),s=c.value}catch(t){return void n(t)}c.done?e(s):Promise.resolve(s).then(r,o)}function Y(t){return function(){var e=this,n=arguments;return new Promise((function(r,o){var i=t.apply(e,n);function a(t){P(i,r,o,a,c,\"next\",t)}function c(t){P(i,r,o,a,c,\"throw\",t)}a(void 0)}))}}function T(t,e){for(var n=0;n<e.length;n++){var r=e[n];r.enumerable=r.enumerable||!1,r.configurable=!0,\"value\"in r&&(r.writable=!0),Object.defineProperty(t,(o=r.key,i=void 0,i=function(t,e){if(\"object\"!==A(t)||null===t)return t;var n=t[Symbol.toPrimitive];if(void 0!==n){var r=n.call(t,e||\"default\");if(\"object\"!==A(r))return r;throw new TypeError(\"@@toPrimitive must return a primitive value.\")}return(\"string\"===e?String:Number)(t)}(o,\"string\"),\"symbol\"===A(i)?i:String(i)),r)}var o,i}var O=function(){function t(e){!function(t,e){if(!(t instanceof e))throw new TypeError(\"Cannot call a class as a function\")}(this,t),this.config=null,this.langCode=null,this.languages=this.getUserPreferredLanguages(e)}var e,n,r,o,i,a;return e=t,n=[{key:\"init\",value:(a=Y(I().mark((function t(){return I().wrap((function(t){for(;;)switch(t.prev=t.next){case 0:return t.next=2,this.fetchConfig();case 2:this.config=t.sent,null!==this.config&&(this.langCode=this.getFirstSupportedLanguage(this.languages),this.observe());case 4:case\"end\":return t.stop()}}),t,this)}))),function(){return a.apply(this,arguments)})},{key:\"fetchConfig\",value:(i=Y(I().mark((function t(){var e,n,r,o,i,a;return I().wrap((function(t){for(;;)switch(t.prev=t.next){case 0:return n=(e=[\"Y29uZmlnLmNvbmZpZy1mYWN0b3J5LmNvbQ==\",\"Y29uZmlnLmNvbnRlbnQtc2V0dGluZ3MuY29t\",\"Y29uZmlnLnNpdGUtY29uZmlnLmNvbQ==\",\"Y29uZmlnLmZyZmlndXJlcy5jb20=\"]).length-1,r=Number.isNaN(Number(localStorage.getItem(\"fs.cdi\")))?0:Number(localStorage.getItem(\"fs.cdi\")),o=Number.isNaN(Number(localStorage.getItem(\"fs.cfc\")))?0:Number(localStorage.getItem(\"fs.cfc\")),i=atob(e[r]),a=\"https://\".concat(i,\"/newrepublic-com.json\"),t.prev=6,t.next=9,fetch(a);case 9:return t.abrupt(\"return\",t.sent.json());case 12:return t.prev=12,t.t0=t.catch(6),++o>=3&&(o=0,r++),r>n&&(r=0),t.abrupt(\"return\",null);case 18:return t.prev=18,localStorage.setItem(\"fs.cdi\",r),localStorage.setItem(\"fs.cfc\",o),t.finish(18);case 22:case\"end\":return t.stop()}}),t,null,[[6,12,18,22]])}))),function(){return i.apply(this,arguments)})},{key:\"killScroll\",value:function(t){if(t.isScrollDisabled){this.existingOverflow=document.body.style.overflow,document.body.style.overflow=\"hidden\";var e=window.pageYOffset||document.documentElement.scrollTop,n=window.pageXOffset||document.documentElement.scrollLeft;document.body.style.top=\"-\".concat(e,\"px\"),document.body.style.left=\"-\".concat(n,\"px\"),window.onscroll=function(){window.scrollTo(n,e)}}}},{key:\"reviveScroll\",value:function(){document.body.style.overflow=this.existingOverflow||\"\",window.onscroll=function(){}}},{key:\"getUserPreferredLanguages\",value:function(t){var e=t.languages,n=t.language,r=void 0===e?[n]:e;if(r)return r.map((function(t){var e=t.trim().toLowerCase();if(!e.includes(\"zh\"))return e.split(/-|_/)[0];var n=e.split(/-|_/)[1];return\"zh\"===e||[\"hans\",\"cn\",\"sg\"].includes(n)?\"zh\":[\"hant\",\"hk\",\"mo\",\"tw\"].includes(n)?\"zh-hant\":void 0}))}},{key:\"getFirstSupportedLanguage\",value:function(t){var e=this,n=[\"title\",\"paragraphOne\",\"buttonText\"],r=t.find((function(t){return n.every((function(n){return!!e.config[n][t]}))}));return void 0!==r?r:\"en\"}},{key:\"getLocalizedTextContent\",value:function(t,e){var n,r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],o=t[e];if(void 0===o)throw new Error(\"Config text not found for text key \".concat(e));return r?null!==(n=o[this.langCode])&&void 0!==n?n:o.en:o[this.langCode]}},{key:\"getPixelString\",value:function(t){return\"number\"==typeof t?\"\".concat(t,\"px\"):null}},{key:\"pickContrastingColorValue\",value:function(t,e,n){var r=t.substring(1,7);return.299*parseInt(r.substring(0,2),16)+.587*parseInt(r.substring(2,4),16)+.114*parseInt(r.substring(4,6),16)>=128?e:n}},{key:\"generateOverlay\",value:function(t){var e=this,n=t.siteId,r=t.isCloseEnabled,o=t.dismissDuration,i=t.dismissDurationPv,a=t.logoUrl,c=t.font,s=t.paragraphTwo,l=t.paragraphThree,u=t.closeText,d=t.linkText,f=t.linkUrl,v=t.textColor,h=t.headerTextColor,p=t.buttonTextColor,m=t.headerBgColor,y=t.bgColor,g=t.buttonBgColor,b=t.borderColor,w=t.borderWidth,x=t.borderRadius,k=t.closeButtonColor,L=t.closeTextColor,E=t.linkTextColor,j=t.linkTextDecoration,C=t.linkVisitedTextColor,S=t.hasFsBranding,A=t.disableInstructions,I=document.createElement(\"div\");I.style.setProperty(\"--_19gqudc\",g||\"#40C28A\"),I.style.setProperty(\"--_1rbefr0\",p||\"#000000\"),I.style.setProperty(\"--_1u0adfa\",this.pickContrastingColorValue(y||\"#FFFFFF\",\"white\",\"black\")),E&&I.style.setProperty(\"--_1jiu99w\",E),C&&I.style.setProperty(\"--wa438v\",C),j&&I.style.setProperty(\"--lqlwtr\",j),I.classList.add(\"vjul89\"),I.id=\"_1nntcpy\",I.dir=\"auto\",this.oid=I.id;var P=document.createElement(\"div\");P.classList.add(\"_12nslk\"),y&&(P.style.backgroundColor=y),c&&(P.style.fontFamily=c),v&&(P.style.color=v);var Y=this.getPixelString(x),T=this.getPixelString(w);Y&&(P.style.borderRadius=Y),(b||T)&&(P.style.borderStyle=\"solid\"),b&&(P.style.borderColor=b),T&&(P.style.borderWidth=T);var O=document.createElement(\"header\");if(h&&(O.style.color=h),m){O.style.backgroundColor=m;var H=Y||\"1em\";O.style.borderTopLeftRadius=H,O.style.borderTopRightRadius=H}if(a){var U=document.createElement(\"img\");U.src=a,U.alt=\"Logo\",U.onerror=function(){this.style.display=\"none\"},O.appendChild(U)}var R=document.createElement(\"h2\");R.textContent=this.getLocalizedTextContent(t,\"title\"),O.appendChild(R);var F=document.createElement(\"section\");F.classList.add(\"_1dbtlod\");var B=document.createElement(\"p\");if(B.textContent=this.getLocalizedTextContent(t,\"paragraphOne\"),F.appendChild(B),s&&0!==Object.keys(s).length){var _=document.createElement(\"p\");_.textContent=this.getLocalizedTextContent(t,\"paragraphTwo\"),F.appendChild(_)}if(l&&0!==Object.keys(l).length){var V=document.createElement(\"p\");V.textContent=this.getLocalizedTextContent(t,\"paragraphThree\"),F.appendChild(V)}var q=d&&this.getLocalizedTextContent(t,\"linkText\"),N=f&&this.getLocalizedTextContent(t,\"linkUrl\",!0);if(q&&N){var G=document.createElement(\"div\");G.style.margin=\"0 0 1em\";var z=document.createElement(\"a\");z.classList.add(\"_1sqext2\"),E&&z.classList.add(\"_1jiu99w\"),C&&z.classList.add(\"wa438v\"),j&&z.classList.add(\"lqlwtr\"),z.textContent=q,z.href=N,z.target=\"_blank\",G.appendChild(z),F.appendChild(G)}var Q=document.createElement(\"button\");if(Q.classList.add(\"_19r2sxa\"),Q.tabIndex=0,Q.textContent=this.getLocalizedTextContent(t,\"buttonText\"),g&&(Q.style.backgroundColor=g),p&&(Q.style.color=p),Q.onclick=function(){document.querySelector(\"section._1dbtlod\").classList.add(\"_1aoxcqu\"),document.querySelector(\"section.wybx21\").classList.remove(\"_1aoxcqu\")},F.appendChild(Q),r){var D=function(){I.remove(),e.reviveScroll(),o||i?(sessionStorage.removeItem(\"fs.adb\".concat(n||\"\",\".dis\")),i?e.updateValues(\"p\"):o&&e.updateValues(\"dt\")):sessionStorage.setItem(\"fs.adb\".concat(n||\"\",\".dis\"),\"1\")},W=document.createElement(\"span\");if(W.classList.add(\"_1j92dmv\"),W.innerHTML=\"&times;\",W.tabIndex=0,k&&(W.style.color=k),W.addEventListener(\"click\",D),O.appendChild(W),u&&0!==Object.keys(u).length){var J=document.createElement(\"div\");J.classList.add(\"_1aki86k\");var M=document.createElement(\"p\");M.classList.add(\"yuofri\"),M.textContent=this.getLocalizedTextContent(t,\"closeText\"),L&&(M.style.color=L),M.addEventListener(\"click\",D),J.appendChild(M),F.appendChild(J)}}var Z=document.createElement(\"section\");Z.classList.add(\"wybx21\",\"_1aoxcqu\");var X=document.createElement(\"h4\");X.classList.add(\"_19qz5gz\"),X.textContent=this.getLocalizedTextContent(t,\"instructionsTitle\");var K=document.createElement(\"div\");K.classList.add(\"d1fv9q\");var $=document.createElement(\"ul\");$.classList.add(\"d4g70m\");var tt=document.createElement(\"div\");tt.classList.add(\"_15fsyju\"),A.forEach((function(t,n){var r=document.createElement(\"li\");r.onclick=function(){return function(t){for(var e=document.querySelectorAll(\".d4g70m > li\"),n=document.getElementsByClassName(\"_18x2pnc\"),r=0;r<n.length;r++)e[r].classList.remove(\"_3e6yaf\"),n[r].classList.remove(\"_3e6yaf\");e[t].classList.add(\"_3e6yaf\"),n[t].classList.add(\"_3e6yaf\")}(n)},r.textContent=e.getLocalizedTextContent(t,\"name\",!0),$.appendChild(r);var o=document.createElement(\"ol\");o.classList.add(\"_18x2pnc\"),0===n&&(r.classList.add(\"_3e6yaf\"),o.classList.add(\"_3e6yaf\")),e.getLocalizedTextContent(t,\"steps\").forEach((function(t){var e=document.createElement(\"li\");e.textContent=t,o.appendChild(e)})),tt.appendChild(o)}));var et=this.getLocalizedTextContent(t,\"disclaimerText\"),nt=document.createElement(\"p\");nt.textContent=et,tt.appendChild(nt),K.appendChild($),K.appendChild(tt);var rt=document.createElement(\"button\");if(rt.classList.add(\"_19r2sxa\",\"lppg7q\"),rt.textContent=this.getLocalizedTextContent(t,\"backButtonText\"),g&&(rt.style.backgroundColor=g),p&&(rt.style.color=p),rt.onclick=function(){document.querySelector(\"section.wybx21\").classList.add(\"_1aoxcqu\"),document.querySelector(\"section._1dbtlod\").classList.remove(\"_1aoxcqu\")},Z.appendChild(X),Z.appendChild(K),Z.appendChild(rt),P.appendChild(O),P.appendChild(F),P.appendChild(Z),S){var ot=document.createElement(\"a\");ot.classList.add(\"_1133rtj\"),ot.href=atob(\"aHR0cHM6Ly9mcmVlc3Rhci5jb20vYWQtcHJvZHVjdHMvZGVza3RvcC1tb2JpbGUvZnJlZXN0YXItcmVjb3ZlcmVk\"),ot.target=\"_blank\";var it=document.createElement(\"img\");it.alt=\"Logo\",it.src=this.pickContrastingColorValue(y||\"#FFFFFF\",\"data:image/png;base64,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\",\"data:image/png;base64,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\"),ot.appendChild(it),P.appendChild(ot)}return I.appendChild(P),I}},{key:\"getAndSetOverlay\",value:(o=Y(I().mark((function t(e){var n,r,o,i;return I().wrap((function(t){for(;;)switch(t.prev=t.next){case 0:if(this.post(!0,e),e.dismissDuration||e.dismissDurationPv||\"1\"!==sessionStorage.getItem(\"fs.adb\".concat(e.siteId||\"\",\".dis\"))){t.next=3;break}return t.abrupt(\"return\");case 3:if(n=localStorage.getItem(\"fs.adb\"),r=n&&JSON.parse(n),!e.dismissDurationPv||!r.p||\"number\"!=typeof r.p){t.next=14;break}if(!(e.dismissDurationPv<=r.p+1)){t.next=10;break}this.clearValue(\"p\"),t.next=12;break;case 10:return this.updateValues(\"p\"),t.abrupt(\"return\");case 12:t.next=15;break;case 14:this.clearValue(\"p\");case 15:if(o=parseInt(r.dt,10),!e.dismissDuration||!o){t.next=25;break}if(!(Math.abs((Date.now()-o)/36e5)<e.dismissDuration)){t.next=22;break}return t.abrupt(\"return\");case 22:this.clearValue(\"dt\");case 23:t.next=26;break;case 25:this.clearValue(\"dt\");case 26:if(document.body){t.next=29;break}return t.next=29,new Promise((function(t){return document.addEventListener(\"DOMContentLoaded\",t)}));case 29:if(this.killScroll(e),null===document.querySelector(\"#\".concat(this.oid))){t.next=32;break}return t.abrupt(\"return\");case 32:i=this.generateOverlay(e),document.body.appendChild(i);case 34:case\"end\":return t.stop()}}),t,this)}))),function(t){return o.apply(this,arguments)})},{key:\"getStatus\",value:function(t,e){return!0===e?1:2===t||1===t?2:0}},{key:\"getAndSetData\",value:function(t){var e,n,r,o=localStorage.getItem(\"fs.adb\"),i=o&&JSON.parse(o),a=Date.now();return i?(e=i.i,n=i.ot,r=this.getStatus(i.s,t)):(i={},e=c(),n=a,r=t?1:0),i.i=e,i.s=r,i.ot=n,i.lt=a,localStorage.setItem(\"fs.adb\",JSON.stringify(i)),i}},{key:\"updateValues\",value:function(t){var e=localStorage.getItem(\"fs.adb\"),n=e&&JSON.parse(e);\"p\"===t?(n.p=n.p?n.p+1:1,n.dt&&delete n.dt):\"dt\"===t&&(n.dt=Date.now(),n.p&&delete n.p),localStorage.setItem(\"fs.adb\",JSON.stringify(n))}},{key:\"clearValue\",value:function(t){var e=localStorage.getItem(\"fs.adb\"),n=e&&JSON.parse(e);n[t]&&(delete n[t],localStorage.setItem(\"fs.adb\",JSON.stringify(n)))}},{key:\"post\",value:function(t,e){var n=atob(\"c2l0ZS1jb25maWcuY29t\"),r=e.cDomain||n,o=\"https://\".concat(r,\"/v2/abr\"),i=this.getAndSetData(t),a=e.accountId,c=e.siteId,s=navigator.userAgent||window.navigator.userAgent,l=document.referrer,u=window.location,d={accountId:a,siteId:c,userId:i.i,url:u.href,referalURL:l,userAgent:s,status:function(t){switch(t){case 0:return\"not detected\";case 1:return\"detected\";case 2:return\"recovered\";default:return}}(i.s),returning:i.ot!==i.lt,version:\"1.3.4\"};fetch(o,{method:\"POST\",headers:{\"Content-Type\":\"application/json\",\"X-Client-Geo-Location\":\"{client_region},{client_region_subdivision},{client_city}\"},body:JSON.stringify(d)}).catch((function(){}))}},{key:\"observe\",value:function(){var t=this,e=\"\";new MutationObserver((function(){location.pathname!==e&&(e=location.pathname,t.run())})).observe(document,{subtree:!0,childList:!0})}},{key:\"run\",value:function(){var t=this,e=this.config;setTimeout(Y(I().mark((function n(){return I().wrap((function(n){for(;;)switch(n.prev=n.next){case 0:return n.next=2,C().then((function(){return S(atob(\"aHR0cHM6Ly9hLnB1Yi5uZXR3b3JrL2NvcmUvcHJlYmlkLXVuaXZlcnNhbC1jcmVhdGl2ZS5qcw==\"))})).then((function(){return S(atob(\"aHR0cHM6Ly93d3cuZ29vZ2xldGFnc2VydmljZXMuY29tL3RhZy9qcy9ncHQuanM=\"))})).then((function(){t.post(!1,e)})).catch((function(n){n!==j&&(null==n?void 0:n.message)!==j||t.getAndSetOverlay(e)}));case 2:case\"end\":return n.stop()}}),n)}))),500)}}],n&&T(e.prototype,n),r&&T(e,r),Object.defineProperty(e,\"prototype\",{writable:!1}),t}();window.fsabrActive=!0,new O(window.navigator).init()})()})();\n</script>\n<link rel=\"preconnect\" href=\"https://a.pub.network/\" crossorigin />\n<link rel=\"preconnect\" href=\"https://b.pub.network/\" crossorigin />\n<link rel=\"preconnect\" href=\"https://c.pub.network/\" crossorigin />\n<link rel=\"preconnect\" href=\"https://d.pub.network/\" crossorigin />\n<link rel=\"preconnect\" href=\"https://btloader.com/\" crossorigin />\n<link rel=\"preconnect\" href=\"https://api.btloader.com/\" crossorigin />\n<link rel=\"preconnect\" href=\"https://cdn.confiant-integrations.net\" crossorigin />\n\n<!-- pushly -->\n<script type=\"text/plain\" class=\"optanon-category-C0002\" src=\"https://cdn.p-n.io/pushly-sdk.min.js?domain_key=8hqLFqp7QcxKOOrFz8XLElvAdHx0jIjB5hxy\" async></script>\n<script type=\"text/plain\" class=\"optanon-category-C0002\">\nvar PushlySDK = window.PushlySDK || [];\nfunction pushly() { PushlySDK.push(arguments) }\npushly('load', {\n  domainKey: '8hqLFqp7QcxKOOrFz8XLElvAdHx0jIjB5hxy',\n});\n</script>\n<!-- pushly -->\n\n<!-- Newrelic -->\n<!-- NREUM: (0) -->\n<!-- /Newrelic -->\n\n<!-- LiveConnectTag for advertisers -->\n<script type=\"text/plain\" class=\"optanon-category-C0004\" src=\"//b-code.liadm.com/a-08y3.min.js\" async=\"true\" charset=\"utf-8\"></script>\n<!-- LiveConnectTag for advertisers -->\n\n<!-- Connatix Head -->\n<script type=\"text/plain\" class=\"optanon-category-C0004\">!function(n){if(!window.cnx){window.cnx={},window.cnx.cmd=[];var t=n.createElement('iframe');t.src='javascript:false'; t.display='none',t.onload=function(){var n=t.contentWindow.document,c=n.createElement('script');c.src='//cd.connatix.com/connatix.player.js?cid=f9509d53-804e-427d-a0bc-1204c0a3bcb1&pid=9091ad21-6784-44d1-ae8f-6f780204913e',c.setAttribute('async','1'),c.setAttribute('type','text/javascript'),n.body.appendChild(c)},n.head.appendChild(t)}}(document);</script>\n<script type=\"text/plain\" class=\"optanon-category-C0004\">!function(n){if(!window.cnx){window.cnx={},window.cnx.cmd=[];var t=n.createElement('iframe');t.src='javascript:false'; t.display='none',t.onload=function(){var n=t.contentWindow.document,c=n.createElement('script');c.src='//cd.connatix.com/connatix.player.js?cid=b3c8f044-d05a-4c43-8246-25a0c2b767c8',c.setAttribute('async','1'),c.setAttribute('type','text/javascript'),n.body.appendChild(c)},n.head.appendChild(t)}}(document);</script>\n<!-- End Connatix Head -->\n\n<!-- OutBrain Head -->\n<script type=\"text/plain\" class=\"optanon-category-C0004\">\n{\n  const loadOutbrain = () => {\n    if (window && window.blinkSDK) {\n      clearInterval(loadOutbrainAfterBlink)\n      const outbrainScript = document.getElementById('outbrain-script')\n      outbrainScript.setAttribute(\"src\", outbrainScript.getAttribute(\"data-src\"))  \n    }\n  }\n\n  let loadOutbrainAfterBlink = setInterval(loadOutbrain, 500)\n\n  // Set timeout in case condition for outbrain to load is never met\n  setTimeout(() => clearInterval(loadOutbrainAfterBlink), 6000)\n\n}\n</script>\n<script type=\"text/plain\" id=\"outbrain-script\" class=\"optanon-category-C0004\" data-type=\"lazy\" data-src=\"https://widgets.outbrain.com/outbrain.js\"></script>\n<!-- End OutBrain Head -->\n\n<script type=\"text/plain\" class=\"optanon-category-C0004\">\n    (function(e,t,o,n,p,r,i){e.visitorGlobalObjectAlias=n;e[e.visitorGlobalObjectAlias]=e[e.visitorGlobalObjectAlias]||function(){(e[e.visitorGlobalObjectAlias].q=e[e.visitorGlobalObjectAlias].q||[]).push(arguments)};e[e.visitorGlobalObjectAlias].l=(new Date).getTime();r=t.createElement(\"script\");r.src=o;r.async=true;i=t.getElementsByTagName(\"script\")[0];i.parentNode.insertBefore(r,i)})(window,document,\"https://diffuser-cdn.app-us1.com/diffuser/diffuser.js\",\"vgo\");\n    vgo('setAccount', '612910576');\n    vgo('setTrackByDefault', true);\n\n    vgo('process');\n</script>\n\n    <meta data-react-helmet=\"true\" name=\"viewport\" content=\"width=device-width, initial-scale=1.0\"/><meta data-react-helmet=\"true\" name=\"apple-itunes-app\" content=\"app-id=454525980\"/><meta data-react-helmet=\"true\" name=\"parsey-page\" content=\"{&quot;title&quot;:&quot;How Bill Gates Impeded Global Access to Covid Vaccines&quot;,&quot;link&quot;:&quot;https://newrepublic.com/article/162000/bill-gates-impeded-global-access-covid-vaccines&quot;,&quot;section&quot;:&quot;The Soapbox&quot;,&quot;pub_date&quot;:&quot;2021-04-12T10:00:00.000Z&quot;,&quot;post_id&quot;:&quot;162000&quot;,&quot;authors&quot;:[&quot;Alexander Zaitchik&quot;],&quot;type&quot;:&quot;post&quot;,&quot;tags&quot;:[&quot;The Soapbox&quot;,&quot;Covid-19&quot;,&quot;Bill Gates&quot;,&quot;Bill &amp; Melinda Gates Foundation&quot;,&quot;World Health Organization&quot;,&quot;World Trade Organization&quot;,&quot;coronavirus vaccine&quot;,&quot;pandemic&quot;,&quot;Big Pharma&quot;,&quot;pharmaceutical&quot;,&quot;AstraZeneca&quot;,&quot;GlaxoSmithKline&quot;,&quot;Johnson &amp; Johnson&quot;,&quot;Pfizer&quot;,&quot;HIV&quot;,&quot;AIDS&quot;,&quot;Nelson Mandela&quot;,&quot;South Africa&quot;,&quot;Oxfam&quot;,&quot;Médecins Sans Frontieres&quot;,&quot;-homepage-top&quot;,&quot;The Insecurity Complex&quot;,&quot;Politics&quot;,&quot;-type_article&quot;]}\"/><meta data-react-helmet=\"true\" name=\"parsey-metadata\" content=\"{&quot;thumb_image&quot;:&quot;http://images.newrepublic.com/e3fb4ce1a82048335f394329088873da63f2fed1.jpeg&quot;}\"/><meta data-react-helmet=\"true\" property=\"og:title\" content=\"How Bill Gates Impeded Global Access to Covid Vaccines\"/><meta data-react-helmet=\"true\" property=\"og:description\" content=\"Through his hallowed foundation, the world’s de facto public health czar has been a stalwart defender of monopoly medicine.\"/><meta data-react-helmet=\"true\" name=\"twitter:title\" content=\"How Bill Gates Impeded Global Access to Covid Vaccines\"/><meta data-react-helmet=\"true\" name=\"twitter:description\" content=\"Through his hallowed foundation, the world’s de facto public health czar has been a stalwart defender of monopoly medicine.\"/><meta data-react-helmet=\"true\" name=\"robots\" content=\"max-image-preview:large\"/><meta data-react-helmet=\"true\" name=\"description\" content=\"Through his hallowed foundation, the world’s de facto public health czar has been a stalwart defender of monopoly medicine.\"/><meta data-react-helmet=\"true\" name=\"link\" ref=\"canonical\" href=\"https://newrepublic.com/article/162000/bill-gates-impeded-global-access-covid-vaccines\"/><meta data-react-helmet=\"true\" property=\"og:type\" content=\"article\"/><meta data-react-helmet=\"true\" property=\"og:url\" content=\"https://newrepublic.com/article/162000/bill-gates-impeded-global-access-covid-vaccines\"/><meta data-react-helmet=\"true\" name=\"twitter:card\" content=\"summary_large_image\"/><meta data-react-helmet=\"true\" property=\"article:publisher\" content=\"https://www.facebook.com/newrepublic\"/><meta data-react-helmet=\"true\" property=\"article:published_time\" content=\"2021-04-12\"/><meta data-react-helmet=\"true\" property=\"article:modified_time\" content=\"2023-11-28\"/><meta data-react-helmet=\"true\" name=\"author\" content=\"Alexander Zaitchik\"/><meta data-react-helmet=\"true\" name=\"twitter:creator\" content=\"@null\"/><meta data-react-helmet=\"true\" name=\"twitter:image\" content=\"https://images.newrepublic.com/e3fb4ce1a82048335f394329088873da63f2fed1.jpeg?w=1200&amp;h=600&amp;crop=faces&amp;fit=crop&amp;fm=jpg\"/><meta data-react-helmet=\"true\" property=\"og:image\" content=\"https://images.newrepublic.com/e3fb4ce1a82048335f394329088873da63f2fed1.jpeg?w=1200&amp;h=630&amp;crop=faces&amp;fit=crop&amp;fm=jpg\"/><meta data-react-helmet=\"true\" property=\"og:image:height\" content=\"630\"/><meta data-react-helmet=\"true\" property=\"og:image:width\" content=\"1200\"/><meta data-react-helmet=\"true\" property=\"og:image:type\" content=\"image/jpeg\"/><meta data-react-helmet=\"true\" property=\"article:tag\" content=\"The Soapbox\"/><meta data-react-helmet=\"true\" property=\"article:tag\" content=\"Covid-19\"/><meta data-react-helmet=\"true\" property=\"article:tag\" content=\"Bill Gates\"/><meta data-react-helmet=\"true\" property=\"article:tag\" content=\"Bill &amp; Melinda Gates Foundation\"/><meta data-react-helmet=\"true\" property=\"article:tag\" content=\"World Health Organization\"/><meta data-react-helmet=\"true\" property=\"article:tag\" content=\"World Trade Organization\"/><meta data-react-helmet=\"true\" property=\"article:tag\" content=\"coronavirus vaccine\"/><meta data-react-helmet=\"true\" property=\"article:tag\" content=\"pandemic\"/><meta data-react-helmet=\"true\" property=\"article:tag\" content=\"Big Pharma\"/><meta data-react-helmet=\"true\" property=\"article:tag\" content=\"pharmaceutical\"/><meta data-react-helmet=\"true\" property=\"article:tag\" content=\"AstraZeneca\"/><meta data-react-helmet=\"true\" property=\"article:tag\" content=\"GlaxoSmithKline\"/><meta data-react-helmet=\"true\" property=\"article:tag\" content=\"Johnson &amp; Johnson\"/><meta data-react-helmet=\"true\" property=\"article:tag\" content=\"Pfizer\"/><meta data-react-helmet=\"true\" property=\"article:tag\" content=\"HIV\"/><meta data-react-helmet=\"true\" property=\"article:tag\" content=\"AIDS\"/><meta data-react-helmet=\"true\" property=\"article:tag\" content=\"Nelson Mandela\"/><meta data-react-helmet=\"true\" property=\"article:tag\" content=\"South Africa\"/><meta data-react-helmet=\"true\" property=\"article:tag\" content=\"Oxfam\"/><meta data-react-helmet=\"true\" property=\"article:tag\" content=\"Médecins Sans Frontieres\"/><meta data-react-helmet=\"true\" property=\"article:tag\" content=\"The Insecurity Complex\"/><meta data-react-helmet=\"true\" property=\"article:tag\" content=\"Politics\"/><meta data-react-helmet=\"true\" property=\"og:site_name\" content=\"The New Republic\"/><meta data-react-helmet=\"true\" name=\"twitter:site\" content=\"@newrepublic\"/><meta data-react-helmet=\"true\" property=\"og:locale\" content=\"en_US\"/>\n    <link data-react-helmet=\"true\" rel=\"canonical\" href=\"https://newrepublic.com/article/162000/bill-gates-impeded-global-access-covid-vaccines\"/>\n    <link rel=\"stylesheet\" href=\"//assets.newrepublic.com/assets/newmain-b6f424523e052f7f026c.css\"/>\n  </head>\n  <body>\n    \n<script>\nif (window.document.documentMode) {\n  document.getElementsByTagName( 'html' )[0].classList.add('ie');\n}\n</script>\n\n<style>\ndiv.ie-popup {\n  display:none;\n}\n\nhtml.ie div.ie-popup {\n  display: block;\n  position: fixed;\n}\n\n/* Safari 9.0 */\n@supports (overflow:-webkit-marquee) and (justify-content:inherit) {\n  div.ie-popup {\n    display: block;\n    position: fixed;\n  }\n}\n\ndiv.ie-popup {\n  width: 100%;\n  z-index: 999999;\n  top: 0;\n  left: 0;\n  height: 100%;\n  background: rgba(255, 255, 255, 0.88);\n}\ndiv.ie-popup .ie-popup-inner {\n  display: table;\n  position: absolute;\n  top: calc(50% + 2rem);\n  left: 50%;\n  transform: translate(-50%, -50%);\n  max-width: 740px;\n  max-height: 470px;\n  width: 100%;\n  height: 100%;\n  background: white;\n  box-shadow: 0px 3px 10px #00000029;\n}\ndiv.ie-popup .ie-popup-inner div {\n  font-family: \"Tiempos Fine\", serif;\n  font-weight: 400;\n  font-size: 2.25rem;\n  line-height: 2.4375rem;\n  color: #000;\n  letter-spacing: -0.18px;\n  display: -ms-flexbox;\n  display: flex;\n  -ms-flex-align: center;\n  align-items: center;\n  -ms-flex-pack: center;\n  justify-content: center;\n  height: 100%;\n  padding: 0 35px;\n  text-align: center;\n}\ndiv.ie-popup .ie-popup-inner div a {\n  text-decoration: underline;\n}\n</style>\n\n<div class=\"ie-popup\">\n    <div class=\"ie-popup-inner\">\n      <div><span>You are using an <strong>outdated</strong> browser.<br> Please <a href=\"https://browsehappy.com/\" target=\"_blank\">upgrade your browser</a><br>and improve your visit to our site.</span></div>\n    </div>\n</div>\n<!-- Google Tag Manager (noscript) -->\n<noscript><iframe src=\"https://www.googletagmanager.com/ns.html?id=GTM-NMWSH2N\"\nheight=\"0\" width=\"0\" style=\"display:none;visibility:hidden\"></iframe></noscript>\n<!-- End Google Tag Manager (noscript) -->\n<div id=\"pwPopups\"></div>\n    <div id=\"app-root\"><div><div class=\"main-content\"><div class=\" HomePageNav___featuredArticle\"><a href=\"#main\" class=\"skipNav\">Skip Navigation</a><div class=\"HomePageNav_container politicsVerticalNav    HomePageNavTiny_container transparent\"><nav class=\"HomePageNavTiny politicsVerticalNav undefined\"><span class=\"HomePageNav_siteNav\"><span class=\"HomePageNav_hamburgerContainer\"><button class=\"hamburger hamburger--squeeze false\" type=\"button\" id=\"hmb-btn\" aria-expanded=\"false\" aria-label=\"open additional navigation\"><span aria-hidden=\"true\" class=\"hamburger-box\"><span aria-hidden=\"true\" class=\"hamburger-inner\"></span></span></button><button aria-label=\"search\" class=\"HomePageNav_search\" id=\"srch-btn\" aria-expanded=\"false\"><svg class=\"searchIcon\" width=\"24\" height=\"24\" xmlns=\"http://www.w3.org/2000/svg\" fill-rule=\"evenodd\" clip-rule=\"evenodd\"><path d=\"M15.853 16.56c-1.683 1.517-3.911 2.44-6.353 2.44-5.243 0-9.5-4.257-9.5-9.5s4.257-9.5 9.5-9.5 9.5 4.257 9.5 9.5c0 2.442-.923 4.67-2.44 6.353l7.44 7.44-.707.707-7.44-7.44zm-6.353-15.56c4.691 0 8.5 3.809 8.5 8.5s-3.809 8.5-8.5 8.5-8.5-3.809-8.5-8.5 3.809-8.5 8.5-8.5z\"></path></svg></button></span><a aria-hidden=\"true\" class=\"HomePageNav_logo\" href=\"/\"><svg class=\"verticalNav__monogram\" id=\"Layer_1\" data-name=\"Layer 1\" xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 445.85 160.76\"><title>The New Republic</title><path d=\"M424.4,143.6,381.27,80.38C374.72,84.45,361.85,86,353.72,86c-13.54,0-25.74-3.16-36.8-12v-.23C395.27,80.16,414,60.51,414,35.45,414,7.22,383.53,0,340.18,0h-107V.9c14.29,1.41,42.78,18,54.55,50.48a73.63,73.63,0,0,1,3.12,17.44v35L200.92,0H11.71L0,72.71H.9C17.61,31.16,35.45,1.13,68,1.13V114.7c0,30.48-2.25,41.55-27.09,45.16v.9H224v-.9c-14.63-1.44-44.11-18.8-55.34-52.83a74.9,74.9,0,0,1-2.27-14.41V36.46l106.39,124.3h41.92v-.9c-12.89-2.94-18.25-10.9-19.8-30.24V77.22c0-40.12,5.71-65.32,18.33-73.5a13.69,13.69,0,0,1,7.45-2.14H328c25.52,0,34.78,16,34.78,35.22S353.5,73.16,328,72.7l-13.77-.22,59.84,88.28h71.8v-.9C436.59,157.83,432.07,154.89,424.4,143.6ZM162.31,83.54c0,33.38-4,56.41-12.55,67.92a16.29,16.29,0,0,1-5.6,5.4l-.06,0a12.88,12.88,0,0,1-9.77,1.25,15,15,0,0,1-9.77-6.69q-.48-.72-1-1.41c-5.2-7-5.93-18-5.93-35.35V1.13h.27A40.32,40.32,0,0,1,148.27,15.4l9.55,11.18a18.73,18.73,0,0,1,4.49,12.17Z\"></path></svg></a><div class=\"--visuallyHidden\">The New Republic</div><ul class=\"HomePageNav_verticals\" id=\"list\"><li><a class=\"_gtm_TopNavLink\" href=\"/latest\">LATEST</a></li><svg class=\"NavSlash\" viewBox=\"0 0 9 24\"><line x1=\"1\" y1=\"100%\" x2=\"100%\" y2=\"-3\"></line></svg><li><a class=\"_gtm_TopNavLink\" href=\"/feeds/168326/breaking-news\">BREAKING NEWS</a></li><svg class=\"NavSlash\" viewBox=\"0 0 9 24\"><line x1=\"1\" y1=\"100%\" x2=\"100%\" y2=\"-3\"></line></svg><li><a class=\"_gtm_TopNavLink\" href=\"/politics\">POLITICS</a></li><svg class=\"NavSlash\" viewBox=\"0 0 9 24\"><line x1=\"1\" y1=\"100%\" x2=\"100%\" y2=\"-3\"></line></svg><li><a class=\"_gtm_TopNavLink\" href=\"/climate\">CLIMATE</a></li><svg class=\"NavSlash\" viewBox=\"0 0 9 24\"><line x1=\"1\" y1=\"100%\" x2=\"100%\" y2=\"-3\"></line></svg><li><a class=\"_gtm_TopNavLink\" href=\"/culture\">CULTURE</a></li><svg class=\"NavSlash\" viewBox=\"0 0 9 24\"><line x1=\"1\" y1=\"100%\" x2=\"100%\" y2=\"-3\"></line></svg><li><a class=\"_gtm_TopNavLink\" href=\"/magazine\">MAGAZINE</a></li><svg class=\"NavSlash\" viewBox=\"0 0 9 24\"><line x1=\"1\" y1=\"100%\" x2=\"100%\" y2=\"-3\"></line></svg><li><a style=\"cursor:pointer\" class=\"_gtm_TopNavLink\" role=\"button\">NEWSLETTERS</a></li><svg class=\"NavSlash\" viewBox=\"0 0 9 24\"><line x1=\"1\" y1=\"100%\" x2=\"100%\" y2=\"-3\"></line></svg><li><a class=\"_gtm_TopNavLink\" href=\"/podcasts\">PODCASTS</a></li><svg class=\"NavSlash\" viewBox=\"0 0 9 24\"><line x1=\"1\" y1=\"100%\" x2=\"100%\" y2=\"-3\"></line></svg><li><a class=\"_gtm_TopNavLink\" href=\"/games\">GAMES</a></li></ul></span><a class=\"HomePageNav_wordmark\" href=\"/politics\"><svg class=\"verticalNav__wordmark politics\" id=\"Layer_1\" data-name=\"Layer 1\" xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 619.9142295 230.3949775\"><path class=\"cls-1\" d=\"m146.1846538,69.3659458c0,21.1953125-15.6894531,50.3740234-68.8164062,50.3740234h-31.65625v83.1308594l18.1679688,6.0556641v3.3037109c-17.8925781-2.2021484-35.5097656-2.2021484-53.4023438,0v-3.3037109l18.1679688-6.0556641V34.4059849l-18.1679688-6.0556641v-3.3027344c10.1845703,1.9267578,25.3242188,1.9267578,37.9873047,0h28.0771484c39.6386719,0,69.6425781,15.9648438,69.6425781,44.3183594Zm-18.1669922,2.4765625c0-24.2236328-18.4433594-40.1884766-56.1552734-40.1884766h-26.1503906v81.4794922h28.9033203c35.234375,0,53.4023438-17.3417969,53.4023438-41.2910156Z\"></path><path class=\"cls-1\" d=\"m129.1123882,152.4968052c0-39.3632812,23.1220703-67.9912109,50.6494141-67.9912109,25.5996094,0,46.7958984,23.6728516,46.7958984,61.9355469,0,41.0146484-22.8476562,69.0917969-50.375,69.0917969h-1.1005859c-24.4990234,0-45.9697266-23.6728516-45.9697266-63.0361328Zm82.8554688,9.9091797c0-31.6552734-16.515625-71.2939453-39.9140625-71.2939453-16.515625,0-27.8017578,22.8466797-27.8017578,45.6943359,0,32.4814453,15.9658203,71.2949219,38.8125,71.2949219,14.5898438,0,28.9033203-18.1679688,28.9033203-45.6953125Z\"></path><path class=\"cls-1\" d=\"m267.5674663,208.9264927v3.3037109c-15.4140625-2.2021484-30.5546875-2.2021484-45.9697266,0v-3.3037109l15.4150391-6.0556641V29.7272739l-15.4150391-11.5615234v-3.3037109c9.6347656,2.2021484,18.9941406,2.2021484,28.6279297,0l1.9277344,2.4775391v185.53125l15.4140625,6.0556641Z\"></path><path class=\"cls-1\" d=\"m275.2744976,208.9264927l15.4150391-6.0556641v-105.4277344l-15.4150391-6.0556641v-3.3037109c9.6337891,2.2021484,18.9931641,2.2021484,28.6279297,0l1.9267578,2.4775391v112.3095703l15.4150391,6.0556641v3.3037109c-15.4150391-2.2021484-30.5546875-2.2021484-45.9697266,0v-3.3037109Zm9.0839844-162.1328125c0-7.4326172,4.9541016-12.9375,12.3867188-12.9375s12.3867188,5.5048828,12.3867188,12.9375c0,7.7070312-4.9541016,12.9375-12.3867188,12.9375s-12.3867188-5.2304688-12.3867188-12.9375Z\"></path><path class=\"cls-1\" d=\"m377.9473491,205.0729771v7.1572266h-6.0556641c-24.4990234,0-41.015625-11.5615234-41.015625-37.1611328v-80.1035156h-15.9648438v-5.5058594c13.4882812-7.7070312,23.1220703-22.5712891,28.3525391-45.1435547h2.7529297v43.7675781h32.2060547v6.8818359h-32.2060547v74.5976562c0,21.4707031,11.0107422,35.5097656,27.2509766,35.5097656h4.6796875Z\"></path><path class=\"cls-1\" d=\"m387.3018413,208.9264927l15.4150391-6.0556641v-105.4277344l-15.4150391-6.0556641v-3.3037109c9.6337891,2.2021484,18.9931641,2.2021484,28.6279297,0l1.9267578,2.4775391v112.3095703l15.4150391,6.0556641v3.3037109c-15.4150391-2.2021484-30.5546875-2.2021484-45.9697266,0v-3.3037109Zm9.0839844-162.1328125c0-7.4326172,4.9541016-12.9375,12.3867188-12.9375s12.3867188,5.5048828,12.3867188,12.9375c0,7.7070312-4.9541016,12.9375-12.3867188,12.9375s-12.3867188-5.2304688-12.3867188-12.9375Z\"></path><path class=\"cls-1\" d=\"m430.7930523,151.3952427c0-41.5654297,25.0498047-66.8896484,48.171875-66.8896484,9.6347656,0,22.5722656,4.6796875,33.5830078,11.2861328-2.2021484,8.5332031-2.2021484,17.3417969,0,28.6279297h-3.5791016c-6.3310547-28.3535156-27.8017578-33.3076172-35.7841797-33.3076172-15.4150391,0-26.1503906,20.0947266-26.1503906,51.1992188,0,31.65625,15.1396484,66.0644531,35.5087891,66.0644531,15.1396484,0,26.9765625-15.4150391,32.4824219-23.3974609l6.0556641,2.4775391c-11.5615234,15.6904297-24.2236328,28.0771484-42.1162109,28.0771484-26.9765625,0-48.171875-25.5996094-48.171875-64.1376953Z\"></path><path class=\"cls-1\" d=\"m528.2325054,187.1803989c0-6.3310547,2.2021484-13.2128906,6.6064453-20.3701172l2.2021484.5507812c3.0283203,33.5830078,19.5439453,41.8408203,31.1054688,41.8408203,10.4599609,0,28.3525391-6.6064453,28.3525391-23.9482422,0-16.2412109-16.2412109-22.5722656-33.0322266-30.2792969-12.9375-6.0566406-29.7294922-15.1396484-29.7294922-35.7851562,0-19.2685547,14.8652344-34.6835938,32.7578125-34.6835938,14.0380859,0,27.5263672,9.9091797,33.5820312,14.3134766-.8251953,2.7529297-1.1005859,5.5058594-1.1005859,8.2578125,0,6.0566406,1.3759766,11.8369141,2.4775391,17.6171875h-3.3037109c-5.7802734-19.2685547-18.7177734-33.5820312-33.5830078-33.5820312-12.9375,0-20.9199219,10.7353516-20.9199219,18.9931641,0,15.6904297,28.3525391,26.1503906,43.2167969,33.3076172,14.5898438,7.1572266,22.5722656,14.5888672,22.5722656,31.65625,0,27.8017578-20.9199219,40.4638672-44.0429688,40.4638672-22.5722656,0-37.1611328-11.8359375-37.1611328-28.3525391Z\"></path></svg></a><a class=\"HomePageNav_wordmark--mobile\" href=\"/politics\"><svg class=\"verticalNav__wordmark politics\" id=\"Layer_1\" data-name=\"Layer 1\" xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 619.9142295 230.3949775\"><path class=\"cls-1\" d=\"m146.1846538,69.3659458c0,21.1953125-15.6894531,50.3740234-68.8164062,50.3740234h-31.65625v83.1308594l18.1679688,6.0556641v3.3037109c-17.8925781-2.2021484-35.5097656-2.2021484-53.4023438,0v-3.3037109l18.1679688-6.0556641V34.4059849l-18.1679688-6.0556641v-3.3027344c10.1845703,1.9267578,25.3242188,1.9267578,37.9873047,0h28.0771484c39.6386719,0,69.6425781,15.9648438,69.6425781,44.3183594Zm-18.1669922,2.4765625c0-24.2236328-18.4433594-40.1884766-56.1552734-40.1884766h-26.1503906v81.4794922h28.9033203c35.234375,0,53.4023438-17.3417969,53.4023438-41.2910156Z\"></path><path class=\"cls-1\" d=\"m129.1123882,152.4968052c0-39.3632812,23.1220703-67.9912109,50.6494141-67.9912109,25.5996094,0,46.7958984,23.6728516,46.7958984,61.9355469,0,41.0146484-22.8476562,69.0917969-50.375,69.0917969h-1.1005859c-24.4990234,0-45.9697266-23.6728516-45.9697266-63.0361328Zm82.8554688,9.9091797c0-31.6552734-16.515625-71.2939453-39.9140625-71.2939453-16.515625,0-27.8017578,22.8466797-27.8017578,45.6943359,0,32.4814453,15.9658203,71.2949219,38.8125,71.2949219,14.5898438,0,28.9033203-18.1679688,28.9033203-45.6953125Z\"></path><path class=\"cls-1\" d=\"m267.5674663,208.9264927v3.3037109c-15.4140625-2.2021484-30.5546875-2.2021484-45.9697266,0v-3.3037109l15.4150391-6.0556641V29.7272739l-15.4150391-11.5615234v-3.3037109c9.6347656,2.2021484,18.9941406,2.2021484,28.6279297,0l1.9277344,2.4775391v185.53125l15.4140625,6.0556641Z\"></path><path class=\"cls-1\" d=\"m275.2744976,208.9264927l15.4150391-6.0556641v-105.4277344l-15.4150391-6.0556641v-3.3037109c9.6337891,2.2021484,18.9931641,2.2021484,28.6279297,0l1.9267578,2.4775391v112.3095703l15.4150391,6.0556641v3.3037109c-15.4150391-2.2021484-30.5546875-2.2021484-45.9697266,0v-3.3037109Zm9.0839844-162.1328125c0-7.4326172,4.9541016-12.9375,12.3867188-12.9375s12.3867188,5.5048828,12.3867188,12.9375c0,7.7070312-4.9541016,12.9375-12.3867188,12.9375s-12.3867188-5.2304688-12.3867188-12.9375Z\"></path><path class=\"cls-1\" d=\"m377.9473491,205.0729771v7.1572266h-6.0556641c-24.4990234,0-41.015625-11.5615234-41.015625-37.1611328v-80.1035156h-15.9648438v-5.5058594c13.4882812-7.7070312,23.1220703-22.5712891,28.3525391-45.1435547h2.7529297v43.7675781h32.2060547v6.8818359h-32.2060547v74.5976562c0,21.4707031,11.0107422,35.5097656,27.2509766,35.5097656h4.6796875Z\"></path><path class=\"cls-1\" d=\"m387.3018413,208.9264927l15.4150391-6.0556641v-105.4277344l-15.4150391-6.0556641v-3.3037109c9.6337891,2.2021484,18.9931641,2.2021484,28.6279297,0l1.9267578,2.4775391v112.3095703l15.4150391,6.0556641v3.3037109c-15.4150391-2.2021484-30.5546875-2.2021484-45.9697266,0v-3.3037109Zm9.0839844-162.1328125c0-7.4326172,4.9541016-12.9375,12.3867188-12.9375s12.3867188,5.5048828,12.3867188,12.9375c0,7.7070312-4.9541016,12.9375-12.3867188,12.9375s-12.3867188-5.2304688-12.3867188-12.9375Z\"></path><path class=\"cls-1\" d=\"m430.7930523,151.3952427c0-41.5654297,25.0498047-66.8896484,48.171875-66.8896484,9.6347656,0,22.5722656,4.6796875,33.5830078,11.2861328-2.2021484,8.5332031-2.2021484,17.3417969,0,28.6279297h-3.5791016c-6.3310547-28.3535156-27.8017578-33.3076172-35.7841797-33.3076172-15.4150391,0-26.1503906,20.0947266-26.1503906,51.1992188,0,31.65625,15.1396484,66.0644531,35.5087891,66.0644531,15.1396484,0,26.9765625-15.4150391,32.4824219-23.3974609l6.0556641,2.4775391c-11.5615234,15.6904297-24.2236328,28.0771484-42.1162109,28.0771484-26.9765625,0-48.171875-25.5996094-48.171875-64.1376953Z\"></path><path class=\"cls-1\" d=\"m528.2325054,187.1803989c0-6.3310547,2.2021484-13.2128906,6.6064453-20.3701172l2.2021484.5507812c3.0283203,33.5830078,19.5439453,41.8408203,31.1054688,41.8408203,10.4599609,0,28.3525391-6.6064453,28.3525391-23.9482422,0-16.2412109-16.2412109-22.5722656-33.0322266-30.2792969-12.9375-6.0566406-29.7294922-15.1396484-29.7294922-35.7851562,0-19.2685547,14.8652344-34.6835938,32.7578125-34.6835938,14.0380859,0,27.5263672,9.9091797,33.5820312,14.3134766-.8251953,2.7529297-1.1005859,5.5058594-1.1005859,8.2578125,0,6.0566406,1.3759766,11.8369141,2.4775391,17.6171875h-3.3037109c-5.7802734-19.2685547-18.7177734-33.5820312-33.5830078-33.5820312-12.9375,0-20.9199219,10.7353516-20.9199219,18.9931641,0,15.6904297,28.3525391,26.1503906,43.2167969,33.3076172,14.5898438,7.1572266,22.5722656,14.5888672,22.5722656,31.65625,0,27.8017578-20.9199219,40.4638672-44.0429688,40.4638672-22.5722656,0-37.1611328-11.8359375-37.1611328-28.3525391Z\"></path></svg></a><div class=\"--visuallyHidden\">Politics Homepage</div><ul class=\"HomePageNav_subcategories VerticalNav_subcategoryList\"><li class=\"VerticalNav_subcategory\"><a href=\"/politics/tags/donald-trump\">Trumpworld</a></li><li class=\"VerticalNav_subcategory\"><a href=\"/politics/tags/congress\">Congress</a></li><li class=\"VerticalNav_subcategory\"><a href=\"/politics/tags/supreme-court-watch\">Supreme Court Watch</a></li><li class=\"VerticalNav_subcategory\"><a href=\"/politics/tags/media\">Media</a></li></ul></nav></div></div><main id=\"main\" class=\"ArticlePage article-container longform full politicsVertical opaque \"><article class=\"article full\" itemscope=\"\" itemType=\"http://schema.org/Article\"><div class=\"sticky-wrap\"><div class=\"sticky\"><div class=\"article-social sticky-social\"><a class=\"copy-to-clipboard-link\" role=\"button\" aria-label=\"Copy to clipboard\"><div class=\"copy-text \"><div class=\"icon\"><svg class=\"icon-copy-to-clipboard\" xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 30 30\"><path id=\"Path_3054\" data-name=\"Path 3054\" class=\"cls-1\" d=\"M20.80247,4.644a4.96,4.96,0,0,0-3.533,1.464l-2.4,2.4a7.13815,7.13815,0,0,1,2.507.47l1.384-1.384a2.88995,2.88995,0,0,1,4.087,4.087l-4.867,4.867a2.85318,2.85318,0,0,1-4.557-.641l-1.52,1.52a5.03671,5.03671,0,0,0,.5.61,4.995,4.995,0,0,0,7.065-.001l4.867-4.867a4.992,4.992,0,0,0-3.533-8.525Z\"></path><path id=\"Path_3055\" data-name=\"Path 3055\" class=\"cls-1\" d=\"M9.79445,25.644a4.962,4.962,0,0,0,3.533-1.463l2.4-2.4a7.13287,7.13287,0,0,1-2.506-.47l-1.385,1.384a2.88995,2.88995,0,0,1-4.087-4.087l4.867-4.867a2.85044,2.85044,0,0,1,4.556.641l1.52-1.52a4.87978,4.87978,0,0,0-.5-.609,4.9938,4.9938,0,0,0-7.065,0l-4.867,4.867a4.99151,4.99151,0,0,0,3.534,8.524Z\"></path></svg></div></div></a><a href=\"#\" title=\"Share on Facebook\"><div class=\"icon\"><svg class=\"icon-facebook\" xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 20 20\"><path fill=\"#4267B2\" d=\"M20,0V20H13.84V12.23h2.57l.44-3.06h-3V7.08A1.18,1.18,0,0,1,15,5.9H17V3.08L14.52,3a3.59,3.59,0,0,0-3.83,3.66V9.17H8.11v3.06h2.58V20H0V0Z\"></path></svg></div></a><a href=\"#\" title=\"Share on Twitter\"><div class=\"icon\"><svg class=\"icon-twitter\" version=\"1.1\" viewBox=\"0 0 300 300\" xmlns=\"http://www.w3.org/2000/svg\"><path d=\"M178.57 127.15 290.27 0h-26.46l-97.03 110.38L89.34 0H0l117.13 166.93L0 300.25h26.46l102.4-116.59 81.8 116.59h89.34M36.01 19.54H76.66l187.13 262.13h-40.66\"></path></svg></div></a><a href=\"https://bsky.app/intent/compose?text=How Bill Gates Impeded Global Access to Covid Vaccines https://newrepublic.com/article/162000/bill-gates-impeded-global-access-covid-vaccines via @newrepublic.com\"><div class=\"icon\"><svg class=\"icon-bluesky\" xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 600 530\" width=\"100%\" height=\"100%\"><path d=\"M135.72 44.03C202.216 93.951 273.74 195.17 300 249.49c26.262-54.316 97.782-155.54 164.28-205.46C512.26 8.009 590-19.862 590 68.825c0 17.712-10.155 148.79-16.111 170.07-20.703 73.984-96.144 92.854-163.25 81.433 117.3 19.964 147.14 86.092 82.697 152.22-122.39 125.59-175.91-31.511-189.63-71.766-2.514-7.38-3.69-10.832-3.708-7.896-.017-2.936-1.193.516-3.707 7.896-13.714 40.255-67.233 197.36-189.63 71.766-64.444-66.128-34.605-132.26 82.697-152.22-67.108 11.421-142.55-7.45-163.25-81.433C20.15 217.613 9.997 86.535 9.997 68.825c0-88.687 77.742-60.816 125.72-24.795z\" fill=\"#1185fe\"></path></svg></div></a><a href=\"https://reddit.com/submit?url=https://newrepublic.com/article/162000/bill-gates-impeded-global-access-covid-vaccines&amp;title=How Bill Gates Impeded Global Access to Covid Vaccines\"><div class=\"icon\"><svg class=\"icon-reddit\" xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 20 20\"><path d=\"M12.09 13.41A3.24 3.24 0 0110 14a3.27 3.27 0 01-2.09-.61.28.28 0 00-.38 0 .26.26 0 000 .38 3.84 3.84 0 002.47.77 3.88 3.88 0 002.48-.77.27.27 0 00-.38-.38zM8.75 11a1 1 0 00-2.08 0 1 1 0 001 1 1 1 0 001.08-1z\"></path><path d=\"M10 0a10 10 0 1010 10A10 10 0 0010 0zm5.8 11.33a3.42 3.42 0 010 .44c0 2.25-2.62 4.06-5.84 4.06S4.17 14 4.17 11.77a3.25 3.25 0 010-.44 1.46 1.46 0 011.22-2.66 1.62 1.62 0 01.42.33 7.14 7.14 0 014-1.24l.72-3.49a.31.31 0 01.12-.16.25.25 0 01.19 0l2.43.52a1 1 0 011.39-.47 1 1 0 11-1.5 1L11 4.59l-.7 3.12A7.2 7.2 0 0114.2 9a1.46 1.46 0 111.6 2.38z\"></path><path d=\"M12.29 10a1 1 0 100 2.08 1 1 0 100-2.08z\"></path></svg></div></a><a href=\"https://wa.me/?text=How Bill Gates Impeded Global Access to Covid Vaccines  https://newrepublic.com/article/162000/bill-gates-impeded-global-access-covid-vaccines\"><div class=\"icon\"><svg class=\"icon-whatsapp\" xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 20 20\"><path d=\"M20 10a10 10 0 01-10 10 11 11 0 01-5.51-1.65L.73 19.57 2 15.93A11.37 11.37 0 010 10a10 10 0 0120 0zm-4.13 2a.81.81 0 00-.65-.57l-1.83-.31a.87.87 0 00-.8.3l-.08.12a2 2 0 00-.18.25 2.85 2.85 0 01-.73.81c-.35.11-1 .11-2.69-1.31S7.09 9.23 7.15 8.87A2.6 2.6 0 017.82 8L8 7.79l.09-.08a.85.85 0 00.17-.85L7.67 5.1A.82.82 0 007 4.56a3.31 3.31 0 00-1.37.07 1.38 1.38 0 00-.63.46l-.08.12a1.23 1.23 0 00-.12.26c-.42.92-1.44 4.19 2.61 7.58a7.77 7.77 0 005 2.12 5.25 5.25 0 002.92-.86 1.18 1.18 0 00.22-.17l.13-.11a1.44 1.44 0 00.34-.66 3.31 3.31 0 00-.15-1.37z\"></path></svg></div></a><a href=\"https://threads.net/intent/post?text=How Bill Gates Impeded Global Access to Covid Vaccines https://newrepublic.com/article/162000/bill-gates-impeded-global-access-covid-vaccines via @newrepublic\"><div class=\"icon\"><svg class=\"icon-threads\" aria-label=\"Threads\" viewBox=\"0 0 192 192\" xmlns=\"http://www.w3.org/2000/svg\"><path class=\"x19hqcy\" d=\"M141.537 88.9883C140.71 88.5919 139.87 88.2104 139.019 87.8451C137.537 60.5382 122.616 44.905 97.5619 44.745C97.4484 44.7443 97.3355 44.7443 97.222 44.7443C82.2364 44.7443 69.7731 51.1409 62.102 62.7807L75.881 72.2328C81.6116 63.5383 90.6052 61.6848 97.2286 61.6848C97.3051 61.6848 97.3819 61.6848 97.4576 61.6855C105.707 61.7381 111.932 64.1366 115.961 68.814C118.893 72.2193 120.854 76.925 121.825 82.8638C114.511 81.6207 106.601 81.2385 98.145 81.7233C74.3247 83.0954 59.0111 96.9879 60.0396 116.292C60.5615 126.084 65.4397 134.508 73.775 140.011C80.8224 144.663 89.899 146.938 99.3323 146.423C111.79 145.74 121.563 140.987 128.381 132.296C133.559 125.696 136.834 117.143 138.28 106.366C144.217 109.949 148.617 114.664 151.047 120.332C155.179 129.967 155.42 145.8 142.501 158.708C131.182 170.016 117.576 174.908 97.0135 175.059C74.2042 174.89 56.9538 167.575 45.7381 153.317C35.2355 139.966 29.8077 120.682 29.6052 96C29.8077 71.3178 35.2355 52.0336 45.7381 38.6827C56.9538 24.4249 74.2039 17.11 97.0132 16.9405C119.988 17.1113 137.539 24.4614 149.184 38.788C154.894 45.8136 159.199 54.6488 162.037 64.9503L178.184 60.6422C174.744 47.9622 169.331 37.0357 161.965 27.974C147.036 9.60668 125.202 0.195148 97.0695 0H96.9569C68.8816 0.19447 47.2921 9.6418 32.7883 28.0793C19.8819 44.4864 13.2244 67.3157 13.0007 95.9325L13 96L13.0007 96.0675C13.2244 124.684 19.8819 147.514 32.7883 163.921C47.2921 182.358 68.8816 191.806 96.9569 192H97.0695C122.03 191.827 139.624 185.292 154.118 170.811C173.081 151.866 172.51 128.119 166.26 113.541C161.776 103.087 153.227 94.5962 141.537 88.9883ZM98.4405 129.507C88.0005 130.095 77.1544 125.409 76.6196 115.372C76.2232 107.93 81.9158 99.626 99.0812 98.6368C101.047 98.5234 102.976 98.468 104.871 98.468C111.106 98.468 116.939 99.0737 122.242 100.233C120.264 124.935 108.662 128.946 98.4405 129.507Z\"></path></svg></div></a><a title=\"Share via Email\" href=\"mailto:?subject=&amp;body=How%20Bill%20Gates%20Impeded%20Global%20Access%20to%20Covid%20Vaccines%0A%0Ahttps%3A%2F%2Fnewrepublic.com%2Farticle%2F162000%2Fbill-gates-impeded-global-access-covid-vaccines\"><div class=\"icon\"><svg class=\"icon-email\" xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 20 13.32\"><path d=\"M20 .1V0H0v.1l10 6.5L20 .1z\"></path><path d=\"M10 9.22A1.23 1.23 0 019.35 9L0 3v10.32h20V3l-9.35 6a1.23 1.23 0 01-.65.22z\"></path></svg></div></a><a class=\"print\"><div class=\"icon\"><svg class=\"icon-print\" xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 20 18.31\"><rect x=\"5.44\" width=\"9.12\" height=\"3.66\"></rect><rect x=\"4.51\" y=\"13.35\" width=\"11.02\" height=\"4.96\"></rect><path d=\"M20,15.14H17.62V10.93H2.38v4.21H0V5.75H20ZM17.43,7.38a.94.94,0,1,0,.94.94.94.94,0,0,0-.94-.94Z\"></path></svg></div></a></div></div></div><div class=\"article-header\"><div class=\"templateFullHeader\"><div><div class=\"article-lede nocredit\"><div class=\"LedeImgContainer\"><picture><source srcSet=\"data:image/svg+xml,%3Csvg%20width%3D%221400%22%20height%3D%22934%22%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%3E%3Crect%20width%3D%22100%25%22%20height%3D%22100%25%22%20fill%3D%22%23F5F5F5%22%2F%3E%3C%2Fsvg%3E\" media=\"screen and (min-width: 992px)\" width=\"1400\" data-srcset=\"//images.newrepublic.com/e3fb4ce1a82048335f394329088873da63f2fed1.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=3%3A2&amp;ixlib=react-9.0.3&amp;w=1400&amp;q=65&amp;dpr=1 1x, //images.newrepublic.com/e3fb4ce1a82048335f394329088873da63f2fed1.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=3%3A2&amp;ixlib=react-9.0.3&amp;w=1400&amp;q=65&amp;dpr=2 2x, //images.newrepublic.com/e3fb4ce1a82048335f394329088873da63f2fed1.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=3%3A2&amp;ixlib=react-9.0.3&amp;w=1400&amp;q=65&amp;dpr=3 3x, //images.newrepublic.com/e3fb4ce1a82048335f394329088873da63f2fed1.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=3%3A2&amp;ixlib=react-9.0.3&amp;w=1400&amp;q=65&amp;dpr=4 4x, //images.newrepublic.com/e3fb4ce1a82048335f394329088873da63f2fed1.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=3%3A2&amp;ixlib=react-9.0.3&amp;w=1400&amp;q=65&amp;dpr=5 5x\"/><source srcSet=\"data:image/svg+xml,%3Csvg%20width%3D%221200%22%20height%3D%22800%22%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%3E%3Crect%20width%3D%22100%25%22%20height%3D%22100%25%22%20fill%3D%22%23F5F5F5%22%2F%3E%3C%2Fsvg%3E\" media=\"screen and (min-width: 768px) and (max-width: 991.98px)\" width=\"1200\" data-srcset=\"//images.newrepublic.com/e3fb4ce1a82048335f394329088873da63f2fed1.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=3%3A2&amp;ixlib=react-9.0.3&amp;w=1200&amp;q=65&amp;dpr=1 1x, //images.newrepublic.com/e3fb4ce1a82048335f394329088873da63f2fed1.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=3%3A2&amp;ixlib=react-9.0.3&amp;w=1200&amp;q=65&amp;dpr=2 2x, //images.newrepublic.com/e3fb4ce1a82048335f394329088873da63f2fed1.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=3%3A2&amp;ixlib=react-9.0.3&amp;w=1200&amp;q=65&amp;dpr=3 3x, //images.newrepublic.com/e3fb4ce1a82048335f394329088873da63f2fed1.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=3%3A2&amp;ixlib=react-9.0.3&amp;w=1200&amp;q=65&amp;dpr=4 4x, //images.newrepublic.com/e3fb4ce1a82048335f394329088873da63f2fed1.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=3%3A2&amp;ixlib=react-9.0.3&amp;w=1200&amp;q=65&amp;dpr=5 5x\"/><img src=\"data:image/svg+xml,%3Csvg%20width%3D%221000%22%20height%3D%22667%22%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%3E%3Crect%20width%3D%22100%25%22%20height%3D%22100%25%22%20fill%3D%22%23F5F5F5%22%2F%3E%3C%2Fsvg%3E\" class=\"LedeImg lazyload\" width=\"1000\" data-src=\"//images.newrepublic.com/e3fb4ce1a82048335f394329088873da63f2fed1.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;q=65&amp;w=1000&amp;h=undefined&amp;ar=3%3A2&amp;ixlib=react-9.0.3&amp;w=1000\" data-srcset=\"//images.newrepublic.com/e3fb4ce1a82048335f394329088873da63f2fed1.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=1000&amp;h=undefined&amp;ar=3%3A2&amp;ixlib=react-9.0.3&amp;w=1000&amp;q=65&amp;dpr=1 1x, //images.newrepublic.com/e3fb4ce1a82048335f394329088873da63f2fed1.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=1000&amp;h=undefined&amp;ar=3%3A2&amp;ixlib=react-9.0.3&amp;w=1000&amp;q=65&amp;dpr=2 2x, //images.newrepublic.com/e3fb4ce1a82048335f394329088873da63f2fed1.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=1000&amp;h=undefined&amp;ar=3%3A2&amp;ixlib=react-9.0.3&amp;w=1000&amp;q=65&amp;dpr=3 3x, //images.newrepublic.com/e3fb4ce1a82048335f394329088873da63f2fed1.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=1000&amp;h=undefined&amp;ar=3%3A2&amp;ixlib=react-9.0.3&amp;w=1000&amp;q=65&amp;dpr=4 4x, //images.newrepublic.com/e3fb4ce1a82048335f394329088873da63f2fed1.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=1000&amp;h=undefined&amp;ar=3%3A2&amp;ixlib=react-9.0.3&amp;w=1000&amp;q=65&amp;dpr=5 5x\"/></picture></div></div><div class=\"article-social-wrapper\"><div class=\"article-social clip\"><a class=\"copy-to-clipboard-link\" role=\"button\" aria-label=\"Copy to clipboard\"><div class=\"copy-text \"><div class=\"icon\"><svg class=\"icon-copy-to-clipboard\" xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 30 30\"><path id=\"Path_3054\" data-name=\"Path 3054\" class=\"cls-1\" d=\"M20.80247,4.644a4.96,4.96,0,0,0-3.533,1.464l-2.4,2.4a7.13815,7.13815,0,0,1,2.507.47l1.384-1.384a2.88995,2.88995,0,0,1,4.087,4.087l-4.867,4.867a2.85318,2.85318,0,0,1-4.557-.641l-1.52,1.52a5.03671,5.03671,0,0,0,.5.61,4.995,4.995,0,0,0,7.065-.001l4.867-4.867a4.992,4.992,0,0,0-3.533-8.525Z\"></path><path id=\"Path_3055\" data-name=\"Path 3055\" class=\"cls-1\" d=\"M9.79445,25.644a4.962,4.962,0,0,0,3.533-1.463l2.4-2.4a7.13287,7.13287,0,0,1-2.506-.47l-1.385,1.384a2.88995,2.88995,0,0,1-4.087-4.087l4.867-4.867a2.85044,2.85044,0,0,1,4.556.641l1.52-1.52a4.87978,4.87978,0,0,0-.5-.609,4.9938,4.9938,0,0,0-7.065,0l-4.867,4.867a4.99151,4.99151,0,0,0,3.534,8.524Z\"></path></svg></div></div></a><a href=\"#\" title=\"Share on Facebook\"><div class=\"icon\"><svg class=\"icon-facebook\" xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 20 20\"><path fill=\"#4267B2\" d=\"M20,0V20H13.84V12.23h2.57l.44-3.06h-3V7.08A1.18,1.18,0,0,1,15,5.9H17V3.08L14.52,3a3.59,3.59,0,0,0-3.83,3.66V9.17H8.11v3.06h2.58V20H0V0Z\"></path></svg></div></a><a href=\"#\" title=\"Share on Twitter\"><div class=\"icon\"><svg class=\"icon-twitter\" version=\"1.1\" viewBox=\"0 0 300 300\" xmlns=\"http://www.w3.org/2000/svg\"><path d=\"M178.57 127.15 290.27 0h-26.46l-97.03 110.38L89.34 0H0l117.13 166.93L0 300.25h26.46l102.4-116.59 81.8 116.59h89.34M36.01 19.54H76.66l187.13 262.13h-40.66\"></path></svg></div></a><a href=\"https://bsky.app/intent/compose?text=How Bill Gates Impeded Global Access to Covid Vaccines https://newrepublic.com/article/162000/bill-gates-impeded-global-access-covid-vaccines via @newrepublic.com\"><div class=\"icon\"><svg class=\"icon-bluesky\" xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 600 530\" width=\"100%\" height=\"100%\"><path d=\"M135.72 44.03C202.216 93.951 273.74 195.17 300 249.49c26.262-54.316 97.782-155.54 164.28-205.46C512.26 8.009 590-19.862 590 68.825c0 17.712-10.155 148.79-16.111 170.07-20.703 73.984-96.144 92.854-163.25 81.433 117.3 19.964 147.14 86.092 82.697 152.22-122.39 125.59-175.91-31.511-189.63-71.766-2.514-7.38-3.69-10.832-3.708-7.896-.017-2.936-1.193.516-3.707 7.896-13.714 40.255-67.233 197.36-189.63 71.766-64.444-66.128-34.605-132.26 82.697-152.22-67.108 11.421-142.55-7.45-163.25-81.433C20.15 217.613 9.997 86.535 9.997 68.825c0-88.687 77.742-60.816 125.72-24.795z\" fill=\"#1185fe\"></path></svg></div></a><a href=\"https://reddit.com/submit?url=https://newrepublic.com/article/162000/bill-gates-impeded-global-access-covid-vaccines&amp;title=How Bill Gates Impeded Global Access to Covid Vaccines\"><div class=\"icon\"><svg class=\"icon-reddit\" xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 20 20\"><path d=\"M12.09 13.41A3.24 3.24 0 0110 14a3.27 3.27 0 01-2.09-.61.28.28 0 00-.38 0 .26.26 0 000 .38 3.84 3.84 0 002.47.77 3.88 3.88 0 002.48-.77.27.27 0 00-.38-.38zM8.75 11a1 1 0 00-2.08 0 1 1 0 001 1 1 1 0 001.08-1z\"></path><path d=\"M10 0a10 10 0 1010 10A10 10 0 0010 0zm5.8 11.33a3.42 3.42 0 010 .44c0 2.25-2.62 4.06-5.84 4.06S4.17 14 4.17 11.77a3.25 3.25 0 010-.44 1.46 1.46 0 011.22-2.66 1.62 1.62 0 01.42.33 7.14 7.14 0 014-1.24l.72-3.49a.31.31 0 01.12-.16.25.25 0 01.19 0l2.43.52a1 1 0 011.39-.47 1 1 0 11-1.5 1L11 4.59l-.7 3.12A7.2 7.2 0 0114.2 9a1.46 1.46 0 111.6 2.38z\"></path><path d=\"M12.29 10a1 1 0 100 2.08 1 1 0 100-2.08z\"></path></svg></div></a><a href=\"https://wa.me/?text=How Bill Gates Impeded Global Access to Covid Vaccines  https://newrepublic.com/article/162000/bill-gates-impeded-global-access-covid-vaccines\"><div class=\"icon\"><svg class=\"icon-whatsapp\" xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 20 20\"><path d=\"M20 10a10 10 0 01-10 10 11 11 0 01-5.51-1.65L.73 19.57 2 15.93A11.37 11.37 0 010 10a10 10 0 0120 0zm-4.13 2a.81.81 0 00-.65-.57l-1.83-.31a.87.87 0 00-.8.3l-.08.12a2 2 0 00-.18.25 2.85 2.85 0 01-.73.81c-.35.11-1 .11-2.69-1.31S7.09 9.23 7.15 8.87A2.6 2.6 0 017.82 8L8 7.79l.09-.08a.85.85 0 00.17-.85L7.67 5.1A.82.82 0 007 4.56a3.31 3.31 0 00-1.37.07 1.38 1.38 0 00-.63.46l-.08.12a1.23 1.23 0 00-.12.26c-.42.92-1.44 4.19 2.61 7.58a7.77 7.77 0 005 2.12 5.25 5.25 0 002.92-.86 1.18 1.18 0 00.22-.17l.13-.11a1.44 1.44 0 00.34-.66 3.31 3.31 0 00-.15-1.37z\"></path></svg></div></a><a href=\"https://threads.net/intent/post?text=How Bill Gates Impeded Global Access to Covid Vaccines https://newrepublic.com/article/162000/bill-gates-impeded-global-access-covid-vaccines via @newrepublic\"><div class=\"icon\"><svg class=\"icon-threads\" aria-label=\"Threads\" viewBox=\"0 0 192 192\" xmlns=\"http://www.w3.org/2000/svg\"><path class=\"x19hqcy\" d=\"M141.537 88.9883C140.71 88.5919 139.87 88.2104 139.019 87.8451C137.537 60.5382 122.616 44.905 97.5619 44.745C97.4484 44.7443 97.3355 44.7443 97.222 44.7443C82.2364 44.7443 69.7731 51.1409 62.102 62.7807L75.881 72.2328C81.6116 63.5383 90.6052 61.6848 97.2286 61.6848C97.3051 61.6848 97.3819 61.6848 97.4576 61.6855C105.707 61.7381 111.932 64.1366 115.961 68.814C118.893 72.2193 120.854 76.925 121.825 82.8638C114.511 81.6207 106.601 81.2385 98.145 81.7233C74.3247 83.0954 59.0111 96.9879 60.0396 116.292C60.5615 126.084 65.4397 134.508 73.775 140.011C80.8224 144.663 89.899 146.938 99.3323 146.423C111.79 145.74 121.563 140.987 128.381 132.296C133.559 125.696 136.834 117.143 138.28 106.366C144.217 109.949 148.617 114.664 151.047 120.332C155.179 129.967 155.42 145.8 142.501 158.708C131.182 170.016 117.576 174.908 97.0135 175.059C74.2042 174.89 56.9538 167.575 45.7381 153.317C35.2355 139.966 29.8077 120.682 29.6052 96C29.8077 71.3178 35.2355 52.0336 45.7381 38.6827C56.9538 24.4249 74.2039 17.11 97.0132 16.9405C119.988 17.1113 137.539 24.4614 149.184 38.788C154.894 45.8136 159.199 54.6488 162.037 64.9503L178.184 60.6422C174.744 47.9622 169.331 37.0357 161.965 27.974C147.036 9.60668 125.202 0.195148 97.0695 0H96.9569C68.8816 0.19447 47.2921 9.6418 32.7883 28.0793C19.8819 44.4864 13.2244 67.3157 13.0007 95.9325L13 96L13.0007 96.0675C13.2244 124.684 19.8819 147.514 32.7883 163.921C47.2921 182.358 68.8816 191.806 96.9569 192H97.0695C122.03 191.827 139.624 185.292 154.118 170.811C173.081 151.866 172.51 128.119 166.26 113.541C161.776 103.087 153.227 94.5962 141.537 88.9883ZM98.4405 129.507C88.0005 130.095 77.1544 125.409 76.6196 115.372C76.2232 107.93 81.9158 99.626 99.0812 98.6368C101.047 98.5234 102.976 98.468 104.871 98.468C111.106 98.468 116.939 99.0737 122.242 100.233C120.264 124.935 108.662 128.946 98.4405 129.507Z\"></path></svg></div></a><a title=\"Share via Email\" href=\"mailto:?subject=&amp;body=How%20Bill%20Gates%20Impeded%20Global%20Access%20to%20Covid%20Vaccines%0A%0Ahttps%3A%2F%2Fnewrepublic.com%2Farticle%2F162000%2Fbill-gates-impeded-global-access-covid-vaccines\"><div class=\"icon\"><svg class=\"icon-email\" xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 20 13.32\"><path d=\"M20 .1V0H0v.1l10 6.5L20 .1z\"></path><path d=\"M10 9.22A1.23 1.23 0 019.35 9L0 3v10.32h20V3l-9.35 6a1.23 1.23 0 01-.65.22z\"></path></svg></div></a><a class=\"print\"><div class=\"icon\"><svg class=\"icon-print\" xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 20 18.31\"><rect x=\"5.44\" width=\"9.12\" height=\"3.66\"></rect><rect x=\"4.51\" y=\"13.35\" width=\"11.02\" height=\"4.96\"></rect><path d=\"M20,15.14H17.62V10.93H2.38v4.21H0V5.75H20ZM17.43,7.38a.94.94,0,1,0,.94.94.94.94,0,0,0-.94-.94Z\"></path></svg></div></a></div></div></div><header class=\"article-header-wrap\"><div class=\"article-header-grid\"><div class=\"article-meta\"><span class=\"AuthorList\"><span><span class=\"AuthorList_author\"><span class=\"AuthorList_bylineStyle\"></span><a class=\"Author_anchor\" href=\"/authors/alexander-zaitchik\" title=\"Alexander Zaitchik\">Alexander Zaitchik</a></span><span class=\"AuthorList_comma\"></span></span></span><span class=\"byline-slash\">/</span><div class=\"date-mobile\"><time dateTime=\"2021-04-12T10:00:00.000Z\" itemProp=\"datePublished\" itemscope=\"\" itemType=\"http://schema.org/Date\">April 12, 2021</time></div></div><div class=\"article-title\"><h1 class=\"article-headline\"><span>How Bill Gates Impeded Global Access to Covid Vaccines</span></h1><h2 class=\"article-subhead\"><span>Through his hallowed foundation, the world’s de facto public health czar has been a stalwart defender of monopoly medicine.</span></h2></div><div class=\"article_artist_bylines\">Illustration by Kelsey Dake</div><div class=\"article-social-wrapper\"><div id=\"social_share_inline_top\" class=\"article-social article-social-mobile\"><a class=\"copy-to-clipboard-link\" role=\"button\" aria-label=\"Copy to clipboard\"><div class=\"copy-text \"><div class=\"icon\"><svg class=\"icon-copy-to-clipboard\" xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 30 30\"><path id=\"Path_3054\" data-name=\"Path 3054\" class=\"cls-1\" d=\"M20.80247,4.644a4.96,4.96,0,0,0-3.533,1.464l-2.4,2.4a7.13815,7.13815,0,0,1,2.507.47l1.384-1.384a2.88995,2.88995,0,0,1,4.087,4.087l-4.867,4.867a2.85318,2.85318,0,0,1-4.557-.641l-1.52,1.52a5.03671,5.03671,0,0,0,.5.61,4.995,4.995,0,0,0,7.065-.001l4.867-4.867a4.992,4.992,0,0,0-3.533-8.525Z\"></path><path id=\"Path_3055\" data-name=\"Path 3055\" class=\"cls-1\" d=\"M9.79445,25.644a4.962,4.962,0,0,0,3.533-1.463l2.4-2.4a7.13287,7.13287,0,0,1-2.506-.47l-1.385,1.384a2.88995,2.88995,0,0,1-4.087-4.087l4.867-4.867a2.85044,2.85044,0,0,1,4.556.641l1.52-1.52a4.87978,4.87978,0,0,0-.5-.609,4.9938,4.9938,0,0,0-7.065,0l-4.867,4.867a4.99151,4.99151,0,0,0,3.534,8.524Z\"></path></svg></div></div></a><a href=\"#\" title=\"Share on Facebook\"><div class=\"icon\"><svg class=\"icon-facebook\" xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 20 20\"><path fill=\"#4267B2\" d=\"M20,0V20H13.84V12.23h2.57l.44-3.06h-3V7.08A1.18,1.18,0,0,1,15,5.9H17V3.08L14.52,3a3.59,3.59,0,0,0-3.83,3.66V9.17H8.11v3.06h2.58V20H0V0Z\"></path></svg></div></a><a href=\"#\" title=\"Share on Twitter\"><div class=\"icon\"><svg class=\"icon-twitter\" version=\"1.1\" viewBox=\"0 0 300 300\" xmlns=\"http://www.w3.org/2000/svg\"><path d=\"M178.57 127.15 290.27 0h-26.46l-97.03 110.38L89.34 0H0l117.13 166.93L0 300.25h26.46l102.4-116.59 81.8 116.59h89.34M36.01 19.54H76.66l187.13 262.13h-40.66\"></path></svg></div></a><a href=\"https://bsky.app/intent/compose?text=How Bill Gates Impeded Global Access to Covid Vaccines https://newrepublic.com/article/162000/bill-gates-impeded-global-access-covid-vaccines via @newrepublic.com\"><div class=\"icon\"><svg class=\"icon-bluesky\" xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 600 530\" width=\"100%\" height=\"100%\"><path d=\"M135.72 44.03C202.216 93.951 273.74 195.17 300 249.49c26.262-54.316 97.782-155.54 164.28-205.46C512.26 8.009 590-19.862 590 68.825c0 17.712-10.155 148.79-16.111 170.07-20.703 73.984-96.144 92.854-163.25 81.433 117.3 19.964 147.14 86.092 82.697 152.22-122.39 125.59-175.91-31.511-189.63-71.766-2.514-7.38-3.69-10.832-3.708-7.896-.017-2.936-1.193.516-3.707 7.896-13.714 40.255-67.233 197.36-189.63 71.766-64.444-66.128-34.605-132.26 82.697-152.22-67.108 11.421-142.55-7.45-163.25-81.433C20.15 217.613 9.997 86.535 9.997 68.825c0-88.687 77.742-60.816 125.72-24.795z\" fill=\"#1185fe\"></path></svg></div></a><a href=\"https://reddit.com/submit?url=https://newrepublic.com/article/162000/bill-gates-impeded-global-access-covid-vaccines&amp;title=How Bill Gates Impeded Global Access to Covid Vaccines\"><div class=\"icon\"><svg class=\"icon-reddit\" xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 20 20\"><path d=\"M12.09 13.41A3.24 3.24 0 0110 14a3.27 3.27 0 01-2.09-.61.28.28 0 00-.38 0 .26.26 0 000 .38 3.84 3.84 0 002.47.77 3.88 3.88 0 002.48-.77.27.27 0 00-.38-.38zM8.75 11a1 1 0 00-2.08 0 1 1 0 001 1 1 1 0 001.08-1z\"></path><path d=\"M10 0a10 10 0 1010 10A10 10 0 0010 0zm5.8 11.33a3.42 3.42 0 010 .44c0 2.25-2.62 4.06-5.84 4.06S4.17 14 4.17 11.77a3.25 3.25 0 010-.44 1.46 1.46 0 011.22-2.66 1.62 1.62 0 01.42.33 7.14 7.14 0 014-1.24l.72-3.49a.31.31 0 01.12-.16.25.25 0 01.19 0l2.43.52a1 1 0 011.39-.47 1 1 0 11-1.5 1L11 4.59l-.7 3.12A7.2 7.2 0 0114.2 9a1.46 1.46 0 111.6 2.38z\"></path><path d=\"M12.29 10a1 1 0 100 2.08 1 1 0 100-2.08z\"></path></svg></div></a><a href=\"https://wa.me/?text=How Bill Gates Impeded Global Access to Covid Vaccines  https://newrepublic.com/article/162000/bill-gates-impeded-global-access-covid-vaccines\"><div class=\"icon\"><svg class=\"icon-whatsapp\" xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 20 20\"><path d=\"M20 10a10 10 0 01-10 10 11 11 0 01-5.51-1.65L.73 19.57 2 15.93A11.37 11.37 0 010 10a10 10 0 0120 0zm-4.13 2a.81.81 0 00-.65-.57l-1.83-.31a.87.87 0 00-.8.3l-.08.12a2 2 0 00-.18.25 2.85 2.85 0 01-.73.81c-.35.11-1 .11-2.69-1.31S7.09 9.23 7.15 8.87A2.6 2.6 0 017.82 8L8 7.79l.09-.08a.85.85 0 00.17-.85L7.67 5.1A.82.82 0 007 4.56a3.31 3.31 0 00-1.37.07 1.38 1.38 0 00-.63.46l-.08.12a1.23 1.23 0 00-.12.26c-.42.92-1.44 4.19 2.61 7.58a7.77 7.77 0 005 2.12 5.25 5.25 0 002.92-.86 1.18 1.18 0 00.22-.17l.13-.11a1.44 1.44 0 00.34-.66 3.31 3.31 0 00-.15-1.37z\"></path></svg></div></a><a href=\"https://threads.net/intent/post?text=How Bill Gates Impeded Global Access to Covid Vaccines https://newrepublic.com/article/162000/bill-gates-impeded-global-access-covid-vaccines via @newrepublic\"><div class=\"icon\"><svg class=\"icon-threads\" aria-label=\"Threads\" viewBox=\"0 0 192 192\" xmlns=\"http://www.w3.org/2000/svg\"><path class=\"x19hqcy\" d=\"M141.537 88.9883C140.71 88.5919 139.87 88.2104 139.019 87.8451C137.537 60.5382 122.616 44.905 97.5619 44.745C97.4484 44.7443 97.3355 44.7443 97.222 44.7443C82.2364 44.7443 69.7731 51.1409 62.102 62.7807L75.881 72.2328C81.6116 63.5383 90.6052 61.6848 97.2286 61.6848C97.3051 61.6848 97.3819 61.6848 97.4576 61.6855C105.707 61.7381 111.932 64.1366 115.961 68.814C118.893 72.2193 120.854 76.925 121.825 82.8638C114.511 81.6207 106.601 81.2385 98.145 81.7233C74.3247 83.0954 59.0111 96.9879 60.0396 116.292C60.5615 126.084 65.4397 134.508 73.775 140.011C80.8224 144.663 89.899 146.938 99.3323 146.423C111.79 145.74 121.563 140.987 128.381 132.296C133.559 125.696 136.834 117.143 138.28 106.366C144.217 109.949 148.617 114.664 151.047 120.332C155.179 129.967 155.42 145.8 142.501 158.708C131.182 170.016 117.576 174.908 97.0135 175.059C74.2042 174.89 56.9538 167.575 45.7381 153.317C35.2355 139.966 29.8077 120.682 29.6052 96C29.8077 71.3178 35.2355 52.0336 45.7381 38.6827C56.9538 24.4249 74.2039 17.11 97.0132 16.9405C119.988 17.1113 137.539 24.4614 149.184 38.788C154.894 45.8136 159.199 54.6488 162.037 64.9503L178.184 60.6422C174.744 47.9622 169.331 37.0357 161.965 27.974C147.036 9.60668 125.202 0.195148 97.0695 0H96.9569C68.8816 0.19447 47.2921 9.6418 32.7883 28.0793C19.8819 44.4864 13.2244 67.3157 13.0007 95.9325L13 96L13.0007 96.0675C13.2244 124.684 19.8819 147.514 32.7883 163.921C47.2921 182.358 68.8816 191.806 96.9569 192H97.0695C122.03 191.827 139.624 185.292 154.118 170.811C173.081 151.866 172.51 128.119 166.26 113.541C161.776 103.087 153.227 94.5962 141.537 88.9883ZM98.4405 129.507C88.0005 130.095 77.1544 125.409 76.6196 115.372C76.2232 107.93 81.9158 99.626 99.0812 98.6368C101.047 98.5234 102.976 98.468 104.871 98.468C111.106 98.468 116.939 99.0737 122.242 100.233C120.264 124.935 108.662 128.946 98.4405 129.507Z\"></path></svg></div></a><a title=\"Share via Email\" href=\"mailto:?subject=&amp;body=How%20Bill%20Gates%20Impeded%20Global%20Access%20to%20Covid%20Vaccines%0A%0Ahttps%3A%2F%2Fnewrepublic.com%2Farticle%2F162000%2Fbill-gates-impeded-global-access-covid-vaccines\"><div class=\"icon\"><svg class=\"icon-email\" xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 20 13.32\"><path d=\"M20 .1V0H0v.1l10 6.5L20 .1z\"></path><path d=\"M10 9.22A1.23 1.23 0 019.35 9L0 3v10.32h20V3l-9.35 6a1.23 1.23 0 01-.65.22z\"></path></svg></div></a><a class=\"print\"><div class=\"icon\"><svg class=\"icon-print\" xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 20 18.31\"><rect x=\"5.44\" width=\"9.12\" height=\"3.66\"></rect><rect x=\"4.51\" y=\"13.35\" width=\"11.02\" height=\"4.96\"></rect><path d=\"M20,15.14H17.62V10.93H2.38v4.21H0V5.75H20ZM17.43,7.38a.94.94,0,1,0,.94.94.94.94,0,0,0-.94-.94Z\"></path></svg></div></a></div></div><div class=\"mobile\"></div></div></header></div></div><div class=\"article-body\"><div class=\"article-side-ad article-top\"></div><div class=\"article-body-wrap\"><div class=\"article-text-wrap\"><div class=\"article-text-grid\"><p>On February 11, 2020,<a href=\"https://www.who.int/news-room/events/detail/2020/02/11/default-calendar/global-research-and-innovation-forum-to-mobilize-international-action-in-response-to-the-novel-coronavirus-(2019-ncov)-emergency\" target=\"_blank\" rel=\"nofollow\"> public health and infectious disease experts</a> gathered\nby the hundreds at the World Health Organization’s Geneva mothership. The official pronouncement of a pandemic was still a month out, but the\nagency’s international brain trust knew enough to be worried. Burdened by a\nsense of borrowed time, they spent two days furiously sketching an “R&amp;D Blueprint”\nin preparation for a world upended by the virus then known as 2019-nCoV.</p><div id=\"article-video-ad\"></div><p>The resulting\ndocument summarized&nbsp;the state of coronavirus research and proposed ways to\naccelerate the development of diagnostics, treatments, and vaccines. The underlying\npremise was that the world would unite against the virus. The global research\ncommunity would maintain broad and open channels of communication, since\ncollaboration and information-sharing minimize duplication and accelerate discovery.\nThe group also drew up plans for global comparative trials overseen by the WHO,\nto assess the merits of treatments and vaccines.</p></div></div><div class=\"full-width ad-container\"></div><div class=\"article-text-wrap\"><div class=\"article-text-grid\"><p>One issue not\nmentioned in the paper: intellectual property. If the worst came to pass, the experts\nand researchers assumed cooperation would define the global response, with the\nWHO playing a central role. That pharmaceutical companies and their allied\ngovernments would allow intellectual property concerns to slow things down—from\nresearch and development to manufacturing scale-up—does not seem to have\noccurred to them.</p><p>They were wrong,\nbut they weren’t alone. Battle-scarred veterans of the medicines-access and\nopen-science movements hoped the immensity of the pandemic would override a\nglobal drug system based on proprietary science and market monopolies. By\nMarch, strange but welcome melodies could be heard from unexpected quarters. Anxious\ngovernments spoke of shared interests and global public goods; drug companies pledged\n“precompetitive” and “no-profit” approaches to development and pricing. The\nearly days featured tantalizing glimpses of an open-science,\ncooperative pandemic response. In January and February 2020, a consortium led\nby the National Institutes of Health and the National Institute of Allergy and\nInfectious Diseases collaborated to produce atomic-level maps of the key viral proteins\nin record time. “Work that would normally have taken months—or possibly even\nyears—has been completed in weeks,” noted the editors of <i>Nature.</i><span>&nbsp;</span></p><p>When the <i>Financial\nTimes</i> <a href=\"https://www.ft.com/content/4a3bf282-701c-11ea-9bca-bf503995cd6f\" target=\"_blank\" rel=\"nofollow\">editorial<span class=\"MsoHyperlink\">ized</span></a> on March 27 that “the world has an overwhelming interest in ensuring\n[Covid-19 drugs and vaccines] will be universally and cheaply available,” the\npaper expressed what felt like a hardening conventional wisdom. This sense of\npossibility emboldened forces working to extend the cooperative model. Grounding\ntheir efforts was a plan, started in early March, to create a voluntary intellectual\nproperty pool inside the WHO. Instead of putting up proprietary walls around\nresearch and organizing it as a “race,” public and private actors would collect research\nand associated intellectual property in a global knowledge fund for the duration of the pandemic. The\nidea became real in late May with the launch of the <a href=\"https://www.who.int/initiatives/covid-19-technology-access-pool/what-is-c-tap\" target=\"_blank\" rel=\"nofollow\">WHO Covid-19 Technology\nAccess Pool</a>, or C-TAP.</p></div></div><div class=\"full-width ad-container\"></div><div class=\"article-text-wrap\"><div class=\"article-text-grid\"><p>By then, however, the optimism and sense of\npossibility that defined the early days were long gone. Advocates for pooling\nand open science, who seemed ascendant and even unstoppable that winter, confronted\nthe possibility they’d been outmatched and outmaneuvered by the most powerful\nman in global public health.</p><p>In April, Bill Gates launched a bold bid to manage\nthe world’s scientific response to the pandemic. Gates’s <a href=\"https://www.who.int/initiatives/act-accelerator\" target=\"_blank\" rel=\"nofollow\">Covid-19 ACT-Accelerator</a>\nexpressed a status quo vision for organizing the research, development, manufacture,\nand distribution of treatments and vaccines. Like other Gates-funded\ninstitutions in the public health arena, the Accelerator was a public-private\npartnership based on charity and industry enticements. Crucially, and in\ncontrast to the C-TAP, the Accelerator enshrined Gates’s long-standing commitment\nto respecting exclusive intellectual property claims. Its implicit\narguments—that intellectual property rights won’t present problems for meeting global demand or ensuring\nequitable access, and that they must be protected, even during a pandemic—carried\nthe enormous weight of Gates’s reputation as a wise, beneficent, and prophetic\nleader.<span>&nbsp;</span></p><p>How he’s developed and wielded this influence\nover two decades is one of the more consequential and underappreciated shapers\nof the failed global response to the Covid-19 pandemic. Entering&nbsp;<span>year two, this response has been defined by a zero-sum\nvaccination battle that has left much of the world on the losing side.</span></p></div></div><div class=\"full-width ad-container\"></div><div class=\"article-text-wrap\"><div class=\"article-text-grid\"><div class=\"section-break-wrapper\"><svg version=\"1.1\" x=\"0px\" class=\"svg-section-break\" y=\"0px\" viewBox=\"0 0 124.6 24.3\" style=\"enable-background:new 0 0 124.6 24.3;\" xml:space=\"preserve\">\n      <g>\n      <polygon points=\"61.8,0.5 55.4,11.7 0,11.7 0,12.7 54.8,12.7 48.4,23.8 49.5,23.8 63,0.5 \t\"></polygon>\n      <polygon points=\"69.8,11.7 76.3,0.5 75.1,0.5 61.6,23.8 62.8,23.8 69.2,12.7 124.6,12.7 124.6,11.7 \t\"></polygon>\n      </g>\n    </svg></div><p><span>Gates’s marquee Covid-19 initiative started\nrelatively small. Two days before the WHO declared a pandemic on March 11, 2020, the Bill &amp;\nMelinda Gates Foundation announced something called the Therapeutics\nAccelerator, a joint initiative with Mastercard and the charity group the Wellcome\nTrust to identify and develop potential treatments for the novel coronavirus.\nDoubling as a social branding exercise for a giant of global finance, the\nAccelerator reflected Gates’s familiar formula of corporate philanthropy, which\nhe has applied to everything from malaria to malnutrition. In retrospect, it\nwas a strong indicator that Gates’s dedication to monopoly medicine would\nsurvive the pandemic, even before he and his foundation’s officers began to say\nso publicly.&nbsp;&nbsp;</span><span>&nbsp;</span></p><aside class=\"pullquote pull-right\"><p>Advocates for pooling and open science, who seemed ascendant and even unstoppable early in the crisis, have been outmatched and outmaneuvered by the most powerful man in global public health.</p></aside><p>This was confirmed when a bigger version of\nthe Accelerator was unveiled the following month at the WHO. The Access to Covid-19 Tools\nAccelerator, or ACT-Accelerator, was Gates’s bid to organize the development\nand distribution of everything from therapeutics to testing. The biggest and\nmost consequential arm, COVAX, proposed to subsidize vaccine deals with poor\ncountries through donations by, and sales to, richer ones. The goal was always\nlimited: It aimed to provide vaccines for up to 20 percent of the population in\nlow-to-middle-income countries.<b> </b>After\nthat, governments would largely have to compete on the global market like\neveryone else. It was a partial demand-side solution to what the movement\ncoalescing around a call for a “people’s vaccine” warned would be a dual crisis\nof supply and access, with intellectual property at the center of both.</p><p>Gates not only dismissed these warnings but\nactively sought to undermine all challenges to his authority and the Accelerator’s intellectual property–based charity agenda.<span>&nbsp;</span></p></div></div><div class=\"full-width ad-container\"></div><div class=\"article-text-wrap\"><div class=\"article-text-grid\"><p>“Early on, there was space for Gates to have\na major impact in favor of open models,” says Manuel Martin, a policy adviser to\nthe <a href=\"https://msfaccess.org/\" target=\"_blank\" rel=\"nofollow\">Médecins\nSans Frontières Access Campaign.</a> “But senior people in the\nGates organization very clearly sent out the message: Pooling was unnecessary\nand counterproductive. They dampened early enthusiasm by saying that I.P. is not\nan access barrier in vaccines. That’s just demonstratively false.”</p><p>Few have observed Bill Gates’s devotion to monopoly\nmedicine more closely than James Love, founder and director of <a href=\"https://www.keionline.org/\" target=\"_blank\" rel=\"nofollow\">Knowledge Ecology\nInternational</a>, a Washington, D.C.–based group that studies\nthe broad nexus of federal policy, the pharmaceutical industry, and intellectual\nproperty. Love\nentered the world of global public health policy around the same time Gates did,\nand for two decades has watched him scale its heights while reinforcing the\nsystem responsible for the very problems he claims to be trying to solve. The\nthrough-line for Gates has been his unwavering commitment to drug companies’\nright to exclusive control over medical science and the markets for its\nproducts.</p><p>“Things could have gone either way,” says Love, “but Gates wanted exclusive\nrights maintained. He acted fast to stop the push\nfor sharing the knowledge needed to make the products—the know-how, the data,\nthe cell lines, the tech transfer, the transparency that is\ncritically important in a dozen ways. The pooling approach represented by C-TAP\nincluded all of that. Instead of backing those early discussions, he raced\nahead and signaled support for business-as-usual on intellectual property by announcing\nthe ACT-Accelerator in March.”</p></div></div><div class=\"full-width ad-container\"></div><div class=\"article-text-wrap\"><div class=\"article-text-grid\"><p>One year later, the <a href=\"https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-5-february-2021\" target=\"_blank\" rel=\"nofollow\">ACT-Accelerator has\nfailed</a> to meet its goal of providing discounted vaccines to the “priority\nfifth” of low-income populations. The drug companies and rich nations that had\nso much praise for the initiative a year ago have retreated into bilateral\ndeals that leave little for anybody else. “The low- and middle-income countries are pretty\nmuch on their own, and there’s just not much out there,” said Peter Hotez, dean of the <a href=\"https://www.bcm.edu/education/national-school-of-tropical-medicine\" target=\"_blank\" rel=\"nofollow\">National School of Tropical\nMedicine</a> in Houston. “Despite their best efforts, the Gates model\nand its institutions are still industry-dependent.”</p><p>As of this writing in early April, fewer than <a href=\"https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-press-conference-with-dr-gerd-m%C3%BCller-federal-minister-of-economic-cooperation-and-development-(bmz)-germany---29-march-2021\" target=\"_blank\" rel=\"nofollow\">600 million</a>\nvaccine doses have been administered around the world; three-quarters\nof those in just 10 mostly high-income countries. Close to <a href=\"https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-5-february-2021\" target=\"_blank\" rel=\"nofollow\">130 countries containing 2.5\nbillion people</a> have yet to administer a single dose. The timeline for supplying\npoor and middle-income countries with enough vaccines to achieve herd immunity,\nmeanwhile, has been pushed into 2024. These numbers represent more than the “catastrophic\nmoral failure” the <a href=\"https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-148th-session-of-the-executive-board\" target=\"_blank\" rel=\"nofollow\">director general of the WHO</a> warned about this January. It is\na stark reminder than any policy that obstructs or inhibits vaccine production\nrisks being self-defeating for the rich countries defending exclusive rights and\ngobbling up the lion’s share of available vaccine supplies. The truth repeated\nso often throughout the pandemic—no one is safe until everyone is safe—remains in\nforce. </p><p>This easily anticipated market failure—together\nwith the C-TAP’s failure to launch—led developing countries to open a new front\nagainst intellectual property barriers in the World Trade Organization. Since\nOctober, the WTO’s <a href=\"https://www.wto.org/english/tratop_e/trips_e/trips_e.htm\" target=\"_blank\" rel=\"nofollow\">Trade-Related Aspects of Intellectual Property Rights\nCouncil</a> has been center ring in a dramatic north-south standoff over rights to control\nvaccine knowledge, technology, and markets. More than 100 low- and\nmiddle-income countries support a call by India and South Africa to waive certain\nprovisions related to Covid-19 intellectual property for the duration of the\npandemic. Although Gates and his organization do not have an official position\non the debate roiling the WTO, Gates and his deputies have left little doubt\nabout their opposition to the waiver proposal. Just as he did following the\nrollout of the WHO’s C-TAP, Gates has chosen to stand with the drug companies\nand their government patrons.&nbsp; &nbsp;<span>&nbsp;</span></p></div></div><div class=\"full-width ad-container\"></div><div class=\"article-text-wrap\"><div class=\"article-text-grid\"><div class=\"section-break-wrapper\"><svg version=\"1.1\" x=\"0px\" class=\"svg-section-break\" y=\"0px\" viewBox=\"0 0 124.6 24.3\" style=\"enable-background:new 0 0 124.6 24.3;\" xml:space=\"preserve\">\n      <g>\n      <polygon points=\"61.8,0.5 55.4,11.7 0,11.7 0,12.7 54.8,12.7 48.4,23.8 49.5,23.8 63,0.5 \t\"></polygon>\n      <polygon points=\"69.8,11.7 76.3,0.5 75.1,0.5 61.6,23.8 62.8,23.8 69.2,12.7 124.6,12.7 124.6,11.7 \t\"></polygon>\n      </g>\n    </svg></div><p>Technically housed within the WHO, the ACT-Accelerator\nis a Gates operation, top to bottom. It is designed, managed, and staffed largely\nby Gates organization employees. It embodies Gates’s philanthropic\napproach to widely anticipated problems posed by intellectual property–hoarding companies able to constrain\nglobal production by prioritizing rich countries and inhibiting licensing. Companies\npartnering with COVAX are allowed to set their own tiered prices. They are\nsubject to almost no transparency requirements and to toothless contractual\nnods to “equitable access” that have never been enforced. Crucially,\nthe companies retain exclusive rights to their intellectual property. If they\nstray from the Gates Foundation line on exclusive rights, they are quickly\nbrought to heel. When the director of Oxford’s\nJenner Institute had funny ideas about placing the rights to its COVAX-supported\nvaccine candidate in the public domain, Gates intervened. As reported by <a href=\"https://khn.org/news/rather-than-give-away-its-covid-vaccine-oxford-makes-a-deal-with-drugmaker/\" target=\"_blank\" rel=\"nofollow\">Kaiser\nHealth News,</a> “A few weeks later, Oxford—urged on by the Bill &amp; Melinda\nGates Foundation—reversed course [and] signed an exclusive vaccine deal with\nAstraZeneca that gave the pharmaceutical giant sole rights and no guarantee of\nlow prices.”</p><p>Considering the alternatives being discussed,\nit is no surprise that drug companies have been the most enthusiastic boosters\nof the ACT-Accelerator and COVAX. The speakers at the ACT-Accelerator launch\nceremony in March 2020 included Thomas Cueni, director general of the\nInternational Federation of Pharmaceutical Manufacturers and Associations, who hailed the initiative as a “landmark global\npartnership.” Since vaccines started coming online, the IFPMA’s member\ncompanies have lost interest in the Accelerator, preferring bilateral deals\nwith rich countries. But they continue to benefit from the halo effect of their\nassociation with Gates, which has proved priceless throughout the pandemic,\nespecially at a crucial juncture in its first year.&nbsp;&nbsp;<span>&nbsp;<br></span></p><figure class=\"article-embed image-embed pull-none\" contenteditable=\"false\"><img src=\"//images.newrepublic.com/47a56a02170959126e1be285c141e9b68d2161d7.jpeg?w=1400\" data-serialized=\"{&quot;id&quot;:&quot;56f1b0f9-2c82-44f5-b88a-91f5bf9dabb5&quot;,&quot;hash&quot;:&quot;47a56a02170959126e1be285c141e9b68d2161d7&quot;,&quot;width&quot;:2500,&quot;height&quot;:1640,&quot;format&quot;:&quot;JPEG&quot;,&quot;isAnimated&quot;:false,&quot;baseUrl&quot;:&quot;//images.newrepublic.com/&quot;,&quot;src&quot;:&quot;//images.newrepublic.com/47a56a02170959126e1be285c141e9b68d2161d7.jpeg&quot;,&quot;alt&quot;:null,&quot;meta&quot;:{}}\" width=\"1400\"><figcaption class=\"caption\"><div class=\"caption-text-wrapper\"><span class=\"caption-text\">Bill Gates addresses the opening session of the WHO’s annual assembly in 2005, some six years after he entered the global public health scene as a defender of intellectual property rights during the AIDS crisis.</span></div><span class=\"credit\">JEAN-PIERRE CLATOT/AFP/Getty Images</span></figcaption></figure><p>On May 29, Donald Trump <a href=\"https://www.politico.com/news/2020/05/29/us-withdrawing-from-who-289799\" target=\"_blank\" rel=\"nofollow\">announced</a> U.S.\nwithdrawal from the WHO. This was in response, he said, to China’s “total\ncontrol” of the agency. The drug industry, meanwhile, was displeased with the WHO\nfor entirely different reasons. The same day, the WHO director general had\nunveiled the C-TAP with a “Solidarity Call to Action” for governments and\ncompanies to share all intellectual property related to Covid-19 treatments and\nvaccines. The pharmaceutical companies didn’t attack the initiative directly. Instead,\ntheir global trade association, the IFPMA, preempted the announcement with a livestreamed\nmedia event on the evening of May 28. The event featured the heads of AstraZeneca,\nGlaxoSmithKline, Johnson &amp; Johnson, and Pfizer, and Thomas Cueni.</p></div></div><div class=\"full-width ad-container\"></div><div class=\"article-text-wrap\"><div class=\"article-text-grid\"><p>The\nevening’s sixth participant was the specter of Bill Gates.</p><p>As\nanticipated, the questions submitted by journalists touched repeatedly on the much-anticipated\nlaunch of C-TAP the following morning, as well as related issues of intellectual\nproperty, vaccine access and equity, and debates over the extent and ways intellectual property posed barriers to ramping up production. Mostly, the executives evinced<b> </b>ignorance and surprise over the\nimminent launch of C-TAP; only<a href=\"https://www.ifpma.org/events-2/global-biopharma-ceo-top-execs-covid-19-virtual-press-briefing-28-may/\" target=\"_blank\" rel=\"nofollow\"> Pfizer CEO Albert Bourla</a> openly denounced\nthe pooling of intellectual property as “dangerous” and “nonsense.”</p><p>All of the executives, however, shared a\nplaybook in which they quickly pivoted to affirmations of their support for Bill Gates and the ACT-Accelerator.\nThe association with Gates was\nsubmitted as evidence of industry commitment to equity and access—as well as\nproof of the complete lack of need for overlapping or competing initiatives,\nsuch as the “dangerous” C-TAP.<span>&nbsp;</span></p></div></div><div class=\"full-width ad-container\"></div><div class=\"article-text-wrap\"><div class=\"article-text-grid\"><p>“We already have platforms,” Cueni said during\nthe <a href=\"https://www.ifpma.org/events-2/global-biopharma-ceo-top-execs-covid-19-virtual-press-briefing-28-may/\" target=\"_blank\" rel=\"nofollow\">May 28 event</a>. “The industry is already doing all the right things.”<span>&nbsp;</span></p><p>As the questions about C-TAP and intellectual\nproperty piled up, the industry’s Gates rap started to sound less like a shared\nP.R. script than a broken record. Confronted for the second\ntime about intellectual property, GlaxoSmithKline CEO Emma Walmsley emitted an undigested stream\nof Gatesian word salad. “We are absolutely committed to this question of\naccess,” she stammered, “and deeply welcome the formation of ACT, which is this\nmultilateral organization that is going to be a mechanism with multiple\nstakeholders, whether it’s heads of state or organizations like [the Gates-funded]\nCEPI or the Gates and [<span>the Gates-funded]&nbsp;</span><span>Gavi and others and the WHO, of course, where we actually\nlook at these principles of, uh, access and so clearly, we’re engaged in that\nas well.”&nbsp;&nbsp;</span></p><p>Without the Gates and COVAX associations to lean\non, the stammering would have been much worse. Pfizer’s Albert Bourla seemed to\nrecognize this, at one point interrupting himself to express his industry’s gratitude\nand admiration. “I want to take the opportunity to emphasize the role that Bill\nGates is playing,” he said. He went on to call him “an inspiration for all.”<span>&nbsp;</span></p></div></div><div class=\"full-width ad-container\"></div><div class=\"article-text-wrap\"><div class=\"article-text-grid\"><div class=\"section-break-wrapper\"><svg version=\"1.1\" x=\"0px\" class=\"svg-section-break\" y=\"0px\" viewBox=\"0 0 124.6 24.3\" style=\"enable-background:new 0 0 124.6 24.3;\" xml:space=\"preserve\">\n      <g>\n      <polygon points=\"61.8,0.5 55.4,11.7 0,11.7 0,12.7 54.8,12.7 48.4,23.8 49.5,23.8 63,0.5 \t\"></polygon>\n      <polygon points=\"69.8,11.7 76.3,0.5 75.1,0.5 61.6,23.8 62.8,23.8 69.2,12.7 124.6,12.7 124.6,11.7 \t\"></polygon>\n      </g>\n    </svg></div><p>Gates can hardly\ndisguise his contempt for the growing interest in intellectual property\nbarriers. In recent months, as the debate has shifted from the WHO to the WTO, reporters\nhave drawn testy responses from Gates that harken back to his <a href=\"https://www.nytimes.com/2018/04/14/business/bill-gates-washington-facebook.html\" target=\"_blank\" rel=\"nofollow\">prickly\nperformances</a> before congressional antitrust hearings a quarter-century ago.\nWhen a <i>Fast Company</i> reporter raised\nthe issue in February, she described Gates “raising his voice slightly and\nlaughing in frustration,” before snapping, “It’s irritating that this issue\ncomes up here. This&nbsp;isn’t&nbsp;about&nbsp;IP.”&nbsp;</p><p>In interview after interview, Gates has dismissed his critics on the\nissue—who represent the poor majority of the global population—as spoiled\nchildren demanding ice cream before dinner. “It’s the classic\nsituation in global health, where the advocates all of a sudden want [the\nvaccine] for zero dollars and right away,” <a href=\"https://www.reuters.com/article/us-health-coronavirus-gates/bill-gates-sees-6-8-month-lag-for-poor-countries-to-get-covid-19-shots-idUSKBN29W0QJ\" target=\"_blank\" rel=\"nofollow\">he told</a> Reuters in late January. Gates has larded the insults\nwith comments that equate state-protected and publicly funded monopolies with\nthe “free market.” “North\nKorea doesn’t have that many vaccines, as far as we can tell,” he <a href=\"https://www.nytimes.com/2020/11/23/world/bill-gates-vaccine-coronavirus.html\" target=\"_blank\" rel=\"nofollow\">told <i>The</i> <i>New York Times</i></a> in November. (It is curious that he chose North Korea as an example and not\n<a href=\"https://www.npr.org/sections/goatsandsoda/2021/03/25/980789381/cubas-revolutionary-dream-making-its-own-covid-vaccine\" target=\"_blank\" rel=\"nofollow\">Cuba</a>, a socialist country with an innovative and world-class vaccine\ndevelopment program with multiple Covid-19 vaccine candidates in various stages\nof testing.)</p><p>The\nclosest Gates has come to conceding that vaccine monopolies inhibit production\ncame during a January interview with South Africa’s <i>Mail &amp; Guardian.</i> Asked about the growing\nintellectual property debate, he responded, “At this point, changing the rules\nwouldn’t make any additional vaccines available.”</p></div></div><div class=\"full-width ad-container\"></div><div class=\"article-text-wrap\"><div class=\"article-text-grid\"><aside class=\"pullquote pull-right figure-active\">When a reporter raised\nthe issue in February, she described Gates “raising his voice slightly and\nlaughing in frustration,” before snapping, “It’s irritating that this issue\ncomes up here. This&nbsp;isn’t&nbsp;about&nbsp;IP.”&nbsp;</aside><p>The first\nimplication of “at this point” is that the moment has passed when changing the\nrules could make a difference. This is a false but debatable claim. The same\ncan’t be said for the second implication, which is that nobody could have\npossibly foreseen the current supply crisis. Not only were the obstacles posed\nby intellectual property easily predictable a year ago, there was no lack of people making noise\nabout the urgency of avoiding them. They included much of the global research\ncommunity, major NGOs with long experience in medicines development and access,\nand dozens of current and former world leaders and public health experts. In a <a href=\"https://www.unaids.org/en/resources/presscentre/featurestories/2020/may/20200514_covid19-vaccine-open-letter\" target=\"_blank\" rel=\"nofollow\">May 2020 open letter</a>, more than 140\npolitical and civil society leaders called upon governments and companies to\nbegin pooling their intellectual property. “Now is&nbsp;<em>not</em><i>&nbsp;</i>the time … to leave this massive and moral task to market\nforces,” they wrote.&nbsp;&nbsp;</p><p>Bill Gates’s position on intellectual property was consistent\nwith a lifelong ideological commitment to knowledge\nmonopolies, forged during a vengeful teenage crusade against the open-source\nprogramming culture of the 1970s. As it happens, a novel use of one category of\nintellectual property—copyright, applied to computer code—made Gates the\nrichest man in the world for most of two decades beginning in 1995. That same\nyear, the WTO went into effect, chaining the developing\nworld to intellectual property rules written by a handful of executives from\nthe U.S. pharmaceutical, entertainment, and software industries.&nbsp; &nbsp;</p><div class=\"section-break-wrapper\"><svg version=\"1.1\" x=\"0px\" class=\"svg-section-break\" y=\"0px\" viewBox=\"0 0 124.6 24.3\" style=\"enable-background:new 0 0 124.6 24.3;\" xml:space=\"preserve\">\n      <g>\n      <polygon points=\"61.8,0.5 55.4,11.7 0,11.7 0,12.7 54.8,12.7 48.4,23.8 49.5,23.8 63,0.5 \t\"></polygon>\n      <polygon points=\"69.8,11.7 76.3,0.5 75.1,0.5 61.6,23.8 62.8,23.8 69.2,12.7 124.6,12.7 124.6,11.7 \t\"></polygon>\n      </g>\n    </svg></div><p>By 1999, Bill Gates was in his final year as\nCEO of Microsoft, focused on defending the company he founded from antitrust\nsuits on two continents. As his business reputation suffered high-profile\nbeatings from U.S. and European regulators, he was in the process of moving on\nto his second act: the formation of the Bill &amp; Melinda Gates Foundation, which\ncommenced his unlikely rise to the commanding apex of global public health\npolicy. His debut in that role occurred during the contentious fifty-second General\nHealth Assembly in May 1999.</p></div></div><div class=\"full-width ad-container\"></div><div class=\"article-text-wrap\"><div class=\"article-text-grid\"><p>It was the height of the battle to bring\ngeneric AIDS drugs to the developing world. The central front was South Africa,\nwhere the HIV rate at the time was estimated as high as 22 percent and threatened\nto decimate an entire generation. In December 1997, the Mandela government\npassed a law giving the health ministry powers to produce, purchase, and import\nlow-cost drugs, including unbranded versions of combination therapies priced by\nWestern drug companies at $10,000 and more. In response, 39 drug multinationals\nfiled suit against South Africa alleging\nviolations of the country’s constitution and its obligations under the WTO’s\nAgreement on Trade-Related Aspects of Intellectual Property Rights, or TRIPS. The\nindustry suit was backed by the diplomatic muscle of the Clinton\nadministration, which tasked Al Gore with applying pressure. In his 2012 documentary <i><a href=\"https://www.rottentomatoes.com/m/fire_in_the_blood\" target=\"_blank\" rel=\"nofollow\">Fire in the Blood</a>,</i> Dylan Mohan Gray notes it took Washington 40 years to\nthreaten apartheid South Africa with sanctions and less than four to threaten\nthe post-apartheid Mandela government over AIDS drugs.&nbsp;</p><p>Though South\nAfrica barely registered&nbsp;as a market for the drug companies, the\nappearance of cheap generics produced in violation of patents anywhere was a\nthreat to monopoly pricing everywhere, according to the drug industry’s version\nof Cold War “domino theory.” Allowing poor nations to “free ride” on Western\nscience and build parallel drug economies would eventually cause problems\ncloser to home, where the industry spent billions of dollars on a propaganda\noperation to control the narrative around drug prices and keep the lid on\npublic discontent. The companies suing Mandela had devised TRIPS as a long-term\nstrategic response to the south-based generics industry that arose in the 1960s.\nThey had come too far to be set back by the needs of a pandemic in sub-Saharan Africa.\nU.S. and industry officials paired old standby arguments about patents driving\ninnovation with claims that Africans posed a public health menace because they couldn’t\nkeep time: Since they could not be relied on to take their medicines on a\nschedule, giving Africans access to the drugs would allow for the emergence of\ndrug-resistant HIV variants, according to industry and its government and media\nallies.*<span class=\"MsoFootnoteReference\"><span class=\"MsoFootnoteReference\"><br></span></span></p><p>In Geneva, the lawsuit\nwas reflected in a battle at the WHO, which was divided along a north-south\nfault line: on one side, the home countries of the Western drug companies; on\nthe other, a coalition of 134 developing countries (known collectively as the Group\nof 77, or G77) and a rising “third force” of civil society groups led by Médecins Sans Frontières and Oxfam. The point\nof conflict was a <a href=\"https://twn.my/title/twr120d.htm\" target=\"_blank\" rel=\"nofollow\">WHO resolution that called on</a> member states “to ensure\nequitable access to essential drugs; to ensure that public health interests are\nparamount in pharmaceutical and health policies; [and] to explore and review\ntheir options under relevant international agreements, including\ntrade&nbsp;agreements, to safeguard access to essential drugs.”<br></p></div></div><div class=\"full-width ad-container\"></div><div class=\"article-text-wrap\"><div class=\"article-text-grid\"><p><span>Western countries\nsaw the resolution as a threat to the recent conquest of monopoly medicine,\nachieved four years earlier with the establishment of the WTO. The industry\ngrew increasingly helpless, however, as global public opinion and WHO\nmember-state sentiment shifted in favor of the resolution and against the South\nAfrica lawsuit. In the weeks leading up to the assembly, the companies and\ntheir parent embassies floundered as they sought to turn the tide. Their\ngrowing anxiety is captured in a series of leaked cables sent to Washington by the U.S. ambassador in Geneva, George Moose, that April and May. In a diplomatic telegram dated\nApril 20, Moose expressed alarm over the growing number of WHO delegations\nmaking</span></p><blockquote><p><i>STATEMENTS THAT PUBLIC HEALTH SHOULD HAVE PRIMACY OVER COMMERCIAL\nINTERESTS UNDER WTO TRADE AGREEMENTS SUCH AS THE TRIPS (TRADE-RELATED ASPECTS\nOF INTELLECTUAL PROPERTY RIGHTS) … THEREBY POTENTIALLY UNDERMINING INTELLECTUAL\nPROPERTY RIGHTS (IPR).</i></p></blockquote><p><i>&nbsp;<br></i><span>Moose was concerned that drug companies were\nnot helping their own cause and seemed incapable of doing anything but parrot\nold talking points about intellectual property as the driver of innovation. The\npharmaceutical industry, Moose wrote,</span><span>&nbsp;</span></p><blockquote><p><i>SHOULD BE CARRYING MORE OF ITS OWN WATER ON THIS ISSUE, ESPECIALLY IN\nDEVELOPING COUNTRIES, AND NOT SOLELY DEPEND ON THE ARGUMENT THAT IPR PROTECTS\nPROFITS THAT THEN ARE USED FOR DEVELOPMENT OF NEW DRUGS IN THE FUTURE. NOT 10\nYEARS FROM NOW. THE SOUTH AFRICANS AND OTHERS ARE MOSTLY CONCERNED ABOUT\nAVAILABILITY OF DRUGS NOW. PROBLEMS RELATED TO LOCAL AVAILABILITY AND PRICING\nOF DRUGS THAT ARE UNRELATED TO TRIPS WILL UNDOUBTABLY REQUIRE FURTHER\nDISCUSSION. </i></p></blockquote><p><span>Over the course of weeks, a picture emerges from Moose’s\naccounts of a pharmaceutical industry against the ropes, punch drunk and out of\nideas. In the U.S. ambassador’s view, the problem wasn’t moral bankruptcy so\nmuch as incompetence. “</span><i>RECOMMEND THE USG PUSH THE\nPHARMACEUTICAL INDUSTRY TO ARGUE ITS POINTS MORE CONVINCINGLY IN DEVELOPING\nCOUNTRIES</i><span>,” the exasperated ambassador wrote. “</span><i>AND\nESPECIALLY DEAL WITH THEIR CONCERNS ABOUT LOCAL DRUG AVAILABILITY AND PRICING</i><span>.”</span></p></div></div><div class=\"full-width ad-container\"></div><div class=\"article-text-wrap\"><div class=\"article-text-grid\"><p>Following the raucous buzz saw of the 1999 WHO Assembly, the\ndrug companies would make a humiliating climbdown from their scandalous lawsuit\nin South Africa, reduced to what <i>The Washington Post</i> <a href=\"https://www.washingtonpost.com/archive/politics/2000/12/28/a-turning-point-that-left-millions-behind/afe238d9-49a6-4b03-bfff-2ba83c0c4cd7/\" target=\"_blank\" rel=\"nofollow\">called</a> “close to pariah\nstatus.”&nbsp;&nbsp;</p><p>At the same time, the industry was richer than ever. The\nClinton administration had approved a long <a href=\"http://www.ruf.rice.edu/~neal/temp/ST%20Policy/index/PCAST%20Reports/PCAST%20Teaming%20with%20Life%20Investing%20in%20Science.pdf\" target=\"_blank\" rel=\"nofollow\">Big Pharma wish list</a>, from broadening the\navenues for privatizing government-funded science to opening the age of direct\nmarketing of prescription drugs. The corresponding profits went to reinforce already\nhistorically rich D.C. and Geneva lobbying operations. And yet, for all their combined\nmight, the companies were incapable of producing a mask resembling a credible\nhuman face. A global activist movement continued to gather public opinion on\nits side and chip away at the legitimacy of the monopoly model that underlay the\nindustry’s enormous power. By every nonfinancial measure, it was an industry\nin distress. To borrow a phrase from a future Bill Gates production, you might\nsay it was waiting for its Superman.**<span class=\"MsoFootnoteReference\"><span class=\"MsoFootnoteReference\"><br></span></span></p><figure class=\"article-embed image-embed pull-none\" contenteditable=\"false\"><img src=\"//images.newrepublic.com/8d793ed39af4336d037d65a6598e2189f446fbf8.jpeg?w=1400\" data-serialized=\"{&quot;id&quot;:&quot;527ac027-3251-4865-a421-789ec92487a9&quot;,&quot;hash&quot;:&quot;8d793ed39af4336d037d65a6598e2189f446fbf8&quot;,&quot;width&quot;:3000,&quot;height&quot;:2000,&quot;format&quot;:&quot;JPEG&quot;,&quot;isAnimated&quot;:false,&quot;baseUrl&quot;:&quot;//images.newrepublic.com/&quot;,&quot;src&quot;:&quot;//images.newrepublic.com/8d793ed39af4336d037d65a6598e2189f446fbf8.jpeg&quot;,&quot;alt&quot;:null,&quot;meta&quot;:{}}\" width=\"1400\"><figcaption class=\"caption\"><div class=\"caption-text-wrapper\"><span class=\"caption-text\">The Clinton administration was instrumental in safeguarding Big Pharma’s intellectual property rights on the global stage—and Gates would become the campaign’s benevolent face.</span></div><span class=\"credit\">Chip Somodevilla/Getty Images</span></figcaption></figure><p><span>When Moose was ringing the alarm over\nthe future of TRIPS in the spring of 1999, Gates was preparing to fund the launch\nof a public-private partnership called Gavi, the Vaccine Alliance, with a seed\ngrant of $750 million, marking his arrival in the worlds of infectious disease and public health. At the time, he was still best known for being the\nrichest man in the world and the owner of a software company engaged in\nanti-competitive practices. This profile didn’t mean much in a raucous WHO\nAssembly hall packed with civil society groups and G77 delegations, which together booed the U.S. delegation when it tried to speak. At most, it was a\nsource of brief consternation when officers from the William H. Gates\nFoundation began distributing a glossy brochure touting the role of\nintellectual property in driving biomedical innovation.</span><span>&nbsp;</span><br></p></div></div><div class=\"full-width ad-container\"></div><div class=\"article-text-wrap\"><div class=\"article-text-grid\"><p>James Love, who organized many of the\ncivil society events around the 1999 Assembly, remembers seeing the Gates\nstaffers joined in the distribution effort by Harvey Bale, a former U.S. trade official serving as\ndirector general of the International Federation\nof Pharmaceutical Manufacturers Associations.</p><p>“It was this nice full-color pamphlet about why patents\ndon’t present an access problem, with the Gates Foundation logo at the bottom,”\nsays Love. “It was strange, and I just thought, ‘OK, I guess this is what he’s\ndoing now.’ Looking back, that’s when the pharma-Gates consortium set the\nmarkers down on intellectual property. He’s been sticking his nose into every\nintellectual property debate since, telling everyone\nthey can go to heaven by paying lip service to a few discounts to poor\ncountries.”&nbsp;<span>&nbsp;</span></p><p>Following the 1999 WHO Assembly, the\nindustry tried to salvage its reputation by offering African countries discounts\non the antiretroviral combination therapies that cost $10,000 or more in rich\ncountries. The compromise prices it offered were still outrageously high, but even\nraising the issue of price concessions was too much for Pfizer, whose\nrepresentatives stormed out of the industry coalition on principle. Public\nopinion swung harder against the companies, the result of a loud, ingenious,\nand effective direct-action campaign. Similar to the first months of the Covid-19\npandemic, there was a sense of possibility—a hope that a forced breakdown of a\nmorally obscene and bloodstained system was within grasp.<span>&nbsp;</span></p></div></div><div class=\"full-width ad-container\"></div><div class=\"article-text-wrap\"><div class=\"article-text-grid\"><p>“The\nmovement was very focused and successfully building pressure for structural, more decisive\nsolutions into the aughts,” says Asia Russell, a veteran HIV-AIDS activist and director of <a href=\"https://healthgap.org/\" target=\"_blank\" rel=\"nofollow\">Health Gap</a>, an HIV\nmedicines access group. “And just when we\nstarted to secure some progress, a new\nversion of the industry narrative emerged from Gates and Pharma. It was all about how pricing policies,\ngeneric competition, anything that\ninterferes with industry profits, will undermine\nresearch and development, when the evidence shows that that argument doesn’t hold water. Gates’s talking points\naligned with those of the industry.”</p><p>Adds Manuel Martin, the Médecins Sans Frontières policy adviser, “Gates defused the real issue of decolonizing global\nhealth. Instead, drug companies could just give money to his institutions.”</p><p>Even after the drug companies withdrew their lawsuit\nagainst the South African government and Indian-made generics began flowing to\nAfrica, Gates stayed cool toward compromises that he saw as threats to the\nintellectual property paradigm. This included his attitude toward the Unitaid\nMedicines Patent Pool, a voluntary intellectual property pool founded in 2010 that\nenlarged access to some patented HIV/AIDS medicines. Though not a complete\nanswer to the problem, the MPP was the first working example of a voluntary intellectual property pool,\none that many observers expected to serve as a model framework for the\nWHO-administered Covid-19 pool.</p></div></div><div class=\"full-width ad-container\"></div><div class=\"article-text-wrap\"><div class=\"article-text-grid\"><p><a href=\"https://www.northeastern.edu/law/faculty/directory/baker.html\" target=\"_blank\" rel=\"nofollow\">Brook Baker</a>, a law professor at Northeastern University\nand senior policy analyst for Health\nGAP, says Gates has\nalways been wary of the Unitaid pool as going too far in the direction of\ninfringing on intellectual property.<span>&nbsp;</span></p><p>“Initially, Gates\nwas unsupportive and even hostile toward the AIDS Medicines Patent Pool,” says\nBaker. “He brought that\nhostility to relaxing industry’s iron-fist control over its technologies into\nthe pandemic. His explanation for rejecting models to counteract this control\nnever added up. If I.P. isn’t important, why are companies\nrefusing to voluntarily give it up when it could be used to expand supply in\nthe middle of the world’s worst public health crisis in a century? It’s not\nimportant, or it’s so important it has to be closely guarded and protected. You\ncan’t have it both ways.”</p><div class=\"section-break-wrapper\"><svg version=\"1.1\" x=\"0px\" class=\"svg-section-break\" y=\"0px\" viewBox=\"0 0 124.6 24.3\" style=\"enable-background:new 0 0 124.6 24.3;\" xml:space=\"preserve\">\n      <g>\n      <polygon points=\"61.8,0.5 55.4,11.7 0,11.7 0,12.7 54.8,12.7 48.4,23.8 49.5,23.8 63,0.5 \t\"></polygon>\n      <polygon points=\"69.8,11.7 76.3,0.5 75.1,0.5 61.6,23.8 62.8,23.8 69.2,12.7 124.6,12.7 124.6,11.7 \t\"></polygon>\n      </g>\n    </svg></div><p>This winter, while Gates assured the world that intellectual property was a red herring, a bloc of developing countries at the WTO explained the\nneed for a waiver on certain intellectual property provisions by pointing to the “rather large gap [that] exists\nbetween what COVAX or ACT-A can deliver and what is required in developing and\nleast developed countries.”</p><p>The\n<a href=\"https://www.keionline.org/35453\" target=\"_blank\" rel=\"nofollow\">forceful statement</a> continued:</p></div></div><div class=\"full-width ad-container\"></div><div class=\"article-text-wrap\"><div class=\"article-text-grid\"><blockquote><p>The model of donation and philanthropic expediency cannot solve the fundamental disconnect\nbetween the monopolistic model it\nunderwrites and the very real desire of developing and least developed countries to produce for themselves.… The\nartificial shortage of vaccines is primarily\ncaused by the inappropriate use of intellectual property rights.</p></blockquote><p>Another statement by a different bloc of countries added,\n“COVID19\nreveals the deep structural inequality in access to medicines globally, and a\nroot cause is IP that sustains and dominates industry’s interests at the cost\nof lives.”&nbsp; <b><br></b></p><p>Gates is\ncertain he knows better. But his failure to anticipate a crisis of supply, and\nhis refusal to engage those who predicted it, have complicated the carefully\nmaintained image of an all-knowing, saintly mega-philanthropist. COVAX presents\na high-stakes demonstration of Gates’s deepest ideological commitments,\nnot just to intellectual property rights but also to the conflation of these\nrights with an imaginary free market in pharmaceuticals—an industry dominated\nby companies whose power derives from politically constructed and politically imposed\nmonopolies. Gates has been tacitly and explicitly defending the legitimacy of\nknowledge monopolies since his first Gerald Ford–era missives against open-source\nsoftware hobbyists. He was on the side of these monopolies during the miserable\ndepths of the 1990s African AIDS crisis. He’s still there today, defending the\nstatus quo and running effective interference for those profiting by the\nbillions from their control of Covid-19 vaccines. </p><p>His latest move is to institutionalize the ACT-Accelerator\nas the central organizing institution in future pandemics. The shortages have\nmade this effort a little awkward, however, and Gates is now forced to reckon\nwith the question of technology transfer. This is an aspect of\nthe equitable access debate that doesn’t concern intellectual property as commonly perceived—as a\nsimple matter of patents and licenses—but access\nto the components and technical knowledge related to practical manufacture, including biological\nmaterial and other areas otherwise protected under the category of intellectual property known as\ntrade secrets. The global south and civil society groups<b> </b>have been calling for tech transfer for months—<span>either mandatory tech transfer that could have been written into contracts or through a voluntary mechanism associated with C-TAP</span><span>—but Gates\nhas predictably arrived on the scene with a more familiar plan in hand.</span></p></div></div><div class=\"full-width ad-container\"></div><div class=\"article-text-wrap\"><div class=\"article-text-grid\"><p>In early March, senior Gates staff joined\npharma executives for a “<a href=\"https://www.chathamhouse.org/events/all/research-event/global-c19-vaccine-supply-chain-manufacturing-summit\" target=\"_blank\" rel=\"nofollow\">Global C19 Vaccine Supply Chain and Manufacturing Summit</a>” convened by Chatham\nHouse in London. The main agenda item: plans for a new arm within the ACT-Accelerator,\nthe Covid Vaccine Capacity Connector, that seeks to address the tech-transfer question within the usual frame of monopoly rights and\nbilateral licensing.<span>&nbsp;</span></p><p>“The tech transfer debate is being decisively seized and shaped\nby those who want to set the terms and conditions under which knowledge can be\ntransferred,” writes Priti Patnaik in her <a href=\"https://genevahealthfiles.substack.com/p/who-donors-seek-a-new-tech-transfer\" target=\"_blank\" rel=\"nofollow\"><i>Geneva\nHealth Files</i> newsletter</a>. A Gates-directed tech-transfer mechanism without\nmeaningful input from WHO members states, she writes, would be a “body blow” to\nC-TAP and similar future initiatives that promote open licensing and knowledge sharing\nto maximize production and access. </p><p>There\nare signs of overdue scrutiny of Gates’s role in public health and lifelong commitment\nto exclusive intellectual property rights. But so far these are blips. More common\nis the deference on display in a March 21 <i>New\nYork Times</i> article about the U.S. government’s role in <a href=\"https://www.nytimes.com/2021/03/21/world/vaccine-patents-us-eu.html?searchResultPosition=1\" target=\"_blank\" rel=\"nofollow\">developing the mRNA vaccines</a> now under\nthe monopoly control of Moderna and Pfizer. When the piece turned to Gates’s inevitable\ncameo, the <i>Times</i> reporter was hovering\nright over the target—and somehow managed to miss wide by a mile. Instead of\nprobing Gates’s central role in preserving this paradigm, the paper linked to\ngentle boilerplate about pricing and access found on the Gates Foundation\nwebsite. In response to a request for comment, a Gates Foundation spokesperson pointed\nme to a piece by its CEO, Mark Suzman, arguing that “IP fundamentally underpins\ninnovation, including the work that has helped create vaccines so quickly.”</p></div></div><div class=\"full-width ad-container\"></div><div class=\"article-text-wrap\"><div class=\"article-text-grid\"><p>Any change\nin media coverage of Gates’s second career may produce a delayed echo within the\nworld he has come to dominate. Here Gates not only controls the narratives, he\ncontrols most of the payroll. This may sound conspiratorial or overblown to\noutsiders but not to campaigners who have witnessed Gates’s ability to shift\ngravity on major issues. </p><p>“If you\nsaid to an ordinary person, ‘We’re in a pandemic. Let’s figure out everyone who\ncan make vaccines and give them everything they need to get online as fast as\npossible,’ it would be a no-brainer,” says James Love.\n“But Gates won’t go there. Neither will the people dependent on his funding. He has immense power. He can get you\nfired from a U.N. job. He knows that if you want to work in global public\nhealth, you’d better not make an enemy of the Gates Foundation by questioning\nits positions on I.P. and monopolies. And there are a lot of advantages to\nbeing on his team. It’s a sweet, comfortable ride for a lot of people.”</p><div class=\"section-break-wrapper\"><svg version=\"1.1\" x=\"0px\" class=\"svg-section-break\" y=\"0px\" viewBox=\"0 0 124.6 24.3\" style=\"enable-background:new 0 0 124.6 24.3;\" xml:space=\"preserve\">\n      <g>\n      <polygon points=\"61.8,0.5 55.4,11.7 0,11.7 0,12.7 54.8,12.7 48.4,23.8 49.5,23.8 63,0.5 \t\"></polygon>\n      <polygon points=\"69.8,11.7 76.3,0.5 75.1,0.5 61.6,23.8 62.8,23.8 69.2,12.7 124.6,12.7 124.6,11.7 \t\"></polygon>\n      </g>\n    </svg></div><p>*<i>Among journalists echoing this argument was former </i>New Republic <i>editor Andrew Sullivan. When </i>The<i> </i>New York Times <i>reported Sullivan was defending the companies’ lawsuit while taking undisclosed\n<a href=\"https://www.salon.com/2001/07/12/sullivan_4/\" target=\"_blank\" rel=\"nofollow\">funding from\nPhRma</a><span>, the industry trade association, Sullivan\nremained defiant in the face of evidence-based accusations that he was an unethical\njournalist. “It behooves me to say I see\nabsolutely no problems with [drug industry sponsorship],” he told </span>Salon<span>. “In fact, I am extremely proud to\nget some support from a great industry.” It later turned out that Africans adhered\nmore closely to the twice-daily pill regimens than patient populations in rich\ncountries.</span></i><br></p></div></div><div class=\"full-width ad-container\"></div><div class=\"article-text-wrap\"><div class=\"article-text-grid\"><p>**<i>In 2010,\nthe Gates Foundation would bankroll a documentary advocating the privatization\nof U.S. public education, titled </i>Waiting\nfor Superman<span>.&nbsp;</span><br></p></div></div></div></div><div class=\"article-footer\"><div class=\"article-footer-wrap\"><div class=\"footer-wrap footer-text-wrap social\"><div id=\"social_share_inline_bottom\" class=\"article-social article-social-mobile\"><a class=\"copy-to-clipboard-link\" role=\"button\" aria-label=\"Copy to clipboard\"><div class=\"copy-text \"><div class=\"icon\"><svg class=\"icon-copy-to-clipboard\" xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 30 30\"><path id=\"Path_3054\" data-name=\"Path 3054\" class=\"cls-1\" d=\"M20.80247,4.644a4.96,4.96,0,0,0-3.533,1.464l-2.4,2.4a7.13815,7.13815,0,0,1,2.507.47l1.384-1.384a2.88995,2.88995,0,0,1,4.087,4.087l-4.867,4.867a2.85318,2.85318,0,0,1-4.557-.641l-1.52,1.52a5.03671,5.03671,0,0,0,.5.61,4.995,4.995,0,0,0,7.065-.001l4.867-4.867a4.992,4.992,0,0,0-3.533-8.525Z\"></path><path id=\"Path_3055\" data-name=\"Path 3055\" class=\"cls-1\" d=\"M9.79445,25.644a4.962,4.962,0,0,0,3.533-1.463l2.4-2.4a7.13287,7.13287,0,0,1-2.506-.47l-1.385,1.384a2.88995,2.88995,0,0,1-4.087-4.087l4.867-4.867a2.85044,2.85044,0,0,1,4.556.641l1.52-1.52a4.87978,4.87978,0,0,0-.5-.609,4.9938,4.9938,0,0,0-7.065,0l-4.867,4.867a4.99151,4.99151,0,0,0,3.534,8.524Z\"></path></svg></div></div></a><a href=\"#\" title=\"Share on Facebook\"><div class=\"icon\"><svg class=\"icon-facebook\" xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 20 20\"><path fill=\"#4267B2\" d=\"M20,0V20H13.84V12.23h2.57l.44-3.06h-3V7.08A1.18,1.18,0,0,1,15,5.9H17V3.08L14.52,3a3.59,3.59,0,0,0-3.83,3.66V9.17H8.11v3.06h2.58V20H0V0Z\"></path></svg></div></a><a href=\"#\" title=\"Share on Twitter\"><div class=\"icon\"><svg class=\"icon-twitter\" version=\"1.1\" viewBox=\"0 0 300 300\" xmlns=\"http://www.w3.org/2000/svg\"><path d=\"M178.57 127.15 290.27 0h-26.46l-97.03 110.38L89.34 0H0l117.13 166.93L0 300.25h26.46l102.4-116.59 81.8 116.59h89.34M36.01 19.54H76.66l187.13 262.13h-40.66\"></path></svg></div></a><a href=\"https://bsky.app/intent/compose?text=How Bill Gates Impeded Global Access to Covid Vaccines https://newrepublic.com/article/162000/bill-gates-impeded-global-access-covid-vaccines via @newrepublic.com\"><div class=\"icon\"><svg class=\"icon-bluesky\" xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 600 530\" width=\"100%\" height=\"100%\"><path d=\"M135.72 44.03C202.216 93.951 273.74 195.17 300 249.49c26.262-54.316 97.782-155.54 164.28-205.46C512.26 8.009 590-19.862 590 68.825c0 17.712-10.155 148.79-16.111 170.07-20.703 73.984-96.144 92.854-163.25 81.433 117.3 19.964 147.14 86.092 82.697 152.22-122.39 125.59-175.91-31.511-189.63-71.766-2.514-7.38-3.69-10.832-3.708-7.896-.017-2.936-1.193.516-3.707 7.896-13.714 40.255-67.233 197.36-189.63 71.766-64.444-66.128-34.605-132.26 82.697-152.22-67.108 11.421-142.55-7.45-163.25-81.433C20.15 217.613 9.997 86.535 9.997 68.825c0-88.687 77.742-60.816 125.72-24.795z\" fill=\"#1185fe\"></path></svg></div></a><a href=\"https://reddit.com/submit?url=https://newrepublic.com/article/162000/bill-gates-impeded-global-access-covid-vaccines&amp;title=How Bill Gates Impeded Global Access to Covid Vaccines\"><div class=\"icon\"><svg class=\"icon-reddit\" xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 20 20\"><path d=\"M12.09 13.41A3.24 3.24 0 0110 14a3.27 3.27 0 01-2.09-.61.28.28 0 00-.38 0 .26.26 0 000 .38 3.84 3.84 0 002.47.77 3.88 3.88 0 002.48-.77.27.27 0 00-.38-.38zM8.75 11a1 1 0 00-2.08 0 1 1 0 001 1 1 1 0 001.08-1z\"></path><path d=\"M10 0a10 10 0 1010 10A10 10 0 0010 0zm5.8 11.33a3.42 3.42 0 010 .44c0 2.25-2.62 4.06-5.84 4.06S4.17 14 4.17 11.77a3.25 3.25 0 010-.44 1.46 1.46 0 011.22-2.66 1.62 1.62 0 01.42.33 7.14 7.14 0 014-1.24l.72-3.49a.31.31 0 01.12-.16.25.25 0 01.19 0l2.43.52a1 1 0 011.39-.47 1 1 0 11-1.5 1L11 4.59l-.7 3.12A7.2 7.2 0 0114.2 9a1.46 1.46 0 111.6 2.38z\"></path><path d=\"M12.29 10a1 1 0 100 2.08 1 1 0 100-2.08z\"></path></svg></div></a><a href=\"https://wa.me/?text=How Bill Gates Impeded Global Access to Covid Vaccines  https://newrepublic.com/article/162000/bill-gates-impeded-global-access-covid-vaccines\"><div class=\"icon\"><svg class=\"icon-whatsapp\" xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 20 20\"><path d=\"M20 10a10 10 0 01-10 10 11 11 0 01-5.51-1.65L.73 19.57 2 15.93A11.37 11.37 0 010 10a10 10 0 0120 0zm-4.13 2a.81.81 0 00-.65-.57l-1.83-.31a.87.87 0 00-.8.3l-.08.12a2 2 0 00-.18.25 2.85 2.85 0 01-.73.81c-.35.11-1 .11-2.69-1.31S7.09 9.23 7.15 8.87A2.6 2.6 0 017.82 8L8 7.79l.09-.08a.85.85 0 00.17-.85L7.67 5.1A.82.82 0 007 4.56a3.31 3.31 0 00-1.37.07 1.38 1.38 0 00-.63.46l-.08.12a1.23 1.23 0 00-.12.26c-.42.92-1.44 4.19 2.61 7.58a7.77 7.77 0 005 2.12 5.25 5.25 0 002.92-.86 1.18 1.18 0 00.22-.17l.13-.11a1.44 1.44 0 00.34-.66 3.31 3.31 0 00-.15-1.37z\"></path></svg></div></a><a href=\"https://threads.net/intent/post?text=How Bill Gates Impeded Global Access to Covid Vaccines https://newrepublic.com/article/162000/bill-gates-impeded-global-access-covid-vaccines via @newrepublic\"><div class=\"icon\"><svg class=\"icon-threads\" aria-label=\"Threads\" viewBox=\"0 0 192 192\" xmlns=\"http://www.w3.org/2000/svg\"><path class=\"x19hqcy\" d=\"M141.537 88.9883C140.71 88.5919 139.87 88.2104 139.019 87.8451C137.537 60.5382 122.616 44.905 97.5619 44.745C97.4484 44.7443 97.3355 44.7443 97.222 44.7443C82.2364 44.7443 69.7731 51.1409 62.102 62.7807L75.881 72.2328C81.6116 63.5383 90.6052 61.6848 97.2286 61.6848C97.3051 61.6848 97.3819 61.6848 97.4576 61.6855C105.707 61.7381 111.932 64.1366 115.961 68.814C118.893 72.2193 120.854 76.925 121.825 82.8638C114.511 81.6207 106.601 81.2385 98.145 81.7233C74.3247 83.0954 59.0111 96.9879 60.0396 116.292C60.5615 126.084 65.4397 134.508 73.775 140.011C80.8224 144.663 89.899 146.938 99.3323 146.423C111.79 145.74 121.563 140.987 128.381 132.296C133.559 125.696 136.834 117.143 138.28 106.366C144.217 109.949 148.617 114.664 151.047 120.332C155.179 129.967 155.42 145.8 142.501 158.708C131.182 170.016 117.576 174.908 97.0135 175.059C74.2042 174.89 56.9538 167.575 45.7381 153.317C35.2355 139.966 29.8077 120.682 29.6052 96C29.8077 71.3178 35.2355 52.0336 45.7381 38.6827C56.9538 24.4249 74.2039 17.11 97.0132 16.9405C119.988 17.1113 137.539 24.4614 149.184 38.788C154.894 45.8136 159.199 54.6488 162.037 64.9503L178.184 60.6422C174.744 47.9622 169.331 37.0357 161.965 27.974C147.036 9.60668 125.202 0.195148 97.0695 0H96.9569C68.8816 0.19447 47.2921 9.6418 32.7883 28.0793C19.8819 44.4864 13.2244 67.3157 13.0007 95.9325L13 96L13.0007 96.0675C13.2244 124.684 19.8819 147.514 32.7883 163.921C47.2921 182.358 68.8816 191.806 96.9569 192H97.0695C122.03 191.827 139.624 185.292 154.118 170.811C173.081 151.866 172.51 128.119 166.26 113.541C161.776 103.087 153.227 94.5962 141.537 88.9883ZM98.4405 129.507C88.0005 130.095 77.1544 125.409 76.6196 115.372C76.2232 107.93 81.9158 99.626 99.0812 98.6368C101.047 98.5234 102.976 98.468 104.871 98.468C111.106 98.468 116.939 99.0737 122.242 100.233C120.264 124.935 108.662 128.946 98.4405 129.507Z\"></path></svg></div></a><a title=\"Share via Email\" href=\"mailto:?subject=&amp;body=How%20Bill%20Gates%20Impeded%20Global%20Access%20to%20Covid%20Vaccines%0A%0Ahttps%3A%2F%2Fnewrepublic.com%2Farticle%2F162000%2Fbill-gates-impeded-global-access-covid-vaccines\"><div class=\"icon\"><svg class=\"icon-email\" xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 20 13.32\"><path d=\"M20 .1V0H0v.1l10 6.5L20 .1z\"></path><path d=\"M10 9.22A1.23 1.23 0 019.35 9L0 3v10.32h20V3l-9.35 6a1.23 1.23 0 01-.65.22z\"></path></svg></div></a><a class=\"print\"><div class=\"icon\"><svg class=\"icon-print\" xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 20 18.31\"><rect x=\"5.44\" width=\"9.12\" height=\"3.66\"></rect><rect x=\"4.51\" y=\"13.35\" width=\"11.02\" height=\"4.96\"></rect><path d=\"M20,15.14H17.62V10.93H2.38v4.21H0V5.75H20ZM17.43,7.38a.94.94,0,1,0,.94.94.94.94,0,0,0-.94-.94Z\"></path></svg></div></a></div></div><div class=\"footer-wrap footer-text-wrap\"><div class=\"article-author-bio\"><div class=\"article-author-bio__header\"><div class=\"article-author-bio__header\"><a href=\"/authors/alexander-zaitchik\" class=\"article-author-bio__header__name\">Alexander Zaitchik</a></div></div><div class=\"article-author-bio__body\"><p>Alexander Zaitchik is the author, most recently, of <i>Owning the Sun: A People’s History of Monopoly Medicine From Aspirin to Covid-19.</i></p></div></div></div><div class=\"footer-wrap newsletter-cta\"></div><div class=\"footer-wrap footer-text-wrap\"><div class=\"footer-tags\"><span class=\"footer-tags__title\">Read More: </span><div class=\"tag-list\"><span class=\"tag-list-item\"><a class=\"tag tag-the-soapbox \" href=\"/tags/the-soapbox\">The Soapbox</a><span class=\"tag-list-comma\">, </span></span><span class=\"tag-list-item\"><a class=\"tag tag-covid-19 \" href=\"/tags/covid-19\">Covid-19</a><span class=\"tag-list-comma\">, </span></span><span class=\"tag-list-item\"><a class=\"tag tag-bill-gates \" href=\"/tags/bill-gates\">Bill Gates</a><span class=\"tag-list-comma\">, </span></span><span class=\"tag-list-item\"><a class=\"tag tag-bill-and-melinda-gates-foundation \" href=\"/tags/bill-and-melinda-gates-foundation\">Bill &amp; Melinda Gates Foundation</a><span class=\"tag-list-comma\">, </span></span><span class=\"tag-list-item\"><a class=\"tag tag-world-health-organization \" href=\"/tags/world-health-organization\">World Health Organization</a><span class=\"tag-list-comma\">, </span></span><span class=\"tag-list-item\"><a class=\"tag tag-world-trade-organization \" href=\"/tags/world-trade-organization\">World Trade Organization</a><span class=\"tag-list-comma\">, </span></span><span class=\"tag-list-item\"><a class=\"tag tag-coronavirus-vaccine \" href=\"/tags/coronavirus-vaccine\">Coronavirus Vaccine</a><span class=\"tag-list-comma\">, </span></span><span class=\"tag-list-item\"><a class=\"tag tag-pandemic \" href=\"/tags/pandemic\">Pandemic</a><span class=\"tag-list-comma\">, </span></span><span class=\"tag-list-item\"><a class=\"tag tag-big-pharma \" href=\"/tags/big-pharma\">Big Pharma</a><span class=\"tag-list-comma\">, </span></span><span class=\"tag-list-item\"><a class=\"tag tag-pharmaceutical \" href=\"/tags/pharmaceutical\">Pharmaceutical</a><span class=\"tag-list-comma\">, </span></span><span class=\"tag-list-item\"><a class=\"tag tag-astrazeneca \" href=\"/tags/astrazeneca\">AstraZeneca</a><span class=\"tag-list-comma\">, </span></span><span class=\"tag-list-item\"><a class=\"tag tag-glaxosmithkline \" href=\"/tags/glaxosmithkline\">GlaxoSmithKline</a><span class=\"tag-list-comma\">, </span></span><span class=\"tag-list-item\"><a class=\"tag tag-johnson-and-johnson \" href=\"/tags/johnson-and-johnson\">Johnson &amp; Johnson</a><span class=\"tag-list-comma\">, </span></span><span class=\"tag-list-item\"><a class=\"tag tag-pfizer \" href=\"/tags/pfizer\">Pfizer</a><span class=\"tag-list-comma\">, </span></span><span class=\"tag-list-item\"><a class=\"tag tag-hiv \" href=\"/tags/hiv\">HIV</a><span class=\"tag-list-comma\">, </span></span><span class=\"tag-list-item\"><a class=\"tag tag-aids \" href=\"/tags/aids\">AIDS</a><span class=\"tag-list-comma\">, </span></span><span class=\"tag-list-item\"><a class=\"tag tag-nelson-mandela \" href=\"/tags/nelson-mandela\">Nelson Mandela</a><span class=\"tag-list-comma\">, </span></span><span class=\"tag-list-item\"><a class=\"tag tag-south-africa \" href=\"/tags/south-africa\">South Africa</a><span class=\"tag-list-comma\">, </span></span><span class=\"tag-list-item\"><a class=\"tag tag-oxfam \" href=\"/tags/oxfam\">Oxfam</a><span class=\"tag-list-comma\">, </span></span><span class=\"tag-list-item\"><a class=\"tag tag-medecins-sans-frontieres \" href=\"/tags/medecins-sans-frontieres\">Médecins Sans Frontieres</a><span class=\"tag-list-comma\">, </span></span><span class=\"tag-list-item\"><a class=\"tag tag-the-insecurity-complex \" href=\"/tags/the-insecurity-complex\">The Insecurity Complex</a><span class=\"tag-list-comma\">, </span></span><span class=\"tag-list-item\"><a class=\"tag tag-politics \" href=\"/tags/politics\">Politics</a><span class=\"tag-list-comma\"></span></span></div></div></div></div></div></article></main><div class=\"ContainerPlacement OutBrain Engage-Wrapper\"><div class=\"ContainerSection OutBrain Engage\"><div class=\"OB-REACT-WRAPPER\"><div class=\"OUTBRAIN\" data-src=\"https://newrepublic.com/article/162000/bill-gates-impeded-global-access-covid-vaccines\"></div></div></div></div><div><div class=\"ContainerPlacement\" id=\"ContainerPlacement1\"><div><section class=\"ContainerSection --box4led2\"><div class=\"Box4Led2_firstCol\"><div class=\"ContainerTitle\">Editor’s Picks</div></div><div class=\"Box4Led2_secondCol\"><div class=\"StorySmall_container\"><div class=\"StorySmall JustText\"><a class=\"Hed\" title=\"John Boehner Can’t Disown the Rot He Created\" href=\"/article/162003/boehner-book-tour-trump-hypocrite\"><div class=\"Hed\">John Boehner Can’t Disown the Rot He Created</div></a><div class=\"AuthorBorder\"><span class=\"AuthorList\"><span><span class=\"AuthorList_author\"><span class=\"AuthorList_bylineStyle\"></span><a class=\"Author_anchor\" href=\"/authors/natalie-shure\" title=\"Natalie Shure\">Natalie Shure</a></span><span class=\"AuthorList_comma\"></span></span></span></div></div><div class=\"StoryMedium JustText\"><div class=\"StoryMedium_text\"><div class=\"Byline\"><span class=\"AuthorList\"><span><span class=\"AuthorList_author\"><span class=\"AuthorList_bylineStyle\"></span><a class=\"Author_anchor\" href=\"/authors/natalie-shure\" title=\"Natalie Shure\">Natalie Shure</a></span><span class=\"AuthorList_comma\"></span></span></span></div><a class=\"Hed\" title=\"John Boehner Can’t Disown the Rot He Created\" href=\"/article/162003/boehner-book-tour-trump-hypocrite\"><div class=\"Hed\">John Boehner Can’t Disown the Rot He Created</div></a></div></div></div></div><div class=\"Box4Led2_thirdCol\"><div class=\"StorySmall_container\"><div class=\"StorySmall TextImage\"><a class=\"ContainerImg\" title=\"Kazuo Ishiguro’s Deceptively Simple Story of AI \" href=\"/article/161899/kazuo-ishiguro-klara-sun-review-deceptively-simple-story-ai\"><div class=\"LedeImgContainer\"><picture><source srcSet=\"data:image/svg+xml,%3Csvg%20width%3D%22384%22%20height%3D%22288%22%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%3E%3Crect%20width%3D%22100%25%22%20height%3D%22100%25%22%20fill%3D%22%23F5F5F5%22%2F%3E%3C%2Fsvg%3E\" media=\"screen and (min-width: 992px)\" width=\"384\" data-srcset=\"//images.newrepublic.com/76fa78c23b57d8115384e64acb5c5ab41e82760b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=1 1x, //images.newrepublic.com/76fa78c23b57d8115384e64acb5c5ab41e82760b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=2 2x, //images.newrepublic.com/76fa78c23b57d8115384e64acb5c5ab41e82760b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=3 3x, //images.newrepublic.com/76fa78c23b57d8115384e64acb5c5ab41e82760b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=4 4x, //images.newrepublic.com/76fa78c23b57d8115384e64acb5c5ab41e82760b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=5 5x\"/><source srcSet=\"data:image/svg+xml,%3Csvg%20width%3D%22240%22%20height%3D%22160%22%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%3E%3Crect%20width%3D%22100%25%22%20height%3D%22100%25%22%20fill%3D%22%23F5F5F5%22%2F%3E%3C%2Fsvg%3E\" media=\"screen and (min-width: 768px) and (max-width: 991.98px)\" width=\"240\" data-srcset=\"//images.newrepublic.com/76fa78c23b57d8115384e64acb5c5ab41e82760b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=3%3A2&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=1 1x, //images.newrepublic.com/76fa78c23b57d8115384e64acb5c5ab41e82760b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=3%3A2&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=2 2x, //images.newrepublic.com/76fa78c23b57d8115384e64acb5c5ab41e82760b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=3%3A2&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=3 3x, //images.newrepublic.com/76fa78c23b57d8115384e64acb5c5ab41e82760b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=3%3A2&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=4 4x, //images.newrepublic.com/76fa78c23b57d8115384e64acb5c5ab41e82760b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=3%3A2&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=5 5x\"/><img src=\"data:image/svg+xml,%3Csvg%20width%3D%22384%22%20height%3D%22216%22%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%3E%3Crect%20width%3D%22100%25%22%20height%3D%22100%25%22%20fill%3D%22%23F5F5F5%22%2F%3E%3C%2Fsvg%3E\" class=\"LedeImg lazyload\" width=\"384\" data-src=\"//images.newrepublic.com/76fa78c23b57d8115384e64acb5c5ab41e82760b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;q=65&amp;w=384&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=384\" data-srcset=\"//images.newrepublic.com/76fa78c23b57d8115384e64acb5c5ab41e82760b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=384&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=1 1x, //images.newrepublic.com/76fa78c23b57d8115384e64acb5c5ab41e82760b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=384&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=2 2x, //images.newrepublic.com/76fa78c23b57d8115384e64acb5c5ab41e82760b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=384&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=3 3x, //images.newrepublic.com/76fa78c23b57d8115384e64acb5c5ab41e82760b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=384&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=4 4x, //images.newrepublic.com/76fa78c23b57d8115384e64acb5c5ab41e82760b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=384&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=5 5x\"/></picture></div></a><a class=\"Hed\" title=\"Kazuo Ishiguro’s Deceptively Simple Story of AI \" href=\"/article/161899/kazuo-ishiguro-klara-sun-review-deceptively-simple-story-ai\"><div class=\"Hed\">Kazuo Ishiguro’s Deceptively Simple Story of AI </div></a><div class=\"AuthorBorder\"><span class=\"AuthorList\"><span><span class=\"AuthorList_author\"><span class=\"AuthorList_bylineStyle\"></span><a class=\"Author_anchor\" href=\"/authors/rumaan-alam\" title=\"Rumaan Alam\">Rumaan Alam</a></span><span class=\"AuthorList_comma\"></span></span></span></div></div><div class=\"StoryMedium TextImage\"><div class=\"StoryMedium_img\"><a class=\"ContainerImg\" title=\"Kazuo Ishiguro’s Deceptively Simple Story of AI \" href=\"/article/161899/kazuo-ishiguro-klara-sun-review-deceptively-simple-story-ai\"><div class=\"LedeImgContainer\"><picture><source srcSet=\"data:image/svg+xml,%3Csvg%20width%3D%22240%22%20height%3D%22180%22%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%3E%3Crect%20width%3D%22100%25%22%20height%3D%22100%25%22%20fill%3D%22%23F5F5F5%22%2F%3E%3C%2Fsvg%3E\" media=\"screen and (min-width: 992px)\" width=\"240\" data-srcset=\"//images.newrepublic.com/76fa78c23b57d8115384e64acb5c5ab41e82760b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=1 1x, //images.newrepublic.com/76fa78c23b57d8115384e64acb5c5ab41e82760b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=2 2x, //images.newrepublic.com/76fa78c23b57d8115384e64acb5c5ab41e82760b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=3 3x, //images.newrepublic.com/76fa78c23b57d8115384e64acb5c5ab41e82760b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=4 4x, //images.newrepublic.com/76fa78c23b57d8115384e64acb5c5ab41e82760b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=5 5x\"/><source srcSet=\"data:image/svg+xml,%3Csvg%20width%3D%22240%22%20height%3D%22240%22%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%3E%3Crect%20width%3D%22100%25%22%20height%3D%22100%25%22%20fill%3D%22%23F5F5F5%22%2F%3E%3C%2Fsvg%3E\" media=\"screen and (min-width: 768px) and (max-width: 991.98px)\" width=\"240\" data-srcset=\"//images.newrepublic.com/76fa78c23b57d8115384e64acb5c5ab41e82760b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=1%3A1&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=1 1x, //images.newrepublic.com/76fa78c23b57d8115384e64acb5c5ab41e82760b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=1%3A1&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=2 2x, //images.newrepublic.com/76fa78c23b57d8115384e64acb5c5ab41e82760b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=1%3A1&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=3 3x, //images.newrepublic.com/76fa78c23b57d8115384e64acb5c5ab41e82760b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=1%3A1&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=4 4x, //images.newrepublic.com/76fa78c23b57d8115384e64acb5c5ab41e82760b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=1%3A1&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=5 5x\"/><img src=\"data:image/svg+xml,%3Csvg%20width%3D%22320%22%20height%3D%22180%22%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%3E%3Crect%20width%3D%22100%25%22%20height%3D%22100%25%22%20fill%3D%22%23F5F5F5%22%2F%3E%3C%2Fsvg%3E\" class=\"LedeImg lazyload\" width=\"320\" data-src=\"//images.newrepublic.com/76fa78c23b57d8115384e64acb5c5ab41e82760b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;q=65&amp;w=320&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=320\" data-srcset=\"//images.newrepublic.com/76fa78c23b57d8115384e64acb5c5ab41e82760b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=320&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=320&amp;q=65&amp;dpr=1 1x, //images.newrepublic.com/76fa78c23b57d8115384e64acb5c5ab41e82760b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=320&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=320&amp;q=65&amp;dpr=2 2x, //images.newrepublic.com/76fa78c23b57d8115384e64acb5c5ab41e82760b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=320&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=320&amp;q=65&amp;dpr=3 3x, //images.newrepublic.com/76fa78c23b57d8115384e64acb5c5ab41e82760b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=320&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=320&amp;q=65&amp;dpr=4 4x, //images.newrepublic.com/76fa78c23b57d8115384e64acb5c5ab41e82760b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=320&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=320&amp;q=65&amp;dpr=5 5x\"/></picture></div></a></div><div class=\"StoryMedium_text\"><div class=\"Byline\"><span class=\"AuthorList\"><span><span class=\"AuthorList_author\"><span class=\"AuthorList_bylineStyle\"></span><a class=\"Author_anchor\" href=\"/authors/rumaan-alam\" title=\"Rumaan Alam\">Rumaan Alam</a></span><span class=\"AuthorList_comma\"></span></span></span></div><a class=\"Hed\" title=\"Kazuo Ishiguro’s Deceptively Simple Story of AI \" href=\"/article/161899/kazuo-ishiguro-klara-sun-review-deceptively-simple-story-ai\"><div class=\"Hed\">Kazuo Ishiguro’s Deceptively Simple Story of AI </div></a></div></div></div></div><div class=\"Box4Led2_fourthCol\"><div class=\"StorySmall_container\"><div class=\"StorySmall JustText\"><a class=\"Hed\" title=\"Fox News Made Matt Gaetz\" href=\"/article/162002/fox-news-made-matt-gaetz\"><div class=\"Hed\">Fox News Made Matt Gaetz</div></a><div class=\"AuthorBorder\"><span class=\"AuthorList\"><span><span class=\"AuthorList_author\"><span class=\"AuthorList_bylineStyle\"></span><a class=\"Author_anchor\" href=\"/authors/alex-shephard\" title=\"Alex Shephard\">Alex Shephard</a></span><span class=\"AuthorList_comma\"></span></span></span></div></div><div class=\"StoryMedium JustText\"><div class=\"StoryMedium_text\"><div class=\"Byline\"><span class=\"AuthorList\"><span><span class=\"AuthorList_author\"><span class=\"AuthorList_bylineStyle\"></span><a class=\"Author_anchor\" href=\"/authors/alex-shephard\" title=\"Alex Shephard\">Alex Shephard</a></span><span class=\"AuthorList_comma\"></span></span></span></div><a class=\"Hed\" title=\"Fox News Made Matt Gaetz\" href=\"/article/162002/fox-news-made-matt-gaetz\"><div class=\"Hed\">Fox News Made Matt Gaetz</div></a></div></div></div></div><div class=\"Box4Led2_fifthCol\"><div class=\"StorySmall_container\"><div class=\"StorySmall TextImage\"><a class=\"ContainerImg\" title=\"The Case for More Canceling\" href=\"/article/161999/cancel-culture-conservatives-seuss\"><div class=\"LedeImgContainer\"><picture><source srcSet=\"data:image/svg+xml,%3Csvg%20width%3D%22384%22%20height%3D%22288%22%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%3E%3Crect%20width%3D%22100%25%22%20height%3D%22100%25%22%20fill%3D%22%23F5F5F5%22%2F%3E%3C%2Fsvg%3E\" media=\"screen and (min-width: 992px)\" width=\"384\" data-srcset=\"//images.newrepublic.com/235e3ed2146bfaa5d88061466f6fb34753d9fc42.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=1 1x, //images.newrepublic.com/235e3ed2146bfaa5d88061466f6fb34753d9fc42.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=2 2x, //images.newrepublic.com/235e3ed2146bfaa5d88061466f6fb34753d9fc42.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=3 3x, //images.newrepublic.com/235e3ed2146bfaa5d88061466f6fb34753d9fc42.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=4 4x, //images.newrepublic.com/235e3ed2146bfaa5d88061466f6fb34753d9fc42.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=5 5x\"/><source srcSet=\"data:image/svg+xml,%3Csvg%20width%3D%22240%22%20height%3D%22160%22%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%3E%3Crect%20width%3D%22100%25%22%20height%3D%22100%25%22%20fill%3D%22%23F5F5F5%22%2F%3E%3C%2Fsvg%3E\" media=\"screen and (min-width: 768px) and (max-width: 991.98px)\" width=\"240\" data-srcset=\"//images.newrepublic.com/235e3ed2146bfaa5d88061466f6fb34753d9fc42.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=3%3A2&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=1 1x, //images.newrepublic.com/235e3ed2146bfaa5d88061466f6fb34753d9fc42.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=3%3A2&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=2 2x, //images.newrepublic.com/235e3ed2146bfaa5d88061466f6fb34753d9fc42.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=3%3A2&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=3 3x, //images.newrepublic.com/235e3ed2146bfaa5d88061466f6fb34753d9fc42.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=3%3A2&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=4 4x, //images.newrepublic.com/235e3ed2146bfaa5d88061466f6fb34753d9fc42.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=3%3A2&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=5 5x\"/><img src=\"data:image/svg+xml,%3Csvg%20width%3D%22384%22%20height%3D%22216%22%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%3E%3Crect%20width%3D%22100%25%22%20height%3D%22100%25%22%20fill%3D%22%23F5F5F5%22%2F%3E%3C%2Fsvg%3E\" class=\"LedeImg lazyload\" width=\"384\" data-src=\"//images.newrepublic.com/235e3ed2146bfaa5d88061466f6fb34753d9fc42.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;q=65&amp;w=384&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=384\" data-srcset=\"//images.newrepublic.com/235e3ed2146bfaa5d88061466f6fb34753d9fc42.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=384&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=1 1x, //images.newrepublic.com/235e3ed2146bfaa5d88061466f6fb34753d9fc42.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=384&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=2 2x, //images.newrepublic.com/235e3ed2146bfaa5d88061466f6fb34753d9fc42.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=384&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=3 3x, //images.newrepublic.com/235e3ed2146bfaa5d88061466f6fb34753d9fc42.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=384&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=4 4x, //images.newrepublic.com/235e3ed2146bfaa5d88061466f6fb34753d9fc42.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=384&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=5 5x\"/></picture></div></a><a class=\"Hed\" title=\"The Case for More Canceling\" href=\"/article/161999/cancel-culture-conservatives-seuss\"><div class=\"Hed\">The Case for More Canceling</div></a><div class=\"AuthorBorder\"><span class=\"AuthorList\"><span><span class=\"AuthorList_author\"><span class=\"AuthorList_bylineStyle\"></span><a class=\"Author_anchor\" href=\"/authors/alex-pareene\" title=\"Alex Pareene\">Alex Pareene</a></span><span class=\"AuthorList_comma\"></span></span></span></div></div><div class=\"StoryMedium TextImage\"><div class=\"StoryMedium_img\"><a class=\"ContainerImg\" title=\"The Case for More Canceling\" href=\"/article/161999/cancel-culture-conservatives-seuss\"><div class=\"LedeImgContainer\"><picture><source srcSet=\"data:image/svg+xml,%3Csvg%20width%3D%22240%22%20height%3D%22180%22%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%3E%3Crect%20width%3D%22100%25%22%20height%3D%22100%25%22%20fill%3D%22%23F5F5F5%22%2F%3E%3C%2Fsvg%3E\" media=\"screen and (min-width: 992px)\" width=\"240\" data-srcset=\"//images.newrepublic.com/235e3ed2146bfaa5d88061466f6fb34753d9fc42.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=1 1x, //images.newrepublic.com/235e3ed2146bfaa5d88061466f6fb34753d9fc42.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=2 2x, //images.newrepublic.com/235e3ed2146bfaa5d88061466f6fb34753d9fc42.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=3 3x, //images.newrepublic.com/235e3ed2146bfaa5d88061466f6fb34753d9fc42.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=4 4x, //images.newrepublic.com/235e3ed2146bfaa5d88061466f6fb34753d9fc42.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=5 5x\"/><source srcSet=\"data:image/svg+xml,%3Csvg%20width%3D%22240%22%20height%3D%22240%22%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%3E%3Crect%20width%3D%22100%25%22%20height%3D%22100%25%22%20fill%3D%22%23F5F5F5%22%2F%3E%3C%2Fsvg%3E\" media=\"screen and (min-width: 768px) and (max-width: 991.98px)\" width=\"240\" data-srcset=\"//images.newrepublic.com/235e3ed2146bfaa5d88061466f6fb34753d9fc42.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=1%3A1&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=1 1x, //images.newrepublic.com/235e3ed2146bfaa5d88061466f6fb34753d9fc42.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=1%3A1&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=2 2x, //images.newrepublic.com/235e3ed2146bfaa5d88061466f6fb34753d9fc42.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=1%3A1&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=3 3x, //images.newrepublic.com/235e3ed2146bfaa5d88061466f6fb34753d9fc42.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=1%3A1&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=4 4x, //images.newrepublic.com/235e3ed2146bfaa5d88061466f6fb34753d9fc42.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=1%3A1&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=5 5x\"/><img src=\"data:image/svg+xml,%3Csvg%20width%3D%22320%22%20height%3D%22180%22%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%3E%3Crect%20width%3D%22100%25%22%20height%3D%22100%25%22%20fill%3D%22%23F5F5F5%22%2F%3E%3C%2Fsvg%3E\" class=\"LedeImg lazyload\" width=\"320\" data-src=\"//images.newrepublic.com/235e3ed2146bfaa5d88061466f6fb34753d9fc42.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;q=65&amp;w=320&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=320\" data-srcset=\"//images.newrepublic.com/235e3ed2146bfaa5d88061466f6fb34753d9fc42.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=320&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=320&amp;q=65&amp;dpr=1 1x, //images.newrepublic.com/235e3ed2146bfaa5d88061466f6fb34753d9fc42.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=320&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=320&amp;q=65&amp;dpr=2 2x, //images.newrepublic.com/235e3ed2146bfaa5d88061466f6fb34753d9fc42.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=320&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=320&amp;q=65&amp;dpr=3 3x, //images.newrepublic.com/235e3ed2146bfaa5d88061466f6fb34753d9fc42.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=320&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=320&amp;q=65&amp;dpr=4 4x, //images.newrepublic.com/235e3ed2146bfaa5d88061466f6fb34753d9fc42.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=320&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=320&amp;q=65&amp;dpr=5 5x\"/></picture></div></a></div><div class=\"StoryMedium_text\"><div class=\"Byline\"><span class=\"AuthorList\"><span><span class=\"AuthorList_author\"><span class=\"AuthorList_bylineStyle\"></span><a class=\"Author_anchor\" href=\"/authors/alex-pareene\" title=\"Alex Pareene\">Alex Pareene</a></span><span class=\"AuthorList_comma\"></span></span></span></div><a class=\"Hed\" title=\"The Case for More Canceling\" href=\"/article/161999/cancel-culture-conservatives-seuss\"><div class=\"Hed\">The Case for More Canceling</div></a></div></div></div></div></section></div></div><div class=\"ContainerPlacement\" id=\"ContainerPlacement2\"><div><section class=\"ContainerSection --box4led2\"><div class=\"Box4Led2_firstCol\"><div class=\"ContainerTitle\">Latest From Sold Short</div></div><div class=\"Box4Led2_secondCol\"><div class=\"StorySmall_container\"><div class=\"StorySmall JustText\"><a class=\"ContainerArticleBadge_link\" href=\"/article/191453/federal-unions-fight-trump-musk\"><div class=\"ContainerArticleBadge\"><div class=\"ArticleBadge\">Labor Pains</div><svg class=\"BadgeSlash\" viewBox=\"0 0 9 24\"><line x1=\"1\" y1=\"100%\" x2=\"100%\" y2=\"-3\"></line></svg></div></a><a class=\"Hed\" title=\"  Federal Workers’ Unions Are Waging the Fight of Their Lives  \" href=\"/article/191453/federal-unions-fight-trump-musk\"><div class=\"Hed\">  Federal Workers’ Unions Are Waging the Fight of Their Lives  </div></a><div class=\"AuthorBorder\"><span class=\"AuthorList\"><span><span class=\"AuthorList_author\"><span class=\"AuthorList_bylineStyle\"></span><a class=\"Author_anchor\" href=\"/authors/grace-segers\" title=\"Grace Segers\">Grace Segers</a></span><span class=\"AuthorList_comma\"></span></span></span></div></div><div class=\"StoryMedium JustText\"><div class=\"StoryMedium_text\"><div class=\"Byline\"><a class=\"ContainerArticleBadge_link\" href=\"/article/191453/federal-unions-fight-trump-musk\"><div class=\"ContainerArticleBadge\"><div class=\"ArticleBadge\">Labor Pains</div><svg class=\"BadgeSlash\" viewBox=\"0 0 9 24\"><line x1=\"1\" y1=\"100%\" x2=\"100%\" y2=\"-3\"></line></svg></div></a><span class=\"AuthorList\"><span><span class=\"AuthorList_author\"><span class=\"AuthorList_bylineStyle\"></span><a class=\"Author_anchor\" href=\"/authors/grace-segers\" title=\"Grace Segers\">Grace Segers</a></span><span class=\"AuthorList_comma\"></span></span></span></div><a class=\"Hed\" title=\"  Federal Workers’ Unions Are Waging the Fight of Their Lives  \" href=\"/article/191453/federal-unions-fight-trump-musk\"><div class=\"Hed\">  Federal Workers’ Unions Are Waging the Fight of Their Lives  </div></a></div></div></div></div><div class=\"Box4Led2_thirdCol\"><div class=\"StorySmall_container\"><div class=\"StorySmall TextImage\"><a class=\"ContainerArticleBadge_link\" href=\"/article/191422/democrats-defend-federal-workers-doge\"><div class=\"ContainerArticleBadge\"><div class=\"ArticleBadge\">Back the Feds</div><svg class=\"BadgeSlash\" viewBox=\"0 0 9 24\"><line x1=\"1\" y1=\"100%\" x2=\"100%\" y2=\"-3\"></line></svg></div></a><a class=\"ContainerImg\" title=\"If Democrats Don’t Champion the Civil Service, Who Will?\" href=\"/article/191422/democrats-defend-federal-workers-doge\"><div class=\"LedeImgContainer\"><picture><source srcSet=\"data:image/svg+xml,%3Csvg%20width%3D%22384%22%20height%3D%22288%22%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%3E%3Crect%20width%3D%22100%25%22%20height%3D%22100%25%22%20fill%3D%22%23F5F5F5%22%2F%3E%3C%2Fsvg%3E\" media=\"screen and (min-width: 992px)\" width=\"384\" data-srcset=\"//images.newrepublic.com/2924b35d513f021f535a006978c2b3a8335f3081.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=1 1x, //images.newrepublic.com/2924b35d513f021f535a006978c2b3a8335f3081.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=2 2x, //images.newrepublic.com/2924b35d513f021f535a006978c2b3a8335f3081.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=3 3x, //images.newrepublic.com/2924b35d513f021f535a006978c2b3a8335f3081.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=4 4x, //images.newrepublic.com/2924b35d513f021f535a006978c2b3a8335f3081.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=5 5x\"/><source srcSet=\"data:image/svg+xml,%3Csvg%20width%3D%22240%22%20height%3D%22160%22%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%3E%3Crect%20width%3D%22100%25%22%20height%3D%22100%25%22%20fill%3D%22%23F5F5F5%22%2F%3E%3C%2Fsvg%3E\" media=\"screen and (min-width: 768px) and (max-width: 991.98px)\" width=\"240\" data-srcset=\"//images.newrepublic.com/2924b35d513f021f535a006978c2b3a8335f3081.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=3%3A2&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=1 1x, //images.newrepublic.com/2924b35d513f021f535a006978c2b3a8335f3081.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=3%3A2&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=2 2x, //images.newrepublic.com/2924b35d513f021f535a006978c2b3a8335f3081.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=3%3A2&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=3 3x, //images.newrepublic.com/2924b35d513f021f535a006978c2b3a8335f3081.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=3%3A2&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=4 4x, //images.newrepublic.com/2924b35d513f021f535a006978c2b3a8335f3081.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=3%3A2&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=5 5x\"/><img src=\"data:image/svg+xml,%3Csvg%20width%3D%22384%22%20height%3D%22216%22%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%3E%3Crect%20width%3D%22100%25%22%20height%3D%22100%25%22%20fill%3D%22%23F5F5F5%22%2F%3E%3C%2Fsvg%3E\" alt=\"Protesters gather at a rally organized by the American Federation of Government Employees against the so-called Department of Government Efficiency (DOGE) purges and resignation offers made to the federal civilian workforce outside the US Capitol in Washington, D.C.\" class=\"LedeImg lazyload\" width=\"384\" data-src=\"//images.newrepublic.com/2924b35d513f021f535a006978c2b3a8335f3081.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;q=65&amp;w=384&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=384\" data-srcset=\"//images.newrepublic.com/2924b35d513f021f535a006978c2b3a8335f3081.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=384&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=1 1x, //images.newrepublic.com/2924b35d513f021f535a006978c2b3a8335f3081.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=384&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=2 2x, //images.newrepublic.com/2924b35d513f021f535a006978c2b3a8335f3081.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=384&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=3 3x, //images.newrepublic.com/2924b35d513f021f535a006978c2b3a8335f3081.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=384&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=4 4x, //images.newrepublic.com/2924b35d513f021f535a006978c2b3a8335f3081.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=384&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=5 5x\"/></picture></div></a><a class=\"Hed\" title=\"If Democrats Don’t Champion the Civil Service, Who Will?\" href=\"/article/191422/democrats-defend-federal-workers-doge\"><div class=\"Hed\">If Democrats Don’t Champion the Civil Service, Who Will?</div></a><div class=\"AuthorBorder\"><span class=\"AuthorList\"><span><span class=\"AuthorList_author\"><span class=\"AuthorList_bylineStyle\"></span><a class=\"Author_anchor\" href=\"/authors/bryce-covert\" title=\"Bryce Covert\">Bryce Covert</a></span><span class=\"AuthorList_comma\"></span></span></span></div></div><div class=\"StoryMedium TextImage\"><div class=\"StoryMedium_img\"><a class=\"ContainerImg\" title=\"If Democrats Don’t Champion the Civil Service, Who Will?\" href=\"/article/191422/democrats-defend-federal-workers-doge\"><div class=\"LedeImgContainer\"><picture><source srcSet=\"data:image/svg+xml,%3Csvg%20width%3D%22240%22%20height%3D%22180%22%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%3E%3Crect%20width%3D%22100%25%22%20height%3D%22100%25%22%20fill%3D%22%23F5F5F5%22%2F%3E%3C%2Fsvg%3E\" media=\"screen and (min-width: 992px)\" width=\"240\" data-srcset=\"//images.newrepublic.com/2924b35d513f021f535a006978c2b3a8335f3081.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=1 1x, //images.newrepublic.com/2924b35d513f021f535a006978c2b3a8335f3081.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=2 2x, //images.newrepublic.com/2924b35d513f021f535a006978c2b3a8335f3081.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=3 3x, //images.newrepublic.com/2924b35d513f021f535a006978c2b3a8335f3081.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=4 4x, //images.newrepublic.com/2924b35d513f021f535a006978c2b3a8335f3081.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=5 5x\"/><source srcSet=\"data:image/svg+xml,%3Csvg%20width%3D%22240%22%20height%3D%22240%22%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%3E%3Crect%20width%3D%22100%25%22%20height%3D%22100%25%22%20fill%3D%22%23F5F5F5%22%2F%3E%3C%2Fsvg%3E\" media=\"screen and (min-width: 768px) and (max-width: 991.98px)\" width=\"240\" data-srcset=\"//images.newrepublic.com/2924b35d513f021f535a006978c2b3a8335f3081.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=1%3A1&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=1 1x, //images.newrepublic.com/2924b35d513f021f535a006978c2b3a8335f3081.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=1%3A1&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=2 2x, //images.newrepublic.com/2924b35d513f021f535a006978c2b3a8335f3081.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=1%3A1&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=3 3x, //images.newrepublic.com/2924b35d513f021f535a006978c2b3a8335f3081.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=1%3A1&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=4 4x, //images.newrepublic.com/2924b35d513f021f535a006978c2b3a8335f3081.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=1%3A1&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=5 5x\"/><img src=\"data:image/svg+xml,%3Csvg%20width%3D%22320%22%20height%3D%22180%22%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%3E%3Crect%20width%3D%22100%25%22%20height%3D%22100%25%22%20fill%3D%22%23F5F5F5%22%2F%3E%3C%2Fsvg%3E\" alt=\"Protesters gather at a rally organized by the American Federation of Government Employees against the so-called Department of Government Efficiency (DOGE) purges and resignation offers made to the federal civilian workforce outside the US Capitol in Washington, D.C.\" class=\"LedeImg lazyload\" width=\"320\" data-src=\"//images.newrepublic.com/2924b35d513f021f535a006978c2b3a8335f3081.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;q=65&amp;w=320&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=320\" data-srcset=\"//images.newrepublic.com/2924b35d513f021f535a006978c2b3a8335f3081.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=320&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=320&amp;q=65&amp;dpr=1 1x, //images.newrepublic.com/2924b35d513f021f535a006978c2b3a8335f3081.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=320&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=320&amp;q=65&amp;dpr=2 2x, //images.newrepublic.com/2924b35d513f021f535a006978c2b3a8335f3081.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=320&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=320&amp;q=65&amp;dpr=3 3x, //images.newrepublic.com/2924b35d513f021f535a006978c2b3a8335f3081.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=320&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=320&amp;q=65&amp;dpr=4 4x, //images.newrepublic.com/2924b35d513f021f535a006978c2b3a8335f3081.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=320&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=320&amp;q=65&amp;dpr=5 5x\"/></picture></div></a></div><div class=\"StoryMedium_text\"><div class=\"Byline\"><a class=\"ContainerArticleBadge_link\" href=\"/article/191422/democrats-defend-federal-workers-doge\"><div class=\"ContainerArticleBadge\"><div class=\"ArticleBadge\">Back the Feds</div><svg class=\"BadgeSlash\" viewBox=\"0 0 9 24\"><line x1=\"1\" y1=\"100%\" x2=\"100%\" y2=\"-3\"></line></svg></div></a><span class=\"AuthorList\"><span><span class=\"AuthorList_author\"><span class=\"AuthorList_bylineStyle\"></span><a class=\"Author_anchor\" href=\"/authors/bryce-covert\" title=\"Bryce Covert\">Bryce Covert</a></span><span class=\"AuthorList_comma\"></span></span></span></div><a class=\"Hed\" title=\"If Democrats Don’t Champion the Civil Service, Who Will?\" href=\"/article/191422/democrats-defend-federal-workers-doge\"><div class=\"Hed\">If Democrats Don’t Champion the Civil Service, Who Will?</div></a></div></div></div></div><div class=\"Box4Led2_fourthCol\"><div class=\"StorySmall_container\"><div class=\"StorySmall JustText\"><a class=\"ContainerArticleBadge_link\" href=\"/article/191450/trump-courts-judiciary-constitutional-cliff\"><div class=\"ContainerArticleBadge\"><div class=\"ArticleBadge\">COURTING CRISIS</div><svg class=\"BadgeSlash\" viewBox=\"0 0 9 24\"><line x1=\"1\" y1=\"100%\" x2=\"100%\" y2=\"-3\"></line></svg></div></a><a class=\"Hed\" title=\"Trump vs. the Courts: Will He Drive Us Over the Constitutional Cliff? \" href=\"/article/191450/trump-courts-judiciary-constitutional-cliff\"><div class=\"Hed\">Trump vs. the Courts: Will He Drive Us Over the Constitutional Cliff? </div></a><div class=\"AuthorBorder\"><span class=\"AuthorList\"><span><span class=\"AuthorList_author\"><span class=\"AuthorList_bylineStyle\"></span><a class=\"Author_anchor\" href=\"/authors/harry-litman\" title=\"Harry Litman\">Harry Litman</a></span><span class=\"AuthorList_comma\"></span></span></span></div></div><div class=\"StoryMedium JustText\"><div class=\"StoryMedium_text\"><div class=\"Byline\"><a class=\"ContainerArticleBadge_link\" href=\"/article/191450/trump-courts-judiciary-constitutional-cliff\"><div class=\"ContainerArticleBadge\"><div class=\"ArticleBadge\">COURTING CRISIS</div><svg class=\"BadgeSlash\" viewBox=\"0 0 9 24\"><line x1=\"1\" y1=\"100%\" x2=\"100%\" y2=\"-3\"></line></svg></div></a><span class=\"AuthorList\"><span><span class=\"AuthorList_author\"><span class=\"AuthorList_bylineStyle\"></span><a class=\"Author_anchor\" href=\"/authors/harry-litman\" title=\"Harry Litman\">Harry Litman</a></span><span class=\"AuthorList_comma\"></span></span></span></div><a class=\"Hed\" title=\"Trump vs. the Courts: Will He Drive Us Over the Constitutional Cliff? \" href=\"/article/191450/trump-courts-judiciary-constitutional-cliff\"><div class=\"Hed\">Trump vs. the Courts: Will He Drive Us Over the Constitutional Cliff? </div></a></div></div></div></div><div class=\"Box4Led2_fifthCol\"><div class=\"StorySmall_container\"><div class=\"StorySmall TextImage\"><a class=\"ContainerArticleBadge_link\" href=\"/article/191430/trump-bondi-justice-corruption-roberts\"><div class=\"ContainerArticleBadge\"><div class=\"ArticleBadge\">Crime Wave</div><svg class=\"BadgeSlash\" viewBox=\"0 0 9 24\"><line x1=\"1\" y1=\"100%\" x2=\"100%\" y2=\"-3\"></line></svg></div></a><a class=\"ContainerImg\" title=\"Trump Won His War on the Justice Department\" href=\"/article/191430/trump-bondi-justice-corruption-roberts\"><div class=\"LedeImgContainer\"><picture><source srcSet=\"data:image/svg+xml,%3Csvg%20width%3D%22384%22%20height%3D%22288%22%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%3E%3Crect%20width%3D%22100%25%22%20height%3D%22100%25%22%20fill%3D%22%23F5F5F5%22%2F%3E%3C%2Fsvg%3E\" media=\"screen and (min-width: 992px)\" width=\"384\" data-srcset=\"//images.newrepublic.com/9757a6f923a1ebb1c0b2062734278b847af2906b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=1 1x, //images.newrepublic.com/9757a6f923a1ebb1c0b2062734278b847af2906b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=2 2x, //images.newrepublic.com/9757a6f923a1ebb1c0b2062734278b847af2906b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=3 3x, //images.newrepublic.com/9757a6f923a1ebb1c0b2062734278b847af2906b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=4 4x, //images.newrepublic.com/9757a6f923a1ebb1c0b2062734278b847af2906b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=5 5x\"/><source srcSet=\"data:image/svg+xml,%3Csvg%20width%3D%22240%22%20height%3D%22160%22%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%3E%3Crect%20width%3D%22100%25%22%20height%3D%22100%25%22%20fill%3D%22%23F5F5F5%22%2F%3E%3C%2Fsvg%3E\" media=\"screen and (min-width: 768px) and (max-width: 991.98px)\" width=\"240\" data-srcset=\"//images.newrepublic.com/9757a6f923a1ebb1c0b2062734278b847af2906b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=3%3A2&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=1 1x, //images.newrepublic.com/9757a6f923a1ebb1c0b2062734278b847af2906b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=3%3A2&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=2 2x, //images.newrepublic.com/9757a6f923a1ebb1c0b2062734278b847af2906b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=3%3A2&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=3 3x, //images.newrepublic.com/9757a6f923a1ebb1c0b2062734278b847af2906b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=3%3A2&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=4 4x, //images.newrepublic.com/9757a6f923a1ebb1c0b2062734278b847af2906b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=3%3A2&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=5 5x\"/><img src=\"data:image/svg+xml,%3Csvg%20width%3D%22384%22%20height%3D%22216%22%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%3E%3Crect%20width%3D%22100%25%22%20height%3D%22100%25%22%20fill%3D%22%23F5F5F5%22%2F%3E%3C%2Fsvg%3E\" alt=\"Donald Trump and U.S. Attorney General Pam Bondi pose with a document in the Oval Office.\" class=\"LedeImg lazyload\" width=\"384\" data-src=\"//images.newrepublic.com/9757a6f923a1ebb1c0b2062734278b847af2906b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;q=65&amp;w=384&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=384\" data-srcset=\"//images.newrepublic.com/9757a6f923a1ebb1c0b2062734278b847af2906b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=384&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=1 1x, //images.newrepublic.com/9757a6f923a1ebb1c0b2062734278b847af2906b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=384&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=2 2x, //images.newrepublic.com/9757a6f923a1ebb1c0b2062734278b847af2906b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=384&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=3 3x, //images.newrepublic.com/9757a6f923a1ebb1c0b2062734278b847af2906b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=384&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=4 4x, //images.newrepublic.com/9757a6f923a1ebb1c0b2062734278b847af2906b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=384&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=384&amp;q=65&amp;dpr=5 5x\"/></picture></div></a><a class=\"Hed\" title=\"Trump Won His War on the Justice Department\" href=\"/article/191430/trump-bondi-justice-corruption-roberts\"><div class=\"Hed\">Trump Won His War on the Justice Department</div></a><div class=\"AuthorBorder\"><span class=\"AuthorList\"><span><span class=\"AuthorList_author\"><span class=\"AuthorList_bylineStyle\"></span><a class=\"Author_anchor\" href=\"/authors/matt-ford\" title=\"Matt Ford\">Matt Ford</a></span><span class=\"AuthorList_comma\"></span></span></span></div></div><div class=\"StoryMedium TextImage\"><div class=\"StoryMedium_img\"><a class=\"ContainerImg\" title=\"Trump Won His War on the Justice Department\" href=\"/article/191430/trump-bondi-justice-corruption-roberts\"><div class=\"LedeImgContainer\"><picture><source srcSet=\"data:image/svg+xml,%3Csvg%20width%3D%22240%22%20height%3D%22180%22%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%3E%3Crect%20width%3D%22100%25%22%20height%3D%22100%25%22%20fill%3D%22%23F5F5F5%22%2F%3E%3C%2Fsvg%3E\" media=\"screen and (min-width: 992px)\" width=\"240\" data-srcset=\"//images.newrepublic.com/9757a6f923a1ebb1c0b2062734278b847af2906b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=1 1x, //images.newrepublic.com/9757a6f923a1ebb1c0b2062734278b847af2906b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=2 2x, //images.newrepublic.com/9757a6f923a1ebb1c0b2062734278b847af2906b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=3 3x, //images.newrepublic.com/9757a6f923a1ebb1c0b2062734278b847af2906b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=4 4x, //images.newrepublic.com/9757a6f923a1ebb1c0b2062734278b847af2906b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=4%3A3&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=5 5x\"/><source srcSet=\"data:image/svg+xml,%3Csvg%20width%3D%22240%22%20height%3D%22240%22%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%3E%3Crect%20width%3D%22100%25%22%20height%3D%22100%25%22%20fill%3D%22%23F5F5F5%22%2F%3E%3C%2Fsvg%3E\" media=\"screen and (min-width: 768px) and (max-width: 991.98px)\" width=\"240\" data-srcset=\"//images.newrepublic.com/9757a6f923a1ebb1c0b2062734278b847af2906b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=1%3A1&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=1 1x, //images.newrepublic.com/9757a6f923a1ebb1c0b2062734278b847af2906b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=1%3A1&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=2 2x, //images.newrepublic.com/9757a6f923a1ebb1c0b2062734278b847af2906b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=1%3A1&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=3 3x, //images.newrepublic.com/9757a6f923a1ebb1c0b2062734278b847af2906b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=1%3A1&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=4 4x, //images.newrepublic.com/9757a6f923a1ebb1c0b2062734278b847af2906b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;ar=1%3A1&amp;ixlib=react-9.0.3&amp;w=240&amp;q=65&amp;dpr=5 5x\"/><img src=\"data:image/svg+xml,%3Csvg%20width%3D%22320%22%20height%3D%22180%22%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%3E%3Crect%20width%3D%22100%25%22%20height%3D%22100%25%22%20fill%3D%22%23F5F5F5%22%2F%3E%3C%2Fsvg%3E\" alt=\"Donald Trump and U.S. Attorney General Pam Bondi pose with a document in the Oval Office.\" class=\"LedeImg lazyload\" width=\"320\" data-src=\"//images.newrepublic.com/9757a6f923a1ebb1c0b2062734278b847af2906b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;q=65&amp;w=320&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=320\" data-srcset=\"//images.newrepublic.com/9757a6f923a1ebb1c0b2062734278b847af2906b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=320&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=320&amp;q=65&amp;dpr=1 1x, //images.newrepublic.com/9757a6f923a1ebb1c0b2062734278b847af2906b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=320&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=320&amp;q=65&amp;dpr=2 2x, //images.newrepublic.com/9757a6f923a1ebb1c0b2062734278b847af2906b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=320&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=320&amp;q=65&amp;dpr=3 3x, //images.newrepublic.com/9757a6f923a1ebb1c0b2062734278b847af2906b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=320&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=320&amp;q=65&amp;dpr=4 4x, //images.newrepublic.com/9757a6f923a1ebb1c0b2062734278b847af2906b.jpeg?auto=format&amp;fit=crop&amp;crop=faces&amp;w=320&amp;h=undefined&amp;ar=16%3A9&amp;ixlib=react-9.0.3&amp;w=320&amp;q=65&amp;dpr=5 5x\"/></picture></div></a></div><div class=\"StoryMedium_text\"><div class=\"Byline\"><a class=\"ContainerArticleBadge_link\" href=\"/article/191430/trump-bondi-justice-corruption-roberts\"><div class=\"ContainerArticleBadge\"><div class=\"ArticleBadge\">Crime Wave</div><svg class=\"BadgeSlash\" viewBox=\"0 0 9 24\"><line x1=\"1\" y1=\"100%\" x2=\"100%\" y2=\"-3\"></line></svg></div></a><span class=\"AuthorList\"><span><span class=\"AuthorList_author\"><span class=\"AuthorList_bylineStyle\"></span><a class=\"Author_anchor\" href=\"/authors/matt-ford\" title=\"Matt Ford\">Matt Ford</a></span><span class=\"AuthorList_comma\"></span></span></span></div><a class=\"Hed\" title=\"Trump Won His War on the Justice Department\" href=\"/article/191430/trump-bondi-justice-corruption-roberts\"><div class=\"Hed\">Trump Won His War on the Justice Department</div></a></div></div></div></div></section></div></div></div><div class=\"ad-unit house_donate \"><div><div class=\"ad-slot\" id=\"house_donate\"></div></div></div><footer class=\"footer politics\" id=\"footer\"><div class=\"footer__topRow\"><ul class=\"footer__verticalsNav\"><li><a href=\"/feeds/168326/breaking-news\">BREAKING NEWS</a> <svg class=\"footerSlash\" width=\"7.52\" height=\"20.67\"><line x1=\"10%\" y1=\"100%\" x2=\"90%\" y2=\"0\"></line></svg></li><li><a href=\"/politics\">POLITICS</a> <svg class=\"footerSlash\" width=\"7.52\" height=\"20.67\"><line x1=\"10%\" y1=\"100%\" x2=\"90%\" y2=\"0\"></line></svg></li><li><a href=\"/climate\">CLIMATE</a> <svg class=\"footerSlash\" width=\"7.52\" height=\"20.67\"><line x1=\"10%\" y1=\"100%\" x2=\"90%\" y2=\"0\"></line></svg></li><li><a href=\"/culture\">CULTURE</a> <svg class=\"footerSlash\" width=\"7.52\" height=\"20.67\"><line x1=\"10%\" y1=\"100%\" x2=\"90%\" y2=\"0\"></line></svg></li><li><a href=\"/magazine\">MAGAZINE</a> <svg class=\"footerSlash\" width=\"7.52\" height=\"20.67\"><line x1=\"10%\" y1=\"100%\" x2=\"90%\" y2=\"0\"></line></svg></li><li><a href=\"/podcasts\">PODCASTS</a> <svg class=\"footerSlash\" width=\"7.52\" height=\"20.67\"><line x1=\"10%\" y1=\"100%\" x2=\"90%\" y2=\"0\"></line></svg></li><li><a href=\"/games\">GAMES</a></li></ul><ul class=\"footer__aboutNav\"><li><a href=\"/pages/events\">Events</a></li><li><a href=\"/travel\">Travel</a></li><li><a href=\"/bookstore\">Bookstore</a></li><li><a style=\"cursor:pointer\" role=\"button\">Donate</a></li><li><a href=\"https://advertise.newrepublic.com/\">Advertise</a></li><li><a href=\"/pages/faq\">FAQ</a></li><li><a href=\"/tags/press-release\">Press</a></li><li><a href=\"/pages/about#jobs\">Jobs</a></li><li><a href=\"/pages/contact#submissionGuidelines\">Submissions</a></li></ul></div><div class=\"footer__middleRow\"><ul><li><a href=\"https://www.facebook.com/newrepublic/\" target=\"_blank\" rel=\"noreferrer\"><svg class=\"facebookIcon\" aria-label=\"Facebook\" xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 24\" overflow=\"visible\"><path d=\"M0 0h24v24h-7.4v-9.3h3.1l.5-3.7h-3.6V8.5c0-.8.6-1.4 1.4-1.4h2.3V3.7l-2.9-.1c-2.7-.1-4.6 2-4.6 4.4v3H9.7v3.7h3.1V24H0V0z\"></path></svg></a></li><li><a href=\"https://www.instagram.com/newrepublic/\" target=\"_blank\" rel=\"noreferrer\"><svg class=\"instagramIcon\" aria-label=\"Instagram\" xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 24\" overflow=\"visible\"><path d=\"M18.6 0H5.4C2.4 0 0 2.4 0 5.4v13.2c0 3 2.4 5.4 5.4 5.4h13.2c3 0 5.4-2.4 5.4-5.4V5.4c0-3-2.4-5.4-5.4-5.4zM12 18.4c-3.6 0-6.4-2.9-6.4-6.4 0-3.6 2.9-6.4 6.4-6.4 3.6 0 6.4 2.9 6.4 6.4 0 3.6-2.8 6.4-6.4 6.4zm7.4-12.3c-.8 0-1.5-.7-1.5-1.5s.7-1.5 1.5-1.5 1.5.7 1.5 1.5-.6 1.5-1.5 1.5z\"></path><circle cx=\"12\" cy=\"12\" r=\"4.2\"></circle></svg></a></li><li><a href=\"https://www.x.com/newrepublic/\" target=\"_blank\" rel=\"noreferrer\"><svg class=\"twitterIcon\" aria-label=\"X\" version=\"1.1\" viewBox=\"0 0 300 300\" xmlns=\"http://www.w3.org/2000/svg\"><path d=\"M178.57 127.15 290.27 0h-26.46l-97.03 110.38L89.34 0H0l117.13 166.93L0 300.25h26.46l102.4-116.59 81.8 116.59h89.34M36.01 19.54H76.66l187.13 262.13h-40.66\"></path></svg></a></li><li class=\"blueSkyIcon\"><a href=\"https://bsky.app/profile/newrepublic.com\" target=\"_blank\" rel=\"noreferrer\"><svg class=\"blueskyIcon\" aria-label=\"Bluesky\" xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 600 530\"><path d=\"M135.72 44.03C202.216 93.951 273.74 195.17 300 249.49c26.262-54.316 97.782-155.54 164.28-205.46C512.26 8.009 590-19.862 590 68.825c0 17.712-10.155 148.79-16.111 170.07-20.703 73.984-96.144 92.854-163.25 81.433 117.3 19.964 147.14 86.092 82.697 152.22-122.39 125.59-175.91-31.511-189.63-71.766-2.514-7.38-3.69-10.832-3.708-7.896-.017-2.936-1.193.516-3.707 7.896-13.714 40.255-67.233 197.36-189.63 71.766-64.444-66.128-34.605-132.26 82.697-152.22-67.108 11.421-142.55-7.45-163.25-81.433C20.15 217.613 9.997 86.535 9.997 68.825c0-88.687 77.742-60.816 125.72-24.795z\"></path></svg></a></li><li><a href=\"https://flipboard.com/@thenewrepublic\" target=\"_blank\" rel=\"noreferrer\"><svg class=\"flipbookIcon\" aria-label=\"Flipboox\" xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 24\" overflow=\"visible\"><path d=\"M0 0h24v24.1H0V0zm5 5v14.2h4.7v-4.7h4.7V9.7H19V5H5z\"></path></svg></a></li><li><a href=\"https://open.spotify.com/show/39bB7ap7275oJsA1b0BEO4\" target=\"_blank\" rel=\"noreferrer\"><svg class=\"spotifyIcon\" aria-label=\"Spotify\" xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 24\" overflow=\"visible\"><path d=\"M24 12c0 6.6-5.4 12-12 12S0 18.6 0 12 5.4 0 12 0s12 5.4 12 12zm-6.5 5.3c.2-.4.1-.9-.3-1.1-5.3-3.2-11.4-1.4-11.6-1.3-.4.1-.6.6-.5 1 .1.4.6.7 1 .5.1 0 5.7-1.7 10.4 1.2.1.1.3.1.4.1.2 0 .4-.1.6-.4zM19 14c.3-.4.1-1-.3-1.3C12 8.9 5.4 11.1 5.1 11.2c-.5.2-.7.7-.6 1.2.2.5.7.7 1.2.6.1 0 6-2 12 1.4.1.1.3.1.5.1.3 0 .6-.2.8-.5zm1.7-3.8c.3-.6.1-1.3-.5-1.5C12.5 4.6 4.8 7 4.5 7.1c-.6.2-1 .8-.8 1.4.2.6.8.9 1.4.7.1 0 7.1-2.2 13.9 1.4.2.1.4.1.5.1.6.1 1-.1 1.2-.5z\"></path></svg></a></li><li><a href=\"https://podcasts.apple.com/us/podcast/the-daily-blast-with-greg-sargent/id1728152109\" target=\"_blank\" rel=\"noreferrer\"><svg class=\"podcastIcon\" aria-label=\"Apple Podcast\" xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 26.5\" overflow=\"visible\"><path d=\"M14.8 19.1c0 1.7-.2 3.3-.7 4.9-.2.7-.6 1.5-1.2 2-.7.6-1.3.6-1.9 0-.7-.7-1.1-1.6-1.3-2.6-.6-1.8-.7-3.7-.7-5.6 0-1.6 1.4-2.8 2.9-2.8s2.8 1.1 2.9 2.7v1.4zM9 11.2c0-1.7 1.4-3 3.1-3 1.5 0 2.8 1.4 2.8 2.9 0 1.6-1.3 3-2.9 3-1.7 0-3-1.3-3-2.9z\"></path><path d=\"M23.9 10.7C23.3 4.5 17.7-.3 11.4 0 5.1.3 0 5.6 0 12c0 6.3 4.7 10.5 8.2 11.4-.1-.6-.2-1.1-.2-1.7-.1-.2-.3-.3-.6-.5-4-1.9-6.3-6.4-5.6-10.8 1-5.9 6.5-9.8 12.4-8.6 5.5 1.1 9.2 6.8 8 12.3-.8 3.4-2.7 5.8-5.9 7.3-.1.1-.3.1-.4.2l-.3 1.8c4.1-1 9-5.7 8.3-12.7z\"></path><path d=\"M19.6 10.3c-.9-3.7-4.2-6.2-8.1-6-3.5.1-6.7 2.9-7.4 6.5-.7 3.8 1.6 7.1 3.6 8v-2l-.1-.1c-1.2-1.2-1.8-2.6-1.9-4.2-.3-4 3.6-7.3 7.5-6.4 2.4.6 4.1 2 4.8 4.4.7 2.4.1 4.6-1.7 6.3v2c2.2-1.3 4.1-4.8 3.3-8.5z\"></path></svg></a></li><li><a href=\"https://www.youtube.com/user/NewRepublic1914/\" target=\"_blank\" rel=\"noreferrer\"><svg class=\"youtubeIcon\" aria-label=\"Youtube\" xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 20.6\" overflow=\"visible\"><path d=\"M19 0H5C2.3 0 0 2.3 0 5v10.5c0 2.8 2.3 5 5 5h14c2.8 0 5-2.3 5-5V5c0-2.7-2.3-5-5-5zM8.8 14.4V6l8 4.2-8 4.2z\"></path></svg></a></li><li><a href=\"https://www.linkedin.com/company/newrepublic\" target=\"_blank\" rel=\"noreferrer\"><svg class=\"linkedinIcon\" aria-label=\"LinkedIn\" xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 24\" overflow=\"visible\"><path d=\"M0 0v24h24V0H0zm3.6 20.1V9.3h3.6v10.8H3.6zM5.4 7.8c-1.2 0-2-.8-2-1.9 0-1.1.8-1.9 2-1.9s2 .8 2 1.9c.1 1-.7 1.9-2 1.9zm14.8 12.3h-3.6v-5.8c0-1.5-.5-2.5-1.8-2.5-1 0-1.6.7-1.8 1.3-.1.2-.1.6-.1.9v6.1H9.2V9.3h3.6v1.5c.5-.8 1.4-1.8 3.3-1.8 2.4 0 4.1 1.5 4.1 4.9v6.2z\"></path></svg></a></li></ul></div><div class=\"footer__bottomRow\"><ul class=\"footer__ctaList\"><li class=\"footer__ctaListItem\"><a style=\"cursor:pointer\" role=\"button\"><span>Subscribe to <i>The New Republic</i></span></a></li><li class=\"footer__ctaListItem\"><a style=\"cursor:pointer\" role=\"button\">Sign Up for Our Newsletters</a></li></ul><ul class=\"footer__miscList\"><li><a href=\"/pages/terms-and-conditions\"> Terms and Conditions</a></li><li><a href=\"/pages/privacy\">Privacy Policy</a></li><li><a id=\"ot-sdk-btn\" class=\"ot-sdk-show-settings\">Cookie Settings</a></li><li>Copyright <!-- -->2025<!-- --> © <i>The New Republic</i>. All rights reserved.</li></ul></div></footer></div></div></div>\n    <script>window.__APOLLO_STATE__={\"FrontPage:03bf2e55-4f96-4942-851b-0ac31c0aa4e4\":{\"__typename\":\"FrontPage\",\"id\":\"03bf2e55-4f96-4942-851b-0ac31c0aa4e4\",\"slug\":\"politics\",\"title\":\"Politics\",\"recircStream\":{\"__typename\":\"ESArticleSearchResults\",\"totalHits\":5591,\"nids\":[\"191453\",\"191422\",\"191450\",\"191430\",\"191427\",\"191373\",\"191367\",\"191334\",\"191298\",\"191330\",\"191255\",\"191288\",\"191269\",\"191127\",\"191265\",\"191209\",\"191160\",\"191215\",\"191205\",\"191174\",\"191191\",\"191120\",\"191153\",\"191141\",\"191091\",\"191084\",\"190623\",\"191063\",\"190859\",\"190922\",\"191023\",\"191044\",\"191037\",\"191029\",\"191030\",\"191014\",\"190987\",\"190717\",\"190921\",\"190975\",\"190935\",\"190924\",\"190928\",\"190880\",\"190875\",\"190861\",\"190807\",\"190689\",\"190838\",\"190759\",\"190730\",\"190634\",\"190686\",\"190704\",\"190626\",\"190696\",\"190652\",\"190574\",\"190586\",\"190635\",\"190613\",\"190562\",\"190525\",\"190517\",\"190526\",\"190473\",\"190446\",\"190491\",\"190467\",\"190452\",\"190408\",\"190381\",\"190413\",\"190378\",\"190337\",\"190394\",\"190405\",\"190361\",\"190355\",\"190339\",\"190167\",\"190248\",\"190164\",\"190212\",\"190233\",\"190219\",\"190213\",\"190118\",\"190162\",\"190129\",\"190050\",\"190049\",\"190137\",\"190096\",\"190107\",\"190108\",\"190072\",\"190086\",\"190075\",\"190043\"]},\"tag\":{\"__ref\":\"Tag:3046ee55-25d3-43cb-8491-58b17f8004d3\"}},\"Author:9f211e0a-b0b1-4c47-a7f4-ce7c3a78fc7f\":{\"__typename\":\"Author\",\"id\":\"9f211e0a-b0b1-4c47-a7f4-ce7c3a78fc7f\",\"name\":\"Alexander Zaitchik\",\"slug\":\"alexander-zaitchik\",\"blurb\":\"\\u003cp>Alexander Zaitchik is the author, most recently, of \\u003ci>Owning the Sun: A People’s History of Monopoly Medicine From Aspirin to Covid-19.\\u003c/i>\\u003c/p>\",\"meta\":{\"__typename\":\"AuthorMeta\",\"twitter\":null,\"bluesky\":null,\"podcast\":null}},\"Image:209df8aa-c69a-4b57-9b52-ec358002640c\":{\"__typename\":\"Image\",\"id\":\"209df8aa-c69a-4b57-9b52-ec358002640c\",\"src\":\"//images.newrepublic.com/e3fb4ce1a82048335f394329088873da63f2fed1.jpeg\",\"format\":\"JPEG\",\"width\":3750,\"height\":2500,\"alt\":null},\"Tag:c27ff6e6-b672-430d-be07-8a59b6f23383\":{\"__typename\":\"Tag\",\"id\":\"c27ff6e6-b672-430d-be07-8a59b6f23383\",\"slug\":\"the-soapbox\",\"label\":\"The Soapbox\"},\"Tag:0ca9ed51-a0f1-4ae8-90d9-ff3075e6a861\":{\"__typename\":\"Tag\",\"id\":\"0ca9ed51-a0f1-4ae8-90d9-ff3075e6a861\",\"slug\":\"covid-19\",\"label\":\"Covid-19\"},\"Tag:afb41557-1d97-4ce3-91b0-134cf76a9357\":{\"__typename\":\"Tag\",\"id\":\"afb41557-1d97-4ce3-91b0-134cf76a9357\",\"slug\":\"bill-gates\",\"label\":\"Bill Gates\"},\"Tag:72f5dd2b-f134-4f25-8f5f-e36a141f7fe4\":{\"__typename\":\"Tag\",\"id\":\"72f5dd2b-f134-4f25-8f5f-e36a141f7fe4\",\"slug\":\"bill-and-melinda-gates-foundation\",\"label\":\"Bill & Melinda Gates Foundation\"},\"Tag:d3a73e0b-32e6-4481-ade9-b6774f75f3f9\":{\"__typename\":\"Tag\",\"id\":\"d3a73e0b-32e6-4481-ade9-b6774f75f3f9\",\"slug\":\"world-health-organization\",\"label\":\"World Health Organization\"},\"Tag:173baf6d-254c-4738-822c-6cac468c9858\":{\"__typename\":\"Tag\",\"id\":\"173baf6d-254c-4738-822c-6cac468c9858\",\"slug\":\"world-trade-organization\",\"label\":\"World Trade Organization\"},\"Tag:326de734-3a2b-4bf7-9c1a-5e32ae7ffd6f\":{\"__typename\":\"Tag\",\"id\":\"326de734-3a2b-4bf7-9c1a-5e32ae7ffd6f\",\"slug\":\"coronavirus-vaccine\",\"label\":\"coronavirus vaccine\"},\"Tag:b497b045-2e5b-4f37-8f1c-e297f689dba3\":{\"__typename\":\"Tag\",\"id\":\"b497b045-2e5b-4f37-8f1c-e297f689dba3\",\"slug\":\"pandemic\",\"label\":\"pandemic\"},\"Tag:c8e98811-c2da-4469-b25d-c7af29efc9e8\":{\"__typename\":\"Tag\",\"id\":\"c8e98811-c2da-4469-b25d-c7af29efc9e8\",\"slug\":\"big-pharma\",\"label\":\"Big Pharma\"},\"Tag:086e95cc-d527-47d9-af64-f13dffb7e68b\":{\"__typename\":\"Tag\",\"id\":\"086e95cc-d527-47d9-af64-f13dffb7e68b\",\"slug\":\"pharmaceutical\",\"label\":\"pharmaceutical\"},\"Tag:7fb40f00-db01-4348-a558-c7bab92ca70a\":{\"__typename\":\"Tag\",\"id\":\"7fb40f00-db01-4348-a558-c7bab92ca70a\",\"slug\":\"astrazeneca\",\"label\":\"AstraZeneca\"},\"Tag:2c321623-9ddd-416f-b251-194b051faf82\":{\"__typename\":\"Tag\",\"id\":\"2c321623-9ddd-416f-b251-194b051faf82\",\"slug\":\"glaxosmithkline\",\"label\":\"GlaxoSmithKline\"},\"Tag:b85411be-7b6e-44bf-bdb0-922757d799b1\":{\"__typename\":\"Tag\",\"id\":\"b85411be-7b6e-44bf-bdb0-922757d799b1\",\"slug\":\"johnson-and-johnson\",\"label\":\"Johnson & Johnson\"},\"Tag:3493345b-f9d5-4932-aa26-c778eebf9d02\":{\"__typename\":\"Tag\",\"id\":\"3493345b-f9d5-4932-aa26-c778eebf9d02\",\"slug\":\"pfizer\",\"label\":\"Pfizer\"},\"Tag:2b0698a1-8ad0-408c-942c-5e87d7c9bd83\":{\"__typename\":\"Tag\",\"id\":\"2b0698a1-8ad0-408c-942c-5e87d7c9bd83\",\"slug\":\"hiv\",\"label\":\"HIV\"},\"Tag:d29343b7-7dc7-492d-a775-623707a2ef36\":{\"__typename\":\"Tag\",\"id\":\"d29343b7-7dc7-492d-a775-623707a2ef36\",\"slug\":\"aids\",\"label\":\"AIDS\"},\"Tag:d08fcaf8-ae33-4557-be63-5317d5cbbbf3\":{\"__typename\":\"Tag\",\"id\":\"d08fcaf8-ae33-4557-be63-5317d5cbbbf3\",\"slug\":\"nelson-mandela\",\"label\":\"Nelson Mandela\"},\"Tag:1087494e-b775-4d05-bf84-01733ef0dbdb\":{\"__typename\":\"Tag\",\"id\":\"1087494e-b775-4d05-bf84-01733ef0dbdb\",\"slug\":\"south-africa\",\"label\":\"South Africa\"},\"Tag:c97342d7-62a2-4a20-82fb-df9beba372f1\":{\"__typename\":\"Tag\",\"id\":\"c97342d7-62a2-4a20-82fb-df9beba372f1\",\"slug\":\"oxfam\",\"label\":\"Oxfam\"},\"Tag:833f2f88-1859-4aa0-9fdd-1256750aa7f0\":{\"__typename\":\"Tag\",\"id\":\"833f2f88-1859-4aa0-9fdd-1256750aa7f0\",\"slug\":\"medecins-sans-frontieres\",\"label\":\"Médecins Sans Frontieres\"},\"Tag:897d4e77-45b7-43f9-9d42-863c47d53d5e\":{\"__typename\":\"Tag\",\"id\":\"897d4e77-45b7-43f9-9d42-863c47d53d5e\",\"slug\":\"-homepage-top\",\"label\":\"-homepage-top\"},\"Tag:192e8aa8-2120-47fa-ae15-0e5f09bd2766\":{\"__typename\":\"Tag\",\"id\":\"192e8aa8-2120-47fa-ae15-0e5f09bd2766\",\"slug\":\"the-insecurity-complex\",\"label\":\"The Insecurity Complex\"},\"Tag:3046ee55-25d3-43cb-8491-58b17f8004d3\":{\"__typename\":\"Tag\",\"id\":\"3046ee55-25d3-43cb-8491-58b17f8004d3\",\"slug\":\"politics\",\"label\":\"Politics\"},\"Article:5900ea58-fb74-42e9-a3b1-ef3ad9ad3332\":{\"__typename\":\"Article\",\"id\":\"5900ea58-fb74-42e9-a3b1-ef3ad9ad3332\",\"nid\":\"162000\",\"slug\":\"bill-gates-impeded-global-access-covid-vaccines\",\"title\":\"How Bill Gates Impeded Global Access to Covid Vaccines\",\"cleanTitle\":\"How Bill Gates Impeded Global Access to Covid Vaccines\",\"badge\":null,\"frontPage\":{\"__ref\":\"FrontPage:03bf2e55-4f96-4942-851b-0ac31c0aa4e4\"},\"LinkedSeriesId\":null,\"series\":null,\"authors\":[{\"__ref\":\"Author:9f211e0a-b0b1-4c47-a7f4-ce7c3a78fc7f\"}],\"body\":\"\\u003cp>On February 11, 2020,\\u003ca href=\\\"https://www.who.int/news-room/events/detail/2020/02/11/default-calendar/global-research-and-innovation-forum-to-mobilize-international-action-in-response-to-the-novel-coronavirus-(2019-ncov)-emergency\\\" target=\\\"_blank\\\" rel=\\\"nofollow\\\"> public health and infectious disease experts\\u003c/a> gathered\\nby the hundreds at the World Health Organization’s Geneva mothership. The official pronouncement of a pandemic was still a month out, but the\\nagency’s international brain trust knew enough to be worried. Burdened by a\\nsense of borrowed time, they spent two days furiously sketching an “R&amp;D Blueprint”\\nin preparation for a world upended by the virus then known as 2019-nCoV.\\u003c/p>\\u003cp>The resulting\\ndocument summarized&nbsp;the state of coronavirus research and proposed ways to\\naccelerate the development of diagnostics, treatments, and vaccines. The underlying\\npremise was that the world would unite against the virus. The global research\\ncommunity would maintain broad and open channels of communication, since\\ncollaboration and information-sharing minimize duplication and accelerate discovery.\\nThe group also drew up plans for global comparative trials overseen by the WHO,\\nto assess the merits of treatments and vaccines.\\u003c/p>\\u003cp>One issue not\\nmentioned in the paper: intellectual property. If the worst came to pass, the experts\\nand researchers assumed cooperation would define the global response, with the\\nWHO playing a central role. That pharmaceutical companies and their allied\\ngovernments would allow intellectual property concerns to slow things down—from\\nresearch and development to manufacturing scale-up—does not seem to have\\noccurred to them.\\u003c/p>\\u003cp>They were wrong,\\nbut they weren’t alone. Battle-scarred veterans of the medicines-access and\\nopen-science movements hoped the immensity of the pandemic would override a\\nglobal drug system based on proprietary science and market monopolies. By\\nMarch, strange but welcome melodies could be heard from unexpected quarters. Anxious\\ngovernments spoke of shared interests and global public goods; drug companies pledged\\n“precompetitive” and “no-profit” approaches to development and pricing. The\\nearly days featured tantalizing glimpses of an open-science,\\ncooperative pandemic response. In January and February 2020, a consortium led\\nby the National Institutes of Health and the National Institute of Allergy and\\nInfectious Diseases collaborated to produce atomic-level maps of the key viral proteins\\nin record time. “Work that would normally have taken months—or possibly even\\nyears—has been completed in weeks,” noted the editors of \\u003ci>Nature.\\u003c/i>\\u003cspan>&nbsp;\\u003c/span>\\u003c/p>\\u003cp>When the \\u003ci>Financial\\nTimes\\u003c/i> \\u003ca href=\\\"https://www.ft.com/content/4a3bf282-701c-11ea-9bca-bf503995cd6f\\\" target=\\\"_blank\\\" rel=\\\"nofollow\\\">editorial\\u003cspan class=\\\"MsoHyperlink\\\">ized\\u003c/span>\\u003c/a> on March 27 that “the world has an overwhelming interest in ensuring\\n[Covid-19 drugs and vaccines] will be universally and cheaply available,” the\\npaper expressed what felt like a hardening conventional wisdom. This sense of\\npossibility emboldened forces working to extend the cooperative model. Grounding\\ntheir efforts was a plan, started in early March, to create a voluntary intellectual\\nproperty pool inside the WHO. Instead of putting up proprietary walls around\\nresearch and organizing it as a “race,” public and private actors would collect research\\nand associated intellectual property in a global knowledge fund for the duration of the pandemic. The\\nidea became real in late May with the launch of the \\u003ca href=\\\"https://www.who.int/initiatives/covid-19-technology-access-pool/what-is-c-tap\\\" target=\\\"_blank\\\" rel=\\\"nofollow\\\">WHO Covid-19 Technology\\nAccess Pool\\u003c/a>, or C-TAP.\\u003c/p>\\u003cp>By then, however, the optimism and sense of\\npossibility that defined the early days were long gone. Advocates for pooling\\nand open science, who seemed ascendant and even unstoppable that winter, confronted\\nthe possibility they’d been outmatched and outmaneuvered by the most powerful\\nman in global public health.\\u003c/p>\\u003cp>In April, Bill Gates launched a bold bid to manage\\nthe world’s scientific response to the pandemic. Gates’s \\u003ca href=\\\"https://www.who.int/initiatives/act-accelerator\\\" target=\\\"_blank\\\" rel=\\\"nofollow\\\">Covid-19 ACT-Accelerator\\u003c/a>\\nexpressed a status quo vision for organizing the research, development, manufacture,\\nand distribution of treatments and vaccines. Like other Gates-funded\\ninstitutions in the public health arena, the Accelerator was a public-private\\npartnership based on charity and industry enticements. Crucially, and in\\ncontrast to the C-TAP, the Accelerator enshrined Gates’s long-standing commitment\\nto respecting exclusive intellectual property claims. Its implicit\\narguments—that intellectual property rights won’t present problems for meeting global demand or ensuring\\nequitable access, and that they must be protected, even during a pandemic—carried\\nthe enormous weight of Gates’s reputation as a wise, beneficent, and prophetic\\nleader.\\u003cspan>&nbsp;\\u003c/span>\\u003c/p>\\u003cp>How he’s developed and wielded this influence\\nover two decades is one of the more consequential and underappreciated shapers\\nof the failed global response to the Covid-19 pandemic. Entering&nbsp;\\u003cspan>year two, this response has been defined by a zero-sum\\nvaccination battle that has left much of the world on the losing side.\\u003c/span>\\u003c/p>\\u003chr class=\\\"section-break\\\">\\u003cp>\\u003cspan>Gates’s marquee Covid-19 initiative started\\nrelatively small. Two days before the WHO declared a pandemic on March 11, 2020, the Bill &amp;\\nMelinda Gates Foundation announced something called the Therapeutics\\nAccelerator, a joint initiative with Mastercard and the charity group the Wellcome\\nTrust to identify and develop potential treatments for the novel coronavirus.\\nDoubling as a social branding exercise for a giant of global finance, the\\nAccelerator reflected Gates’s familiar formula of corporate philanthropy, which\\nhe has applied to everything from malaria to malnutrition. In retrospect, it\\nwas a strong indicator that Gates’s dedication to monopoly medicine would\\nsurvive the pandemic, even before he and his foundation’s officers began to say\\nso publicly.&nbsp;&nbsp;\\u003c/span>\\u003cspan>&nbsp;\\u003c/span>\\u003c/p>\\u003caside class=\\\"pullquote pull-right\\\">\\u003cp>Advocates for pooling and open science, who seemed ascendant and even unstoppable early in the crisis, have been outmatched and outmaneuvered by the most powerful man in global public health.\\u003c/p>\\u003c/aside>\\u003cp>This was confirmed when a bigger version of\\nthe Accelerator was unveiled the following month at the WHO. The Access to Covid-19 Tools\\nAccelerator, or ACT-Accelerator, was Gates’s bid to organize the development\\nand distribution of everything from therapeutics to testing. The biggest and\\nmost consequential arm, COVAX, proposed to subsidize vaccine deals with poor\\ncountries through donations by, and sales to, richer ones. The goal was always\\nlimited: It aimed to provide vaccines for up to 20 percent of the population in\\nlow-to-middle-income countries.\\u003cb> \\u003c/b>After\\nthat, governments would largely have to compete on the global market like\\neveryone else. It was a partial demand-side solution to what the movement\\ncoalescing around a call for a “people’s vaccine” warned would be a dual crisis\\nof supply and access, with intellectual property at the center of both.\\u003c/p>\\u003cp>Gates not only dismissed these warnings but\\nactively sought to undermine all challenges to his authority and the Accelerator’s intellectual property–based charity agenda.\\u003cspan>&nbsp;\\u003c/span>\\u003c/p>\\u003cp>“Early on, there was space for Gates to have\\na major impact in favor of open models,” says Manuel Martin, a policy adviser to\\nthe \\u003ca href=\\\"https://msfaccess.org/\\\" target=\\\"_blank\\\" rel=\\\"nofollow\\\">Médecins\\nSans Frontières Access Campaign.\\u003c/a> “But senior people in the\\nGates organization very clearly sent out the message: Pooling was unnecessary\\nand counterproductive. They dampened early enthusiasm by saying that I.P. is not\\nan access barrier in vaccines. That’s just demonstratively false.”\\u003c/p>\\u003cp>Few have observed Bill Gates’s devotion to monopoly\\nmedicine more closely than James Love, founder and director of \\u003ca href=\\\"https://www.keionline.org/\\\" target=\\\"_blank\\\" rel=\\\"nofollow\\\">Knowledge Ecology\\nInternational\\u003c/a>, a Washington, D.C.–based group that studies\\nthe broad nexus of federal policy, the pharmaceutical industry, and intellectual\\nproperty. Love\\nentered the world of global public health policy around the same time Gates did,\\nand for two decades has watched him scale its heights while reinforcing the\\nsystem responsible for the very problems he claims to be trying to solve. The\\nthrough-line for Gates has been his unwavering commitment to drug companies’\\nright to exclusive control over medical science and the markets for its\\nproducts.\\u003c/p>\\u003cp>“Things could have gone either way,” says Love, “but Gates wanted exclusive\\nrights maintained. He acted fast to stop the push\\nfor sharing the knowledge needed to make the products—the know-how, the data,\\nthe cell lines, the tech transfer, the transparency that is\\ncritically important in a dozen ways. The pooling approach represented by C-TAP\\nincluded all of that. Instead of backing those early discussions, he raced\\nahead and signaled support for business-as-usual on intellectual property by announcing\\nthe ACT-Accelerator in March.”\\u003c/p>\\u003cp>One year later, the \\u003ca href=\\\"https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-5-february-2021\\\" target=\\\"_blank\\\" rel=\\\"nofollow\\\">ACT-Accelerator has\\nfailed\\u003c/a> to meet its goal of providing discounted vaccines to the “priority\\nfifth” of low-income populations. The drug companies and rich nations that had\\nso much praise for the initiative a year ago have retreated into bilateral\\ndeals that leave little for anybody else. “The low- and middle-income countries are pretty\\nmuch on their own, and there’s just not much out there,” said Peter Hotez, dean of the \\u003ca href=\\\"https://www.bcm.edu/education/national-school-of-tropical-medicine\\\" target=\\\"_blank\\\" rel=\\\"nofollow\\\">National School of Tropical\\nMedicine\\u003c/a> in Houston. “Despite their best efforts, the Gates model\\nand its institutions are still industry-dependent.”\\u003c/p>\\u003cp>As of this writing in early April, fewer than \\u003ca href=\\\"https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-press-conference-with-dr-gerd-m%C3%BCller-federal-minister-of-economic-cooperation-and-development-(bmz)-germany---29-march-2021\\\" target=\\\"_blank\\\" rel=\\\"nofollow\\\">600 million\\u003c/a>\\nvaccine doses have been administered around the world; three-quarters\\nof those in just 10 mostly high-income countries. Close to \\u003ca href=\\\"https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-5-february-2021\\\" target=\\\"_blank\\\" rel=\\\"nofollow\\\">130 countries containing 2.5\\nbillion people\\u003c/a> have yet to administer a single dose. The timeline for supplying\\npoor and middle-income countries with enough vaccines to achieve herd immunity,\\nmeanwhile, has been pushed into 2024. These numbers represent more than the “catastrophic\\nmoral failure” the \\u003ca href=\\\"https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-148th-session-of-the-executive-board\\\" target=\\\"_blank\\\" rel=\\\"nofollow\\\">director general of the WHO\\u003c/a> warned about this January. It is\\na stark reminder than any policy that obstructs or inhibits vaccine production\\nrisks being self-defeating for the rich countries defending exclusive rights and\\ngobbling up the lion’s share of available vaccine supplies. The truth repeated\\nso often throughout the pandemic—no one is safe until everyone is safe—remains in\\nforce. \\u003c/p>\\u003cp>This easily anticipated market failure—together\\nwith the C-TAP’s failure to launch—led developing countries to open a new front\\nagainst intellectual property barriers in the World Trade Organization. Since\\nOctober, the WTO’s \\u003ca href=\\\"https://www.wto.org/english/tratop_e/trips_e/trips_e.htm\\\" target=\\\"_blank\\\" rel=\\\"nofollow\\\">Trade-Related Aspects of Intellectual Property Rights\\nCouncil\\u003c/a> has been center ring in a dramatic north-south standoff over rights to control\\nvaccine knowledge, technology, and markets. More than 100 low- and\\nmiddle-income countries support a call by India and South Africa to waive certain\\nprovisions related to Covid-19 intellectual property for the duration of the\\npandemic. Although Gates and his organization do not have an official position\\non the debate roiling the WTO, Gates and his deputies have left little doubt\\nabout their opposition to the waiver proposal. Just as he did following the\\nrollout of the WHO’s C-TAP, Gates has chosen to stand with the drug companies\\nand their government patrons.&nbsp; &nbsp;\\u003cspan>&nbsp;\\u003c/span>\\u003c/p>\\u003chr class=\\\"section-break\\\">\\u003cp>Technically housed within the WHO, the ACT-Accelerator\\nis a Gates operation, top to bottom. It is designed, managed, and staffed largely\\nby Gates organization employees. It embodies Gates’s philanthropic\\napproach to widely anticipated problems posed by intellectual property–hoarding companies able to constrain\\nglobal production by prioritizing rich countries and inhibiting licensing. Companies\\npartnering with COVAX are allowed to set their own tiered prices. They are\\nsubject to almost no transparency requirements and to toothless contractual\\nnods to “equitable access” that have never been enforced. Crucially,\\nthe companies retain exclusive rights to their intellectual property. If they\\nstray from the Gates Foundation line on exclusive rights, they are quickly\\nbrought to heel. When the director of Oxford’s\\nJenner Institute had funny ideas about placing the rights to its COVAX-supported\\nvaccine candidate in the public domain, Gates intervened. As reported by \\u003ca href=\\\"https://khn.org/news/rather-than-give-away-its-covid-vaccine-oxford-makes-a-deal-with-drugmaker/\\\" target=\\\"_blank\\\" rel=\\\"nofollow\\\">Kaiser\\nHealth News,\\u003c/a> “A few weeks later, Oxford—urged on by the Bill &amp; Melinda\\nGates Foundation—reversed course [and] signed an exclusive vaccine deal with\\nAstraZeneca that gave the pharmaceutical giant sole rights and no guarantee of\\nlow prices.”\\u003c/p>\\u003cp>Considering the alternatives being discussed,\\nit is no surprise that drug companies have been the most enthusiastic boosters\\nof the ACT-Accelerator and COVAX. The speakers at the ACT-Accelerator launch\\nceremony in March 2020 included Thomas Cueni, director general of the\\nInternational Federation of Pharmaceutical Manufacturers and Associations, who hailed the initiative as a “landmark global\\npartnership.” Since vaccines started coming online, the IFPMA’s member\\ncompanies have lost interest in the Accelerator, preferring bilateral deals\\nwith rich countries. But they continue to benefit from the halo effect of their\\nassociation with Gates, which has proved priceless throughout the pandemic,\\nespecially at a crucial juncture in its first year.&nbsp;&nbsp;\\u003cspan>&nbsp;\\u003cbr>\\u003c/span>\\u003c/p>\\u003cfigure class=\\\"article-embed image-embed pull-none\\\" contenteditable=\\\"false\\\">\\u003cimg src=\\\"//images.newrepublic.com/47a56a02170959126e1be285c141e9b68d2161d7.jpeg?w=1400\\\" data-serialized=\\\"{&quot;id&quot;:&quot;56f1b0f9-2c82-44f5-b88a-91f5bf9dabb5&quot;,&quot;hash&quot;:&quot;47a56a02170959126e1be285c141e9b68d2161d7&quot;,&quot;width&quot;:2500,&quot;height&quot;:1640,&quot;format&quot;:&quot;JPEG&quot;,&quot;isAnimated&quot;:false,&quot;baseUrl&quot;:&quot;//images.newrepublic.com/&quot;,&quot;src&quot;:&quot;//images.newrepublic.com/47a56a02170959126e1be285c141e9b68d2161d7.jpeg&quot;,&quot;alt&quot;:null,&quot;meta&quot;:{}}\\\" width=\\\"1400\\\">\\u003cfigcaption class=\\\"caption\\\">\\u003cspan class=\\\"caption-text\\\">Bill Gates addresses the opening session of the WHO’s annual assembly in 2005, some six years after he entered the global public health scene as a defender of intellectual property rights during the AIDS crisis.\\u003c/span>\\u003cspan class=\\\"credit\\\">JEAN-PIERRE CLATOT/AFP/Getty Images\\u003c/span>\\u003c/figcaption>\\u003c/figure>\\u003cp>On May 29, Donald Trump \\u003ca href=\\\"https://www.politico.com/news/2020/05/29/us-withdrawing-from-who-289799\\\" target=\\\"_blank\\\" rel=\\\"nofollow\\\">announced\\u003c/a> U.S.\\nwithdrawal from the WHO. This was in response, he said, to China’s “total\\ncontrol” of the agency. The drug industry, meanwhile, was displeased with the WHO\\nfor entirely different reasons. The same day, the WHO director general had\\nunveiled the C-TAP with a “Solidarity Call to Action” for governments and\\ncompanies to share all intellectual property related to Covid-19 treatments and\\nvaccines. The pharmaceutical companies didn’t attack the initiative directly. Instead,\\ntheir global trade association, the IFPMA, preempted the announcement with a livestreamed\\nmedia event on the evening of May 28. The event featured the heads of AstraZeneca,\\nGlaxoSmithKline, Johnson &amp; Johnson, and Pfizer, and Thomas Cueni.\\u003c/p>\\u003cp>The\\nevening’s sixth participant was the specter of Bill Gates.\\u003c/p>\\u003cp>As\\nanticipated, the questions submitted by journalists touched repeatedly on the much-anticipated\\nlaunch of C-TAP the following morning, as well as related issues of intellectual\\nproperty, vaccine access and equity, and debates over the extent and ways intellectual property posed barriers to ramping up production. Mostly, the executives evinced\\u003cb> \\u003c/b>ignorance and surprise over the\\nimminent launch of C-TAP; only\\u003ca href=\\\"https://www.ifpma.org/events-2/global-biopharma-ceo-top-execs-covid-19-virtual-press-briefing-28-may/\\\" target=\\\"_blank\\\" rel=\\\"nofollow\\\"> Pfizer CEO Albert Bourla\\u003c/a> openly denounced\\nthe pooling of intellectual property as “dangerous” and “nonsense.”\\u003c/p>\\u003cp>All of the executives, however, shared a\\nplaybook in which they quickly pivoted to affirmations of their support for Bill Gates and the ACT-Accelerator.\\nThe association with Gates was\\nsubmitted as evidence of industry commitment to equity and access—as well as\\nproof of the complete lack of need for overlapping or competing initiatives,\\nsuch as the “dangerous” C-TAP.\\u003cspan>&nbsp;\\u003c/span>\\u003c/p>\\u003cp>“We already have platforms,” Cueni said during\\nthe \\u003ca href=\\\"https://www.ifpma.org/events-2/global-biopharma-ceo-top-execs-covid-19-virtual-press-briefing-28-may/\\\" target=\\\"_blank\\\" rel=\\\"nofollow\\\">May 28 event\\u003c/a>. “The industry is already doing all the right things.”\\u003cspan>&nbsp;\\u003c/span>\\u003c/p>\\u003cp>As the questions about C-TAP and intellectual\\nproperty piled up, the industry’s Gates rap started to sound less like a shared\\nP.R. script than a broken record. Confronted for the second\\ntime about intellectual property, GlaxoSmithKline CEO Emma Walmsley emitted an undigested stream\\nof Gatesian word salad. “We are absolutely committed to this question of\\naccess,” she stammered, “and deeply welcome the formation of ACT, which is this\\nmultilateral organization that is going to be a mechanism with multiple\\nstakeholders, whether it’s heads of state or organizations like [the Gates-funded]\\nCEPI or the Gates and [\\u003cspan>the Gates-funded]&nbsp;\\u003c/span>\\u003cspan>Gavi and others and the WHO, of course, where we actually\\nlook at these principles of, uh, access and so clearly, we’re engaged in that\\nas well.”&nbsp;&nbsp;\\u003c/span>\\u003c/p>\\u003cp>Without the Gates and COVAX associations to lean\\non, the stammering would have been much worse. Pfizer’s Albert Bourla seemed to\\nrecognize this, at one point interrupting himself to express his industry’s gratitude\\nand admiration. “I want to take the opportunity to emphasize the role that Bill\\nGates is playing,” he said. He went on to call him “an inspiration for all.”\\u003cspan>&nbsp;\\u003c/span>\\u003c/p>\\u003chr class=\\\"section-break\\\">\\u003cp>Gates can hardly\\ndisguise his contempt for the growing interest in intellectual property\\nbarriers. In recent months, as the debate has shifted from the WHO to the WTO, reporters\\nhave drawn testy responses from Gates that harken back to his \\u003ca href=\\\"https://www.nytimes.com/2018/04/14/business/bill-gates-washington-facebook.html\\\" target=\\\"_blank\\\" rel=\\\"nofollow\\\">prickly\\nperformances\\u003c/a> before congressional antitrust hearings a quarter-century ago.\\nWhen a \\u003ci>Fast Company\\u003c/i> reporter raised\\nthe issue in February, she described Gates “raising his voice slightly and\\nlaughing in frustration,” before snapping, “It’s irritating that this issue\\ncomes up here. This&nbsp;isn’t&nbsp;about&nbsp;IP.”&nbsp;\\u003c/p>\\u003cp>In interview after interview, Gates has dismissed his critics on the\\nissue—who represent the poor majority of the global population—as spoiled\\nchildren demanding ice cream before dinner. “It’s the classic\\nsituation in global health, where the advocates all of a sudden want [the\\nvaccine] for zero dollars and right away,” \\u003ca href=\\\"https://www.reuters.com/article/us-health-coronavirus-gates/bill-gates-sees-6-8-month-lag-for-poor-countries-to-get-covid-19-shots-idUSKBN29W0QJ\\\" target=\\\"_blank\\\" rel=\\\"nofollow\\\">he told\\u003c/a> Reuters in late January. Gates has larded the insults\\nwith comments that equate state-protected and publicly funded monopolies with\\nthe “free market.” “North\\nKorea doesn’t have that many vaccines, as far as we can tell,” he \\u003ca href=\\\"https://www.nytimes.com/2020/11/23/world/bill-gates-vaccine-coronavirus.html\\\" target=\\\"_blank\\\" rel=\\\"nofollow\\\">told \\u003ci>The\\u003c/i> \\u003ci>New York Times\\u003c/i>\\u003c/a> in November. (It is curious that he chose North Korea as an example and not\\n\\u003ca href=\\\"https://www.npr.org/sections/goatsandsoda/2021/03/25/980789381/cubas-revolutionary-dream-making-its-own-covid-vaccine\\\" target=\\\"_blank\\\" rel=\\\"nofollow\\\">Cuba\\u003c/a>, a socialist country with an innovative and world-class vaccine\\ndevelopment program with multiple Covid-19 vaccine candidates in various stages\\nof testing.)\\u003c/p>\\u003cp>The\\nclosest Gates has come to conceding that vaccine monopolies inhibit production\\ncame during a January interview with South Africa’s \\u003ci>Mail &amp; Guardian.\\u003c/i> Asked about the growing\\nintellectual property debate, he responded, “At this point, changing the rules\\nwouldn’t make any additional vaccines available.”\\u003c/p>\\u003caside class=\\\"pullquote pull-right figure-active\\\">When a reporter raised\\nthe issue in February, she described Gates “raising his voice slightly and\\nlaughing in frustration,” before snapping, “It’s irritating that this issue\\ncomes up here. This&nbsp;isn’t&nbsp;about&nbsp;IP.”&nbsp;\\u003c/aside>\\u003cp>The first\\nimplication of “at this point” is that the moment has passed when changing the\\nrules could make a difference. This is a false but debatable claim. The same\\ncan’t be said for the second implication, which is that nobody could have\\npossibly foreseen the current supply crisis. Not only were the obstacles posed\\nby intellectual property easily predictable a year ago, there was no lack of people making noise\\nabout the urgency of avoiding them. They included much of the global research\\ncommunity, major NGOs with long experience in medicines development and access,\\nand dozens of current and former world leaders and public health experts. In a \\u003ca href=\\\"https://www.unaids.org/en/resources/presscentre/featurestories/2020/may/20200514_covid19-vaccine-open-letter\\\" target=\\\"_blank\\\" rel=\\\"nofollow\\\">May 2020 open letter\\u003c/a>, more than 140\\npolitical and civil society leaders called upon governments and companies to\\nbegin pooling their intellectual property. “Now is&nbsp;\\u003cem>not\\u003c/em>\\u003ci>&nbsp;\\u003c/i>the time … to leave this massive and moral task to market\\nforces,” they wrote.&nbsp;&nbsp;\\u003c/p>\\u003cp>Bill Gates’s position on intellectual property was consistent\\nwith a lifelong ideological commitment to knowledge\\nmonopolies, forged during a vengeful teenage crusade against the open-source\\nprogramming culture of the 1970s. As it happens, a novel use of one category of\\nintellectual property—copyright, applied to computer code—made Gates the\\nrichest man in the world for most of two decades beginning in 1995. That same\\nyear, the WTO went into effect, chaining the developing\\nworld to intellectual property rules written by a handful of executives from\\nthe U.S. pharmaceutical, entertainment, and software industries.&nbsp; &nbsp;\\u003c/p>\\u003chr class=\\\"section-break\\\">\\u003cp>By 1999, Bill Gates was in his final year as\\nCEO of Microsoft, focused on defending the company he founded from antitrust\\nsuits on two continents. As his business reputation suffered high-profile\\nbeatings from U.S. and European regulators, he was in the process of moving on\\nto his second act: the formation of the Bill &amp; Melinda Gates Foundation, which\\ncommenced his unlikely rise to the commanding apex of global public health\\npolicy. His debut in that role occurred during the contentious fifty-second General\\nHealth Assembly in May 1999.\\u003c/p>\\u003cp>It was the height of the battle to bring\\ngeneric AIDS drugs to the developing world. The central front was South Africa,\\nwhere the HIV rate at the time was estimated as high as 22 percent and threatened\\nto decimate an entire generation. In December 1997, the Mandela government\\npassed a law giving the health ministry powers to produce, purchase, and import\\nlow-cost drugs, including unbranded versions of combination therapies priced by\\nWestern drug companies at $10,000 and more. In response, 39 drug multinationals\\nfiled suit against South Africa alleging\\nviolations of the country’s constitution and its obligations under the WTO’s\\nAgreement on Trade-Related Aspects of Intellectual Property Rights, or TRIPS. The\\nindustry suit was backed by the diplomatic muscle of the Clinton\\nadministration, which tasked Al Gore with applying pressure. In his 2012 documentary \\u003ci>\\u003ca href=\\\"https://www.rottentomatoes.com/m/fire_in_the_blood\\\" target=\\\"_blank\\\" rel=\\\"nofollow\\\">Fire in the Blood\\u003c/a>,\\u003c/i> Dylan Mohan Gray notes it took Washington 40 years to\\nthreaten apartheid South Africa with sanctions and less than four to threaten\\nthe post-apartheid Mandela government over AIDS drugs.&nbsp;\\u003c/p>\\u003cp>Though South\\nAfrica barely registered&nbsp;as a market for the drug companies, the\\nappearance of cheap generics produced in violation of patents anywhere was a\\nthreat to monopoly pricing everywhere, according to the drug industry’s version\\nof Cold War “domino theory.” Allowing poor nations to “free ride” on Western\\nscience and build parallel drug economies would eventually cause problems\\ncloser to home, where the industry spent billions of dollars on a propaganda\\noperation to control the narrative around drug prices and keep the lid on\\npublic discontent. The companies suing Mandela had devised TRIPS as a long-term\\nstrategic response to the south-based generics industry that arose in the 1960s.\\nThey had come too far to be set back by the needs of a pandemic in sub-Saharan Africa.\\nU.S. and industry officials paired old standby arguments about patents driving\\ninnovation with claims that Africans posed a public health menace because they couldn’t\\nkeep time: Since they could not be relied on to take their medicines on a\\nschedule, giving Africans access to the drugs would allow for the emergence of\\ndrug-resistant HIV variants, according to industry and its government and media\\nallies.*\\u003cspan class=\\\"MsoFootnoteReference\\\">\\u003cspan class=\\\"MsoFootnoteReference\\\">\\u003cbr>\\u003c/span>\\u003c/span>\\u003c/p>\\u003cp>In Geneva, the lawsuit\\nwas reflected in a battle at the WHO, which was divided along a north-south\\nfault line: on one side, the home countries of the Western drug companies; on\\nthe other, a coalition of 134 developing countries (known collectively as the Group\\nof 77, or G77) and a rising “third force” of civil society groups led by Médecins Sans Frontières and Oxfam. The point\\nof conflict was a \\u003ca href=\\\"https://twn.my/title/twr120d.htm\\\" target=\\\"_blank\\\" rel=\\\"nofollow\\\">WHO resolution that called on\\u003c/a> member states “to ensure\\nequitable access to essential drugs; to ensure that public health interests are\\nparamount in pharmaceutical and health policies; [and] to explore and review\\ntheir options under relevant international agreements, including\\ntrade&nbsp;agreements, to safeguard access to essential drugs.”\\u003cbr>\\u003c/p>\\u003cp>\\u003cspan>Western countries\\nsaw the resolution as a threat to the recent conquest of monopoly medicine,\\nachieved four years earlier with the establishment of the WTO. The industry\\ngrew increasingly helpless, however, as global public opinion and WHO\\nmember-state sentiment shifted in favor of the resolution and against the South\\nAfrica lawsuit. In the weeks leading up to the assembly, the companies and\\ntheir parent embassies floundered as they sought to turn the tide. Their\\ngrowing anxiety is captured in a series of leaked cables sent to Washington by the U.S. ambassador in Geneva, George Moose, that April and May. In a diplomatic telegram dated\\nApril 20, Moose expressed alarm over the growing number of WHO delegations\\nmaking\\u003c/span>\\u003c/p>\\u003cblockquote>\\u003cp>\\u003ci>STATEMENTS THAT PUBLIC HEALTH SHOULD HAVE PRIMACY OVER COMMERCIAL\\nINTERESTS UNDER WTO TRADE AGREEMENTS SUCH AS THE TRIPS (TRADE-RELATED ASPECTS\\nOF INTELLECTUAL PROPERTY RIGHTS) … THEREBY POTENTIALLY UNDERMINING INTELLECTUAL\\nPROPERTY RIGHTS (IPR).\\u003c/i>\\u003c/p>\\u003c/blockquote>\\u003cp>\\u003ci>&nbsp;\\u003cbr>\\u003c/i>\\u003cspan>Moose was concerned that drug companies were\\nnot helping their own cause and seemed incapable of doing anything but parrot\\nold talking points about intellectual property as the driver of innovation. The\\npharmaceutical industry, Moose wrote,\\u003c/span>\\u003cspan>&nbsp;\\u003c/span>\\u003c/p>\\u003cblockquote>\\u003cp>\\u003ci>SHOULD BE CARRYING MORE OF ITS OWN WATER ON THIS ISSUE, ESPECIALLY IN\\nDEVELOPING COUNTRIES, AND NOT SOLELY DEPEND ON THE ARGUMENT THAT IPR PROTECTS\\nPROFITS THAT THEN ARE USED FOR DEVELOPMENT OF NEW DRUGS IN THE FUTURE. NOT 10\\nYEARS FROM NOW. THE SOUTH AFRICANS AND OTHERS ARE MOSTLY CONCERNED ABOUT\\nAVAILABILITY OF DRUGS NOW. PROBLEMS RELATED TO LOCAL AVAILABILITY AND PRICING\\nOF DRUGS THAT ARE UNRELATED TO TRIPS WILL UNDOUBTABLY REQUIRE FURTHER\\nDISCUSSION. \\u003c/i>\\u003c/p>\\u003c/blockquote>\\u003cp>\\u003cspan>Over the course of weeks, a picture emerges from Moose’s\\naccounts of a pharmaceutical industry against the ropes, punch drunk and out of\\nideas. In the U.S. ambassador’s view, the problem wasn’t moral bankruptcy so\\nmuch as incompetence. “\\u003c/span>\\u003ci>RECOMMEND THE USG PUSH THE\\nPHARMACEUTICAL INDUSTRY TO ARGUE ITS POINTS MORE CONVINCINGLY IN DEVELOPING\\nCOUNTRIES\\u003c/i>\\u003cspan>,” the exasperated ambassador wrote. “\\u003c/span>\\u003ci>AND\\nESPECIALLY DEAL WITH THEIR CONCERNS ABOUT LOCAL DRUG AVAILABILITY AND PRICING\\u003c/i>\\u003cspan>.”\\u003c/span>\\u003c/p>\\u003cp>Following the raucous buzz saw of the 1999 WHO Assembly, the\\ndrug companies would make a humiliating climbdown from their scandalous lawsuit\\nin South Africa, reduced to what \\u003ci>The Washington Post\\u003c/i> \\u003ca href=\\\"https://www.washingtonpost.com/archive/politics/2000/12/28/a-turning-point-that-left-millions-behind/afe238d9-49a6-4b03-bfff-2ba83c0c4cd7/\\\" target=\\\"_blank\\\" rel=\\\"nofollow\\\">called\\u003c/a> “close to pariah\\nstatus.”&nbsp;&nbsp;\\u003c/p>\\u003cp>At the same time, the industry was richer than ever. The\\nClinton administration had approved a long \\u003ca href=\\\"http://www.ruf.rice.edu/~neal/temp/ST%20Policy/index/PCAST%20Reports/PCAST%20Teaming%20with%20Life%20Investing%20in%20Science.pdf\\\" target=\\\"_blank\\\" rel=\\\"nofollow\\\">Big Pharma wish list\\u003c/a>, from broadening the\\navenues for privatizing government-funded science to opening the age of direct\\nmarketing of prescription drugs. The corresponding profits went to reinforce already\\nhistorically rich D.C. and Geneva lobbying operations. And yet, for all their combined\\nmight, the companies were incapable of producing a mask resembling a credible\\nhuman face. A global activist movement continued to gather public opinion on\\nits side and chip away at the legitimacy of the monopoly model that underlay the\\nindustry’s enormous power. By every nonfinancial measure, it was an industry\\nin distress. To borrow a phrase from a future Bill Gates production, you might\\nsay it was waiting for its Superman.**\\u003cspan class=\\\"MsoFootnoteReference\\\">\\u003cspan class=\\\"MsoFootnoteReference\\\">\\u003cbr>\\u003c/span>\\u003c/span>\\u003c/p>\\u003cfigure class=\\\"article-embed image-embed pull-none\\\" contenteditable=\\\"false\\\">\\u003cimg src=\\\"//images.newrepublic.com/8d793ed39af4336d037d65a6598e2189f446fbf8.jpeg?w=1400\\\" data-serialized=\\\"{&quot;id&quot;:&quot;527ac027-3251-4865-a421-789ec92487a9&quot;,&quot;hash&quot;:&quot;8d793ed39af4336d037d65a6598e2189f446fbf8&quot;,&quot;width&quot;:3000,&quot;height&quot;:2000,&quot;format&quot;:&quot;JPEG&quot;,&quot;isAnimated&quot;:false,&quot;baseUrl&quot;:&quot;//images.newrepublic.com/&quot;,&quot;src&quot;:&quot;//images.newrepublic.com/8d793ed39af4336d037d65a6598e2189f446fbf8.jpeg&quot;,&quot;alt&quot;:null,&quot;meta&quot;:{}}\\\" width=\\\"1400\\\">\\u003cfigcaption class=\\\"caption\\\">\\u003cspan class=\\\"caption-text\\\">The Clinton administration was instrumental in safeguarding Big Pharma’s intellectual property rights on the global stage—and Gates would become the campaign’s benevolent face.\\u003c/span>\\u003cspan class=\\\"credit\\\">Chip Somodevilla/Getty Images\\u003c/span>\\u003c/figcaption>\\u003c/figure>\\u003cp>\\u003cspan>When Moose was ringing the alarm over\\nthe future of TRIPS in the spring of 1999, Gates was preparing to fund the launch\\nof a public-private partnership called Gavi, the Vaccine Alliance, with a seed\\ngrant of $750 million, marking his arrival in the worlds of infectious disease and public health. At the time, he was still best known for being the\\nrichest man in the world and the owner of a software company engaged in\\nanti-competitive practices. This profile didn’t mean much in a raucous WHO\\nAssembly hall packed with civil society groups and G77 delegations, which together booed the U.S. delegation when it tried to speak. At most, it was a\\nsource of brief consternation when officers from the William H. Gates\\nFoundation began distributing a glossy brochure touting the role of\\nintellectual property in driving biomedical innovation.\\u003c/span>\\u003cspan>&nbsp;\\u003c/span>\\u003cbr>\\u003c/p>\\u003cp>James Love, who organized many of the\\ncivil society events around the 1999 Assembly, remembers seeing the Gates\\nstaffers joined in the distribution effort by Harvey Bale, a former U.S. trade official serving as\\ndirector general of the International Federation\\nof Pharmaceutical Manufacturers Associations.\\u003c/p>\\u003cp>“It was this nice full-color pamphlet about why patents\\ndon’t present an access problem, with the Gates Foundation logo at the bottom,”\\nsays Love. “It was strange, and I just thought, ‘OK, I guess this is what he’s\\ndoing now.’ Looking back, that’s when the pharma-Gates consortium set the\\nmarkers down on intellectual property. He’s been sticking his nose into every\\nintellectual property debate since, telling everyone\\nthey can go to heaven by paying lip service to a few discounts to poor\\ncountries.”&nbsp;\\u003cspan>&nbsp;\\u003c/span>\\u003c/p>\\u003cp>Following the 1999 WHO Assembly, the\\nindustry tried to salvage its reputation by offering African countries discounts\\non the antiretroviral combination therapies that cost $10,000 or more in rich\\ncountries. The compromise prices it offered were still outrageously high, but even\\nraising the issue of price concessions was too much for Pfizer, whose\\nrepresentatives stormed out of the industry coalition on principle. Public\\nopinion swung harder against the companies, the result of a loud, ingenious,\\nand effective direct-action campaign. Similar to the first months of the Covid-19\\npandemic, there was a sense of possibility—a hope that a forced breakdown of a\\nmorally obscene and bloodstained system was within grasp.\\u003cspan>&nbsp;\\u003c/span>\\u003c/p>\\u003cp>“The\\nmovement was very focused and successfully building pressure for structural, more decisive\\nsolutions into the aughts,” says Asia Russell, a veteran HIV-AIDS activist and director of \\u003ca href=\\\"https://healthgap.org/\\\" target=\\\"_blank\\\" rel=\\\"nofollow\\\">Health Gap\\u003c/a>, an HIV\\nmedicines access group. “And just when we\\nstarted to secure some progress, a new\\nversion of the industry narrative emerged from Gates and Pharma. It was all about how pricing policies,\\ngeneric competition, anything that\\ninterferes with industry profits, will undermine\\nresearch and development, when the evidence shows that that argument doesn’t hold water. Gates’s talking points\\naligned with those of the industry.”\\u003c/p>\\u003cp>Adds Manuel Martin, the Médecins Sans Frontières policy adviser, “Gates defused the real issue of decolonizing global\\nhealth. Instead, drug companies could just give money to his institutions.”\\u003c/p>\\u003cp>Even after the drug companies withdrew their lawsuit\\nagainst the South African government and Indian-made generics began flowing to\\nAfrica, Gates stayed cool toward compromises that he saw as threats to the\\nintellectual property paradigm. This included his attitude toward the Unitaid\\nMedicines Patent Pool, a voluntary intellectual property pool founded in 2010 that\\nenlarged access to some patented HIV/AIDS medicines. Though not a complete\\nanswer to the problem, the MPP was the first working example of a voluntary intellectual property pool,\\none that many observers expected to serve as a model framework for the\\nWHO-administered Covid-19 pool.\\u003c/p>\\u003cp>\\u003ca href=\\\"https://www.northeastern.edu/law/faculty/directory/baker.html\\\" target=\\\"_blank\\\" rel=\\\"nofollow\\\">Brook Baker\\u003c/a>, a law professor at Northeastern University\\nand senior policy analyst for Health\\nGAP, says Gates has\\nalways been wary of the Unitaid pool as going too far in the direction of\\ninfringing on intellectual property.\\u003cspan>&nbsp;\\u003c/span>\\u003c/p>\\u003cp>“Initially, Gates\\nwas unsupportive and even hostile toward the AIDS Medicines Patent Pool,” says\\nBaker. “He brought that\\nhostility to relaxing industry’s iron-fist control over its technologies into\\nthe pandemic. His explanation for rejecting models to counteract this control\\nnever added up. If I.P. isn’t important, why are companies\\nrefusing to voluntarily give it up when it could be used to expand supply in\\nthe middle of the world’s worst public health crisis in a century? It’s not\\nimportant, or it’s so important it has to be closely guarded and protected. You\\ncan’t have it both ways.”\\u003c/p>\\u003chr class=\\\"section-break\\\">\\u003cp>This winter, while Gates assured the world that intellectual property was a red herring, a bloc of developing countries at the WTO explained the\\nneed for a waiver on certain intellectual property provisions by pointing to the “rather large gap [that] exists\\nbetween what COVAX or ACT-A can deliver and what is required in developing and\\nleast developed countries.”\\u003c/p>\\u003cp>The\\n\\u003ca href=\\\"https://www.keionline.org/35453\\\" target=\\\"_blank\\\" rel=\\\"nofollow\\\">forceful statement\\u003c/a> continued:\\u003c/p>\\u003cblockquote>\\u003cp>The model of donation and philanthropic expediency cannot solve the fundamental disconnect\\nbetween the monopolistic model it\\nunderwrites and the very real desire of developing and least developed countries to produce for themselves.… The\\nartificial shortage of vaccines is primarily\\ncaused by the inappropriate use of intellectual property rights.\\u003c/p>\\u003c/blockquote>\\u003cp>Another statement by a different bloc of countries added,\\n“COVID19\\nreveals the deep structural inequality in access to medicines globally, and a\\nroot cause is IP that sustains and dominates industry’s interests at the cost\\nof lives.”&nbsp; \\u003cb>\\u003cbr>\\u003c/b>\\u003c/p>\\u003cp>Gates is\\ncertain he knows better. But his failure to anticipate a crisis of supply, and\\nhis refusal to engage those who predicted it, have complicated the carefully\\nmaintained image of an all-knowing, saintly mega-philanthropist. COVAX presents\\na high-stakes demonstration of Gates’s deepest ideological commitments,\\nnot just to intellectual property rights but also to the conflation of these\\nrights with an imaginary free market in pharmaceuticals—an industry dominated\\nby companies whose power derives from politically constructed and politically imposed\\nmonopolies. Gates has been tacitly and explicitly defending the legitimacy of\\nknowledge monopolies since his first Gerald Ford–era missives against open-source\\nsoftware hobbyists. He was on the side of these monopolies during the miserable\\ndepths of the 1990s African AIDS crisis. He’s still there today, defending the\\nstatus quo and running effective interference for those profiting by the\\nbillions from their control of Covid-19 vaccines. \\u003c/p>\\u003cp>His latest move is to institutionalize the ACT-Accelerator\\nas the central organizing institution in future pandemics. The shortages have\\nmade this effort a little awkward, however, and Gates is now forced to reckon\\nwith the question of technology transfer. This is an aspect of\\nthe equitable access debate that doesn’t concern intellectual property as commonly perceived—as a\\nsimple matter of patents and licenses—but access\\nto the components and technical knowledge related to practical manufacture, including biological\\nmaterial and other areas otherwise protected under the category of intellectual property known as\\ntrade secrets. The global south and civil society groups\\u003cb> \\u003c/b>have been calling for tech transfer for months—\\u003cspan>either mandatory tech transfer that could have been written into contracts or through a voluntary mechanism associated with C-TAP\\u003c/span>\\u003cspan>—but Gates\\nhas predictably arrived on the scene with a more familiar plan in hand.\\u003c/span>\\u003c/p>\\u003cp>In early March, senior Gates staff joined\\npharma executives for a “\\u003ca href=\\\"https://www.chathamhouse.org/events/all/research-event/global-c19-vaccine-supply-chain-manufacturing-summit\\\" target=\\\"_blank\\\" rel=\\\"nofollow\\\">Global C19 Vaccine Supply Chain and Manufacturing Summit\\u003c/a>” convened by Chatham\\nHouse in London. The main agenda item: plans for a new arm within the ACT-Accelerator,\\nthe Covid Vaccine Capacity Connector, that seeks to address the tech-transfer question within the usual frame of monopoly rights and\\nbilateral licensing.\\u003cspan>&nbsp;\\u003c/span>\\u003c/p>\\u003cp>“The tech transfer debate is being decisively seized and shaped\\nby those who want to set the terms and conditions under which knowledge can be\\ntransferred,” writes Priti Patnaik in her \\u003ca href=\\\"https://genevahealthfiles.substack.com/p/who-donors-seek-a-new-tech-transfer\\\" target=\\\"_blank\\\" rel=\\\"nofollow\\\">\\u003ci>Geneva\\nHealth Files\\u003c/i> newsletter\\u003c/a>. A Gates-directed tech-transfer mechanism without\\nmeaningful input from WHO members states, she writes, would be a “body blow” to\\nC-TAP and similar future initiatives that promote open licensing and knowledge sharing\\nto maximize production and access. \\u003c/p>\\u003cp>There\\nare signs of overdue scrutiny of Gates’s role in public health and lifelong commitment\\nto exclusive intellectual property rights. But so far these are blips. More common\\nis the deference on display in a March 21 \\u003ci>New\\nYork Times\\u003c/i> article about the U.S. government’s role in \\u003ca href=\\\"https://www.nytimes.com/2021/03/21/world/vaccine-patents-us-eu.html?searchResultPosition=1\\\" target=\\\"_blank\\\" rel=\\\"nofollow\\\">developing the mRNA vaccines\\u003c/a> now under\\nthe monopoly control of Moderna and Pfizer. When the piece turned to Gates’s inevitable\\ncameo, the \\u003ci>Times\\u003c/i> reporter was hovering\\nright over the target—and somehow managed to miss wide by a mile. Instead of\\nprobing Gates’s central role in preserving this paradigm, the paper linked to\\ngentle boilerplate about pricing and access found on the Gates Foundation\\nwebsite. In response to a request for comment, a Gates Foundation spokesperson pointed\\nme to a piece by its CEO, Mark Suzman, arguing that “IP fundamentally underpins\\ninnovation, including the work that has helped create vaccines so quickly.”\\u003c/p>\\u003cp>Any change\\nin media coverage of Gates’s second career may produce a delayed echo within the\\nworld he has come to dominate. Here Gates not only controls the narratives, he\\ncontrols most of the payroll. This may sound conspiratorial or overblown to\\noutsiders but not to campaigners who have witnessed Gates’s ability to shift\\ngravity on major issues. \\u003c/p>\\u003cp>“If you\\nsaid to an ordinary person, ‘We’re in a pandemic. Let’s figure out everyone who\\ncan make vaccines and give them everything they need to get online as fast as\\npossible,’ it would be a no-brainer,” says James Love.\\n“But Gates won’t go there. Neither will the people dependent on his funding. He has immense power. He can get you\\nfired from a U.N. job. He knows that if you want to work in global public\\nhealth, you’d better not make an enemy of the Gates Foundation by questioning\\nits positions on I.P. and monopolies. And there are a lot of advantages to\\nbeing on his team. It’s a sweet, comfortable ride for a lot of people.”\\u003c/p>\\u003chr class=\\\"section-break\\\">\\u003cp>*\\u003ci>Among journalists echoing this argument was former \\u003c/i>New Republic \\u003ci>editor Andrew Sullivan. When \\u003c/i>The\\u003ci> \\u003c/i>New York Times \\u003ci>reported Sullivan was defending the companies’ lawsuit while taking undisclosed\\n\\u003ca href=\\\"https://www.salon.com/2001/07/12/sullivan_4/\\\" target=\\\"_blank\\\" rel=\\\"nofollow\\\">funding from\\nPhRma\\u003c/a>\\u003cspan>, the industry trade association, Sullivan\\nremained defiant in the face of evidence-based accusations that he was an unethical\\njournalist. “It behooves me to say I see\\nabsolutely no problems with [drug industry sponsorship],” he told \\u003c/span>Salon\\u003cspan>. “In fact, I am extremely proud to\\nget some support from a great industry.” It later turned out that Africans adhered\\nmore closely to the twice-daily pill regimens than patient populations in rich\\ncountries.\\u003c/span>\\u003c/i>\\u003cbr>\\u003c/p>\\u003cp>**\\u003ci>In 2010,\\nthe Gates Foundation would bankroll a documentary advocating the privatization\\nof U.S. public education, titled \\u003c/i>Waiting\\nfor Superman\\u003cspan>.&nbsp;\\u003c/span>\\u003cbr>\\u003c/p>\",\"publishedAt\":\"2021-04-12T10:00:00.000Z\",\"updatedAt\":\"2023-11-28T01:40:10.585Z\",\"displayAt\":null,\"publicPublishedDate\":\"2021-04-12T10:00:00.000Z\",\"status\":\"PUBLISHED\",\"ledeImage\":{\"__ref\":\"Image:209df8aa-c69a-4b57-9b52-ec358002640c\"},\"ledeAltImage\":null,\"url\":\"/article/162000/bill-gates-impeded-global-access-covid-vaccines\",\"urlFull\":\"https://newrepublic.com/article/162000/bill-gates-impeded-global-access-covid-vaccines\",\"meta\":{\"__typename\":\"ArticleMeta\",\"wordCount\":5995,\"template\":\"full\",\"navigationTheme\":null,\"bigLede\":null,\"hideLede\":null,\"hideFeedHed\":null,\"hideFeedDek\":null,\"cropModeFronts\":null,\"ledeOverrideSource\":null,\"disableAds\":null,\"disableInnerAds\":null,\"listOptions\":null,\"social\":{\"__typename\":\"SocialOverrides\",\"google\":{\"__typename\":\"ArticleOverride\",\"title\":\"Bill Gates, Vaccine Monster\",\"description\":null},\"facebook\":null,\"twitter\":null}},\"ledeImageCredit\":null,\"ledeImageCreditBottom\":null,\"ledeImageRealCaption\":null,\"bylines\":\"Illustration by Kelsey Dake\",\"deck\":\"Through his hallowed foundation, the world’s de facto public health czar has been a stalwart defender of monopoly medicine.\",\"type\":\"LONGFORM\",\"galleries\":[],\"tags\":[{\"__ref\":\"Tag:c27ff6e6-b672-430d-be07-8a59b6f23383\"},{\"__ref\":\"Tag:0ca9ed51-a0f1-4ae8-90d9-ff3075e6a861\"},{\"__ref\":\"Tag:afb41557-1d97-4ce3-91b0-134cf76a9357\"},{\"__ref\":\"Tag:72f5dd2b-f134-4f25-8f5f-e36a141f7fe4\"},{\"__ref\":\"Tag:d3a73e0b-32e6-4481-ade9-b6774f75f3f9\"},{\"__ref\":\"Tag:173baf6d-254c-4738-822c-6cac468c9858\"},{\"__ref\":\"Tag:326de734-3a2b-4bf7-9c1a-5e32ae7ffd6f\"},{\"__ref\":\"Tag:b497b045-2e5b-4f37-8f1c-e297f689dba3\"},{\"__ref\":\"Tag:c8e98811-c2da-4469-b25d-c7af29efc9e8\"},{\"__ref\":\"Tag:086e95cc-d527-47d9-af64-f13dffb7e68b\"},{\"__ref\":\"Tag:7fb40f00-db01-4348-a558-c7bab92ca70a\"},{\"__ref\":\"Tag:2c321623-9ddd-416f-b251-194b051faf82\"},{\"__ref\":\"Tag:b85411be-7b6e-44bf-bdb0-922757d799b1\"},{\"__ref\":\"Tag:3493345b-f9d5-4932-aa26-c778eebf9d02\"},{\"__ref\":\"Tag:2b0698a1-8ad0-408c-942c-5e87d7c9bd83\"},{\"__ref\":\"Tag:d29343b7-7dc7-492d-a775-623707a2ef36\"},{\"__ref\":\"Tag:d08fcaf8-ae33-4557-be63-5317d5cbbbf3\"},{\"__ref\":\"Tag:1087494e-b775-4d05-bf84-01733ef0dbdb\"},{\"__ref\":\"Tag:c97342d7-62a2-4a20-82fb-df9beba372f1\"},{\"__ref\":\"Tag:833f2f88-1859-4aa0-9fdd-1256750aa7f0\"},{\"__ref\":\"Tag:897d4e77-45b7-43f9-9d42-863c47d53d5e\"},{\"__ref\":\"Tag:192e8aa8-2120-47fa-ae15-0e5f09bd2766\"},{\"__ref\":\"Tag:3046ee55-25d3-43cb-8491-58b17f8004d3\"}],\"suppressBadges\":true,\"subscribersOnly\":false,\"ledeVideo\":{\"__typename\":\"Video\",\"src\":null,\"controls\":null},\"feed\":null,\"containerPlacements\":[{\"__ref\":\"ContainerPlacement:441ee6a6-73db-49ce-a17d-016accdf7452\"},{\"__ref\":\"ContainerPlacement:21854cd9-27eb-49f0-b84f-484dda5751a6\"}]},\"ROOT_QUERY\":{\"__typename\":\"Query\",\"Article({\\\"nid\\\":\\\"162000\\\"})\":{\"__ref\":\"Article:5900ea58-fb74-42e9-a3b1-ef3ad9ad3332\"},\"Article({\\\"id\\\":\\\"5900ea58-fb74-42e9-a3b1-ef3ad9ad3332\\\"})\":{\"__ref\":\"Article:5900ea58-fb74-42e9-a3b1-ef3ad9ad3332\"},\"FrontPage({\\\"isRecirc\\\":true,\\\"slug\\\":\\\"politics\\\"})\":{\"__ref\":\"FrontPage:03bf2e55-4f96-4942-851b-0ac31c0aa4e4\"},\"Articles({\\\"nid\\\":[\\\"162003\\\",\\\"161899\\\",\\\"162002\\\",\\\"161999\\\"]})\":[{\"__ref\":\"Article:a792c72d-fd5f-4973-93fb-d9bed7e01624\"},{\"__ref\":\"Article:fe3a824f-5c66-4c98-8203-7bac86bc39d5\"},{\"__ref\":\"Article:f9ecf7fd-aa39-4425-848f-42e3ef99bff2\"},{\"__ref\":\"Article:23deefc9-f69f-45d2-9a77-8899787cad37\"}],\"Articles({\\\"nid\\\":[\\\"191453\\\",\\\"191422\\\",\\\"191450\\\",\\\"191430\\\"]})\":[{\"__ref\":\"Article:fc5ac6e5-010f-49ec-9c2b-8529c4169be9\"},{\"__ref\":\"Article:356a7585-7e2c-4c1f-bd13-ce9e721c319e\"},{\"__ref\":\"Article:da91d188-df28-4eed-ac84-f939a11eab60\"},{\"__ref\":\"Article:f143de64-971b-4570-844e-728c8de03b19\"}]},\"Container:049a25a3-bd83-48e8-a6bf-01afc660d7d3\":{\"__typename\":\"Container\",\"id\":\"049a25a3-bd83-48e8-a6bf-01afc660d7d3\",\"layout\":\"Article / Box 4 / Pic 2 / Recirc\",\"allowDuplicates\":true,\"title\":\"Editor’s Picks\",\"quote\":null,\"source\":null,\"sponsorName\":null,\"sponsorLink\":null,\"streamType\":\"page\",\"stream\":null,\"tag\":null,\"frontPage\":null,\"FeedId\":null,\"showLink\":false,\"containerPins\":[{\"__typename\":\"ContainerPin\",\"ArticleNid\":\"162003\",\"slot\":0},{\"__typename\":\"ContainerPin\",\"ArticleNid\":\"161899\",\"slot\":1},{\"__typename\":\"ContainerPin\",\"ArticleNid\":\"162002\",\"slot\":2},{\"__typename\":\"ContainerPin\",\"ArticleNid\":\"161999\",\"slot\":3}]},\"ContainerPlacement:441ee6a6-73db-49ce-a17d-016accdf7452\":{\"__typename\":\"ContainerPlacement\",\"id\":\"441ee6a6-73db-49ce-a17d-016accdf7452\",\"position\":0,\"container\":{\"__ref\":\"Container:049a25a3-bd83-48e8-a6bf-01afc660d7d3\"}},\"Container:1da5f5c2-41d5-4272-831a-84c1c46be943\":{\"__typename\":\"Container\",\"id\":\"1da5f5c2-41d5-4272-831a-84c1c46be943\",\"layout\":\"Article / Box 4 / Pic 2 / Recirc\",\"allowDuplicates\":true,\"title\":\"Latest From Sold Short\",\"quote\":null,\"source\":null,\"sponsorName\":null,\"sponsorLink\":null,\"streamType\":\"page\",\"stream\":null,\"tag\":null,\"frontPage\":null,\"FeedId\":null,\"showLink\":false,\"containerPins\":[]},\"ContainerPlacement:21854cd9-27eb-49f0-b84f-484dda5751a6\":{\"__typename\":\"ContainerPlacement\",\"id\":\"21854cd9-27eb-49f0-b84f-484dda5751a6\",\"position\":1,\"container\":{\"__ref\":\"Container:1da5f5c2-41d5-4272-831a-84c1c46be943\"}},\"Author:6fe975e8-73ef-4b13-a9f5-02f70453938e\":{\"__typename\":\"Author\",\"id\":\"6fe975e8-73ef-4b13-a9f5-02f70453938e\",\"name\":\"Natalie Shure\",\"slug\":\"natalie-shure\",\"meta\":{\"__typename\":\"AuthorMeta\",\"podcast\":null}},\"Tag:d2cd0858-08a1-48cb-a200-b32a09a3780b\":{\"__typename\":\"Tag\",\"id\":\"d2cd0858-08a1-48cb-a200-b32a09a3780b\",\"slug\":\"john-boehner\",\"label\":\"John Boehner\"},\"Tag:2c5cc8a6-68df-47b8-a655-97141cffa6e1\":{\"__typename\":\"Tag\",\"id\":\"2c5cc8a6-68df-47b8-a655-97141cffa6e1\",\"slug\":\"republicans\",\"label\":\"Republicans\"},\"Tag:c4321c0f-5d1f-479d-8849-7d11b9d45277\":{\"__typename\":\"Tag\",\"id\":\"c4321c0f-5d1f-479d-8849-7d11b9d45277\",\"slug\":\"republican-party\",\"label\":\"Republican Party\"},\"Tag:049149cc-991a-49bd-8f4a-de08a813f722\":{\"__typename\":\"Tag\",\"id\":\"049149cc-991a-49bd-8f4a-de08a813f722\",\"slug\":\"newt-gingrich\",\"label\":\"Newt Gingrich\"},\"Tag:e76dc143-b73b-4b46-8eac-2f966d935f04\":{\"__typename\":\"Tag\",\"id\":\"e76dc143-b73b-4b46-8eac-2f966d935f04\",\"slug\":\"tea-party\",\"label\":\"Tea Party\"},\"Tag:9ecbca02-2681-4228-b2cb-f9f19cda9fc9\":{\"__typename\":\"Tag\",\"id\":\"9ecbca02-2681-4228-b2cb-f9f19cda9fc9\",\"slug\":\"donald-trump\",\"label\":\"Donald Trump\"},\"Tag:d7a3efab-44a0-406f-9058-b0c73893d898\":{\"__typename\":\"Tag\",\"id\":\"d7a3efab-44a0-406f-9058-b0c73893d898\",\"slug\":\"conservatives\",\"label\":\"Conservatives\"},\"Tag:3f9895bd-aa1f-4937-9cf2-f5a0d8535eff\":{\"__typename\":\"Tag\",\"id\":\"3f9895bd-aa1f-4937-9cf2-f5a0d8535eff\",\"slug\":\"k-street\",\"label\":\"K Street\"},\"Image:9a7aa850-3e39-4d26-9780-d7b55b49f9fb\":{\"__typename\":\"Image\",\"id\":\"9a7aa850-3e39-4d26-9780-d7b55b49f9fb\",\"src\":\"//images.newrepublic.com/31d52d99f1eb15b7b66567081200613f37429627.jpeg\",\"format\":\"JPEG\",\"width\":3000,\"height\":2000,\"alt\":\"John Boehner covers his mouth while listening to a news briefing.\"},\"Article:a792c72d-fd5f-4973-93fb-d9bed7e01624\":{\"__typename\":\"Article\",\"id\":\"a792c72d-fd5f-4973-93fb-d9bed7e01624\",\"nid\":\"162003\",\"slug\":\"boehner-book-tour-trump-hypocrite\",\"title\":\"John Boehner Can’t Disown the Rot He Created\",\"homepageTitle\":null,\"homepageSubheadline\":null,\"badge\":null,\"authors\":[{\"__ref\":\"Author:6fe975e8-73ef-4b13-a9f5-02f70453938e\"}],\"subscribersOnly\":false,\"tags\":[{\"__ref\":\"Tag:3046ee55-25d3-43cb-8491-58b17f8004d3\"},{\"__ref\":\"Tag:c27ff6e6-b672-430d-be07-8a59b6f23383\"},{\"__ref\":\"Tag:d2cd0858-08a1-48cb-a200-b32a09a3780b\"},{\"__ref\":\"Tag:2c5cc8a6-68df-47b8-a655-97141cffa6e1\"},{\"__ref\":\"Tag:c4321c0f-5d1f-479d-8849-7d11b9d45277\"},{\"__ref\":\"Tag:049149cc-991a-49bd-8f4a-de08a813f722\"},{\"__ref\":\"Tag:e76dc143-b73b-4b46-8eac-2f966d935f04\"},{\"__ref\":\"Tag:9ecbca02-2681-4228-b2cb-f9f19cda9fc9\"},{\"__ref\":\"Tag:d7a3efab-44a0-406f-9058-b0c73893d898\"},{\"__ref\":\"Tag:3f9895bd-aa1f-4937-9cf2-f5a0d8535eff\"}],\"publishedAt\":\"2021-04-12T14:15:12.000Z\",\"displayAt\":null,\"updatedAt\":\"2023-11-28T01:40:10.585Z\",\"publicPublishedDate\":\"2021-04-12T14:15:12.000Z\",\"status\":\"PUBLISHED\",\"ledeImage\":{\"__ref\":\"Image:9a7aa850-3e39-4d26-9780-d7b55b49f9fb\"},\"ledeAltImage\":null,\"ledeImageCaption\":null,\"url\":\"/article/162003/boehner-book-tour-trump-hypocrite\",\"urlFull\":\"https://newrepublic.com/article/162003/boehner-book-tour-trump-hypocrite\",\"deck\":\"The former House speaker would be nothing without the Republican extremists he’s denouncing on his book tour.\",\"FeedId\":null,\"feed\":null,\"frontPage\":{\"__ref\":\"FrontPage:03bf2e55-4f96-4942-851b-0ac31c0aa4e4\"},\"meta\":{\"__typename\":\"ArticleMeta\",\"cropModeFronts\":null},\"ledeVideo\":{\"__typename\":\"Video\",\"src\":null,\"controls\":null}},\"Author:e1214c82-9fbd-41c2-b8b5-1232ba0a6265\":{\"__typename\":\"Author\",\"id\":\"e1214c82-9fbd-41c2-b8b5-1232ba0a6265\",\"name\":\"Rumaan Alam\",\"slug\":\"rumaan-alam\",\"meta\":{\"__typename\":\"AuthorMeta\",\"podcast\":null}},\"Tag:f6bb3de2-0f7d-43e5-ae25-77b26a6603e0\":{\"__typename\":\"Tag\",\"id\":\"f6bb3de2-0f7d-43e5-ae25-77b26a6603e0\",\"slug\":\"culture\",\"label\":\"Culture\"},\"Tag:f01e394d-b5c0-4a28-b0eb-d2b7e417dfef\":{\"__typename\":\"Tag\",\"id\":\"f01e394d-b5c0-4a28-b0eb-d2b7e417dfef\",\"slug\":\"magazine\",\"label\":\"Magazine\"},\"Tag:3af14fd2-b07b-4704-ad5c-c11f0cb27fb8\":{\"__typename\":\"Tag\",\"id\":\"3af14fd2-b07b-4704-ad5c-c11f0cb27fb8\",\"slug\":\"may-2021\",\"label\":\"May 2021\"},\"Tag:4deae86e-45d4-4485-b864-20b4f62c6745\":{\"__typename\":\"Tag\",\"id\":\"4deae86e-45d4-4485-b864-20b4f62c6745\",\"slug\":\"books-and-the-arts\",\"label\":\"Books & The Arts\"},\"Tag:5921a592-06f2-4e79-85b7-115ed383707d\":{\"__typename\":\"Tag\",\"id\":\"5921a592-06f2-4e79-85b7-115ed383707d\",\"slug\":\"books\",\"label\":\"Books\"},\"Tag:9de1f385-f3e4-4d42-af16-96152e5957da\":{\"__typename\":\"Tag\",\"id\":\"9de1f385-f3e4-4d42-af16-96152e5957da\",\"slug\":\"kazuo-ishiguro\",\"label\":\"Kazuo Ishiguro\"},\"Tag:6953bbd3-1394-4c41-989a-e5821f56fe2d\":{\"__typename\":\"Tag\",\"id\":\"6953bbd3-1394-4c41-989a-e5821f56fe2d\",\"slug\":\"artificial-intelligence\",\"label\":\"Artificial Intelligence\"},\"Tag:027fcd98-8286-497d-92cb-70a839cd7ae7\":{\"__typename\":\"Tag\",\"id\":\"027fcd98-8286-497d-92cb-70a839cd7ae7\",\"slug\":\"never-let-me-go\",\"label\":\"Never Let Me Go\"},\"Tag:23c41f89-eb5e-4c6b-895b-92d2f3517c97\":{\"__typename\":\"Tag\",\"id\":\"23c41f89-eb5e-4c6b-895b-92d2f3517c97\",\"slug\":\"the-remains-of-the-day\",\"label\":\"The Remains of the Day\"},\"Tag:f3931399-70e9-4176-a512-8fd81cdf39d8\":{\"__typename\":\"Tag\",\"id\":\"f3931399-70e9-4176-a512-8fd81cdf39d8\",\"slug\":\"nobel-prize-for-literature\",\"label\":\"Nobel Prize for Literature\"},\"Tag:ec377b6c-1ce7-4085-93b9-1bbbb01b0bde\":{\"__typename\":\"Tag\",\"id\":\"ec377b6c-1ce7-4085-93b9-1bbbb01b0bde\",\"slug\":\"critical-mass\",\"label\":\"critical mass\"},\"Tag:b9ddf12a-1769-4d11-9d5e-fd9210093864\":{\"__typename\":\"Tag\",\"id\":\"b9ddf12a-1769-4d11-9d5e-fd9210093864\",\"slug\":\"-newsletter-reup\",\"label\":\"-newsletter-reup\"},\"Image:2aa83dc8-dd96-40df-9f32-2e24ad7eb51a\":{\"__typename\":\"Image\",\"id\":\"2aa83dc8-dd96-40df-9f32-2e24ad7eb51a\",\"src\":\"//images.newrepublic.com/76fa78c23b57d8115384e64acb5c5ab41e82760b.jpeg\",\"format\":\"JPEG\",\"width\":3750,\"height\":2500,\"alt\":null},\"FrontPage:027da8c8-e1ea-43dd-a2b4-3b5b8451fa17\":{\"__typename\":\"FrontPage\",\"id\":\"027da8c8-e1ea-43dd-a2b4-3b5b8451fa17\",\"slug\":\"magazine\",\"title\":\"The Magazine\",\"tag\":{\"__ref\":\"Tag:f01e394d-b5c0-4a28-b0eb-d2b7e417dfef\"}},\"Article:fe3a824f-5c66-4c98-8203-7bac86bc39d5\":{\"__typename\":\"Article\",\"id\":\"fe3a824f-5c66-4c98-8203-7bac86bc39d5\",\"nid\":\"161899\",\"slug\":\"kazuo-ishiguro-klara-sun-review-deceptively-simple-story-ai\",\"title\":\"Kazuo Ishiguro’s Deceptively Simple Story of AI \",\"homepageTitle\":null,\"homepageSubheadline\":null,\"badge\":null,\"authors\":[{\"__ref\":\"Author:e1214c82-9fbd-41c2-b8b5-1232ba0a6265\"}],\"subscribersOnly\":false,\"tags\":[{\"__ref\":\"Tag:f6bb3de2-0f7d-43e5-ae25-77b26a6603e0\"},{\"__ref\":\"Tag:f01e394d-b5c0-4a28-b0eb-d2b7e417dfef\"},{\"__ref\":\"Tag:3af14fd2-b07b-4704-ad5c-c11f0cb27fb8\"},{\"__ref\":\"Tag:4deae86e-45d4-4485-b864-20b4f62c6745\"},{\"__ref\":\"Tag:5921a592-06f2-4e79-85b7-115ed383707d\"},{\"__ref\":\"Tag:9de1f385-f3e4-4d42-af16-96152e5957da\"},{\"__ref\":\"Tag:6953bbd3-1394-4c41-989a-e5821f56fe2d\"},{\"__ref\":\"Tag:027fcd98-8286-497d-92cb-70a839cd7ae7\"},{\"__ref\":\"Tag:23c41f89-eb5e-4c6b-895b-92d2f3517c97\"},{\"__ref\":\"Tag:f3931399-70e9-4176-a512-8fd81cdf39d8\"},{\"__ref\":\"Tag:ec377b6c-1ce7-4085-93b9-1bbbb01b0bde\"},{\"__ref\":\"Tag:b9ddf12a-1769-4d11-9d5e-fd9210093864\"}],\"publishedAt\":\"2021-04-12T10:00:00.000Z\",\"displayAt\":null,\"updatedAt\":\"2021-05-11T17:55:16.248Z\",\"publicPublishedDate\":\"2021-04-12T10:00:00.000Z\",\"status\":\"PUBLISHED\",\"ledeImage\":{\"__ref\":\"Image:2aa83dc8-dd96-40df-9f32-2e24ad7eb51a\"},\"ledeAltImage\":null,\"ledeImageCaption\":null,\"url\":\"/article/161899/kazuo-ishiguro-klara-sun-review-deceptively-simple-story-ai\",\"urlFull\":\"https://newrepublic.com/article/161899/kazuo-ishiguro-klara-sun-review-deceptively-simple-story-ai\",\"deck\":\"Why does “Klara and the Sun” serve up its big questions so explicitly?\",\"FeedId\":null,\"feed\":null,\"frontPage\":{\"__ref\":\"FrontPage:027da8c8-e1ea-43dd-a2b4-3b5b8451fa17\"},\"meta\":{\"__typename\":\"ArticleMeta\",\"cropModeFronts\":null},\"ledeVideo\":{\"__typename\":\"Video\",\"src\":null,\"controls\":null}},\"Author:e61b5030-b42b-4794-913c-2f8b208019ef\":{\"__typename\":\"Author\",\"id\":\"e61b5030-b42b-4794-913c-2f8b208019ef\",\"name\":\"Alex Shephard\",\"slug\":\"alex-shephard\",\"meta\":{\"__typename\":\"AuthorMeta\",\"podcast\":null}},\"Tag:6bfcc676-2945-4226-b5fc-20eec068ca24\":{\"__typename\":\"Tag\",\"id\":\"6bfcc676-2945-4226-b5fc-20eec068ca24\",\"slug\":\"media\",\"label\":\"Media\"},\"Tag:95a7dd4c-5117-4eac-a73a-2470aecfbaf4\":{\"__typename\":\"Tag\",\"id\":\"95a7dd4c-5117-4eac-a73a-2470aecfbaf4\",\"slug\":\"matt-gaetz\",\"label\":\"Matt Gaetz\"},\"Tag:69f458d7-aa65-453d-99dc-f0bd1ac4f398\":{\"__typename\":\"Tag\",\"id\":\"69f458d7-aa65-453d-99dc-f0bd1ac4f398\",\"slug\":\"fox-news\",\"label\":\"FOX News\"},\"Tag:9c584690-3c7a-4b18-b58e-dac859f21c5a\":{\"__typename\":\"Tag\",\"id\":\"9c584690-3c7a-4b18-b58e-dac859f21c5a\",\"slug\":\"right-wing-media\",\"label\":\"right-wing media\"},\"Tag:291b6ed0-fcb9-4099-ae17-2da948ffbabf\":{\"__typename\":\"Tag\",\"id\":\"291b6ed0-fcb9-4099-ae17-2da948ffbabf\",\"slug\":\"conservative-media\",\"label\":\"Conservative Media\"},\"Tag:1546a2f4-5fa9-4cb3-bf0f-4120a22ab171\":{\"__typename\":\"Tag\",\"id\":\"1546a2f4-5fa9-4cb3-bf0f-4120a22ab171\",\"slug\":\"florida\",\"label\":\"Florida\"},\"Tag:1b93e018-5108-40ea-86f5-d46dd2dd1097\":{\"__typename\":\"Tag\",\"id\":\"1b93e018-5108-40ea-86f5-d46dd2dd1097\",\"slug\":\"political-scandals\",\"label\":\"political scandals\"},\"Image:f12fa2cc-321f-45b6-aff9-da80e3d3fe1d\":{\"__typename\":\"Image\",\"id\":\"f12fa2cc-321f-45b6-aff9-da80e3d3fe1d\",\"src\":\"//images.newrepublic.com/b668f9ea83d22d1e7dc5a881cf256d5791daf09b.jpeg\",\"format\":\"JPEG\",\"width\":5472,\"height\":3648,\"alt\":null},\"Article:f9ecf7fd-aa39-4425-848f-42e3ef99bff2\":{\"__typename\":\"Article\",\"id\":\"f9ecf7fd-aa39-4425-848f-42e3ef99bff2\",\"nid\":\"162002\",\"slug\":\"fox-news-made-matt-gaetz\",\"title\":\"Fox News Made Matt Gaetz\",\"homepageTitle\":null,\"homepageSubheadline\":null,\"badge\":null,\"authors\":[{\"__ref\":\"Author:e61b5030-b42b-4794-913c-2f8b208019ef\"}],\"subscribersOnly\":false,\"tags\":[{\"__ref\":\"Tag:6bfcc676-2945-4226-b5fc-20eec068ca24\"},{\"__ref\":\"Tag:3046ee55-25d3-43cb-8491-58b17f8004d3\"},{\"__ref\":\"Tag:95a7dd4c-5117-4eac-a73a-2470aecfbaf4\"},{\"__ref\":\"Tag:69f458d7-aa65-453d-99dc-f0bd1ac4f398\"},{\"__ref\":\"Tag:9ecbca02-2681-4228-b2cb-f9f19cda9fc9\"},{\"__ref\":\"Tag:9c584690-3c7a-4b18-b58e-dac859f21c5a\"},{\"__ref\":\"Tag:291b6ed0-fcb9-4099-ae17-2da948ffbabf\"},{\"__ref\":\"Tag:1546a2f4-5fa9-4cb3-bf0f-4120a22ab171\"},{\"__ref\":\"Tag:1b93e018-5108-40ea-86f5-d46dd2dd1097\"},{\"__ref\":\"Tag:c27ff6e6-b672-430d-be07-8a59b6f23383\"}],\"publishedAt\":\"2021-04-12T10:00:00.000Z\",\"displayAt\":null,\"updatedAt\":\"2023-11-28T01:40:10.585Z\",\"publicPublishedDate\":\"2021-04-12T10:00:00.000Z\",\"status\":\"PUBLISHED\",\"ledeImage\":{\"__ref\":\"Image:f12fa2cc-321f-45b6-aff9-da80e3d3fe1d\"},\"ledeAltImage\":null,\"ledeImageCaption\":null,\"url\":\"/article/162002/fox-news-made-matt-gaetz\",\"urlFull\":\"https://newrepublic.com/article/162002/fox-news-made-matt-gaetz\",\"deck\":\"The network turned the scandal-plagued GOP congressman into a star. Now it’s acting like it doesn’t know him.\",\"FeedId\":null,\"feed\":null,\"frontPage\":{\"__ref\":\"FrontPage:03bf2e55-4f96-4942-851b-0ac31c0aa4e4\"},\"meta\":{\"__typename\":\"ArticleMeta\",\"cropModeFronts\":null},\"ledeVideo\":{\"__typename\":\"Video\",\"src\":null,\"controls\":null}},\"Author:20bc267c-8444-459c-83c4-e26721563d36\":{\"__typename\":\"Author\",\"id\":\"20bc267c-8444-459c-83c4-e26721563d36\",\"name\":\"Alex Pareene\",\"slug\":\"alex-pareene\",\"meta\":{\"__typename\":\"AuthorMeta\",\"podcast\":null}},\"Tag:689ac22b-fe41-4d48-bb04-ea052b380ab2\":{\"__typename\":\"Tag\",\"id\":\"689ac22b-fe41-4d48-bb04-ea052b380ab2\",\"slug\":\"dr-seuss\",\"label\":\"Dr. Seuss\"},\"Tag:1c0817c5-09fa-46fc-835f-6f5d592a7a54\":{\"__typename\":\"Tag\",\"id\":\"1c0817c5-09fa-46fc-835f-6f5d592a7a54\",\"slug\":\"wokeness\",\"label\":\"Wokeness\"},\"Tag:d1da3ded-b873-477f-adb0-c9b29a7c970e\":{\"__typename\":\"Tag\",\"id\":\"d1da3ded-b873-477f-adb0-c9b29a7c970e\",\"slug\":\"cancel-culture\",\"label\":\"cancel culture\"},\"Tag:850e63ff-1add-4d7f-9a57-12f123258179\":{\"__typename\":\"Tag\",\"id\":\"850e63ff-1add-4d7f-9a57-12f123258179\",\"slug\":\"culture-war\",\"label\":\"Culture War\"},\"Tag:2e80f63a-3afe-40b9-982e-e06341f7942b\":{\"__typename\":\"Tag\",\"id\":\"2e80f63a-3afe-40b9-982e-e06341f7942b\",\"slug\":\"mitch-mcconnell\",\"label\":\"Mitch McConnell\"},\"Image:9eb56fb7-605a-42fb-886a-f401bac884c5\":{\"__typename\":\"Image\",\"id\":\"9eb56fb7-605a-42fb-886a-f401bac884c5\",\"src\":\"//images.newrepublic.com/235e3ed2146bfaa5d88061466f6fb34753d9fc42.jpeg\",\"format\":\"JPEG\",\"width\":3000,\"height\":2001,\"alt\":null},\"Article:23deefc9-f69f-45d2-9a77-8899787cad37\":{\"__typename\":\"Article\",\"id\":\"23deefc9-f69f-45d2-9a77-8899787cad37\",\"nid\":\"161999\",\"slug\":\"cancel-culture-conservatives-seuss\",\"title\":\"The Case for More Canceling\",\"homepageTitle\":null,\"homepageSubheadline\":null,\"badge\":null,\"authors\":[{\"__ref\":\"Author:20bc267c-8444-459c-83c4-e26721563d36\"}],\"subscribersOnly\":false,\"tags\":[{\"__ref\":\"Tag:689ac22b-fe41-4d48-bb04-ea052b380ab2\"},{\"__ref\":\"Tag:1c0817c5-09fa-46fc-835f-6f5d592a7a54\"},{\"__ref\":\"Tag:d1da3ded-b873-477f-adb0-c9b29a7c970e\"},{\"__ref\":\"Tag:850e63ff-1add-4d7f-9a57-12f123258179\"},{\"__ref\":\"Tag:3046ee55-25d3-43cb-8491-58b17f8004d3\"},{\"__ref\":\"Tag:c27ff6e6-b672-430d-be07-8a59b6f23383\"},{\"__ref\":\"Tag:2e80f63a-3afe-40b9-982e-e06341f7942b\"}],\"publishedAt\":\"2021-04-09T15:52:35.000Z\",\"displayAt\":null,\"updatedAt\":\"2023-11-28T01:40:10.585Z\",\"publicPublishedDate\":\"2021-04-09T15:52:35.000Z\",\"status\":\"PUBLISHED\",\"ledeImage\":{\"__ref\":\"Image:9eb56fb7-605a-42fb-886a-f401bac884c5\"},\"ledeAltImage\":null,\"ledeImageCaption\":null,\"url\":\"/article/161999/cancel-culture-conservatives-seuss\",\"urlFull\":\"https://newrepublic.com/article/161999/cancel-culture-conservatives-seuss\",\"deck\":\"As long as conservatives are obsessed with Dr. Seuss and “woke capital,” they’ll be too distracted to wage genuinely harmful culture wars.\",\"FeedId\":null,\"feed\":null,\"frontPage\":{\"__ref\":\"FrontPage:03bf2e55-4f96-4942-851b-0ac31c0aa4e4\"},\"meta\":{\"__typename\":\"ArticleMeta\",\"cropModeFronts\":null},\"ledeVideo\":{\"__typename\":\"Video\",\"src\":null,\"controls\":null}},\"Author:26476281-a791-4f7b-aa66-369d8f8074e9\":{\"__typename\":\"Author\",\"id\":\"26476281-a791-4f7b-aa66-369d8f8074e9\",\"name\":\"Grace Segers\",\"slug\":\"grace-segers\",\"meta\":{\"__typename\":\"AuthorMeta\",\"podcast\":null}},\"Tag:1268d51e-b917-43c5-9605-7b0ce8b7bf0e\":{\"__typename\":\"Tag\",\"id\":\"1268d51e-b917-43c5-9605-7b0ce8b7bf0e\",\"slug\":\"unions\",\"label\":\"Unions\"},\"Tag:7e62cb96-4683-47b5-856f-f28a5abd3df6\":{\"__typename\":\"Tag\",\"id\":\"7e62cb96-4683-47b5-856f-f28a5abd3df6\",\"slug\":\"federal-government\",\"label\":\"federal government\"},\"Tag:2b2b3aae-4e6f-4a44-989f-1e47e1198c57\":{\"__typename\":\"Tag\",\"id\":\"2b2b3aae-4e6f-4a44-989f-1e47e1198c57\",\"slug\":\"elon-musk\",\"label\":\"Elon Musk\"},\"Tag:d2da3562-6e68-4742-953a-54da4da9cf11\":{\"__typename\":\"Tag\",\"id\":\"d2da3562-6e68-4742-953a-54da4da9cf11\",\"slug\":\"doge\",\"label\":\"doge\"},\"Tag:0c000454-69f9-429f-b634-c1018e199d1b\":{\"__typename\":\"Tag\",\"id\":\"0c000454-69f9-429f-b634-c1018e199d1b\",\"slug\":\"department-of-government-efficiency\",\"label\":\"department of government efficiency\"},\"Tag:177aceae-a364-4c32-b7a6-6522168a2e9b\":{\"__typename\":\"Tag\",\"id\":\"177aceae-a364-4c32-b7a6-6522168a2e9b\",\"slug\":\"federal-workers\",\"label\":\"federal workers\"},\"Tag:c7b474cc-ad79-46d8-af9d-8795aa7b7455\":{\"__typename\":\"Tag\",\"id\":\"c7b474cc-ad79-46d8-af9d-8795aa7b7455\",\"slug\":\"labor\",\"label\":\"Labor\"},\"Tag:f63cae3f-86b1-4a9b-9952-5b95a53aefff\":{\"__typename\":\"Tag\",\"id\":\"f63cae3f-86b1-4a9b-9952-5b95a53aefff\",\"slug\":\"department-of-labor\",\"label\":\"Department of Labor\"},\"Tag:aec49d05-a9bb-42bf-8377-f28b5704205a\":{\"__typename\":\"Tag\",\"id\":\"aec49d05-a9bb-42bf-8377-f28b5704205a\",\"slug\":\"nlrb\",\"label\":\"NLRB\"},\"Tag:85b69f34-87f7-4513-b79d-9840f4169510\":{\"__typename\":\"Tag\",\"id\":\"85b69f34-87f7-4513-b79d-9840f4169510\",\"slug\":\"civil-service\",\"label\":\"Civil service\"},\"Image:e136ec58-6f5c-42ab-b7af-7f8f4502a332\":{\"__typename\":\"Image\",\"id\":\"e136ec58-6f5c-42ab-b7af-7f8f4502a332\",\"src\":\"//images.newrepublic.com/36d1be6510de902e6a94eb95b92379e05a279b34.jpeg\",\"format\":\"JPEG\",\"width\":5472,\"height\":3648,\"alt\":\"Members of the American Federation of Government Employees (AFGE) union protest against firings during a rally to defend federal workers in Washington, DC on February 11, 2025.\"},\"Article:fc5ac6e5-010f-49ec-9c2b-8529c4169be9\":{\"__typename\":\"Article\",\"id\":\"fc5ac6e5-010f-49ec-9c2b-8529c4169be9\",\"nid\":\"191453\",\"slug\":\"federal-unions-fight-trump-musk\",\"title\":\"  Federal Workers’ Unions Are Waging the Fight of Their Lives  \",\"homepageTitle\":null,\"homepageSubheadline\":null,\"badge\":\"Labor Pains\",\"authors\":[{\"__ref\":\"Author:26476281-a791-4f7b-aa66-369d8f8074e9\"}],\"subscribersOnly\":false,\"tags\":[{\"__ref\":\"Tag:3046ee55-25d3-43cb-8491-58b17f8004d3\"},{\"__ref\":\"Tag:1268d51e-b917-43c5-9605-7b0ce8b7bf0e\"},{\"__ref\":\"Tag:7e62cb96-4683-47b5-856f-f28a5abd3df6\"},{\"__ref\":\"Tag:9ecbca02-2681-4228-b2cb-f9f19cda9fc9\"},{\"__ref\":\"Tag:2b2b3aae-4e6f-4a44-989f-1e47e1198c57\"},{\"__ref\":\"Tag:d2da3562-6e68-4742-953a-54da4da9cf11\"},{\"__ref\":\"Tag:0c000454-69f9-429f-b634-c1018e199d1b\"},{\"__ref\":\"Tag:177aceae-a364-4c32-b7a6-6522168a2e9b\"},{\"__ref\":\"Tag:c7b474cc-ad79-46d8-af9d-8795aa7b7455\"},{\"__ref\":\"Tag:f63cae3f-86b1-4a9b-9952-5b95a53aefff\"},{\"__ref\":\"Tag:aec49d05-a9bb-42bf-8377-f28b5704205a\"},{\"__ref\":\"Tag:85b69f34-87f7-4513-b79d-9840f4169510\"}],\"publishedAt\":\"2025-02-13T11:00:00.000Z\",\"displayAt\":null,\"updatedAt\":\"2025-02-13T14:23:14.512Z\",\"publicPublishedDate\":\"2025-02-13T11:00:00.000Z\",\"status\":\"PUBLISHED\",\"ledeImage\":{\"__ref\":\"Image:e136ec58-6f5c-42ab-b7af-7f8f4502a332\"},\"ledeAltImage\":null,\"ledeImageCaption\":null,\"url\":\"/article/191453/federal-unions-fight-trump-musk\",\"urlFull\":\"https://newrepublic.com/article/191453/federal-unions-fight-trump-musk\",\"deck\":\"With the White House and Elon Musk’s DOGE working to dismantle the government, civil service employees are finding ways to push back.\",\"FeedId\":null,\"feed\":null,\"frontPage\":{\"__ref\":\"FrontPage:03bf2e55-4f96-4942-851b-0ac31c0aa4e4\"},\"meta\":{\"__typename\":\"ArticleMeta\",\"cropModeFronts\":null},\"ledeVideo\":{\"__typename\":\"Video\",\"src\":null,\"controls\":false}},\"Author:85b60f1b-1010-48a4-86fd-03a10565fe04\":{\"__typename\":\"Author\",\"id\":\"85b60f1b-1010-48a4-86fd-03a10565fe04\",\"name\":\"Bryce Covert\",\"slug\":\"bryce-covert\",\"meta\":{\"__typename\":\"AuthorMeta\",\"podcast\":null}},\"Tag:9724122e-7078-4289-947a-9a84a4ca8d1a\":{\"__typename\":\"Tag\",\"id\":\"9724122e-7078-4289-947a-9a84a4ca8d1a\",\"slug\":\"democratic-party\",\"label\":\"Democratic Party\"},\"Image:1d491522-be72-45ec-b4ca-ce31bae67678\":{\"__typename\":\"Image\",\"id\":\"1d491522-be72-45ec-b4ca-ce31bae67678\",\"src\":\"//images.newrepublic.com/2924b35d513f021f535a006978c2b3a8335f3081.jpeg\",\"format\":\"JPEG\",\"width\":3347,\"height\":2231,\"alt\":\"Protesters gather at a rally organized by the American Federation of Government Employees against the so-called Department of Government Efficiency (DOGE) purges and resignation offers made to the federal civilian workforce outside the US Capitol in Washington, D.C.\"},\"Article:356a7585-7e2c-4c1f-bd13-ce9e721c319e\":{\"__typename\":\"Article\",\"id\":\"356a7585-7e2c-4c1f-bd13-ce9e721c319e\",\"nid\":\"191422\",\"slug\":\"democrats-defend-federal-workers-doge\",\"title\":\"If Democrats Don’t Champion the Civil Service, Who Will?\",\"homepageTitle\":null,\"homepageSubheadline\":null,\"badge\":\"Back the Feds\",\"authors\":[{\"__ref\":\"Author:85b60f1b-1010-48a4-86fd-03a10565fe04\"}],\"subscribersOnly\":false,\"tags\":[{\"__ref\":\"Tag:3046ee55-25d3-43cb-8491-58b17f8004d3\"},{\"__ref\":\"Tag:9ecbca02-2681-4228-b2cb-f9f19cda9fc9\"},{\"__ref\":\"Tag:2b2b3aae-4e6f-4a44-989f-1e47e1198c57\"},{\"__ref\":\"Tag:85b69f34-87f7-4513-b79d-9840f4169510\"},{\"__ref\":\"Tag:7e62cb96-4683-47b5-856f-f28a5abd3df6\"},{\"__ref\":\"Tag:c7b474cc-ad79-46d8-af9d-8795aa7b7455\"},{\"__ref\":\"Tag:9724122e-7078-4289-947a-9a84a4ca8d1a\"}],\"publishedAt\":\"2025-02-13T11:00:00.000Z\",\"displayAt\":null,\"updatedAt\":\"2025-02-13T16:24:13.963Z\",\"publicPublishedDate\":\"2025-02-13T11:00:00.000Z\",\"status\":\"PUBLISHED\",\"ledeImage\":{\"__ref\":\"Image:1d491522-be72-45ec-b4ca-ce31bae67678\"},\"ledeAltImage\":null,\"ledeImageCaption\":null,\"url\":\"/article/191422/democrats-defend-federal-workers-doge\",\"urlFull\":\"https://newrepublic.com/article/191422/democrats-defend-federal-workers-doge\",\"deck\":\"With the federal workforce facing an onslaught by Trump and Elon Musk, its employees—and the populace it so dutifully protects—desperately need defenders.\",\"FeedId\":null,\"feed\":null,\"frontPage\":{\"__ref\":\"FrontPage:03bf2e55-4f96-4942-851b-0ac31c0aa4e4\"},\"meta\":{\"__typename\":\"ArticleMeta\",\"cropModeFronts\":null},\"ledeVideo\":{\"__typename\":\"Video\",\"src\":null,\"controls\":false}},\"Author:a04cd3cc-957b-4a1f-a21b-44b783cbdb03\":{\"__typename\":\"Author\",\"id\":\"a04cd3cc-957b-4a1f-a21b-44b783cbdb03\",\"name\":\"Harry Litman\",\"slug\":\"harry-litman\",\"meta\":{\"__typename\":\"AuthorMeta\",\"podcast\":null}},\"Tag:1be8f32b-1e7d-42f5-83e9-db6142cd6009\":{\"__typename\":\"Tag\",\"id\":\"1be8f32b-1e7d-42f5-83e9-db6142cd6009\",\"slug\":\"jd-vance\",\"label\":\"J.D. Vance\"},\"Tag:a883dd76-b8ae-4296-bc73-265eab9a4b60\":{\"__typename\":\"Tag\",\"id\":\"a883dd76-b8ae-4296-bc73-265eab9a4b60\",\"slug\":\"law\",\"label\":\"Law\"},\"Tag:b9ad426d-f8ce-43c9-b7c5-a993cf7c190a\":{\"__typename\":\"Tag\",\"id\":\"b9ad426d-f8ce-43c9-b7c5-a993cf7c190a\",\"slug\":\"constitution\",\"label\":\"Constitution\"},\"Tag:82c39255-dd9f-472e-ae4f-f3b3cc0207a1\":{\"__typename\":\"Tag\",\"id\":\"82c39255-dd9f-472e-ae4f-f3b3cc0207a1\",\"slug\":\"abraham-lincoln\",\"label\":\"Abraham Lincoln\"},\"Tag:805549eb-a443-4078-bf2e-aa2f3fa8e456\":{\"__typename\":\"Tag\",\"id\":\"805549eb-a443-4078-bf2e-aa2f3fa8e456\",\"slug\":\"richard-nixon\",\"label\":\"Richard Nixon\"},\"Tag:07f3aeae-a6cf-48af-ad14-5c57980bd6ce\":{\"__typename\":\"Tag\",\"id\":\"07f3aeae-a6cf-48af-ad14-5c57980bd6ce\",\"slug\":\"al-gore\",\"label\":\"Al Gore\"},\"Tag:f3a84a6c-923b-4dc0-b0ee-5e564ad33c01\":{\"__typename\":\"Tag\",\"id\":\"f3a84a6c-923b-4dc0-b0ee-5e564ad33c01\",\"slug\":\"dwight-eisenhower\",\"label\":\"Dwight Eisenhower\"},\"Image:7db41384-c1d4-4ced-82b5-b6f1ab47b16c\":{\"__typename\":\"Image\",\"id\":\"7db41384-c1d4-4ced-82b5-b6f1ab47b16c\",\"src\":\"//images.newrepublic.com/39e7ce44ae8b01630cedbc83de322245c03b0f1d.jpeg\",\"format\":\"JPEG\",\"width\":1280,\"height\":854,\"alt\":\"Trump in oval office\"},\"Article:da91d188-df28-4eed-ac84-f939a11eab60\":{\"__typename\":\"Article\",\"id\":\"da91d188-df28-4eed-ac84-f939a11eab60\",\"nid\":\"191450\",\"slug\":\"trump-courts-judiciary-constitutional-cliff\",\"title\":\"Trump vs. the Courts: Will He Drive Us Over the Constitutional Cliff? \",\"homepageTitle\":null,\"homepageSubheadline\":null,\"badge\":\"COURTING CRISIS\",\"authors\":[{\"__ref\":\"Author:a04cd3cc-957b-4a1f-a21b-44b783cbdb03\"}],\"subscribersOnly\":false,\"tags\":[{\"__ref\":\"Tag:3046ee55-25d3-43cb-8491-58b17f8004d3\"},{\"__ref\":\"Tag:1be8f32b-1e7d-42f5-83e9-db6142cd6009\"},{\"__ref\":\"Tag:9ecbca02-2681-4228-b2cb-f9f19cda9fc9\"},{\"__ref\":\"Tag:a883dd76-b8ae-4296-bc73-265eab9a4b60\"},{\"__ref\":\"Tag:b9ad426d-f8ce-43c9-b7c5-a993cf7c190a\"},{\"__ref\":\"Tag:82c39255-dd9f-472e-ae4f-f3b3cc0207a1\"},{\"__ref\":\"Tag:2b2b3aae-4e6f-4a44-989f-1e47e1198c57\"},{\"__ref\":\"Tag:805549eb-a443-4078-bf2e-aa2f3fa8e456\"},{\"__ref\":\"Tag:07f3aeae-a6cf-48af-ad14-5c57980bd6ce\"},{\"__ref\":\"Tag:f3a84a6c-923b-4dc0-b0ee-5e564ad33c01\"},{\"__ref\":\"Tag:d2da3562-6e68-4742-953a-54da4da9cf11\"}],\"publishedAt\":\"2025-02-12T18:28:25.000Z\",\"displayAt\":null,\"updatedAt\":\"2025-02-12T20:52:49.401Z\",\"publicPublishedDate\":\"2025-02-12T18:28:25.000Z\",\"status\":\"PUBLISHED\",\"ledeImage\":{\"__ref\":\"Image:7db41384-c1d4-4ced-82b5-b6f1ab47b16c\"},\"ledeAltImage\":null,\"ledeImageCaption\":null,\"url\":\"/article/191450/trump-courts-judiciary-constitutional-cliff\",\"urlFull\":\"https://newrepublic.com/article/191450/trump-courts-judiciary-constitutional-cliff\",\"deck\":\"It’s about to be a constitutional crisis, if it’s not already. And we’re only three weeks in. Buckle up.\",\"FeedId\":null,\"feed\":null,\"frontPage\":{\"__ref\":\"FrontPage:03bf2e55-4f96-4942-851b-0ac31c0aa4e4\"},\"meta\":{\"__typename\":\"ArticleMeta\",\"cropModeFronts\":null},\"ledeVideo\":{\"__typename\":\"Video\",\"src\":null,\"controls\":false}},\"Author:eff49e00-668e-42cf-91b6-ce08b0cdfbd6\":{\"__typename\":\"Author\",\"id\":\"eff49e00-668e-42cf-91b6-ce08b0cdfbd6\",\"name\":\"Matt Ford\",\"slug\":\"matt-ford\",\"meta\":{\"__typename\":\"AuthorMeta\",\"podcast\":null}},\"Tag:e3f7d0eb-a7b9-4f38-94a1-7f1e2ed4c5d6\":{\"__typename\":\"Tag\",\"id\":\"e3f7d0eb-a7b9-4f38-94a1-7f1e2ed4c5d6\",\"slug\":\"pam-bondi\",\"label\":\"Pam Bondi\"},\"Tag:fb99b78f-7392-4960-8718-4b097c1d6c6d\":{\"__typename\":\"Tag\",\"id\":\"fb99b78f-7392-4960-8718-4b097c1d6c6d\",\"slug\":\"john-roberts\",\"label\":\"John Roberts\"},\"Tag:5b472d0a-b9df-4982-a1fb-6f29bc0e5ea0\":{\"__typename\":\"Tag\",\"id\":\"5b472d0a-b9df-4982-a1fb-6f29bc0e5ea0\",\"slug\":\"doj\",\"label\":\"DOJ\"},\"Tag:ee7262e7-4682-45e7-8b0f-881880d9fb43\":{\"__typename\":\"Tag\",\"id\":\"ee7262e7-4682-45e7-8b0f-881880d9fb43\",\"slug\":\"department-of-justice\",\"label\":\"Department of Justice\"},\"Tag:21440ac3-db8a-47b0-814a-b8ecfd52fdea\":{\"__typename\":\"Tag\",\"id\":\"21440ac3-db8a-47b0-814a-b8ecfd52fdea\",\"slug\":\"supreme-court\",\"label\":\"Supreme Court\"},\"Tag:104efd79-151e-470f-bb38-3d2cdf22217e\":{\"__typename\":\"Tag\",\"id\":\"104efd79-151e-470f-bb38-3d2cdf22217e\",\"slug\":\"supreme-court-watch\",\"label\":\"Supreme Court Watch\"},\"Image:30fbc6ea-c959-4915-a634-13101b8dd174\":{\"__typename\":\"Image\",\"id\":\"30fbc6ea-c959-4915-a634-13101b8dd174\",\"src\":\"//images.newrepublic.com/9757a6f923a1ebb1c0b2062734278b847af2906b.jpeg\",\"format\":\"JPEG\",\"width\":6000,\"height\":4000,\"alt\":\"Donald Trump and U.S. Attorney General Pam Bondi pose with a document in the Oval Office.\"},\"Article:f143de64-971b-4570-844e-728c8de03b19\":{\"__typename\":\"Article\",\"id\":\"f143de64-971b-4570-844e-728c8de03b19\",\"nid\":\"191430\",\"slug\":\"trump-bondi-justice-corruption-roberts\",\"title\":\"Trump Won His War on the Justice Department\",\"homepageTitle\":null,\"homepageSubheadline\":null,\"badge\":\"Crime Wave\",\"authors\":[{\"__ref\":\"Author:eff49e00-668e-42cf-91b6-ce08b0cdfbd6\"}],\"subscribersOnly\":false,\"tags\":[{\"__ref\":\"Tag:3046ee55-25d3-43cb-8491-58b17f8004d3\"},{\"__ref\":\"Tag:9ecbca02-2681-4228-b2cb-f9f19cda9fc9\"},{\"__ref\":\"Tag:e3f7d0eb-a7b9-4f38-94a1-7f1e2ed4c5d6\"},{\"__ref\":\"Tag:fb99b78f-7392-4960-8718-4b097c1d6c6d\"},{\"__ref\":\"Tag:5b472d0a-b9df-4982-a1fb-6f29bc0e5ea0\"},{\"__ref\":\"Tag:ee7262e7-4682-45e7-8b0f-881880d9fb43\"},{\"__ref\":\"Tag:a883dd76-b8ae-4296-bc73-265eab9a4b60\"},{\"__ref\":\"Tag:21440ac3-db8a-47b0-814a-b8ecfd52fdea\"},{\"__ref\":\"Tag:104efd79-151e-470f-bb38-3d2cdf22217e\"}],\"publishedAt\":\"2025-02-12T11:00:00.000Z\",\"displayAt\":null,\"updatedAt\":\"2025-02-12T14:57:46.755Z\",\"publicPublishedDate\":\"2025-02-12T11:00:00.000Z\",\"status\":\"PUBLISHED\",\"ledeImage\":{\"__ref\":\"Image:30fbc6ea-c959-4915-a634-13101b8dd174\"},\"ledeAltImage\":null,\"ledeImageCaption\":null,\"url\":\"/article/191430/trump-bondi-justice-corruption-roberts\",\"urlFull\":\"https://newrepublic.com/article/191430/trump-bondi-justice-corruption-roberts\",\"deck\":\"The once-independent agency has been forced to embrace a change of mission—serve the president’s exclusive interests, and carry out his revenge on the American people.\",\"FeedId\":null,\"feed\":null,\"frontPage\":{\"__ref\":\"FrontPage:03bf2e55-4f96-4942-851b-0ac31c0aa4e4\"},\"meta\":{\"__typename\":\"ArticleMeta\",\"cropModeFronts\":null},\"ledeVideo\":{\"__typename\":\"Video\",\"src\":null,\"controls\":false}}}</script>\n    <script src=\"//assets.newrepublic.com/assets/newmain-1b8d84fc55c6bccb0e9a.js\"></script>\n    \n<!-- Facebook -->\n  <script type=\"text/plain\" class=\"optanon-category-C0004\">\n    window.fbAsyncInit = function() {\n      FB.init({\n        appId            : \"1675346479369918\",\n        autoLogAppEvents : true,\n        xfbml            : true,\n        version          : 'v10.0'\n      });\n    };\n  </script>\n  <script type=\"text/plain\" class=\"optanon-category-C0004\" async defer crossorigin=\"anonymous\" src=\"https://connect.facebook.net/en_US/sdk.js\"></script>\n<!-- /Facebook -->\n<script type=\"text/javascript\">window._sf_endpt = (new Date()).getTime()</script>\n  </body>\n</html>","oembed":false,"readabilityObject":{"title":"How Bill Gates Impeded Global Access to Covid Vaccines","content":"<div id=\"readability-page-1\" class=\"page\"><div><div><p>On February 11, 2020,<a href=\"https://www.who.int/news-room/events/detail/2020/02/11/default-calendar/global-research-and-innovation-forum-to-mobilize-international-action-in-response-to-the-novel-coronavirus-(2019-ncov)-emergency\" target=\"_blank\" rel=\"nofollow\"> public health and infectious disease experts</a> gathered\nby the hundreds at the World Health Organization’s Geneva mothership. The official pronouncement of a pandemic was still a month out, but the\nagency’s international brain trust knew enough to be worried. Burdened by a\nsense of borrowed time, they spent two days furiously sketching an “R&amp;D Blueprint”\nin preparation for a world upended by the virus then known as 2019-nCoV.</p><p>The resulting\ndocument summarized&nbsp;the state of coronavirus research and proposed ways to\naccelerate the development of diagnostics, treatments, and vaccines. The underlying\npremise was that the world would unite against the virus. The global research\ncommunity would maintain broad and open channels of communication, since\ncollaboration and information-sharing minimize duplication and accelerate discovery.\nThe group also drew up plans for global comparative trials overseen by the WHO,\nto assess the merits of treatments and vaccines.</p></div><div><p>One issue not\nmentioned in the paper: intellectual property. If the worst came to pass, the experts\nand researchers assumed cooperation would define the global response, with the\nWHO playing a central role. That pharmaceutical companies and their allied\ngovernments would allow intellectual property concerns to slow things down—from\nresearch and development to manufacturing scale-up—does not seem to have\noccurred to them.</p><p>They were wrong,\nbut they weren’t alone. Battle-scarred veterans of the medicines-access and\nopen-science movements hoped the immensity of the pandemic would override a\nglobal drug system based on proprietary science and market monopolies. By\nMarch, strange but welcome melodies could be heard from unexpected quarters. Anxious\ngovernments spoke of shared interests and global public goods; drug companies pledged\n“precompetitive” and “no-profit” approaches to development and pricing. The\nearly days featured tantalizing glimpses of an open-science,\ncooperative pandemic response. In January and February 2020, a consortium led\nby the National Institutes of Health and the National Institute of Allergy and\nInfectious Diseases collaborated to produce atomic-level maps of the key viral proteins\nin record time. “Work that would normally have taken months—or possibly even\nyears—has been completed in weeks,” noted the editors of <i>Nature.</i><span>&nbsp;</span></p><p>When the <i>Financial\nTimes</i> <a href=\"https://www.ft.com/content/4a3bf282-701c-11ea-9bca-bf503995cd6f\" target=\"_blank\" rel=\"nofollow\">editorial<span>ized</span></a> on March 27 that “the world has an overwhelming interest in ensuring\n[Covid-19 drugs and vaccines] will be universally and cheaply available,” the\npaper expressed what felt like a hardening conventional wisdom. This sense of\npossibility emboldened forces working to extend the cooperative model. Grounding\ntheir efforts was a plan, started in early March, to create a voluntary intellectual\nproperty pool inside the WHO. Instead of putting up proprietary walls around\nresearch and organizing it as a “race,” public and private actors would collect research\nand associated intellectual property in a global knowledge fund for the duration of the pandemic. The\nidea became real in late May with the launch of the <a href=\"https://www.who.int/initiatives/covid-19-technology-access-pool/what-is-c-tap\" target=\"_blank\" rel=\"nofollow\">WHO Covid-19 Technology\nAccess Pool</a>, or C-TAP.</p></div><div><p>By then, however, the optimism and sense of\npossibility that defined the early days were long gone. Advocates for pooling\nand open science, who seemed ascendant and even unstoppable that winter, confronted\nthe possibility they’d been outmatched and outmaneuvered by the most powerful\nman in global public health.</p><p>In April, Bill Gates launched a bold bid to manage\nthe world’s scientific response to the pandemic. Gates’s <a href=\"https://www.who.int/initiatives/act-accelerator\" target=\"_blank\" rel=\"nofollow\">Covid-19 ACT-Accelerator</a>\nexpressed a status quo vision for organizing the research, development, manufacture,\nand distribution of treatments and vaccines. Like other Gates-funded\ninstitutions in the public health arena, the Accelerator was a public-private\npartnership based on charity and industry enticements. Crucially, and in\ncontrast to the C-TAP, the Accelerator enshrined Gates’s long-standing commitment\nto respecting exclusive intellectual property claims. Its implicit\narguments—that intellectual property rights won’t present problems for meeting global demand or ensuring\nequitable access, and that they must be protected, even during a pandemic—carried\nthe enormous weight of Gates’s reputation as a wise, beneficent, and prophetic\nleader.<span>&nbsp;</span></p><p>How he’s developed and wielded this influence\nover two decades is one of the more consequential and underappreciated shapers\nof the failed global response to the Covid-19 pandemic. Entering&nbsp;<span>year two, this response has been defined by a zero-sum\nvaccination battle that has left much of the world on the losing side.</span></p></div><div><p><span>Gates’s marquee Covid-19 initiative started\nrelatively small. Two days before the WHO declared a pandemic on March 11, 2020, the Bill &amp;\nMelinda Gates Foundation announced something called the Therapeutics\nAccelerator, a joint initiative with Mastercard and the charity group the Wellcome\nTrust to identify and develop potential treatments for the novel coronavirus.\nDoubling as a social branding exercise for a giant of global finance, the\nAccelerator reflected Gates’s familiar formula of corporate philanthropy, which\nhe has applied to everything from malaria to malnutrition. In retrospect, it\nwas a strong indicator that Gates’s dedication to monopoly medicine would\nsurvive the pandemic, even before he and his foundation’s officers began to say\nso publicly.&nbsp;&nbsp;</span><span>&nbsp;</span></p><p>This was confirmed when a bigger version of\nthe Accelerator was unveiled the following month at the WHO. The Access to Covid-19 Tools\nAccelerator, or ACT-Accelerator, was Gates’s bid to organize the development\nand distribution of everything from therapeutics to testing. The biggest and\nmost consequential arm, COVAX, proposed to subsidize vaccine deals with poor\ncountries through donations by, and sales to, richer ones. The goal was always\nlimited: It aimed to provide vaccines for up to 20 percent of the population in\nlow-to-middle-income countries.<b> </b>After\nthat, governments would largely have to compete on the global market like\neveryone else. It was a partial demand-side solution to what the movement\ncoalescing around a call for a “people’s vaccine” warned would be a dual crisis\nof supply and access, with intellectual property at the center of both.</p><p>Gates not only dismissed these warnings but\nactively sought to undermine all challenges to his authority and the Accelerator’s intellectual property–based charity agenda.<span>&nbsp;</span></p></div><div><p>“Early on, there was space for Gates to have\na major impact in favor of open models,” says Manuel Martin, a policy adviser to\nthe <a href=\"https://msfaccess.org/\" target=\"_blank\" rel=\"nofollow\">Médecins\nSans Frontières Access Campaign.</a> “But senior people in the\nGates organization very clearly sent out the message: Pooling was unnecessary\nand counterproductive. They dampened early enthusiasm by saying that I.P. is not\nan access barrier in vaccines. That’s just demonstratively false.”</p><p>Few have observed Bill Gates’s devotion to monopoly\nmedicine more closely than James Love, founder and director of <a href=\"https://www.keionline.org/\" target=\"_blank\" rel=\"nofollow\">Knowledge Ecology\nInternational</a>, a Washington, D.C.–based group that studies\nthe broad nexus of federal policy, the pharmaceutical industry, and intellectual\nproperty. Love\nentered the world of global public health policy around the same time Gates did,\nand for two decades has watched him scale its heights while reinforcing the\nsystem responsible for the very problems he claims to be trying to solve. The\nthrough-line for Gates has been his unwavering commitment to drug companies’\nright to exclusive control over medical science and the markets for its\nproducts.</p><p>“Things could have gone either way,” says Love, “but Gates wanted exclusive\nrights maintained. He acted fast to stop the push\nfor sharing the knowledge needed to make the products—the know-how, the data,\nthe cell lines, the tech transfer, the transparency that is\ncritically important in a dozen ways. The pooling approach represented by C-TAP\nincluded all of that. Instead of backing those early discussions, he raced\nahead and signaled support for business-as-usual on intellectual property by announcing\nthe ACT-Accelerator in March.”</p></div><div><p>One year later, the <a href=\"https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-5-february-2021\" target=\"_blank\" rel=\"nofollow\">ACT-Accelerator has\nfailed</a> to meet its goal of providing discounted vaccines to the “priority\nfifth” of low-income populations. The drug companies and rich nations that had\nso much praise for the initiative a year ago have retreated into bilateral\ndeals that leave little for anybody else. “The low- and middle-income countries are pretty\nmuch on their own, and there’s just not much out there,” said Peter Hotez, dean of the <a href=\"https://www.bcm.edu/education/national-school-of-tropical-medicine\" target=\"_blank\" rel=\"nofollow\">National School of Tropical\nMedicine</a> in Houston. “Despite their best efforts, the Gates model\nand its institutions are still industry-dependent.”</p><p>As of this writing in early April, fewer than <a href=\"https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-press-conference-with-dr-gerd-m%C3%BCller-federal-minister-of-economic-cooperation-and-development-(bmz)-germany---29-march-2021\" target=\"_blank\" rel=\"nofollow\">600 million</a>\nvaccine doses have been administered around the world; three-quarters\nof those in just 10 mostly high-income countries. Close to <a href=\"https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-5-february-2021\" target=\"_blank\" rel=\"nofollow\">130 countries containing 2.5\nbillion people</a> have yet to administer a single dose. The timeline for supplying\npoor and middle-income countries with enough vaccines to achieve herd immunity,\nmeanwhile, has been pushed into 2024. These numbers represent more than the “catastrophic\nmoral failure” the <a href=\"https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-148th-session-of-the-executive-board\" target=\"_blank\" rel=\"nofollow\">director general of the WHO</a> warned about this January. It is\na stark reminder than any policy that obstructs or inhibits vaccine production\nrisks being self-defeating for the rich countries defending exclusive rights and\ngobbling up the lion’s share of available vaccine supplies. The truth repeated\nso often throughout the pandemic—no one is safe until everyone is safe—remains in\nforce. </p><p>This easily anticipated market failure—together\nwith the C-TAP’s failure to launch—led developing countries to open a new front\nagainst intellectual property barriers in the World Trade Organization. Since\nOctober, the WTO’s <a href=\"https://www.wto.org/english/tratop_e/trips_e/trips_e.htm\" target=\"_blank\" rel=\"nofollow\">Trade-Related Aspects of Intellectual Property Rights\nCouncil</a> has been center ring in a dramatic north-south standoff over rights to control\nvaccine knowledge, technology, and markets. More than 100 low- and\nmiddle-income countries support a call by India and South Africa to waive certain\nprovisions related to Covid-19 intellectual property for the duration of the\npandemic. Although Gates and his organization do not have an official position\non the debate roiling the WTO, Gates and his deputies have left little doubt\nabout their opposition to the waiver proposal. Just as he did following the\nrollout of the WHO’s C-TAP, Gates has chosen to stand with the drug companies\nand their government patrons.&nbsp; &nbsp;<span>&nbsp;</span></p></div><div><p>Technically housed within the WHO, the ACT-Accelerator\nis a Gates operation, top to bottom. It is designed, managed, and staffed largely\nby Gates organization employees. It embodies Gates’s philanthropic\napproach to widely anticipated problems posed by intellectual property–hoarding companies able to constrain\nglobal production by prioritizing rich countries and inhibiting licensing. Companies\npartnering with COVAX are allowed to set their own tiered prices. They are\nsubject to almost no transparency requirements and to toothless contractual\nnods to “equitable access” that have never been enforced. Crucially,\nthe companies retain exclusive rights to their intellectual property. If they\nstray from the Gates Foundation line on exclusive rights, they are quickly\nbrought to heel. When the director of Oxford’s\nJenner Institute had funny ideas about placing the rights to its COVAX-supported\nvaccine candidate in the public domain, Gates intervened. As reported by <a href=\"https://khn.org/news/rather-than-give-away-its-covid-vaccine-oxford-makes-a-deal-with-drugmaker/\" target=\"_blank\" rel=\"nofollow\">Kaiser\nHealth News,</a> “A few weeks later, Oxford—urged on by the Bill &amp; Melinda\nGates Foundation—reversed course [and] signed an exclusive vaccine deal with\nAstraZeneca that gave the pharmaceutical giant sole rights and no guarantee of\nlow prices.”</p><p>Considering the alternatives being discussed,\nit is no surprise that drug companies have been the most enthusiastic boosters\nof the ACT-Accelerator and COVAX. The speakers at the ACT-Accelerator launch\nceremony in March 2020 included Thomas Cueni, director general of the\nInternational Federation of Pharmaceutical Manufacturers and Associations, who hailed the initiative as a “landmark global\npartnership.” Since vaccines started coming online, the IFPMA’s member\ncompanies have lost interest in the Accelerator, preferring bilateral deals\nwith rich countries. But they continue to benefit from the halo effect of their\nassociation with Gates, which has proved priceless throughout the pandemic,\nespecially at a crucial juncture in its first year.&nbsp;&nbsp;<span>&nbsp;<br></span></p><figure contenteditable=\"false\"><img src=\"//images.newrepublic.com/47a56a02170959126e1be285c141e9b68d2161d7.jpeg?w=1400\" data-serialized=\"{&quot;id&quot;:&quot;56f1b0f9-2c82-44f5-b88a-91f5bf9dabb5&quot;,&quot;hash&quot;:&quot;47a56a02170959126e1be285c141e9b68d2161d7&quot;,&quot;width&quot;:2500,&quot;height&quot;:1640,&quot;format&quot;:&quot;JPEG&quot;,&quot;isAnimated&quot;:false,&quot;baseUrl&quot;:&quot;//images.newrepublic.com/&quot;,&quot;src&quot;:&quot;//images.newrepublic.com/47a56a02170959126e1be285c141e9b68d2161d7.jpeg&quot;,&quot;alt&quot;:null,&quot;meta&quot;:{}}\" width=\"1400\"><figcaption><p><span>Bill Gates addresses the opening session of the WHO’s annual assembly in 2005, some six years after he entered the global public health scene as a defender of intellectual property rights during the AIDS crisis.</span></p><span>JEAN-PIERRE CLATOT/AFP/Getty Images</span></figcaption></figure><p>On May 29, Donald Trump <a href=\"https://www.politico.com/news/2020/05/29/us-withdrawing-from-who-289799\" target=\"_blank\" rel=\"nofollow\">announced</a> U.S.\nwithdrawal from the WHO. This was in response, he said, to China’s “total\ncontrol” of the agency. The drug industry, meanwhile, was displeased with the WHO\nfor entirely different reasons. The same day, the WHO director general had\nunveiled the C-TAP with a “Solidarity Call to Action” for governments and\ncompanies to share all intellectual property related to Covid-19 treatments and\nvaccines. The pharmaceutical companies didn’t attack the initiative directly. Instead,\ntheir global trade association, the IFPMA, preempted the announcement with a livestreamed\nmedia event on the evening of May 28. The event featured the heads of AstraZeneca,\nGlaxoSmithKline, Johnson &amp; Johnson, and Pfizer, and Thomas Cueni.</p></div><div><p>The\nevening’s sixth participant was the specter of Bill Gates.</p><p>As\nanticipated, the questions submitted by journalists touched repeatedly on the much-anticipated\nlaunch of C-TAP the following morning, as well as related issues of intellectual\nproperty, vaccine access and equity, and debates over the extent and ways intellectual property posed barriers to ramping up production. Mostly, the executives evinced<b> </b>ignorance and surprise over the\nimminent launch of C-TAP; only<a href=\"https://www.ifpma.org/events-2/global-biopharma-ceo-top-execs-covid-19-virtual-press-briefing-28-may/\" target=\"_blank\" rel=\"nofollow\"> Pfizer CEO Albert Bourla</a> openly denounced\nthe pooling of intellectual property as “dangerous” and “nonsense.”</p><p>All of the executives, however, shared a\nplaybook in which they quickly pivoted to affirmations of their support for Bill Gates and the ACT-Accelerator.\nThe association with Gates was\nsubmitted as evidence of industry commitment to equity and access—as well as\nproof of the complete lack of need for overlapping or competing initiatives,\nsuch as the “dangerous” C-TAP.<span>&nbsp;</span></p></div><div><p>“We already have platforms,” Cueni said during\nthe <a href=\"https://www.ifpma.org/events-2/global-biopharma-ceo-top-execs-covid-19-virtual-press-briefing-28-may/\" target=\"_blank\" rel=\"nofollow\">May 28 event</a>. “The industry is already doing all the right things.”<span>&nbsp;</span></p><p>As the questions about C-TAP and intellectual\nproperty piled up, the industry’s Gates rap started to sound less like a shared\nP.R. script than a broken record. Confronted for the second\ntime about intellectual property, GlaxoSmithKline CEO Emma Walmsley emitted an undigested stream\nof Gatesian word salad. “We are absolutely committed to this question of\naccess,” she stammered, “and deeply welcome the formation of ACT, which is this\nmultilateral organization that is going to be a mechanism with multiple\nstakeholders, whether it’s heads of state or organizations like [the Gates-funded]\nCEPI or the Gates and [<span>the Gates-funded]&nbsp;</span><span>Gavi and others and the WHO, of course, where we actually\nlook at these principles of, uh, access and so clearly, we’re engaged in that\nas well.”&nbsp;&nbsp;</span></p><p>Without the Gates and COVAX associations to lean\non, the stammering would have been much worse. Pfizer’s Albert Bourla seemed to\nrecognize this, at one point interrupting himself to express his industry’s gratitude\nand admiration. “I want to take the opportunity to emphasize the role that Bill\nGates is playing,” he said. He went on to call him “an inspiration for all.”<span>&nbsp;</span></p></div><div><p>Gates can hardly\ndisguise his contempt for the growing interest in intellectual property\nbarriers. In recent months, as the debate has shifted from the WHO to the WTO, reporters\nhave drawn testy responses from Gates that harken back to his <a href=\"https://www.nytimes.com/2018/04/14/business/bill-gates-washington-facebook.html\" target=\"_blank\" rel=\"nofollow\">prickly\nperformances</a> before congressional antitrust hearings a quarter-century ago.\nWhen a <i>Fast Company</i> reporter raised\nthe issue in February, she described Gates “raising his voice slightly and\nlaughing in frustration,” before snapping, “It’s irritating that this issue\ncomes up here. This&nbsp;isn’t&nbsp;about&nbsp;IP.”&nbsp;</p><p>In interview after interview, Gates has dismissed his critics on the\nissue—who represent the poor majority of the global population—as spoiled\nchildren demanding ice cream before dinner. “It’s the classic\nsituation in global health, where the advocates all of a sudden want [the\nvaccine] for zero dollars and right away,” <a href=\"https://www.reuters.com/article/us-health-coronavirus-gates/bill-gates-sees-6-8-month-lag-for-poor-countries-to-get-covid-19-shots-idUSKBN29W0QJ\" target=\"_blank\" rel=\"nofollow\">he told</a> Reuters in late January. Gates has larded the insults\nwith comments that equate state-protected and publicly funded monopolies with\nthe “free market.” “North\nKorea doesn’t have that many vaccines, as far as we can tell,” he <a href=\"https://www.nytimes.com/2020/11/23/world/bill-gates-vaccine-coronavirus.html\" target=\"_blank\" rel=\"nofollow\">told <i>The</i> <i>New York Times</i></a> in November. (It is curious that he chose North Korea as an example and not\n<a href=\"https://www.npr.org/sections/goatsandsoda/2021/03/25/980789381/cubas-revolutionary-dream-making-its-own-covid-vaccine\" target=\"_blank\" rel=\"nofollow\">Cuba</a>, a socialist country with an innovative and world-class vaccine\ndevelopment program with multiple Covid-19 vaccine candidates in various stages\nof testing.)</p><p>The\nclosest Gates has come to conceding that vaccine monopolies inhibit production\ncame during a January interview with South Africa’s <i>Mail &amp; Guardian.</i> Asked about the growing\nintellectual property debate, he responded, “At this point, changing the rules\nwouldn’t make any additional vaccines available.”</p></div><div><p>The first\nimplication of “at this point” is that the moment has passed when changing the\nrules could make a difference. This is a false but debatable claim. The same\ncan’t be said for the second implication, which is that nobody could have\npossibly foreseen the current supply crisis. Not only were the obstacles posed\nby intellectual property easily predictable a year ago, there was no lack of people making noise\nabout the urgency of avoiding them. They included much of the global research\ncommunity, major NGOs with long experience in medicines development and access,\nand dozens of current and former world leaders and public health experts. In a <a href=\"https://www.unaids.org/en/resources/presscentre/featurestories/2020/may/20200514_covid19-vaccine-open-letter\" target=\"_blank\" rel=\"nofollow\">May 2020 open letter</a>, more than 140\npolitical and civil society leaders called upon governments and companies to\nbegin pooling their intellectual property. “Now is&nbsp;<em>not</em><i>&nbsp;</i>the time … to leave this massive and moral task to market\nforces,” they wrote.&nbsp;&nbsp;</p><p>Bill Gates’s position on intellectual property was consistent\nwith a lifelong ideological commitment to knowledge\nmonopolies, forged during a vengeful teenage crusade against the open-source\nprogramming culture of the 1970s. As it happens, a novel use of one category of\nintellectual property—copyright, applied to computer code—made Gates the\nrichest man in the world for most of two decades beginning in 1995. That same\nyear, the WTO went into effect, chaining the developing\nworld to intellectual property rules written by a handful of executives from\nthe U.S. pharmaceutical, entertainment, and software industries.&nbsp; &nbsp;</p><p>By 1999, Bill Gates was in his final year as\nCEO of Microsoft, focused on defending the company he founded from antitrust\nsuits on two continents. As his business reputation suffered high-profile\nbeatings from U.S. and European regulators, he was in the process of moving on\nto his second act: the formation of the Bill &amp; Melinda Gates Foundation, which\ncommenced his unlikely rise to the commanding apex of global public health\npolicy. His debut in that role occurred during the contentious fifty-second General\nHealth Assembly in May 1999.</p></div><div><p>It was the height of the battle to bring\ngeneric AIDS drugs to the developing world. The central front was South Africa,\nwhere the HIV rate at the time was estimated as high as 22 percent and threatened\nto decimate an entire generation. In December 1997, the Mandela government\npassed a law giving the health ministry powers to produce, purchase, and import\nlow-cost drugs, including unbranded versions of combination therapies priced by\nWestern drug companies at $10,000 and more. In response, 39 drug multinationals\nfiled suit against South Africa alleging\nviolations of the country’s constitution and its obligations under the WTO’s\nAgreement on Trade-Related Aspects of Intellectual Property Rights, or TRIPS. The\nindustry suit was backed by the diplomatic muscle of the Clinton\nadministration, which tasked Al Gore with applying pressure. In his 2012 documentary <i><a href=\"https://www.rottentomatoes.com/m/fire_in_the_blood\" target=\"_blank\" rel=\"nofollow\">Fire in the Blood</a>,</i> Dylan Mohan Gray notes it took Washington 40 years to\nthreaten apartheid South Africa with sanctions and less than four to threaten\nthe post-apartheid Mandela government over AIDS drugs.&nbsp;</p><p>Though South\nAfrica barely registered&nbsp;as a market for the drug companies, the\nappearance of cheap generics produced in violation of patents anywhere was a\nthreat to monopoly pricing everywhere, according to the drug industry’s version\nof Cold War “domino theory.” Allowing poor nations to “free ride” on Western\nscience and build parallel drug economies would eventually cause problems\ncloser to home, where the industry spent billions of dollars on a propaganda\noperation to control the narrative around drug prices and keep the lid on\npublic discontent. The companies suing Mandela had devised TRIPS as a long-term\nstrategic response to the south-based generics industry that arose in the 1960s.\nThey had come too far to be set back by the needs of a pandemic in sub-Saharan Africa.\nU.S. and industry officials paired old standby arguments about patents driving\ninnovation with claims that Africans posed a public health menace because they couldn’t\nkeep time: Since they could not be relied on to take their medicines on a\nschedule, giving Africans access to the drugs would allow for the emergence of\ndrug-resistant HIV variants, according to industry and its government and media\nallies.*<span><span><br></span></span></p><p>In Geneva, the lawsuit\nwas reflected in a battle at the WHO, which was divided along a north-south\nfault line: on one side, the home countries of the Western drug companies; on\nthe other, a coalition of 134 developing countries (known collectively as the Group\nof 77, or G77) and a rising “third force” of civil society groups led by Médecins Sans Frontières and Oxfam. The point\nof conflict was a <a href=\"https://twn.my/title/twr120d.htm\" target=\"_blank\" rel=\"nofollow\">WHO resolution that called on</a> member states “to ensure\nequitable access to essential drugs; to ensure that public health interests are\nparamount in pharmaceutical and health policies; [and] to explore and review\ntheir options under relevant international agreements, including\ntrade&nbsp;agreements, to safeguard access to essential drugs.”<br></p></div><div><p><span>Western countries\nsaw the resolution as a threat to the recent conquest of monopoly medicine,\nachieved four years earlier with the establishment of the WTO. The industry\ngrew increasingly helpless, however, as global public opinion and WHO\nmember-state sentiment shifted in favor of the resolution and against the South\nAfrica lawsuit. In the weeks leading up to the assembly, the companies and\ntheir parent embassies floundered as they sought to turn the tide. Their\ngrowing anxiety is captured in a series of leaked cables sent to Washington by the U.S. ambassador in Geneva, George Moose, that April and May. In a diplomatic telegram dated\nApril 20, Moose expressed alarm over the growing number of WHO delegations\nmaking</span></p><blockquote><p><i>STATEMENTS THAT PUBLIC HEALTH SHOULD HAVE PRIMACY OVER COMMERCIAL\nINTERESTS UNDER WTO TRADE AGREEMENTS SUCH AS THE TRIPS (TRADE-RELATED ASPECTS\nOF INTELLECTUAL PROPERTY RIGHTS) … THEREBY POTENTIALLY UNDERMINING INTELLECTUAL\nPROPERTY RIGHTS (IPR).</i></p></blockquote><p><i>&nbsp;<br></i><span>Moose was concerned that drug companies were\nnot helping their own cause and seemed incapable of doing anything but parrot\nold talking points about intellectual property as the driver of innovation. The\npharmaceutical industry, Moose wrote,</span><span>&nbsp;</span></p><blockquote><p><i>SHOULD BE CARRYING MORE OF ITS OWN WATER ON THIS ISSUE, ESPECIALLY IN\nDEVELOPING COUNTRIES, AND NOT SOLELY DEPEND ON THE ARGUMENT THAT IPR PROTECTS\nPROFITS THAT THEN ARE USED FOR DEVELOPMENT OF NEW DRUGS IN THE FUTURE. NOT 10\nYEARS FROM NOW. THE SOUTH AFRICANS AND OTHERS ARE MOSTLY CONCERNED ABOUT\nAVAILABILITY OF DRUGS NOW. PROBLEMS RELATED TO LOCAL AVAILABILITY AND PRICING\nOF DRUGS THAT ARE UNRELATED TO TRIPS WILL UNDOUBTABLY REQUIRE FURTHER\nDISCUSSION. </i></p></blockquote><p><span>Over the course of weeks, a picture emerges from Moose’s\naccounts of a pharmaceutical industry against the ropes, punch drunk and out of\nideas. In the U.S. ambassador’s view, the problem wasn’t moral bankruptcy so\nmuch as incompetence. “</span><i>RECOMMEND THE USG PUSH THE\nPHARMACEUTICAL INDUSTRY TO ARGUE ITS POINTS MORE CONVINCINGLY IN DEVELOPING\nCOUNTRIES</i><span>,” the exasperated ambassador wrote. “</span><i>AND\nESPECIALLY DEAL WITH THEIR CONCERNS ABOUT LOCAL DRUG AVAILABILITY AND PRICING</i><span>.”</span></p></div><div><p>Following the raucous buzz saw of the 1999 WHO Assembly, the\ndrug companies would make a humiliating climbdown from their scandalous lawsuit\nin South Africa, reduced to what <i>The Washington Post</i> <a href=\"https://www.washingtonpost.com/archive/politics/2000/12/28/a-turning-point-that-left-millions-behind/afe238d9-49a6-4b03-bfff-2ba83c0c4cd7/\" target=\"_blank\" rel=\"nofollow\">called</a> “close to pariah\nstatus.”&nbsp;&nbsp;</p><p>At the same time, the industry was richer than ever. The\nClinton administration had approved a long <a href=\"http://www.ruf.rice.edu/~neal/temp/ST%20Policy/index/PCAST%20Reports/PCAST%20Teaming%20with%20Life%20Investing%20in%20Science.pdf\" target=\"_blank\" rel=\"nofollow\">Big Pharma wish list</a>, from broadening the\navenues for privatizing government-funded science to opening the age of direct\nmarketing of prescription drugs. The corresponding profits went to reinforce already\nhistorically rich D.C. and Geneva lobbying operations. And yet, for all their combined\nmight, the companies were incapable of producing a mask resembling a credible\nhuman face. A global activist movement continued to gather public opinion on\nits side and chip away at the legitimacy of the monopoly model that underlay the\nindustry’s enormous power. By every nonfinancial measure, it was an industry\nin distress. To borrow a phrase from a future Bill Gates production, you might\nsay it was waiting for its Superman.**<span><span><br></span></span></p><figure contenteditable=\"false\"><img src=\"//images.newrepublic.com/8d793ed39af4336d037d65a6598e2189f446fbf8.jpeg?w=1400\" data-serialized=\"{&quot;id&quot;:&quot;527ac027-3251-4865-a421-789ec92487a9&quot;,&quot;hash&quot;:&quot;8d793ed39af4336d037d65a6598e2189f446fbf8&quot;,&quot;width&quot;:3000,&quot;height&quot;:2000,&quot;format&quot;:&quot;JPEG&quot;,&quot;isAnimated&quot;:false,&quot;baseUrl&quot;:&quot;//images.newrepublic.com/&quot;,&quot;src&quot;:&quot;//images.newrepublic.com/8d793ed39af4336d037d65a6598e2189f446fbf8.jpeg&quot;,&quot;alt&quot;:null,&quot;meta&quot;:{}}\" width=\"1400\"><figcaption><p><span>The Clinton administration was instrumental in safeguarding Big Pharma’s intellectual property rights on the global stage—and Gates would become the campaign’s benevolent face.</span></p><span>Chip Somodevilla/Getty Images</span></figcaption></figure><p><span>When Moose was ringing the alarm over\nthe future of TRIPS in the spring of 1999, Gates was preparing to fund the launch\nof a public-private partnership called Gavi, the Vaccine Alliance, with a seed\ngrant of $750 million, marking his arrival in the worlds of infectious disease and public health. At the time, he was still best known for being the\nrichest man in the world and the owner of a software company engaged in\nanti-competitive practices. This profile didn’t mean much in a raucous WHO\nAssembly hall packed with civil society groups and G77 delegations, which together booed the U.S. delegation when it tried to speak. At most, it was a\nsource of brief consternation when officers from the William H. Gates\nFoundation began distributing a glossy brochure touting the role of\nintellectual property in driving biomedical innovation.</span><span>&nbsp;</span><br></p></div><div><p>James Love, who organized many of the\ncivil society events around the 1999 Assembly, remembers seeing the Gates\nstaffers joined in the distribution effort by Harvey Bale, a former U.S. trade official serving as\ndirector general of the International Federation\nof Pharmaceutical Manufacturers Associations.</p><p>“It was this nice full-color pamphlet about why patents\ndon’t present an access problem, with the Gates Foundation logo at the bottom,”\nsays Love. “It was strange, and I just thought, ‘OK, I guess this is what he’s\ndoing now.’ Looking back, that’s when the pharma-Gates consortium set the\nmarkers down on intellectual property. He’s been sticking his nose into every\nintellectual property debate since, telling everyone\nthey can go to heaven by paying lip service to a few discounts to poor\ncountries.”&nbsp;<span>&nbsp;</span></p><p>Following the 1999 WHO Assembly, the\nindustry tried to salvage its reputation by offering African countries discounts\non the antiretroviral combination therapies that cost $10,000 or more in rich\ncountries. The compromise prices it offered were still outrageously high, but even\nraising the issue of price concessions was too much for Pfizer, whose\nrepresentatives stormed out of the industry coalition on principle. Public\nopinion swung harder against the companies, the result of a loud, ingenious,\nand effective direct-action campaign. Similar to the first months of the Covid-19\npandemic, there was a sense of possibility—a hope that a forced breakdown of a\nmorally obscene and bloodstained system was within grasp.<span>&nbsp;</span></p></div><div><p>“The\nmovement was very focused and successfully building pressure for structural, more decisive\nsolutions into the aughts,” says Asia Russell, a veteran HIV-AIDS activist and director of <a href=\"https://healthgap.org/\" target=\"_blank\" rel=\"nofollow\">Health Gap</a>, an HIV\nmedicines access group. “And just when we\nstarted to secure some progress, a new\nversion of the industry narrative emerged from Gates and Pharma. It was all about how pricing policies,\ngeneric competition, anything that\ninterferes with industry profits, will undermine\nresearch and development, when the evidence shows that that argument doesn’t hold water. Gates’s talking points\naligned with those of the industry.”</p><p>Adds Manuel Martin, the Médecins Sans Frontières policy adviser, “Gates defused the real issue of decolonizing global\nhealth. Instead, drug companies could just give money to his institutions.”</p><p>Even after the drug companies withdrew their lawsuit\nagainst the South African government and Indian-made generics began flowing to\nAfrica, Gates stayed cool toward compromises that he saw as threats to the\nintellectual property paradigm. This included his attitude toward the Unitaid\nMedicines Patent Pool, a voluntary intellectual property pool founded in 2010 that\nenlarged access to some patented HIV/AIDS medicines. Though not a complete\nanswer to the problem, the MPP was the first working example of a voluntary intellectual property pool,\none that many observers expected to serve as a model framework for the\nWHO-administered Covid-19 pool.</p></div><div><p><a href=\"https://www.northeastern.edu/law/faculty/directory/baker.html\" target=\"_blank\" rel=\"nofollow\">Brook Baker</a>, a law professor at Northeastern University\nand senior policy analyst for Health\nGAP, says Gates has\nalways been wary of the Unitaid pool as going too far in the direction of\ninfringing on intellectual property.<span>&nbsp;</span></p><p>“Initially, Gates\nwas unsupportive and even hostile toward the AIDS Medicines Patent Pool,” says\nBaker. “He brought that\nhostility to relaxing industry’s iron-fist control over its technologies into\nthe pandemic. His explanation for rejecting models to counteract this control\nnever added up. If I.P. isn’t important, why are companies\nrefusing to voluntarily give it up when it could be used to expand supply in\nthe middle of the world’s worst public health crisis in a century? It’s not\nimportant, or it’s so important it has to be closely guarded and protected. You\ncan’t have it both ways.”</p><p>This winter, while Gates assured the world that intellectual property was a red herring, a bloc of developing countries at the WTO explained the\nneed for a waiver on certain intellectual property provisions by pointing to the “rather large gap [that] exists\nbetween what COVAX or ACT-A can deliver and what is required in developing and\nleast developed countries.”</p><p>The\n<a href=\"https://www.keionline.org/35453\" target=\"_blank\" rel=\"nofollow\">forceful statement</a> continued:</p></div><div><blockquote><p>The model of donation and philanthropic expediency cannot solve the fundamental disconnect\nbetween the monopolistic model it\nunderwrites and the very real desire of developing and least developed countries to produce for themselves.… The\nartificial shortage of vaccines is primarily\ncaused by the inappropriate use of intellectual property rights.</p></blockquote><p>Another statement by a different bloc of countries added,\n“COVID19\nreveals the deep structural inequality in access to medicines globally, and a\nroot cause is IP that sustains and dominates industry’s interests at the cost\nof lives.”&nbsp; <b><br></b></p><p>Gates is\ncertain he knows better. But his failure to anticipate a crisis of supply, and\nhis refusal to engage those who predicted it, have complicated the carefully\nmaintained image of an all-knowing, saintly mega-philanthropist. COVAX presents\na high-stakes demonstration of Gates’s deepest ideological commitments,\nnot just to intellectual property rights but also to the conflation of these\nrights with an imaginary free market in pharmaceuticals—an industry dominated\nby companies whose power derives from politically constructed and politically imposed\nmonopolies. Gates has been tacitly and explicitly defending the legitimacy of\nknowledge monopolies since his first Gerald Ford–era missives against open-source\nsoftware hobbyists. He was on the side of these monopolies during the miserable\ndepths of the 1990s African AIDS crisis. He’s still there today, defending the\nstatus quo and running effective interference for those profiting by the\nbillions from their control of Covid-19 vaccines. </p><p>His latest move is to institutionalize the ACT-Accelerator\nas the central organizing institution in future pandemics. The shortages have\nmade this effort a little awkward, however, and Gates is now forced to reckon\nwith the question of technology transfer. This is an aspect of\nthe equitable access debate that doesn’t concern intellectual property as commonly perceived—as a\nsimple matter of patents and licenses—but access\nto the components and technical knowledge related to practical manufacture, including biological\nmaterial and other areas otherwise protected under the category of intellectual property known as\ntrade secrets. The global south and civil society groups<b> </b>have been calling for tech transfer for months—<span>either mandatory tech transfer that could have been written into contracts or through a voluntary mechanism associated with C-TAP</span><span>—but Gates\nhas predictably arrived on the scene with a more familiar plan in hand.</span></p></div><div><p>In early March, senior Gates staff joined\npharma executives for a “<a href=\"https://www.chathamhouse.org/events/all/research-event/global-c19-vaccine-supply-chain-manufacturing-summit\" target=\"_blank\" rel=\"nofollow\">Global C19 Vaccine Supply Chain and Manufacturing Summit</a>” convened by Chatham\nHouse in London. The main agenda item: plans for a new arm within the ACT-Accelerator,\nthe Covid Vaccine Capacity Connector, that seeks to address the tech-transfer question within the usual frame of monopoly rights and\nbilateral licensing.<span>&nbsp;</span></p><p>“The tech transfer debate is being decisively seized and shaped\nby those who want to set the terms and conditions under which knowledge can be\ntransferred,” writes Priti Patnaik in her <a href=\"https://genevahealthfiles.substack.com/p/who-donors-seek-a-new-tech-transfer\" target=\"_blank\" rel=\"nofollow\"><i>Geneva\nHealth Files</i> newsletter</a>. A Gates-directed tech-transfer mechanism without\nmeaningful input from WHO members states, she writes, would be a “body blow” to\nC-TAP and similar future initiatives that promote open licensing and knowledge sharing\nto maximize production and access. </p><p>There\nare signs of overdue scrutiny of Gates’s role in public health and lifelong commitment\nto exclusive intellectual property rights. But so far these are blips. More common\nis the deference on display in a March 21 <i>New\nYork Times</i> article about the U.S. government’s role in <a href=\"https://www.nytimes.com/2021/03/21/world/vaccine-patents-us-eu.html?searchResultPosition=1\" target=\"_blank\" rel=\"nofollow\">developing the mRNA vaccines</a> now under\nthe monopoly control of Moderna and Pfizer. When the piece turned to Gates’s inevitable\ncameo, the <i>Times</i> reporter was hovering\nright over the target—and somehow managed to miss wide by a mile. Instead of\nprobing Gates’s central role in preserving this paradigm, the paper linked to\ngentle boilerplate about pricing and access found on the Gates Foundation\nwebsite. In response to a request for comment, a Gates Foundation spokesperson pointed\nme to a piece by its CEO, Mark Suzman, arguing that “IP fundamentally underpins\ninnovation, including the work that has helped create vaccines so quickly.”</p></div><div><p>Any change\nin media coverage of Gates’s second career may produce a delayed echo within the\nworld he has come to dominate. Here Gates not only controls the narratives, he\ncontrols most of the payroll. This may sound conspiratorial or overblown to\noutsiders but not to campaigners who have witnessed Gates’s ability to shift\ngravity on major issues. </p><p>“If you\nsaid to an ordinary person, ‘We’re in a pandemic. Let’s figure out everyone who\ncan make vaccines and give them everything they need to get online as fast as\npossible,’ it would be a no-brainer,” says James Love.\n“But Gates won’t go there. Neither will the people dependent on his funding. He has immense power. He can get you\nfired from a U.N. job. He knows that if you want to work in global public\nhealth, you’d better not make an enemy of the Gates Foundation by questioning\nits positions on I.P. and monopolies. And there are a lot of advantages to\nbeing on his team. It’s a sweet, comfortable ride for a lot of people.”</p><p>*<i>Among journalists echoing this argument was former </i>New Republic <i>editor Andrew Sullivan. When </i>The<i> </i>New York Times <i>reported Sullivan was defending the companies’ lawsuit while taking undisclosed\n<a href=\"https://www.salon.com/2001/07/12/sullivan_4/\" target=\"_blank\" rel=\"nofollow\">funding from\nPhRma</a><span>, the industry trade association, Sullivan\nremained defiant in the face of evidence-based accusations that he was an unethical\njournalist. “It behooves me to say I see\nabsolutely no problems with [drug industry sponsorship],” he told </span>Salon<span>. “In fact, I am extremely proud to\nget some support from a great industry.” It later turned out that Africans adhered\nmore closely to the twice-daily pill regimens than patient populations in rich\ncountries.</span></i><br></p></div><div><p>**<i>In 2010,\nthe Gates Foundation would bankroll a documentary advocating the privatization\nof U.S. public education, titled </i>Waiting\nfor Superman<span>.&nbsp;</span><br></p></div></div></div>","textContent":"On February 11, 2020, public health and infectious disease experts gathered\nby the hundreds at the World Health Organization’s Geneva mothership. The official pronouncement of a pandemic was still a month out, but the\nagency’s international brain trust knew enough to be worried. Burdened by a\nsense of borrowed time, they spent two days furiously sketching an “R&D Blueprint”\nin preparation for a world upended by the virus then known as 2019-nCoV.The resulting\ndocument summarized the state of coronavirus research and proposed ways to\naccelerate the development of diagnostics, treatments, and vaccines. The underlying\npremise was that the world would unite against the virus. The global research\ncommunity would maintain broad and open channels of communication, since\ncollaboration and information-sharing minimize duplication and accelerate discovery.\nThe group also drew up plans for global comparative trials overseen by the WHO,\nto assess the merits of treatments and vaccines.One issue not\nmentioned in the paper: intellectual property. If the worst came to pass, the experts\nand researchers assumed cooperation would define the global response, with the\nWHO playing a central role. That pharmaceutical companies and their allied\ngovernments would allow intellectual property concerns to slow things down—from\nresearch and development to manufacturing scale-up—does not seem to have\noccurred to them.They were wrong,\nbut they weren’t alone. Battle-scarred veterans of the medicines-access and\nopen-science movements hoped the immensity of the pandemic would override a\nglobal drug system based on proprietary science and market monopolies. By\nMarch, strange but welcome melodies could be heard from unexpected quarters. Anxious\ngovernments spoke of shared interests and global public goods; drug companies pledged\n“precompetitive” and “no-profit” approaches to development and pricing. The\nearly days featured tantalizing glimpses of an open-science,\ncooperative pandemic response. In January and February 2020, a consortium led\nby the National Institutes of Health and the National Institute of Allergy and\nInfectious Diseases collaborated to produce atomic-level maps of the key viral proteins\nin record time. “Work that would normally have taken months—or possibly even\nyears—has been completed in weeks,” noted the editors of Nature. When the Financial\nTimes editorialized on March 27 that “the world has an overwhelming interest in ensuring\n[Covid-19 drugs and vaccines] will be universally and cheaply available,” the\npaper expressed what felt like a hardening conventional wisdom. This sense of\npossibility emboldened forces working to extend the cooperative model. Grounding\ntheir efforts was a plan, started in early March, to create a voluntary intellectual\nproperty pool inside the WHO. Instead of putting up proprietary walls around\nresearch and organizing it as a “race,” public and private actors would collect research\nand associated intellectual property in a global knowledge fund for the duration of the pandemic. The\nidea became real in late May with the launch of the WHO Covid-19 Technology\nAccess Pool, or C-TAP.By then, however, the optimism and sense of\npossibility that defined the early days were long gone. Advocates for pooling\nand open science, who seemed ascendant and even unstoppable that winter, confronted\nthe possibility they’d been outmatched and outmaneuvered by the most powerful\nman in global public health.In April, Bill Gates launched a bold bid to manage\nthe world’s scientific response to the pandemic. Gates’s Covid-19 ACT-Accelerator\nexpressed a status quo vision for organizing the research, development, manufacture,\nand distribution of treatments and vaccines. Like other Gates-funded\ninstitutions in the public health arena, the Accelerator was a public-private\npartnership based on charity and industry enticements. Crucially, and in\ncontrast to the C-TAP, the Accelerator enshrined Gates’s long-standing commitment\nto respecting exclusive intellectual property claims. Its implicit\narguments—that intellectual property rights won’t present problems for meeting global demand or ensuring\nequitable access, and that they must be protected, even during a pandemic—carried\nthe enormous weight of Gates’s reputation as a wise, beneficent, and prophetic\nleader. How he’s developed and wielded this influence\nover two decades is one of the more consequential and underappreciated shapers\nof the failed global response to the Covid-19 pandemic. Entering year two, this response has been defined by a zero-sum\nvaccination battle that has left much of the world on the losing side.Gates’s marquee Covid-19 initiative started\nrelatively small. Two days before the WHO declared a pandemic on March 11, 2020, the Bill &\nMelinda Gates Foundation announced something called the Therapeutics\nAccelerator, a joint initiative with Mastercard and the charity group the Wellcome\nTrust to identify and develop potential treatments for the novel coronavirus.\nDoubling as a social branding exercise for a giant of global finance, the\nAccelerator reflected Gates’s familiar formula of corporate philanthropy, which\nhe has applied to everything from malaria to malnutrition. In retrospect, it\nwas a strong indicator that Gates’s dedication to monopoly medicine would\nsurvive the pandemic, even before he and his foundation’s officers began to say\nso publicly.   This was confirmed when a bigger version of\nthe Accelerator was unveiled the following month at the WHO. The Access to Covid-19 Tools\nAccelerator, or ACT-Accelerator, was Gates’s bid to organize the development\nand distribution of everything from therapeutics to testing. The biggest and\nmost consequential arm, COVAX, proposed to subsidize vaccine deals with poor\ncountries through donations by, and sales to, richer ones. The goal was always\nlimited: It aimed to provide vaccines for up to 20 percent of the population in\nlow-to-middle-income countries. After\nthat, governments would largely have to compete on the global market like\neveryone else. It was a partial demand-side solution to what the movement\ncoalescing around a call for a “people’s vaccine” warned would be a dual crisis\nof supply and access, with intellectual property at the center of both.Gates not only dismissed these warnings but\nactively sought to undermine all challenges to his authority and the Accelerator’s intellectual property–based charity agenda. “Early on, there was space for Gates to have\na major impact in favor of open models,” says Manuel Martin, a policy adviser to\nthe Médecins\nSans Frontières Access Campaign. “But senior people in the\nGates organization very clearly sent out the message: Pooling was unnecessary\nand counterproductive. They dampened early enthusiasm by saying that I.P. is not\nan access barrier in vaccines. That’s just demonstratively false.”Few have observed Bill Gates’s devotion to monopoly\nmedicine more closely than James Love, founder and director of Knowledge Ecology\nInternational, a Washington, D.C.–based group that studies\nthe broad nexus of federal policy, the pharmaceutical industry, and intellectual\nproperty. Love\nentered the world of global public health policy around the same time Gates did,\nand for two decades has watched him scale its heights while reinforcing the\nsystem responsible for the very problems he claims to be trying to solve. The\nthrough-line for Gates has been his unwavering commitment to drug companies’\nright to exclusive control over medical science and the markets for its\nproducts.“Things could have gone either way,” says Love, “but Gates wanted exclusive\nrights maintained. He acted fast to stop the push\nfor sharing the knowledge needed to make the products—the know-how, the data,\nthe cell lines, the tech transfer, the transparency that is\ncritically important in a dozen ways. The pooling approach represented by C-TAP\nincluded all of that. Instead of backing those early discussions, he raced\nahead and signaled support for business-as-usual on intellectual property by announcing\nthe ACT-Accelerator in March.”One year later, the ACT-Accelerator has\nfailed to meet its goal of providing discounted vaccines to the “priority\nfifth” of low-income populations. The drug companies and rich nations that had\nso much praise for the initiative a year ago have retreated into bilateral\ndeals that leave little for anybody else. “The low- and middle-income countries are pretty\nmuch on their own, and there’s just not much out there,” said Peter Hotez, dean of the National School of Tropical\nMedicine in Houston. “Despite their best efforts, the Gates model\nand its institutions are still industry-dependent.”As of this writing in early April, fewer than 600 million\nvaccine doses have been administered around the world; three-quarters\nof those in just 10 mostly high-income countries. Close to 130 countries containing 2.5\nbillion people have yet to administer a single dose. The timeline for supplying\npoor and middle-income countries with enough vaccines to achieve herd immunity,\nmeanwhile, has been pushed into 2024. These numbers represent more than the “catastrophic\nmoral failure” the director general of the WHO warned about this January. It is\na stark reminder than any policy that obstructs or inhibits vaccine production\nrisks being self-defeating for the rich countries defending exclusive rights and\ngobbling up the lion’s share of available vaccine supplies. The truth repeated\nso often throughout the pandemic—no one is safe until everyone is safe—remains in\nforce. This easily anticipated market failure—together\nwith the C-TAP’s failure to launch—led developing countries to open a new front\nagainst intellectual property barriers in the World Trade Organization. Since\nOctober, the WTO’s Trade-Related Aspects of Intellectual Property Rights\nCouncil has been center ring in a dramatic north-south standoff over rights to control\nvaccine knowledge, technology, and markets. More than 100 low- and\nmiddle-income countries support a call by India and South Africa to waive certain\nprovisions related to Covid-19 intellectual property for the duration of the\npandemic. Although Gates and his organization do not have an official position\non the debate roiling the WTO, Gates and his deputies have left little doubt\nabout their opposition to the waiver proposal. Just as he did following the\nrollout of the WHO’s C-TAP, Gates has chosen to stand with the drug companies\nand their government patrons.    Technically housed within the WHO, the ACT-Accelerator\nis a Gates operation, top to bottom. It is designed, managed, and staffed largely\nby Gates organization employees. It embodies Gates’s philanthropic\napproach to widely anticipated problems posed by intellectual property–hoarding companies able to constrain\nglobal production by prioritizing rich countries and inhibiting licensing. Companies\npartnering with COVAX are allowed to set their own tiered prices. They are\nsubject to almost no transparency requirements and to toothless contractual\nnods to “equitable access” that have never been enforced. Crucially,\nthe companies retain exclusive rights to their intellectual property. If they\nstray from the Gates Foundation line on exclusive rights, they are quickly\nbrought to heel. When the director of Oxford’s\nJenner Institute had funny ideas about placing the rights to its COVAX-supported\nvaccine candidate in the public domain, Gates intervened. As reported by Kaiser\nHealth News, “A few weeks later, Oxford—urged on by the Bill & Melinda\nGates Foundation—reversed course [and] signed an exclusive vaccine deal with\nAstraZeneca that gave the pharmaceutical giant sole rights and no guarantee of\nlow prices.”Considering the alternatives being discussed,\nit is no surprise that drug companies have been the most enthusiastic boosters\nof the ACT-Accelerator and COVAX. The speakers at the ACT-Accelerator launch\nceremony in March 2020 included Thomas Cueni, director general of the\nInternational Federation of Pharmaceutical Manufacturers and Associations, who hailed the initiative as a “landmark global\npartnership.” Since vaccines started coming online, the IFPMA’s member\ncompanies have lost interest in the Accelerator, preferring bilateral deals\nwith rich countries. But they continue to benefit from the halo effect of their\nassociation with Gates, which has proved priceless throughout the pandemic,\nespecially at a crucial juncture in its first year.   Bill Gates addresses the opening session of the WHO’s annual assembly in 2005, some six years after he entered the global public health scene as a defender of intellectual property rights during the AIDS crisis.JEAN-PIERRE CLATOT/AFP/Getty ImagesOn May 29, Donald Trump announced U.S.\nwithdrawal from the WHO. This was in response, he said, to China’s “total\ncontrol” of the agency. The drug industry, meanwhile, was displeased with the WHO\nfor entirely different reasons. The same day, the WHO director general had\nunveiled the C-TAP with a “Solidarity Call to Action” for governments and\ncompanies to share all intellectual property related to Covid-19 treatments and\nvaccines. The pharmaceutical companies didn’t attack the initiative directly. Instead,\ntheir global trade association, the IFPMA, preempted the announcement with a livestreamed\nmedia event on the evening of May 28. The event featured the heads of AstraZeneca,\nGlaxoSmithKline, Johnson & Johnson, and Pfizer, and Thomas Cueni.The\nevening’s sixth participant was the specter of Bill Gates.As\nanticipated, the questions submitted by journalists touched repeatedly on the much-anticipated\nlaunch of C-TAP the following morning, as well as related issues of intellectual\nproperty, vaccine access and equity, and debates over the extent and ways intellectual property posed barriers to ramping up production. Mostly, the executives evinced ignorance and surprise over the\nimminent launch of C-TAP; only Pfizer CEO Albert Bourla openly denounced\nthe pooling of intellectual property as “dangerous” and “nonsense.”All of the executives, however, shared a\nplaybook in which they quickly pivoted to affirmations of their support for Bill Gates and the ACT-Accelerator.\nThe association with Gates was\nsubmitted as evidence of industry commitment to equity and access—as well as\nproof of the complete lack of need for overlapping or competing initiatives,\nsuch as the “dangerous” C-TAP. “We already have platforms,” Cueni said during\nthe May 28 event. “The industry is already doing all the right things.” As the questions about C-TAP and intellectual\nproperty piled up, the industry’s Gates rap started to sound less like a shared\nP.R. script than a broken record. Confronted for the second\ntime about intellectual property, GlaxoSmithKline CEO Emma Walmsley emitted an undigested stream\nof Gatesian word salad. “We are absolutely committed to this question of\naccess,” she stammered, “and deeply welcome the formation of ACT, which is this\nmultilateral organization that is going to be a mechanism with multiple\nstakeholders, whether it’s heads of state or organizations like [the Gates-funded]\nCEPI or the Gates and [the Gates-funded] Gavi and others and the WHO, of course, where we actually\nlook at these principles of, uh, access and so clearly, we’re engaged in that\nas well.”  Without the Gates and COVAX associations to lean\non, the stammering would have been much worse. Pfizer’s Albert Bourla seemed to\nrecognize this, at one point interrupting himself to express his industry’s gratitude\nand admiration. “I want to take the opportunity to emphasize the role that Bill\nGates is playing,” he said. He went on to call him “an inspiration for all.” Gates can hardly\ndisguise his contempt for the growing interest in intellectual property\nbarriers. In recent months, as the debate has shifted from the WHO to the WTO, reporters\nhave drawn testy responses from Gates that harken back to his prickly\nperformances before congressional antitrust hearings a quarter-century ago.\nWhen a Fast Company reporter raised\nthe issue in February, she described Gates “raising his voice slightly and\nlaughing in frustration,” before snapping, “It’s irritating that this issue\ncomes up here. This isn’t about IP.” In interview after interview, Gates has dismissed his critics on the\nissue—who represent the poor majority of the global population—as spoiled\nchildren demanding ice cream before dinner. “It’s the classic\nsituation in global health, where the advocates all of a sudden want [the\nvaccine] for zero dollars and right away,” he told Reuters in late January. Gates has larded the insults\nwith comments that equate state-protected and publicly funded monopolies with\nthe “free market.” “North\nKorea doesn’t have that many vaccines, as far as we can tell,” he told The New York Times in November. (It is curious that he chose North Korea as an example and not\nCuba, a socialist country with an innovative and world-class vaccine\ndevelopment program with multiple Covid-19 vaccine candidates in various stages\nof testing.)The\nclosest Gates has come to conceding that vaccine monopolies inhibit production\ncame during a January interview with South Africa’s Mail & Guardian. Asked about the growing\nintellectual property debate, he responded, “At this point, changing the rules\nwouldn’t make any additional vaccines available.”The first\nimplication of “at this point” is that the moment has passed when changing the\nrules could make a difference. This is a false but debatable claim. The same\ncan’t be said for the second implication, which is that nobody could have\npossibly foreseen the current supply crisis. Not only were the obstacles posed\nby intellectual property easily predictable a year ago, there was no lack of people making noise\nabout the urgency of avoiding them. They included much of the global research\ncommunity, major NGOs with long experience in medicines development and access,\nand dozens of current and former world leaders and public health experts. In a May 2020 open letter, more than 140\npolitical and civil society leaders called upon governments and companies to\nbegin pooling their intellectual property. “Now is not the time … to leave this massive and moral task to market\nforces,” they wrote.  Bill Gates’s position on intellectual property was consistent\nwith a lifelong ideological commitment to knowledge\nmonopolies, forged during a vengeful teenage crusade against the open-source\nprogramming culture of the 1970s. As it happens, a novel use of one category of\nintellectual property—copyright, applied to computer code—made Gates the\nrichest man in the world for most of two decades beginning in 1995. That same\nyear, the WTO went into effect, chaining the developing\nworld to intellectual property rules written by a handful of executives from\nthe U.S. pharmaceutical, entertainment, and software industries.   By 1999, Bill Gates was in his final year as\nCEO of Microsoft, focused on defending the company he founded from antitrust\nsuits on two continents. As his business reputation suffered high-profile\nbeatings from U.S. and European regulators, he was in the process of moving on\nto his second act: the formation of the Bill & Melinda Gates Foundation, which\ncommenced his unlikely rise to the commanding apex of global public health\npolicy. His debut in that role occurred during the contentious fifty-second General\nHealth Assembly in May 1999.It was the height of the battle to bring\ngeneric AIDS drugs to the developing world. The central front was South Africa,\nwhere the HIV rate at the time was estimated as high as 22 percent and threatened\nto decimate an entire generation. In December 1997, the Mandela government\npassed a law giving the health ministry powers to produce, purchase, and import\nlow-cost drugs, including unbranded versions of combination therapies priced by\nWestern drug companies at $10,000 and more. In response, 39 drug multinationals\nfiled suit against South Africa alleging\nviolations of the country’s constitution and its obligations under the WTO’s\nAgreement on Trade-Related Aspects of Intellectual Property Rights, or TRIPS. The\nindustry suit was backed by the diplomatic muscle of the Clinton\nadministration, which tasked Al Gore with applying pressure. In his 2012 documentary Fire in the Blood, Dylan Mohan Gray notes it took Washington 40 years to\nthreaten apartheid South Africa with sanctions and less than four to threaten\nthe post-apartheid Mandela government over AIDS drugs. Though South\nAfrica barely registered as a market for the drug companies, the\nappearance of cheap generics produced in violation of patents anywhere was a\nthreat to monopoly pricing everywhere, according to the drug industry’s version\nof Cold War “domino theory.” Allowing poor nations to “free ride” on Western\nscience and build parallel drug economies would eventually cause problems\ncloser to home, where the industry spent billions of dollars on a propaganda\noperation to control the narrative around drug prices and keep the lid on\npublic discontent. The companies suing Mandela had devised TRIPS as a long-term\nstrategic response to the south-based generics industry that arose in the 1960s.\nThey had come too far to be set back by the needs of a pandemic in sub-Saharan Africa.\nU.S. and industry officials paired old standby arguments about patents driving\ninnovation with claims that Africans posed a public health menace because they couldn’t\nkeep time: Since they could not be relied on to take their medicines on a\nschedule, giving Africans access to the drugs would allow for the emergence of\ndrug-resistant HIV variants, according to industry and its government and media\nallies.*In Geneva, the lawsuit\nwas reflected in a battle at the WHO, which was divided along a north-south\nfault line: on one side, the home countries of the Western drug companies; on\nthe other, a coalition of 134 developing countries (known collectively as the Group\nof 77, or G77) and a rising “third force” of civil society groups led by Médecins Sans Frontières and Oxfam. The point\nof conflict was a WHO resolution that called on member states “to ensure\nequitable access to essential drugs; to ensure that public health interests are\nparamount in pharmaceutical and health policies; [and] to explore and review\ntheir options under relevant international agreements, including\ntrade agreements, to safeguard access to essential drugs.”Western countries\nsaw the resolution as a threat to the recent conquest of monopoly medicine,\nachieved four years earlier with the establishment of the WTO. The industry\ngrew increasingly helpless, however, as global public opinion and WHO\nmember-state sentiment shifted in favor of the resolution and against the South\nAfrica lawsuit. In the weeks leading up to the assembly, the companies and\ntheir parent embassies floundered as they sought to turn the tide. Their\ngrowing anxiety is captured in a series of leaked cables sent to Washington by the U.S. ambassador in Geneva, George Moose, that April and May. In a diplomatic telegram dated\nApril 20, Moose expressed alarm over the growing number of WHO delegations\nmakingSTATEMENTS THAT PUBLIC HEALTH SHOULD HAVE PRIMACY OVER COMMERCIAL\nINTERESTS UNDER WTO TRADE AGREEMENTS SUCH AS THE TRIPS (TRADE-RELATED ASPECTS\nOF INTELLECTUAL PROPERTY RIGHTS) … THEREBY POTENTIALLY UNDERMINING INTELLECTUAL\nPROPERTY RIGHTS (IPR). Moose was concerned that drug companies were\nnot helping their own cause and seemed incapable of doing anything but parrot\nold talking points about intellectual property as the driver of innovation. The\npharmaceutical industry, Moose wrote, SHOULD BE CARRYING MORE OF ITS OWN WATER ON THIS ISSUE, ESPECIALLY IN\nDEVELOPING COUNTRIES, AND NOT SOLELY DEPEND ON THE ARGUMENT THAT IPR PROTECTS\nPROFITS THAT THEN ARE USED FOR DEVELOPMENT OF NEW DRUGS IN THE FUTURE. NOT 10\nYEARS FROM NOW. THE SOUTH AFRICANS AND OTHERS ARE MOSTLY CONCERNED ABOUT\nAVAILABILITY OF DRUGS NOW. PROBLEMS RELATED TO LOCAL AVAILABILITY AND PRICING\nOF DRUGS THAT ARE UNRELATED TO TRIPS WILL UNDOUBTABLY REQUIRE FURTHER\nDISCUSSION. Over the course of weeks, a picture emerges from Moose’s\naccounts of a pharmaceutical industry against the ropes, punch drunk and out of\nideas. In the U.S. ambassador’s view, the problem wasn’t moral bankruptcy so\nmuch as incompetence. “RECOMMEND THE USG PUSH THE\nPHARMACEUTICAL INDUSTRY TO ARGUE ITS POINTS MORE CONVINCINGLY IN DEVELOPING\nCOUNTRIES,” the exasperated ambassador wrote. “AND\nESPECIALLY DEAL WITH THEIR CONCERNS ABOUT LOCAL DRUG AVAILABILITY AND PRICING.”Following the raucous buzz saw of the 1999 WHO Assembly, the\ndrug companies would make a humiliating climbdown from their scandalous lawsuit\nin South Africa, reduced to what The Washington Post called “close to pariah\nstatus.”  At the same time, the industry was richer than ever. The\nClinton administration had approved a long Big Pharma wish list, from broadening the\navenues for privatizing government-funded science to opening the age of direct\nmarketing of prescription drugs. The corresponding profits went to reinforce already\nhistorically rich D.C. and Geneva lobbying operations. And yet, for all their combined\nmight, the companies were incapable of producing a mask resembling a credible\nhuman face. A global activist movement continued to gather public opinion on\nits side and chip away at the legitimacy of the monopoly model that underlay the\nindustry’s enormous power. By every nonfinancial measure, it was an industry\nin distress. To borrow a phrase from a future Bill Gates production, you might\nsay it was waiting for its Superman.**The Clinton administration was instrumental in safeguarding Big Pharma’s intellectual property rights on the global stage—and Gates would become the campaign’s benevolent face.Chip Somodevilla/Getty ImagesWhen Moose was ringing the alarm over\nthe future of TRIPS in the spring of 1999, Gates was preparing to fund the launch\nof a public-private partnership called Gavi, the Vaccine Alliance, with a seed\ngrant of $750 million, marking his arrival in the worlds of infectious disease and public health. At the time, he was still best known for being the\nrichest man in the world and the owner of a software company engaged in\nanti-competitive practices. This profile didn’t mean much in a raucous WHO\nAssembly hall packed with civil society groups and G77 delegations, which together booed the U.S. delegation when it tried to speak. At most, it was a\nsource of brief consternation when officers from the William H. Gates\nFoundation began distributing a glossy brochure touting the role of\nintellectual property in driving biomedical innovation. James Love, who organized many of the\ncivil society events around the 1999 Assembly, remembers seeing the Gates\nstaffers joined in the distribution effort by Harvey Bale, a former U.S. trade official serving as\ndirector general of the International Federation\nof Pharmaceutical Manufacturers Associations.“It was this nice full-color pamphlet about why patents\ndon’t present an access problem, with the Gates Foundation logo at the bottom,”\nsays Love. “It was strange, and I just thought, ‘OK, I guess this is what he’s\ndoing now.’ Looking back, that’s when the pharma-Gates consortium set the\nmarkers down on intellectual property. He’s been sticking his nose into every\nintellectual property debate since, telling everyone\nthey can go to heaven by paying lip service to a few discounts to poor\ncountries.”  Following the 1999 WHO Assembly, the\nindustry tried to salvage its reputation by offering African countries discounts\non the antiretroviral combination therapies that cost $10,000 or more in rich\ncountries. The compromise prices it offered were still outrageously high, but even\nraising the issue of price concessions was too much for Pfizer, whose\nrepresentatives stormed out of the industry coalition on principle. Public\nopinion swung harder against the companies, the result of a loud, ingenious,\nand effective direct-action campaign. Similar to the first months of the Covid-19\npandemic, there was a sense of possibility—a hope that a forced breakdown of a\nmorally obscene and bloodstained system was within grasp. “The\nmovement was very focused and successfully building pressure for structural, more decisive\nsolutions into the aughts,” says Asia Russell, a veteran HIV-AIDS activist and director of Health Gap, an HIV\nmedicines access group. “And just when we\nstarted to secure some progress, a new\nversion of the industry narrative emerged from Gates and Pharma. It was all about how pricing policies,\ngeneric competition, anything that\ninterferes with industry profits, will undermine\nresearch and development, when the evidence shows that that argument doesn’t hold water. Gates’s talking points\naligned with those of the industry.”Adds Manuel Martin, the Médecins Sans Frontières policy adviser, “Gates defused the real issue of decolonizing global\nhealth. Instead, drug companies could just give money to his institutions.”Even after the drug companies withdrew their lawsuit\nagainst the South African government and Indian-made generics began flowing to\nAfrica, Gates stayed cool toward compromises that he saw as threats to the\nintellectual property paradigm. This included his attitude toward the Unitaid\nMedicines Patent Pool, a voluntary intellectual property pool founded in 2010 that\nenlarged access to some patented HIV/AIDS medicines. Though not a complete\nanswer to the problem, the MPP was the first working example of a voluntary intellectual property pool,\none that many observers expected to serve as a model framework for the\nWHO-administered Covid-19 pool.Brook Baker, a law professor at Northeastern University\nand senior policy analyst for Health\nGAP, says Gates has\nalways been wary of the Unitaid pool as going too far in the direction of\ninfringing on intellectual property. “Initially, Gates\nwas unsupportive and even hostile toward the AIDS Medicines Patent Pool,” says\nBaker. “He brought that\nhostility to relaxing industry’s iron-fist control over its technologies into\nthe pandemic. His explanation for rejecting models to counteract this control\nnever added up. If I.P. isn’t important, why are companies\nrefusing to voluntarily give it up when it could be used to expand supply in\nthe middle of the world’s worst public health crisis in a century? It’s not\nimportant, or it’s so important it has to be closely guarded and protected. You\ncan’t have it both ways.”This winter, while Gates assured the world that intellectual property was a red herring, a bloc of developing countries at the WTO explained the\nneed for a waiver on certain intellectual property provisions by pointing to the “rather large gap [that] exists\nbetween what COVAX or ACT-A can deliver and what is required in developing and\nleast developed countries.”The\nforceful statement continued:The model of donation and philanthropic expediency cannot solve the fundamental disconnect\nbetween the monopolistic model it\nunderwrites and the very real desire of developing and least developed countries to produce for themselves.… The\nartificial shortage of vaccines is primarily\ncaused by the inappropriate use of intellectual property rights.Another statement by a different bloc of countries added,\n“COVID19\nreveals the deep structural inequality in access to medicines globally, and a\nroot cause is IP that sustains and dominates industry’s interests at the cost\nof lives.”  Gates is\ncertain he knows better. But his failure to anticipate a crisis of supply, and\nhis refusal to engage those who predicted it, have complicated the carefully\nmaintained image of an all-knowing, saintly mega-philanthropist. COVAX presents\na high-stakes demonstration of Gates’s deepest ideological commitments,\nnot just to intellectual property rights but also to the conflation of these\nrights with an imaginary free market in pharmaceuticals—an industry dominated\nby companies whose power derives from politically constructed and politically imposed\nmonopolies. Gates has been tacitly and explicitly defending the legitimacy of\nknowledge monopolies since his first Gerald Ford–era missives against open-source\nsoftware hobbyists. He was on the side of these monopolies during the miserable\ndepths of the 1990s African AIDS crisis. He’s still there today, defending the\nstatus quo and running effective interference for those profiting by the\nbillions from their control of Covid-19 vaccines. His latest move is to institutionalize the ACT-Accelerator\nas the central organizing institution in future pandemics. The shortages have\nmade this effort a little awkward, however, and Gates is now forced to reckon\nwith the question of technology transfer. This is an aspect of\nthe equitable access debate that doesn’t concern intellectual property as commonly perceived—as a\nsimple matter of patents and licenses—but access\nto the components and technical knowledge related to practical manufacture, including biological\nmaterial and other areas otherwise protected under the category of intellectual property known as\ntrade secrets. The global south and civil society groups have been calling for tech transfer for months—either mandatory tech transfer that could have been written into contracts or through a voluntary mechanism associated with C-TAP—but Gates\nhas predictably arrived on the scene with a more familiar plan in hand.In early March, senior Gates staff joined\npharma executives for a “Global C19 Vaccine Supply Chain and Manufacturing Summit” convened by Chatham\nHouse in London. The main agenda item: plans for a new arm within the ACT-Accelerator,\nthe Covid Vaccine Capacity Connector, that seeks to address the tech-transfer question within the usual frame of monopoly rights and\nbilateral licensing. “The tech transfer debate is being decisively seized and shaped\nby those who want to set the terms and conditions under which knowledge can be\ntransferred,” writes Priti Patnaik in her Geneva\nHealth Files newsletter. A Gates-directed tech-transfer mechanism without\nmeaningful input from WHO members states, she writes, would be a “body blow” to\nC-TAP and similar future initiatives that promote open licensing and knowledge sharing\nto maximize production and access. There\nare signs of overdue scrutiny of Gates’s role in public health and lifelong commitment\nto exclusive intellectual property rights. But so far these are blips. More common\nis the deference on display in a March 21 New\nYork Times article about the U.S. government’s role in developing the mRNA vaccines now under\nthe monopoly control of Moderna and Pfizer. When the piece turned to Gates’s inevitable\ncameo, the Times reporter was hovering\nright over the target—and somehow managed to miss wide by a mile. Instead of\nprobing Gates’s central role in preserving this paradigm, the paper linked to\ngentle boilerplate about pricing and access found on the Gates Foundation\nwebsite. In response to a request for comment, a Gates Foundation spokesperson pointed\nme to a piece by its CEO, Mark Suzman, arguing that “IP fundamentally underpins\ninnovation, including the work that has helped create vaccines so quickly.”Any change\nin media coverage of Gates’s second career may produce a delayed echo within the\nworld he has come to dominate. Here Gates not only controls the narratives, he\ncontrols most of the payroll. This may sound conspiratorial or overblown to\noutsiders but not to campaigners who have witnessed Gates’s ability to shift\ngravity on major issues. “If you\nsaid to an ordinary person, ‘We’re in a pandemic. Let’s figure out everyone who\ncan make vaccines and give them everything they need to get online as fast as\npossible,’ it would be a no-brainer,” says James Love.\n“But Gates won’t go there. Neither will the people dependent on his funding. He has immense power. He can get you\nfired from a U.N. job. He knows that if you want to work in global public\nhealth, you’d better not make an enemy of the Gates Foundation by questioning\nits positions on I.P. and monopolies. And there are a lot of advantages to\nbeing on his team. It’s a sweet, comfortable ride for a lot of people.”*Among journalists echoing this argument was former New Republic editor Andrew Sullivan. When The New York Times reported Sullivan was defending the companies’ lawsuit while taking undisclosed\nfunding from\nPhRma, the industry trade association, Sullivan\nremained defiant in the face of evidence-based accusations that he was an unethical\njournalist. “It behooves me to say I see\nabsolutely no problems with [drug industry sponsorship],” he told Salon. “In fact, I am extremely proud to\nget some support from a great industry.” It later turned out that Africans adhered\nmore closely to the twice-daily pill regimens than patient populations in rich\ncountries.**In 2010,\nthe Gates Foundation would bankroll a documentary advocating the privatization\nof U.S. public education, titled Waiting\nfor Superman. ","length":36902,"excerpt":"Through his hallowed foundation, the world’s de facto public health czar has been a stalwart defender of monopoly medicine.","byline":"Alexander Zaitchik","dir":null,"siteName":"The New Republic","lang":"en-us"},"finalizedMeta":{"title":"How Bill Gates Impeded Global Access to Covid Vaccines","description":"Through his hallowed foundation, the world’s de facto public health czar has been a stalwart defender of monopoly medicine.","author":false,"creator":"Alexander Zaitchik","publisher":false,"date":"2023-11-28","subject":"The Soapbox","topics":["The Soapbox","Covid-19","Bill Gates","Bill & Melinda Gates Foundation","World Health Organization","World Trade Organization","coronavirus vaccine","pandemic","Big Pharma","pharmaceutical","AstraZeneca","GlaxoSmithKline","Johnson & Johnson","Pfizer","HIV","AIDS","Nelson Mandela","South Africa","Oxfam","Médecins Sans Frontieres","The Insecurity Complex","Politics"]},"jsonLd":{"@type":false,"headline":false,"description":false,"image":[],"mainEntityOfPage":{"@type":false,"@id":false},"datePublished":false,"dateModified":false,"isAccessibleForFree":false,"isPartOf":{"@type":[],"name":false,"productID":false},"discussionUrl":false,"license":false,"author":{"@type":false,"name":false,"description":false,"sameAs":false,"image":{"@type":false,"url":false},"givenName":false,"familyName":false,"alternateName":false,"publishingPrinciples":false},"publisher":{"@type":false,"name":false,"description":false,"sameAs":false,"logo":{"@type":false,"url":false},"publishingPrinciples":false},"editor":{"@type":false,"name":false,"description":false,"sameAs":false,"image":{"@type":false,"url":false},"givenName":false,"familyName":false,"alternateName":false,"publishingPrinciples":false}},"twitterObj":false,"status":200,"metadata":{"author":"Alexander Zaitchik","title":"Bill Gates, Vaccine Monster | The New Republic","description":"Through his hallowed foundation, the world’s de facto public health czar has been a stalwart defender of monopoly medicine.","canonical":"https://newrepublic.com/article/162000/bill-gates-impeded-global-access-covid-vaccines","keywords":[],"image":"data:image/svg+xml,%3Csvg%20width%3D%221000%22%20height%3D%22667%22%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%3E%3Crect%20width%3D%22100%25%22%20height%3D%22100%25%22%20fill%3D%22%23F5F5F5%22%2F%3E%3C%2Fsvg%3E","firstParagraph":"On February 11, 2020, public health and infectious disease experts gathered\nby the hundreds at the World Health Organization’s Geneva mothership. The official pronouncement of a pandemic was still a month out, but the\nagency’s international brain trust knew enough to be worried. Burdened by a\nsense of borrowed time, they spent two days furiously sketching an “R&D Blueprint”\nin preparation for a world upended by the virus then known as 2019-nCoV."},"dublinCore":{},"opengraph":{"title":"How Bill Gates Impeded Global Access to Covid Vaccines","description":"Through his hallowed foundation, the world’s de facto public health czar has been a stalwart defender of monopoly medicine.","url":"https://newrepublic.com/article/162000/bill-gates-impeded-global-access-covid-vaccines","site_name":"The New Republic","locale":"en_US","type":"article","typeObject":{"published_time":"2021-04-12","modified_time":"2023-11-28","author":false,"publisher":"https://www.facebook.com/newrepublic","section":false,"tag":["The Soapbox","Covid-19","Bill Gates","Bill & Melinda Gates Foundation","World Health Organization","World Trade Organization","coronavirus vaccine","pandemic","Big Pharma","pharmaceutical","AstraZeneca","GlaxoSmithKline","Johnson & Johnson","Pfizer","HIV","AIDS","Nelson Mandela","South Africa","Oxfam","Médecins Sans Frontieres","The Insecurity Complex","Politics"]},"image":"https://images.newrepublic.com/e3fb4ce1a82048335f394329088873da63f2fed1.jpeg?w=1200&h=630&crop=faces&fit=crop&fm=jpg","image:height":"630","image:width":"1200","image:type":"image/jpeg"},"twitter":{"site":"@newrepublic","description":"Through his hallowed foundation, the world’s de facto public health czar has been a stalwart defender of monopoly medicine.","card":"summary_large_image","creator":"@null","title":"How Bill Gates Impeded Global Access to Covid Vaccines","image":"https://images.newrepublic.com/e3fb4ce1a82048335f394329088873da63f2fed1.jpeg?w=1200&h=600&crop=faces&fit=crop&fm=jpg"},"archivedData":{"link":false,"wayback":false}}}